KR20230093503A - Compositions and methods modulating delta-gamma chain-mediated immunity - Google Patents

Abstract

Provided herein is, in certain embodiments, an antibody that binds T cell receptor (TCR) Vγ9 (TRGV9), TCR Vδ2 (TRDV2), or TCR gamma/delta constant region (TRGDC), and is a recombinant cell comprising a vector, , A composition comprising an antibody. Methods of making and using the antibodies are also provided.

Description

Compositions and methods modulating delta-gamma chain-mediated immunity

Cross reference of related applications

This application claims the benefit of US Serial No. 63/106,703, filed on October 28, 2020, the disclosure of which is incorporated herein in its entirety.

technology field

Provided herein is, in certain embodiments, an antibody that binds T cell receptor (TCR) Vγ9 (TRGV9), TCR Vδ2 (TRDV2), or TCR gamma/delta constant region (TRGDC), and is a recombinant cell comprising a vector, , A composition comprising an antibody. Methods of making and using the antibodies are also provided.

Reference to Electronically Submitted Sequence Listings

This application contains a sequence listing submitted electronically via EFS-Web as an ASCII format sequence listing with the file name "14620-236-228_SL.txt", a creation date of October 7, 2021, and a size of 2,092,176 bytes. . Sequence listings submitted via EFS-Web are part of this specification and are incorporated herein in their entirety.

In one aspect, provided herein are antibodies that bind TRGV9. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 31, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 32, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 65, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 66, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 99, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 100, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 133, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 134, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 167, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 168, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 201, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 202, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 235, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 236, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 269, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 270, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 303, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 304, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 337, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 338, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 371, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 372, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 405, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 406, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 439, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 440, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 473, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 474, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 507, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 508, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 541, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 542, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 575, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 576, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 609, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 610, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 643, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 644, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 677, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 678, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 711, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 712, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 745, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 746, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 779, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 780, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 813, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 814, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 847, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 848, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 881, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 882, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 915, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL comprising the VL having the amino acid sequence of SEQ ID NO: 916, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 949, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 950, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 983, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 984, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1017, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1018, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1051, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1052, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1085, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1086, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1119, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1120, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1153, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1154, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1187, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1188, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1221, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1222, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1255, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1256, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1289, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1290, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1323, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1324, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1357, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1358, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1391, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1392, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1425, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1426, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1459, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1460, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1493, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1494, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1527, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1528, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1561, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1562, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1595, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1596, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1629, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1630, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1663, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1664, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1697, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1698, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1731, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1732, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1765, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1766, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1799, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1800, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1833, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1834, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1867, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1868, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1901, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1902, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1935, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1936, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 1969, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1970, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. One embodiment wherein the TRGV9 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2003, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2004, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively.

In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Kabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody conform to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody are according to a contact numbering scheme. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody conform to the IMGT numbering system.

In some embodiments, the antibody binds to the TRGV9 antigen. In some embodiments, the antibody binds to a TRGV9 epitope. In some embodiments, the antibody specifically binds TRGV9. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an antigen of TRGV9. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an epitope of TRGV9. In some embodiments, TRGV9 is on the surface of a T cell.

In some embodiments, the TRGV9 antibody is a humanized antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, the TRGV9 antibody is an IgG1 antibody. In some embodiments, the TRGV9 antibody is an IgG2 antibody. In some embodiments, the TRGV9 antibody is an IgG3 antibody. In some embodiments, the TRGV9 antibody is an IgG4 antibody. In some embodiments, the TRGV9 antibody comprises a kappa light chain. In some embodiments, the TRGV9 antibody comprises a lambda light chain. In some embodiments, the TRGV9 antibody is a monoclonal antibody. In some embodiments, the TRGV9 antibody is multivalent. In some embodiments, a TRGV9 antibody is capable of binding at least three antigens. In some embodiments, a TRGV9 antibody is capable of binding at least 5 antigens. In some embodiments, the TRGV9 antibody is a multispecific antibody. In some embodiments, the TRGV9 antibody is a bispecific antibody.

In another aspect, nucleic acid sequences encoding the TRGV9 antibodies provided herein are provided. Vectors comprising nucleic acid sequences encoding the TRGV9 antibodies provided herein are also provided. Host cells comprising vectors comprising nucleic acid sequences encoding the TRGV9 antibodies provided herein are also provided. Also provided are kits comprising vectors comprising nucleic acid sequences encoding the TRGV9 antibodies provided herein and packaging therefor.

In another aspect, a kit comprising a TRGV9 antibody provided herein and packaging therefor is provided.

In another aspect, a pharmaceutical composition comprising a TRGV9 antibody provided herein and a pharmaceutically acceptable carrier is provided.

In another aspect, a method of producing a pharmaceutical composition comprising a TRGV9 antibody provided herein is provided, the method comprising combining the TRGV9 antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

In another aspect, a method of activating a T cell expressing TRGV9 is provided, the method comprising contacting the T cell with a TRGV9 antibody provided herein. In certain embodiments, the contacting results in increased expression of CD69, CD25, and/or Granzyme B as compared to control T cells expressing TRGV9.

In another aspect, provided herein are antibodies that bind TRDV2. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2037, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2038, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2071, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2072, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2105, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2106, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2139, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2140, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2173, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2174, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2207, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2208, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2241, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2242, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2275, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2276, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2309, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2310, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2343, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2344, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2377, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2378, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2411, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2412, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2445, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2446, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2479, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2480, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2513, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2514, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2547, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2548, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2581, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2582, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2615, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2616, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2649, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2650, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2683, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2684, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2717, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL comprising the VL having the amino acid sequence of SEQ ID NO: 2718, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2751, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2752, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2785, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2786, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2819, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2820, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2853, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2854, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2887, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2888, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2921, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2922, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2955, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2956, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 2989, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2990, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3023, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3024, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3057, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3058, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3091, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3092, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3125, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3126, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3159, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3160, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3193, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3194, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3227, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3228, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3261, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3262, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3295, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3296, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3329, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3330, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3363, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3364, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3397, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3398, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3431, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3432, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3465, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3466, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3499, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3500, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3533, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3534, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3567, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3568, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3601, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3602, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3635, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3636, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3669, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3670, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3703, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3704, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3737, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3738, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3771, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3772, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3805, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3806, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3839, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3840, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3873, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3874, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3907, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3908, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3941, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3942, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 3975, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3976, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4009, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4010, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4043, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4044, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4077, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4078, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. One embodiment wherein the TRDV2 antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4111, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4112, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively.

In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 antibody are according to the Kabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 antibody are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 antibody conform to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 antibody are according to a contact numbering scheme. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 antibody conform to the IMGT numbering system.

In some embodiments, the antibody binds the TRDV2 antigen. In some embodiments, the antibody binds to a TRDV2 epitope. In some embodiments, the antibody specifically binds TRDV2. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for the antigen of TRDV2. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an epitope of TRDV2. In some embodiments, TRDV2 is on the surface of a T cell.

In some embodiments, the TRDV2 antibody is a humanized antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, the TRDV2 antibody is an IgG1 antibody. In some embodiments, the TRDV2 antibody is an IgG2 antibody. In some embodiments, the TRDV2 antibody is an IgG3 antibody. In some embodiments, the TRDV2 antibody is an IgG4 antibody. In some embodiments, the TRDV2 antibody comprises a kappa light chain. In some embodiments, the TRDV2 antibody comprises a lambda light chain. In some embodiments, the TRDV2 antibody is a monoclonal antibody. In some embodiments, the TRDV2 antibody is multivalent. In some embodiments, a TRDV2 antibody is capable of binding at least three antigens. In some embodiments, a TRDV2 antibody is capable of binding at least 5 antigens. In some embodiments, the TRDV2 antibody is a multispecific antibody. In some embodiments, the TRDV2 antibody is a bispecific antibody.

In another aspect, nucleic acid sequences encoding the TRDV2 antibodies provided herein are provided. Vectors comprising nucleic acid sequences encoding the TRDV2 antibodies provided herein are also provided. Host cells comprising vectors comprising nucleic acid sequences encoding the TRDV2 antibodies provided herein are also provided. Also provided are kits comprising vectors comprising nucleic acid sequences encoding the TRDV2 antibodies provided herein and packaging therefor.

In another aspect, a kit comprising a TRDV2 antibody provided herein and packaging therefor is provided.

In another aspect, a pharmaceutical composition comprising a TRDV2 antibody provided herein and a pharmaceutically acceptable carrier is provided.

In another aspect, a method of producing a pharmaceutical composition comprising a TRDV2 antibody provided herein is provided, the method comprising combining the TRDV2 antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

In another aspect, a method of activating a T cell expressing TRDV2 is provided, the method comprising contacting the T cell with a TRDV2 antibody provided herein. In certain embodiments, the contacting step results in increased expression of CD69, CD25, and/or granzyme B as compared to control T cells expressing TRDV2.

In another aspect, provided herein are antibodies that bind TRGDC. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4145, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4146, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4179, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4180, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4213, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4214, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4247, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4248, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4281, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4282, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4315, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4316, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4349, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4350, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4383, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4384, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4417, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4418, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4451, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4452, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4485, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4486, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4519, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4520, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4553, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4554, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4587, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4588, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4621, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4622, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises (i) a VH having the amino acid sequence of SEQ ID NO: 4655, a VH CDR1 comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. ; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4656, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively.

In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC antibody are according to the Kabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC antibody are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC antibody conform to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC antibody are according to a contact numbering scheme. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC antibody conform to the IMGT numbering system.

In some embodiments, the antibody binds the TRGDC antigen. In some embodiments, the antibody binds to a TRGDC epitope. In some embodiments, the antibody specifically binds TRGDC. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an antigen of TRGDC. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an epitope of TRGDC. In some embodiments, TRGDCs are on the surface of T cells.

In some embodiments, the TRGDC antibody is a humanized antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, the TRGDC antibody is an IgG1 antibody. In some embodiments, the TRGDC antibody is an IgG2 antibody. In some embodiments, the TRGDC antibody is an IgG3 antibody. In some embodiments, the TRGDC antibody is an IgG4 antibody. In some embodiments, the TRGDC antibody comprises a kappa light chain. In some embodiments, the TRGDC antibody comprises a lambda light chain. In some embodiments, the TRGDC antibody is a monoclonal antibody. In some embodiments, the TRGDC antibody is multivalent. In some embodiments, a TRGDC antibody is capable of binding at least three antigens. In some embodiments, a TRGDC antibody is capable of binding at least 5 antigens. In some embodiments, the TRGDC antibody is a multispecific antibody. In some embodiments, the TRGDC antibody is a bispecific antibody.

In another aspect, nucleic acid sequences encoding the TRGDC antibodies provided herein are provided. Vectors comprising nucleic acid sequences encoding the TRGDC antibodies provided herein are also provided. Host cells comprising vectors comprising nucleic acid sequences encoding the TRGDC antibodies provided herein are also provided. Kits comprising vectors comprising nucleic acid sequences encoding the TRGDC antibodies provided herein and packaging therefor are also provided.

In another aspect, a kit comprising a TRGDC antibody provided herein and packaging therefor is provided.

In another aspect, a pharmaceutical composition comprising a TRGDC antibody provided herein and a pharmaceutically acceptable carrier is provided.

In another aspect, a method of producing a pharmaceutical composition comprising a TRGDC antibody provided herein is provided, the method comprising combining the TRGDC antibody with a pharmaceutically acceptable carrier to obtain a pharmaceutical composition.

In another aspect, a method of activating a T cell expressing TRGDC is provided, the method comprising contacting the T cell with a TRGDC antibody provided herein. In certain embodiments, the contacting results in increased expression of CD69, CD25, and/or granzyme B as compared to control T cells expressing TRGDC.

Various publications, articles, and patents are cited or described in the background section and throughout the specification, each of which references are incorporated herein by reference in their entirety. Discussion of documents, practices, materials, devices, articles, etc. included herein is intended to provide a context for the present invention. Such discussion is not an admission that any or all of the contents form part of prior art with respect to any invention disclosed or claimed.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. On the contrary, certain terms used herein have the same meanings as set forth herein.

It should be noted that, as used in this specification and the appended claims, the singular forms (indefinite and definite) include plural referents unless the context clearly dictates otherwise.

Unless otherwise stated, any numerical value, such as a concentration or range of concentrations described herein, is to be understood in all instances as being modified by the term "about." Thus, numerical values typically include ±10% of the recited value. For example, a concentration of 1 mg/mL includes 0.9 mg/mL to 1.1 mg/mL. Similarly, a concentration range of 1% to 10% (w/v) includes 0.9% (w/v) to 11% (w/v). As used herein, the use of a range of values expressly includes all possible subranges, ie, all individual numbers within that range, including whole numbers and fractions of that value, unless the context clearly dictates otherwise.

Unless otherwise indicated, the term “at least” before a series of elements should be understood to refer to all elements within that series.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. Such equivalents are intended to be included in this invention.

As used herein, the terms "comprises", "comprising", "includes", "including", "has", "having", "contains" or "including", or any of these Other variations of ? will be understood to imply the inclusion of a stated integer or group of integers, but not the exclusion of any other integer or group of integers, and are intended to be non-exclusive or open-ended. For example, a composition, mixture, process, method, article, or apparatus that includes a list of elements is not necessarily limited to only those elements, but is unique to or explicitly stated in such composition, mixture, process, method, article, or apparatus. It may contain other elements not listed as . Also, unless explicitly stated to the contrary, “or” refers to an inclusive or rather than an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is false (or not present) is true (or present), both A and B are true (or present).

As used herein, the junctional term “and/or” between multiple recited elements is understood to include both individual options and combined options. For example, where two elements are joined by "and/or", the first option refers to the applicability of the first element without the second element. The second option refers to the applicability of the second element without the first element. The third option indicates that the first element and the second element are applicable together. Any one of these options is understood to fall within this meaning and thus fulfills the requirements of the term “and/or” as used herein. The possibility of simultaneous application of more than one of these options is also understood to fall within this meaning, and thus fulfills the requirement of the term "and/or".

As used herein, the term "consisting of", or variations such as "consisting of" or "consisting of", as used throughout this specification and claims, refers to any recited integer. or the inclusion of a group of integers, but no additional integer or group of integers may be added to the specified method, structure, or composition.

As used herein, the term “consisting essentially of,” or variations such as “consisting essentially of” or “consisting essentially of”, as used throughout this specification and claims, , indicates the inclusion of any recited integer or group of integers, and indicates the optional inclusion of any recited integer or group of integers that does not materially change the basic or novel characteristics of the specified method, structure or composition. M.P.E.P. See § 2111.03.

As used herein, “subject” means any animal, preferably a mammal, and most preferably a human. As used herein, the term "mammal" encompasses any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, and the like. In certain embodiments, the subject is a human.

In addition, the terms “about,” “approximately,” “substantially,” “substantially,” and similar terms used when referring to dimensions or characteristics of components of embodiments provided herein shall be delimited or parameters where the stated dimensions/characteristics are tight. , and functionally identical or similar minor variations therefrom are not excluded, as will be understood by those skilled in the art. At a minimum, such statements involving numerical parameters will use art-accepted mathematical and industrial principles (eg, rounding, measurement or other systematic errors, manufacturing tolerances, etc.) so as not to change the least significant digit. will contain variations.

When referring to two or more nucleic acid or polypeptide sequences (e.g., a TRGV9 antibody and a polynucleotide encoding the same, a TRDV2 antibody and a polynucleotide encoding the same, or a TRGDC antibody and a polynucleotide encoding the same), the term "identical" or percentage "Identity" is a specified number of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured by visual inspection or using one of the following sequence comparison algorithms. Refers to two or more sequences or subsequences with a percentage.

For sequence comparison, typically one sequence serves as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates percent sequence identity for the test sequence(s) relative to the reference sequence, based on the specified program parameters.

Optimal sequence alignments for comparison are described, eg, in Smith & Waterman, Adv. Appl. Math. 2:482 (1981) by the local homology algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970)] by the homology alignment algorithm [Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988)], computer implementations of these algorithms (GAP, BESTFIT, FASTA, and Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI) TFASTA), or by visual inspection (see generally Current Protocols in Molecular Biology, FM Ausubel et al. , eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. , (1995 Supplement) (Ausubel)).

Examples of suitable algorithms for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410] and Altschul et al. (1997) Nucleic Acids Res. 25: 3389-3402. Software for performing BLAST analyzes is publicly available through the National Center for Biotechnology Information. The algorithm first identifies short words of length W in a query sequence that match or satisfy some positive-valued threshold score T when aligned with words of the same length in a database sequence, thereby providing high-scoring sequence pairs ( It involves identifying high scoring sequence pairs (HSPs). T is referred to as the neighborhood word score threshold (see Altschul et al., supra). These initial neighborhood word hits act as seeds to initiate searches to find longer HSPs that contain them. Then, expand the word hits in both directions along each sequence as long as the cumulative alignment score can be increased.

Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for matching residue pairs, always > 0) and N (penalty score for mismatching residue pairs, always < 0). For amino acid sequences, a cumulative score is calculated using a scoring matrix. Expansion in each direction of a word hit when the cumulative alignment score falls a quantity X away from the maximum achieved value, when the cumulative score becomes less than or equal to zero due to the accumulation of one or more negative score residue alignments, or when either end of the sequence is reached. is stopped The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) defaults to using a word length (W) of 11, an expected value (E) of 10, M=5, N=-4, and a comparison of the two strands. For amino acid sequences, the BLASTP program defaults to a word length (W) of 3, an expected value (E) of 10, and uses the BLOSUM62 scoring matrix (Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89: 10915 (1989)).

In addition to calculating percent sequence identity, the BLAST algorithm also performs statistical analysis of similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873- 5787 (1993)). One measure of similarity provided by the BLAST algorithm is the minimum sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of a test nucleic acid to a reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

A further indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross-reactive with the polypeptide encoded by the second nucleic acid, as described below. Thus, the only time a polypeptide is typically substantially identical to a second polypeptide is, for example, the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions.

As used herein, the term "polynucleotide", referred to synonymously as "nucleic acid molecule", "nucleotide", or "nucleic acid", refers to any polyribonucleotide or polydeoxyribonucleotide, which is unmodified RNA. or DNA, or modified RNA or DNA. "Polynucleotide" refers to, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA, which may be single-stranded, or more typically double-stranded, or comprising a mixture of single- and double-stranded regions. Moreover, "polynucleotide" refers to a triple-stranded region comprising RNA, or DNA, or both RNA and DNA. The term polynucleotide also includes DNA or RNA containing one or more modified bases, and DNA or RNA whose backbone has been modified for stability or other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA, and thus "polynucleotide" refers to chemically, enzymatically, or metabolically modified forms of polynucleotides as typically found in nature, as well as to viruses and cells. It also includes the characteristic chemical forms of DNA and RNA. "Polynucleotide" also includes relatively short nucleic acid chains, often referred to as oligonucleotides.

As used herein, the term “vector” is a replicon into which other nucleic acid segments may be operably inserted to effect replication or expression of the segment.

As used herein, the term "host cell" refers to a cell comprising a nucleic acid molecule provided herein. A “host cell” can be any type of cell, eg, a primary cell, a cell in culture, or a cell from a cell line. In one embodiment, a “host cell” is a cell transfected with a nucleic acid molecule provided herein. In another embodiment, a “host cell” is a progeny or potential progeny of such a transfected cell. The progeny of a cell may or may not be identical to the parent cell, for example, due to mutations or environmental influences that may occur in subsequent generations or due to integration of a nucleic acid molecule into the host cell genome.

As used herein, the term "expression" refers to the biosynthesis of a gene product. This term includes transcription of a gene into RNA. The term also includes translation of RNA into one or more polypeptides, and further includes all naturally occurring post-transcriptional and post-translational modifications. The expressed antibody may be in the cytoplasm of the host cell, in an extracellular environment such as the growth medium of a cell culture, or anchored to a cell membrane.

As used herein, the terms "peptide", "polypeptide", or "protein" can refer to a molecule that is composed of amino acids and can be recognized as a protein by those skilled in the art. Conventional one-letter or three-letter codes for amino acid residues are used herein. The terms "peptide", "polypeptide" and "protein" may be used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. The term may also be modified naturally or by intervention, eg disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification such as conjugation with a labeling component. , including modified amino acid polymers. Also included within this definition are, for example, polypeptides containing one or more analogs of amino acids (eg, including unnatural amino acids, etc.) as well as other modifications known in the art.

The peptide sequences described herein are written according to the conventional convention that the N-terminal region of a peptide is on the left and the C-terminal region is on the right. Although isomeric forms of amino acids are known, they are the L-forms of the amino acids represented unless expressly indicated otherwise.

antibody

Provided herein are TRGV9 antibodies or antigen-binding fragments thereof, nucleic acids encoding the antibodies and expression vectors, recombinant cells containing the vectors, and compositions comprising the antibodies. The antibodies disclosed herein possess one or more desirable functional properties, including but not limited to, high affinity binding to TRGV9 or high specificity to TRGV9. Provided herein are TRDV2 antibodies or antigen-binding fragments thereof, nucleic acids encoding the antibodies and expression vectors, recombinant cells containing the vectors, and compositions comprising the antibodies. Antibodies disclosed herein have one or more desirable functional properties including, but not limited to, high affinity binding to TRDV2 or high specificity to TRDV2. Antibodies or antigen-binding fragments thereof that bind TRGDC, nucleic acids encoding the antibodies and expression vectors, recombinant cells containing the vectors, and compositions comprising the antibodies are provided herein. Antibodies disclosed herein have one or more desirable functional properties including, but not limited to, high affinity binding to TRGDC or high specificity to TRGDC. Methods of making the antibodies and methods for treating disease using the antibodies are also provided. In certain embodiments, an antibody disclosed herein has the ability to treat or prevent a disease or disorder when administered to a subject alone or in combination with other therapies.

As used herein, the term "antibody" is used in a broad sense and includes immunoglobulins or antibody molecules, including human antibodies, humanized antibodies, complex antibodies, and chimeric antibodies, whether monoclonal or polyclonal, and antibody fragments. do. Generally, an antibody is a protein or peptide chain that exhibits binding specificity for a particular antigen. Antibody structures are well known. Immunoglobulins can be assigned to five major classes (ie, IgA, IgD, IgE, IgG and IgM), depending on their heavy chain constant domain amino acid sequence. IgA and IgG are further subclassed into the isotypes IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4. Thus, antibodies provided herein may be of any of the five major classes or corresponding subclasses. In certain embodiments, an antibody provided herein is an IgG1, IgG2, IgG3, or IgG4. Antibody light chains of vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda, based on the amino acid sequences of their constant domains. Thus, antibodies provided herein may, in certain embodiments, include a kappa light chain constant domain. Antibodies provided herein may, in certain embodiments, also include a lambda light chain constant domain. According to certain embodiments, an antibody provided herein comprises heavy and/or light chain constant regions from a rat or human antibody. In certain embodiments, the constant region is a human constant region.

In addition to the heavy and light chain constant domains, the antibody comprises an antigen-binding region consisting of a light chain variable region (VL) and a heavy chain variable region (VH), each of which has three domains: complementarity determining region 1 (CDR1); CDR2 and CDR3). "CDR" refers to one of three hypervariable regions (HCDR1, HCDR2, or HCDR3) within the non-framework region of an immunoglobulin (Ig or antibody) VH β-sheet framework, or a ratio of an antibody VL β-sheet framework. -refers to one of the three hypervariable regions (LCDR1, LCDR2, or LCDR3) within the framework region. Thus, CDRs are variable region sequences interspersed within framework region sequences. CDR regions are well known to those skilled in the art and are defined, for example, by Kabat as the most hypervariable regions within antibody variable (V) domains (Kabat et al. , J. Biol. Chem. 252:6609-6616 (1977); Kabat, Adv. Prot. Chem. 32:1-75 (1978)). In addition, the CDR region sequences, according to Chothia, are defined in structural terms as residues that are not part of the conserved β-sheet framework and therefore adaptable to various conformations (Chothia and Lesk, J Mol. Biol. 196:901-917 (1987)). Both terms are well recognized in the art. CDR region sequences are also defined by AbM, Contact, and IMGT. Exemplary CDR region sequences are exemplified herein, eg in the tables provided in the Examples below. The location of the CDRs within the variable regions of standard antibodies has been determined by comparison of a number of structures (Al-Lazikani et al. , J. Mol. Biol. 273:927-948 (1997); Morea et al. , Methods 20:267-279 (2000)). Because the number of residues within the hypervariable region varies in different antibodies, additional residues relative to the canonical position are usually numbered immediately adjacent to the residue number in the standard variable region numbering scheme as a, b, c, etc. see Al-Lazikani et al. (1997). Such nomenclature is likewise well known to those skilled in the art.

The light chain variable region CDR1 domain is interchangeably referred to herein as LCDR1 or VL CDR1. The light chain variable region CDR2 domain is interchangeably referred to herein as LCDR2 or VL CDR2. Light chain variable region CDR3 domains are interchangeably referred to herein as LCDR3 or VL CDR3. Heavy chain variable region CDR1 domains are interchangeably referred to herein as HCDR1 or VH CDR1. Heavy chain variable region CDR2 domains are interchangeably referred to herein as HCDR2 or VH CDR2. Heavy chain variable region CDR1 domains are interchangeably referred to herein as HCDR3 or VH CDR3.

The term "hypervariable region" as used herein, such as VH or Vl, refers to regions of an antibody variable region that form defined loops in terms of structure and/or are hypervariable in sequence. In general, an antibody comprises six hypervariable regions, three in VH (HCDR1, HCDR2, HCDR3) and three in VL (LCDR1, LCDR2, LCDR3). A number of hypervariable region notations are in use and are incorporated herein. "Kabat" CDRs are based on sequence variability and are the most commonly used (see, e.g., Kabat et al. , Sequences of Proteins of Immunological Interest , 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)]). "Chothia" instead indicates the position of a structural loop (see, eg, Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)). When numbering using the Kabat numbering rules, the ends of the Chotia CDR-HCDR1 loops vary between H32 and H34 depending on the length of the loop (because the Kabat numbering scheme places insertions in H35A and H35B). This is because if both 35A and 35B are missing, the loop ends at 32, if there is only 35A, the loop ends at 33, and if both 35A and 35B are present, the loop ends at 34). "AbM" hypervariable regions represent a compromise between the Kabat CDRs and Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software (see, e.g., Martin, in Antibody Engineering , Vol. 2, Chapter 3 , Springer Verlag]). “Contact” hypervariable regions are based on analysis of available complex crystal structures.

에 의해 개발되어 있다(문헌[J. Mol. Biol. 309: 657-670 (2001)] 참조). 예를 들어 카바트 번호 부여 체계 및 IMGT 고유 번호 부여 체계를 포함한 번호 부여 체계 사이의 상응성은 당업자에게 잘 알려져 있다(예를 들어, Kabat의 전게서; Chothia 및 Lesk의 전게서; Martin의 전게서; Lefranc 등의 전게서 참조). 본원에 나타낸 예시적인 체계는 카바트와 초티아를 조합한다.Recently, a universal numbering scheme, ImMunoGeneTics (IMGT) Information System ^® , has been developed and is widely adopted (see Lafranc et al. , Dev. Comp. Immunol. 27(1):55-77 (2003)). . The IMGT is an integrated information system specialized for immunoglobulin (IG), T cell receptor (TR), and major histocompatibility complex (MHC) in humans and other vertebrates. Here, CDRs are presented in terms of both amino acid sequence and location within the light or heavy chain. Because the "positions" of CDRs within the structure of immunoglobulin variable domains are conserved between species and exist in structures called loops, CDRs and framework residues are easily identified by using a numbering system that aligns variable domain sequences according to structural features. sympathize with This information can be used to graft and replace CDR residues from one species of immunoglobulin into an acceptor framework, typically from a human antibody. An additional numbering scheme (AHon) is available for Honegger and

(see J. Mol. Biol. 309: 657-670 (2001)). Correspondence between numbering schemes, including, for example, the Kabat numbering system and the IMGT unique numbering scheme, is well known to those skilled in the art (see, e.g., Kabat, Chothia and Lesk, Martin, Lefranc et al. see ii). An exemplary system presented herein combines Kabat and Chothia.

The hypervariable region may include “extended hypervariable regions” as follows: 24 to 36, or 24 to 34 (LCDR1), 46 to 56, or 50 to 56 (LCDR2), and 89 to 97 within the VL. ( HCDR3). CDR sequences reflecting each of the above numbering schemes are provided herein, included in Tables 2-7.

The term “constant region” or “constant domain” refers to the carboxy-terminal portions of the light and heavy chains that are not directly involved in binding the antibody to antigen, but exhibit various effector functions, such as interaction with Fc receptors. These terms refer to that part of an immunoglobulin molecule that has a more conserved amino acid sequence compared to other parts of the immunoglobulin that contain the antigen-binding site, ie the variable region. The constant region may include the CH1, CH2, and CH3 regions of the heavy chain and the CL region of the light chain.

The term “framework” or “FR” residues are variable region residues that flank a CDR. FR residues are present in, for example, chimeric antibodies, humanized antibodies, human antibodies, domain antibodies, diabodies, linear antibodies, and bispecific antibodies. FR residues are variable domain residues other than hypervariable region residues or CDR residues.

As used herein, the term “isolated antibody” refers to an antibody that is substantially free of other antibodies having various antigenic specificities (e.g., an isolated antibody that specifically binds TRGV9 is substantially free of other antibodies that do not bind TRGV9). or the isolated antibody that specifically binds TRDV2 is substantially free of antibodies that do not bind TRDV2; or the isolated antibody that specifically binds TRDV is substantially free of antibodies that do not bind TRGDC. refers to Also, an isolated antibody is substantially free of other cellular material and/or chemicals.

As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population exclude the possibility of naturally occurring mutations that may be present in minor amounts. and, the same Monoclonal antibodies provided herein can be made by hybridoma methods, phage display technology, single lymphocyte gene cloning technology, or by recombinant DNA methods. For example, a monoclonal antibody can be produced by a hybridoma comprising B cells obtained from a transgenic non-human animal, such as a transgenic mouse or rat, having a genome comprising a human heavy chain transgene and a light chain transgene. .

As used herein, the term "antigen-binding fragment" refers to antibody fragments such as diabodies, Fab, Fab', F(ab')2, Fv fragments, disulfide stabilized Fv fragments (dsFv), (dsFv) ₂ , a bispecific dsFv (dsFv-dsFv'), a disulfide stabilized diabody (ds diabody), a single chain antibody molecule (scFv), a single domain antibody (sdAb), a scFv dimer (bivalent diabody), one multispecific antibodies, camelized single domain antibodies, nanobodies, domain antibodies, bivalent domain antibodies, or any other antibody that binds to an antigen but does not comprise the complete antibody structure, formed from a portion of an antibody comprising the above CDRs. refers to fragments. An antigen-binding fragment may bind the same antigen as the parent antibody or parent antibody fragment binds. According to certain embodiments, the antigen-binding fragment comprises a light chain variable region, a light chain constant region, and an Fd segment of a heavy chain. According to another specific embodiment, the antigen-binding fragment comprises Fab and F(ab').

As used herein, the term "single chain antibody" refers to a single chain antibody conventional in the art, which comprises a heavy chain variable region and a light chain variable region linked by short peptides of about 15 to about 20 amino acids. include As used herein, the term "single domain antibody" refers to a single domain antibody conventional in the art, which comprises a heavy chain variable region and a heavy chain constant region, or only a heavy chain variable region.

As used herein, the term "human antibody" refers to an antibody produced by a human or having an amino acid sequence corresponding to a human produced antibody prepared using any technique known in the art. . This definition of a human antibody includes intact or full-length antibodies, fragments thereof, and/or antibodies comprising at least one human heavy and/or light chain polypeptide.

As used herein, the term “humanized antibody” refers to a non-humanized antibody that has been modified to increase sequence homology with a human antibody, such that the antigen-binding properties of the antibody are retained but its antigenicity in humans is reduced. Refers to human antibodies.

As used herein, the term "chimeric antibody" refers to an antibody in which the amino acid sequence of an immunoglobulin molecule is derived from two or more species. The variable regions of both the light and heavy chains often correspond to those of antibodies derived from one species of mammal (e.g., mouse, rat, rabbit, etc.) having the desired specificity, affinity, and ability; On the other hand, the constant region corresponds to the sequence of an antibody derived from another species of mammal (eg, human), in order to avoid induction of an immune response in such species.

As used herein, the term "multispecific antibody" refers to an antibody comprising a plurality of immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence of the plurality of immunoglobulin variable domain sequences is directed against a first epitope. has binding specificity, and a second immunoglobulin variable domain sequence of the plurality of immunoglobulin variable domain sequences has binding specificity for a second epitope. In one embodiment, the first epitope and the second epitope do not overlap or do not substantially overlap. In one embodiment, the first epitope and the second epitope are on different antigens, eg, different proteins (or different subunits of a multimeric protein). In one embodiment, the multispecific antibody comprises a third, fourth, or fifth immunoglobulin variable domain. In one embodiment, the multispecific antibody is a bispecific antibody molecule, a trispecific antibody molecule, or a tetraspecific antibody molecule.

As used herein, the term “bispecific antibody” refers to a multispecific antibody that binds no more than two epitopes or no more than two antigens. The bispecific antibody comprises a first immunoglobulin variable domain sequence having binding specificity for a first epitope (e.g., an epitope on a TRGV9 antigen, an epitope on a TRDV2 antigen, an epitope on a TRGDC antigen) and a binding specificity for a second epitope. and a second immunoglobulin variable domain sequence having In one embodiment, the first epitope and the second epitope are on different antigens, eg, different proteins (or different subunits of a multimeric protein). In one embodiment, the bispecific antibody comprises a heavy and light chain variable domain sequence that has binding specificity for a first epitope and a heavy and light chain variable domain sequence that has binding specificity for a second epitope. In one embodiment, a bispecific antibody comprises a half antibody or fragment thereof having binding specificity for a first epitope and a half antibody or fragment thereof having binding specificity for a second epitope. In one embodiment, the bispecific antibody comprises an scFv or fragment thereof having binding specificity for a first epitope and an scFv or fragment thereof having binding specificity for a second epitope. "Trispecific antibody" refers to a multispecific antibody that binds to three distinct antigens or to three distinct epitopes within the same antigen. A "tetraspecific antibody" is a multispecific antibody that binds to four distinct antigens or to four distinct epitopes within the same antigen.

As used herein, the term “TRGV9” refers to a polypeptide capable of forming a T cell receptor when expressed on the surface of γδ T cells. TRGV9-expressing γδ T cells are among the first T cells to develop in the human fetus and are the predominant γδ T cell subset in healthy adult peripheral blood cells. The terms “TRGV9”, “Vγ9”, and “VG9” are used interchangeably herein. The term "TRGV9" includes any TRGV9 variant, isoform, and species homolog, which is naturally expressed by cells (including T cells) or encodes a polypeptide. expression on cells transfected with the gene or cDNA. In certain embodiments, TRGV9 is human TRGV9. An exemplary human TRGV9 amino acid sequence is provided by GenBank accession number NG_001336.2.

As used herein, an antibody that “binds specifically to TRGV9” is 1×10 ⁻⁷ M or less, such as 1×10 ⁻⁸ M or less, 5×10 ⁻⁹ M or less, 1×10 ⁻⁹ M or less. , an antibody that binds TRGV9, such as human TRGV9, with a KD of 5×10 ⁻¹⁰ M or less, or 1×10 ⁻¹⁰ M or less.

As used herein, the term “TRDV2” refers to a polypeptide capable of forming a T cell receptor when expressed on the surface of γδ T cells. TRDV2-expressing γδ T cells are among the first T cells to develop in the human fetus and are the predominant γδ T cell subset in healthy adult peripheral blood cells. The terms "TRDV2", "Vδ2", and "VD2" are used interchangeably herein. The term "TRDV2" includes any TRDV2 variants, isoforms, and species homologues, which are naturally expressed by cells (including T cells) or expressed on cells transfected with a gene or cDNA encoding a polypeptide. It can be. In certain embodiments, TRDV2 is human TRDV2. An exemplary human TRDV2 amino acid sequence is provided by GenBank accession number NG_001332.3.

As used herein, an antibody that “specifically binds to TRDV2” is 1×10 ⁻⁷ M or less, such as 1×10 ⁻⁸ M or less, 5×10 ⁻⁹ M or less, 1×10 ⁻⁹ M or less. , an antibody that binds TRDV2, such as human TRDV2, with a KD of 5×10 ⁻¹⁰ M or less, or 1×10 ⁻¹⁰ M or less.

As used herein, the term “TRGDC” refers to a polypeptide capable of forming a T cell receptor when expressed on the surface of γδ T cells. The terms “TRGDC” and “gamma delta constant” are used interchangeably herein. The term "TRGDC" includes any TRGDC variants, isoforms, and species homologues, which are naturally expressed by cells (including T cells) or expressed on cells transfected with a gene or cDNA encoding a polypeptide. It can be. In certain embodiments, the TRGDCs are human TRGDCs. An exemplary human T cell receptor delta constant (TRDC) amino acid sequence is provided by GenBank accession number NG 001332.3, and an exemplary human T cell receptor gamma constant (TRGC) amino acid sequence is provided by GenBank accession number NC 000007.14 (TRGC1) or NC 000007.14 ( provided by TRGC2).

As used herein, an antibody that “specifically binds to TRGDC” is 1×10 ⁻⁷ M or less, such as 1×10 ⁻⁸ M or less, 5×10 ⁻⁹ M or less, 1×10 ⁻⁹ M or less. , an antibody that binds TRGDC, such as human TRGDC, with a KD of 5×10 ⁻¹⁰ M or less, or 1×10 ⁻¹⁰ M or less.

The term “KD” refers to the dissociation constant, which is obtained from the ratio of Kd to Ka (ie, Kd/Ka) and is expressed as molarity (M). KD values for antibodies can be determined using methods in the art in view of the present disclosure. For example, the KD of an antibody can be determined by using surface plasmon resonance, such as by using a biosensor system, such as the Biacore® system, or by using a biolayer interferometry technique, such as the Octet RED96 system. The smaller the KD value of an antibody, the higher the affinity with which the antibody binds to the target antigen.

In one aspect, provided herein are antibodies that bind TRGV9. In some embodiments, provided herein are antibodies that bind to the TRGV9 antigen. In some embodiments, provided herein are antibodies that bind to a TRGV9 epitope.

In some embodiments, an antibody comprises a heavy chain variable region and a light chain variable region. In some embodiments, the TRGV9 antibody is not a single domain antibody or nanobody. In some embodiments, the TRGV9 antibody is a humanized antibody. In some embodiments, the TRGV9 antibody is a fully human antibody.

In certain embodiments, provided herein is a TRGV9 antibody comprising a VH region, a VL region, a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and/or a VL CDR3 of any of the antibodies described herein. . In some embodiments, provided herein is a TRGV9 antibody comprising the VH region of any of the antibodies described herein. In some embodiments, provided herein is a TRGV9 antibody comprising the VL region of any of the antibodies described herein. In some embodiments, provided herein is a TRGV9 antibody comprising a VH region of any of the antibodies described herein and a VL region of any of the antibodies described herein. In some embodiments, provided herein is a TRGV9 antibody comprising the VH CDR1, VH CDR2, and VH CDR3 of any of the antibodies described herein. In some embodiments, provided herein is a TRGV9 antibody comprising the VL CDR1, VL CDR2, and VL CDR3 of any of the antibodies described herein. In some embodiments, VH CDR1, VH CDR2, and VH CDR3 of any of the antibodies described herein; and a TRGV9 antibody comprising the VL CDR1, VL CDR2, and VL CDR3 of any of the antibodies described herein. Representative VH and VL amino acid sequences of TRGV9 antibodies provided herein, including VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences, are provided in Tables 2-7.

In one aspect, antibodies that bind TRDV2 are provided herein. In some embodiments, provided herein are antibodies that bind to the TRDV2 antigen. In some embodiments, provided herein are antibodies that bind to a TRDV2 epitope.

In some embodiments, an antibody comprises a heavy chain variable region and a light chain variable region. In some embodiments, the TRDV2 antibody is not a single domain antibody or nanobody. In some embodiments, the TRDV2 antibody is a humanized antibody. In some embodiments, the TRDV2 antibody is a fully human antibody.

In certain embodiments, provided herein is a TRDV2 antibody comprising a VH region, a VL region, a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and/or a VL CDR3 of any of the antibodies described herein. . In some embodiments, provided herein is a TRDV2 antibody comprising a VH region of any of the antibodies described herein. In some embodiments, provided herein is a TRDV2 antibody comprising the VL region of any of the antibodies described herein. In some embodiments, provided herein is a TRDV2 antibody comprising a VH region of any of the antibodies described herein and a VL region of any of the antibodies described herein. In some embodiments, provided herein is a TRDV2 antibody comprising the VH CDR1, VH CDR2, and VH CDR3 of any of the antibodies described herein. In some embodiments, provided herein is a TRDV2 antibody comprising the VL CDR1, VL CDR2, and VL CDR3 of any of the antibodies described herein. In some embodiments, VH CDR1, VH CDR2, and VH CDR3 of any of the antibodies described herein; and a TRDV2 antibody comprising the VL CDR1, VL CDR2, and VL CDR3 of any of the antibodies described herein. Representative VH and VL amino acid sequences of TRDV2 antibodies provided herein, including VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences, are provided in Tables 2-7.

In one aspect, provided herein are antibodies that bind TRGDC. In some embodiments, provided herein are antibodies that bind TRGDC antigen. In some embodiments, provided herein are antibodies that bind to TRGDC epitopes.

In some embodiments, an antibody comprises a heavy chain variable region and a light chain variable region. In some embodiments, the TRGDC antibody is not a single domain antibody or nanobody. In some embodiments, the TRGDC antibody is a humanized antibody. In some embodiments, the TRGDC antibody is a fully human antibody.

In certain embodiments, provided herein is a TRGDC antibody comprising a VH region, VL region, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 of any of the antibodies described herein. . In some embodiments, provided herein is a TRGDC antibody comprising the VH region of any of the antibodies described herein. In some embodiments, provided herein is a TRGDC antibody comprising the VL region of any of the antibodies described herein. In some embodiments, provided herein is a TRGDC antibody comprising a VH region of any of the antibodies described herein and a VL region of any of the antibodies described herein. In some embodiments, provided herein is a TRGDC antibody comprising the VH CDR1, VH CDR2, and VH CDR3 of any of the antibodies described herein. In some embodiments, provided herein is a TRGDC antibody comprising the VL CDR1, VL CDR2, and VL CDR3 of any of the antibodies described herein. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 of any of the antibodies described herein; and a TRGDC antibody comprising the VL CDR1, VL CDR2, and VL CDR3 of any of the antibodies described herein. Representative VH and VL amino acid sequences of TRGDC antibodies provided herein, including VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences, are provided in Tables 2-7.

In some embodiments, the antibody specifically binds TRGV9. In another embodiment, TRGV9 is present on the surface of a T cell. In some embodiments, the antibody specifically binds TRDV2. In another embodiment, TRDV2 is present on the surface of a T cell. In some embodiments, the antibody specifically binds TRGDC. In another embodiment, TRGDCs are on the surface of T cells.

In some embodiments, the antibody is a humanized antibody. In certain embodiments, the antibody is an IgG antibody. In another embodiment, the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibody is a bispecific antibody. In some embodiments, the antibody is a trispecific antibody. In some embodiments, the antibody is a tetraspecific antibody. In certain embodiments, the antibody is multivalent. In another embodiment, the antibody is capable of binding at least three antigens. In some embodiments, an antibody is capable of binding at least 4 antigens. In some embodiments, an antibody is capable of binding at least 5 antigens.

In certain embodiments, TRGV9 antibodies are provided that are intact antibodies. In another embodiment, a TRGV9 antibody is provided, which is an antigen-binding fragment of a TRGV9 antibody. In some embodiments, an antigen-binding fragment of a TRGV9 antibody is a functional fragment. In certain embodiments, TRDV2 antibodies are provided that are intact antibodies. In another embodiment, a TRDV2 antibody is provided, which is an antigen-binding fragment of a TRDV2 antibody. In some embodiments, an antigen-binding fragment of a TRDV2 antibody is a functional fragment. In certain embodiments, TRGDC antibodies are provided that are intact antibodies. In another embodiment, a TRGDC antibody is provided, which is an antigen-binding fragment of a TRGDC antibody. In some embodiments, an antigen-binding fragment of a TRGDC antibody is a functional fragment.

In some embodiments, the antigen-binding fragment is a diabody. In some embodiments, the antigen-binding fragment is a Fab. In some embodiments, the antigen-binding fragment is Fab'. In some embodiments, the antigen-binding fragment is F(ab')2. In some embodiments, the antigen-binding fragment is an Fv fragment. In some embodiments, the antigen binding fragment is a disulfide stabilized Fv fragment (dsFv). In some embodiments, the antigen-binding fragment is (dsFv) ₂ . In some embodiments, the antigen-binding fragment is a bispecific dsFv (dsFv-dsFv'). In some embodiments, the antigen-binding fragment is a disulfide stabilized diabody (ds diabody). In some embodiments, the antigen-binding fragment is a single chain antibody molecule (scFv). In some embodiments, the antigen-binding fragment is a single domain antibody (sdAb). In some embodiments, the antigen-binding fragment is a scFv dimer (bivalent diabody). In some embodiments, an antigen-binding fragment is a multispecific antibody formed from a portion of an antibody comprising one or more CDRs. In some embodiments, the antigen-binding fragment is a camelized single domain antibody. In some embodiments, the antigen-binding fragment is a Nanobody. In some embodiments, an antigen-binding fragment is a domain antibody. In some embodiments, the antigen-binding fragment is a bivalent domain antibody. In some embodiments, an antigen-binding fragment is an antibody fragment that binds an antigen but does not comprise the complete antibody structure.

In certain embodiments, a TRGV9 antibody comprises a VH region and a VL region. In some embodiments, the TRGV9 antibody is a single chain antibody. In some embodiments, the TRGV9 antibody is a single domain antibody. In some embodiments, the TRGV9 antibody is a nanobody. In certain embodiments, the TRGV9 antibody is a VHH antibody. In certain embodiments, the TRGV9 antibody is a llama antibody. In some embodiments, the TRGV9 antibody is not a single chain antibody. In some embodiments, the TRGV9 antibody is not a single domain antibody. In some embodiments, the TRGV9 antibody is not a Nanobody. In certain embodiments, the TRGV9 antibody is not a VHH antibody. In certain embodiments, the TRGV9 antibody is not a llama antibody. In some embodiments, the TRGV9 antibody is a multispecific antibody. In another embodiment, the TRGV9 antibody is a bispecific antibody. In another embodiment, the TRGV9 antibody is a trispecific antibody. In another embodiment, the TRGV9 antibody is a tetraspecific antibody. In certain embodiments, the multispecific antibody comprises an antigen-binding fragment of a TRGV9 antibody provided herein. In another embodiment, the bispecific antibody comprises an antigen-binding fragment of a TRGV9 antibody provided herein. In another embodiment, the trispecific antibody comprises an antigen-binding fragment of a TRGV9 antibody provided herein. In another embodiment, a tetraspecific antibody comprises an antigen-binding fragment of a TRGV9 antibody provided herein. In certain embodiments, the TRGV9 antibody activates T cells. In another embodiment, the TRGV9 antibody is an antagonistic antibody. In certain embodiments, the TRGV9 antibody inactivates T cells. In some embodiments, the TRGV9 antibody blocks activation of T cells. In some embodiments, the TRGV9 antibody modulates the activity of a T cell. In some embodiments, the TRGV9 antibody neither activates nor inactivates the activity of T cells. In certain embodiments, the T cell is a human T cell.

In certain embodiments, a TRDV2 antibody comprises a VH region and a VL region. In some embodiments, the TRDV2 antibody is a single chain antibody. In some embodiments, the TRDV2 antibody is a single domain antibody. In some embodiments, the TRDV2 antibody is a nanobody. In certain embodiments, the TRDV2 antibody is a VHH antibody. In certain embodiments, the TRDV2 antibody is a llama antibody. In some embodiments, the TRDV2 antibody is not a single chain antibody. In some embodiments, the TRDV2 antibody is not a single domain antibody. In some embodiments, the TRDV2 antibody is not a Nanobody. In certain embodiments, the TRDV2 antibody is not a VHH antibody. In certain embodiments, the TRDV2 antibody is not a llama antibody. In some embodiments, the TRDV2 antibody is a multispecific antibody. In another embodiment, the TRDV2 antibody is a bispecific antibody. In another embodiment, the TRDV2 antibody is a trispecific antibody. In another embodiment, the TRDV2 antibody is a tetraspecific antibody. In certain embodiments, the multispecific antibody comprises an antigen-binding fragment of a TRDV2 antibody provided herein. In another embodiment, the bispecific antibody comprises an antigen-binding fragment of a TRDV2 antibody provided herein. In another embodiment, the trispecific antibody comprises an antigen-binding fragment of a TRDV2 antibody provided herein. In another embodiment, a tetraspecific antibody comprises an antigen-binding fragment of a TRDV2 antibody provided herein. In certain embodiments, the TRDV2 antibody activates T cells. In another embodiment, the TRDV2 antibody is an antagonistic antibody. In certain embodiments, the TRDV2 antibody inactivates T cells. In some embodiments, the TRDV2 antibody blocks activation of T cells. In some embodiments, the TRDV2 antibody modulates the activity of a T cell. In some embodiments, the TRDV2 antibody neither activates nor inactivates the activity of T cells. In certain embodiments, the T cell is a human T cell.

In certain embodiments, a TRGDC antibody comprises a VH region and a VL region. In some embodiments, the TRGDC antibody is a single chain antibody. In some embodiments, the TRGDC antibody is a single domain antibody. In some embodiments, the TRGDC antibody is a nanobody. In certain embodiments, the TRGDC antibody is a VHH antibody. In certain embodiments, the TRGDC antibody is a llama antibody. In some embodiments, the TRGDC antibody is not a single chain antibody. In some embodiments, the TRGDC antibody is not a single domain antibody. In some embodiments, the TRGDC antibody is not a Nanobody. In certain embodiments, the TRGDC antibody is not a VHH antibody. In certain embodiments, the TRGDC antibody is not a llama antibody. In some embodiments, the TRGDC antibody is a multispecific antibody. In another embodiment, the TRGDC antibody is a bispecific antibody. In another embodiment, the TRGDC antibody is a trispecific antibody. In another embodiment, the TRGDC antibody is a tetraspecific antibody. In certain embodiments, a multispecific antibody comprises an antigen-binding fragment of a TRGDC antibody provided herein. In another embodiment, the bispecific antibody comprises an antigen-binding fragment of a TRGDC antibody provided herein. In another embodiment, the trispecific antibody comprises an antigen-binding fragment of a TRGDC antibody provided herein. In another embodiment, a tetraspecific antibody comprises an antigen-binding fragment of a TRGDC antibody provided herein. In certain embodiments, TRGDC antibodies activate T cells. In another embodiment, the TRGDC antibody is an antagonistic antibody. In certain embodiments, TRGDC antibodies inactivate T cells. In some embodiments, the TRGDC antibody blocks activation of T cells. In some embodiments, the TRGDC antibody modulates the activity of a T cell. In some embodiments, the TRGDC antibody neither activates nor inactivates the activity of T cells. In certain embodiments, the T cell is a human T cell.

In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences are according to the Kabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences conform to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences conform to an exemplary numbering scheme. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences conform to a contact numbering scheme. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences conform to the IMGT numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences conform to the AbM numbering system. An exemplary set of six CDRs (VH CDR1 to CDR3 and VL CDR1 to CDR3) of a particular antibody embodiment are provided herein. Other sets of CDRs are contemplated and are within the scope of the antibody embodiments provided herein.

In one aspect, provided herein are antibodies that bind TRGV9. In some embodiments, an antibody comprises a heavy chain variable region and a light chain variable region. In some embodiments, the TRGV9 antibody is a humanized antibody.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and (ii) amino acids of SEQ ID NOs: 4, 5, and 6, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and (ii) amino acids of SEQ ID NOs: 10, 11, and 12, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 13, 14, and 15, respectively, and (ii) amino acids of SEQ ID NOs: 16, 17, and 18, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising the VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 19, 20, and 21, respectively, and (ii) amino acids of SEQ ID NOs: 22, 23, and 24, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising the VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 25, 26, and 27, respectively, and (ii) amino acids of SEQ ID NOs: 28, 29, and 30, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 31, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 32, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 31. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 32. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 31, and a VL having the amino acid sequence of SEQ ID NO: 32. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 33. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 34. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 33 and a light chain having the amino acid sequence of SEQ ID NO: 34. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 31. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 32. In one aspect herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 31, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 32 An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:33. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 34. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 33 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 34, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 35, 36, and 37, respectively, and (ii) amino acids of SEQ ID NOs: 38, 39, and 40, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising the VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 41, 42, and 43, respectively, and (ii) amino acids of SEQ ID NOs: 44, 45, and 46, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising the VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 47, 48, and 49, respectively, and (ii) amino acids of SEQ ID NOs: 50, 51, and 52, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 53, 54, and 55, respectively, and (ii) amino acids of SEQ ID NOs: 56, 57, and 58, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 59, 60, and 61, respectively, and (ii) amino acids of SEQ ID NOs: 62, 63, and 64, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 65, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 66, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 65. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 66. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 65, and a VL having the amino acid sequence of SEQ ID NO: 66. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 67. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO:68. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 67 and a light chain having the amino acid sequence of SEQ ID NO: 68. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:65. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:66. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 65, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 66. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:67. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:68. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 67 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 68, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 69, 70, and 71, respectively, and (ii) amino acids of SEQ ID NOs: 72, 73, and 74, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 75, 76, and 77, respectively, and (ii) amino acids of SEQ ID NOs: 78, 79, and 80, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 81, 82, and 83, respectively, and (ii) amino acids of SEQ ID NOs: 84, 85, and 86, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 87, 88, and 89, respectively, and (ii) amino acids of SEQ ID NOs: 90, 91, and 92, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 93, 94, and 95, respectively, and (ii) amino acids of SEQ ID NOs: 96, 97, and 98, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 99, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 100, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO:99. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 100. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 99, and a VL having the amino acid sequence of SEQ ID NO: 100. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 101. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 102. In one aspect, provided herein is an antibody that binds to TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 101 and a light chain having the amino acid sequence of SEQ ID NO: 102. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:99. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 100. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 99, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 100. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 101. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 102. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 101 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 102, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 103, 104, and 105, respectively, and (ii) amino acids of SEQ ID NOs: 106, 107, and 108, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 109, 110, and 111, respectively, and (ii) amino acids of SEQ ID NOs: 112, 113, and 114, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 115, 116, and 117, respectively, and (ii) amino acids of SEQ ID NOs: 118, 119, and 120, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 121, 122, and 123, respectively, and (ii) amino acids of SEQ ID NOs: 124, 125, and 126, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 127, 128, and 129, respectively, and (ii) amino acids of SEQ ID NOs: 130, 131, and 132, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 133, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 134, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 133. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 134. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 133, and a VL having the amino acid sequence of SEQ ID NO: 134. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 135. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 136. In one aspect, provided herein is an antibody that binds to TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 135 and a light chain having the amino acid sequence of SEQ ID NO: 136. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 133. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 134. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 133, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 134. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 135. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 136. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 135 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 136, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively, and (ii) amino acids of SEQ ID NOs: 140, 141, and 142, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 143, 144, and 145, respectively, and (ii) amino acids of SEQ ID NOs: 146, 147, and 148, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 149, 150, and 151, respectively, and (ii) amino acids of SEQ ID NOs: 152, 153, and 154, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 155, 156, and 157, respectively, and (ii) amino acids of SEQ ID NOs: 158, 159, and 160, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 161, 162, and 163, respectively, and (ii) amino acids of SEQ ID NOs: 164, 165, and 166, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 167, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 168, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 167. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 168. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 167, and a VL having the amino acid sequence of SEQ ID NO: 168. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 169. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 170. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 169 and a light chain having the amino acid sequence of SEQ ID NO: 170. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 167. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 168. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 167, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 168. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 169. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 170. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 169 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 170, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 171, 172, and 173, respectively, and (ii) amino acids of SEQ ID NOs: 174, 175, and 176, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 177, 178, and 179, respectively, and (ii) amino acids of SEQ ID NOs: 180, 181, and 182, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 183, 184, and 185, respectively, and (ii) amino acids of SEQ ID NOs: 186, 187, and 188, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 189, 190, and 191, respectively, and (ii) amino acids of SEQ ID NOs: 192, 193, and 194, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 195, 196, and 197, respectively, and (ii) amino acids of SEQ ID NOs: 198, 199, and 200, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 201, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 202, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 201. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 202. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 201, and a VL having the amino acid sequence of SEQ ID NO: 202. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 203. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 204. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 203 and a light chain having the amino acid sequence of SEQ ID NO: 204. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 201. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 202. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 201, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 202. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 203. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 204. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 203 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 204, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 205, 206, and 207, respectively, and (ii) amino acids of SEQ ID NOs: 208, 209, and 210, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 211, 212, and 213, respectively, and (ii) amino acids of SEQ ID NOs: 214, 215, and 216, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 217, 218, and 219, respectively, and (ii) amino acids of SEQ ID NOs: 220, 221, and 222, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 223, 224, and 225, respectively, and (ii) amino acids of SEQ ID NOs: 226, 227, and 228, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 229, 230, and 231, respectively, and (ii) amino acids of SEQ ID NOs: 232, 233, and 234, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 235, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 236, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 235. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 236. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 235, and a VL having the amino acid sequence of SEQ ID NO: 236. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 237. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 238. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 237 and a light chain having the amino acid sequence of SEQ ID NO: 238. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 235. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 236. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 235, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 236. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 237. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 238. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 237 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 238, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 239, 240, and 241, respectively, and (ii) amino acids of SEQ ID NOs: 242, 243, and 244, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 245, 246, and 247, respectively, and (ii) amino acids of SEQ ID NOs: 248, 249, and 250, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 251, 252, and 253, respectively, and (ii) amino acids of SEQ ID NOs: 254, 255, and 256, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 257, 258, and 259, respectively, and (ii) amino acids of SEQ ID NOs: 260, 261, and 262, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 263, 264, and 265, respectively, and (ii) amino acids of SEQ ID NOs: 266, 267, and 268, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 269, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 270, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 269. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 270. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 269, and a VL having the amino acid sequence of SEQ ID NO: 270. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 271. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 272. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 271 and a light chain having the amino acid sequence of SEQ ID NO: 272. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 269. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 270. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 269, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 270. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 271. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 272. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 271 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 272, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 273, 274, and 275, respectively, and (ii) amino acids of SEQ ID NOs: 276, 277, and 278, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 279, 280, and 281, respectively, and (ii) amino acids of SEQ ID NOs: 282, 283, and 284, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 285, 286, and 287, respectively, and (ii) amino acids of SEQ ID NOs: 288, 289, and 290, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 291, 292, and 293, respectively, and (ii) amino acids of SEQ ID NOs: 294, 295, and 296, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 297, 298, and 299, respectively, and (ii) amino acids of SEQ ID NOs: 300, 301, and 302, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 303, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 304, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 303. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 304. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 303, and a VL having the amino acid sequence of SEQ ID NO: 304. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 305. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 306. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 305 and a light chain having the amino acid sequence of SEQ ID NO: 306. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 303. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 304. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 303, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 304. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 305. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 306. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 305 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 306, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 307, 308, and 309, respectively, and (ii) amino acids of SEQ ID NOs: 310, 311, and 312, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 313, 314, and 315, respectively, and (ii) amino acids of SEQ ID NOs: 316, 317, and 318, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 319, 320, and 321, respectively, and (ii) amino acids of SEQ ID NOs: 322, 323, and 324, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 325, 326, and 327, respectively, and (ii) amino acids of SEQ ID NOs: 328, 329, and 330, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 331, 332, and 333, respectively, and (ii) amino acids of SEQ ID NOs: 334, 335, and 336, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 337, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 338, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 337. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 338. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 337, and a VL having the amino acid sequence of SEQ ID NO: 338. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 339. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 340. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 339 and a light chain having the amino acid sequence of SEQ ID NO: 340. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 337. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 338. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 337, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 338. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 339. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 340. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 339 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 340, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 341, 342, and 343, respectively, and (ii) amino acids of SEQ ID NOs: 344, 345, and 346, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 347, 348, and 349, respectively, and (ii) amino acids of SEQ ID NOs: 350, 351, and 352, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 353, 354, and 355, respectively, and (ii) amino acids of SEQ ID NOs: 356, 357, and 358, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 359, 360, and 361, respectively, and (ii) amino acids of SEQ ID NOs: 362, 363, and 364, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 365, 366, and 367, respectively, and (ii) amino acids of SEQ ID NOs: 368, 369, and 370, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 371, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 372, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 371. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 372. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 371, and a VL having the amino acid sequence of SEQ ID NO: 372. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 373. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 374. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 373 and a light chain having the amino acid sequence of SEQ ID NO: 374. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 371. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 372. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 371, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 372. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 373. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 374. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 373 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 374, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 375, 376, and 377, respectively, and (ii) amino acids of SEQ ID NOs: 378, 379, and 380, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 381, 382, and 383, respectively, and (ii) amino acids of SEQ ID NOs: 384, 385, and 386, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 387, 388, and 389, respectively, and (ii) amino acids of SEQ ID NOs: 390, 391, and 392, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 393, 394, and 395, respectively, and (ii) amino acids of SEQ ID NOs: 396, 397, and 398, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 399, 400, and 401, respectively, and (ii) amino acids of SEQ ID NOs: 402, 403, and 404, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 405, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 406, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 405. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 406. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 405, and a VL having the amino acid sequence of SEQ ID NO: 406. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 407. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 408. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 407 and a light chain having the amino acid sequence of SEQ ID NO: 408. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 405. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 406. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 405, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 406. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 407. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 408. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 407 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 408, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 409, 410, and 411, respectively, and (ii) amino acids of SEQ ID NOs: 412, 413, and 414, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 415, 416, and 417, respectively, and (ii) amino acids of SEQ ID NOs: 418, 419, and 420, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 421, 422, and 423, respectively, and (ii) amino acids of SEQ ID NOs: 424, 425, and 426, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 427, 428, and 429, respectively, and (ii) amino acids of SEQ ID NOs: 430, 431, and 432, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 433, 434, and 435, respectively, and (ii) amino acids of SEQ ID NOs: 436, 437, and 438, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 439, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 440, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 439. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 440. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 439, and a VL having the amino acid sequence of SEQ ID NO: 440. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 441. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 442. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 441 and a light chain having the amino acid sequence of SEQ ID NO: 442. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 439. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 440. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 439, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 440. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 441. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 442. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 441 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 442, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 443, 444, and 445, respectively, and (ii) amino acids of SEQ ID NOs: 446, 447, and 448, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 449, 450, and 451, respectively, and (ii) amino acids of SEQ ID NOs: 452, 453, and 454, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 455, 456, and 457, respectively, and (ii) amino acids of SEQ ID NOs: 458, 459, and 460, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 461, 462, and 463, respectively, and (ii) amino acids of SEQ ID NOs: 464, 465, and 466, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 467, 468, and 469, respectively, and (ii) amino acids of SEQ ID NOs: 470, 471, and 472, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 473, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 474, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 473. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 474. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 473, and a VL having the amino acid sequence of SEQ ID NO: 474. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 475. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 476. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 475 and a light chain having the amino acid sequence of SEQ ID NO: 476. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 473. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 474. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 473, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 474. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 475. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 476. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 475 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 476, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 477, 478, and 479, respectively, and (ii) amino acids of SEQ ID NOs: 480, 481, and 482, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 483, 484, and 485, respectively, and (ii) amino acids of SEQ ID NOs: 486, 487, and 488, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 489, 490, and 491, respectively, and (ii) amino acids of SEQ ID NOs: 492, 493, and 494, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 495, 496, and 497, respectively, and (ii) amino acids of SEQ ID NOs: 498, 499, and 500, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 501, 502, and 503, respectively, and (ii) amino acids of SEQ ID NOs: 504, 505, and 506, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 507, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 508, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 507. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 508. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 507, and a VL having the amino acid sequence of SEQ ID NO: 508. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 509. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 510. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 509 and a light chain having the amino acid sequence of SEQ ID NO: 510. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 507. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 508. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 507, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 508. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 509. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 510. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 509 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 510, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 511, 512, and 513, respectively, and (ii) amino acids of SEQ ID NOs: 514, 515, and 516, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 517, 518, and 519, respectively, and (ii) amino acids of SEQ ID NOs: 520, 521, and 522, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 523, 524, and 525, respectively, and (ii) amino acids of SEQ ID NOs: 526, 527, and 528, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 529, 530, and 531, respectively, and (ii) amino acids of SEQ ID NOs: 532, 533, and 534, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 535, 536, and 537, respectively, and (ii) amino acids of SEQ ID NOs: 538, 539, and 540, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 541, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 542, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 541. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 542. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 541, and a VL having the amino acid sequence of SEQ ID NO: 542. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 543. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 544. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 543 and a light chain having the amino acid sequence of SEQ ID NO: 544. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 541. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 542. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 541, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 542. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 543. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 544. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 543 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 544, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 545, 546, and 547, respectively, and (ii) amino acids of SEQ ID NOs: 548, 549, and 550, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 551, 552, and 553, respectively, and (ii) amino acids of SEQ ID NOs: 554, 555, and 556, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 557, 558, and 559, respectively, and (ii) amino acids of SEQ ID NOs: 560, 561, and 562, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 563, 564, and 565, respectively, and (ii) amino acids of SEQ ID NOs: 566, 567, and 568, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 569, 570, and 571, respectively, and (ii) amino acids of SEQ ID NOs: 572, 573, and 574, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 575, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 576, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 575. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 576. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 575, and a VL having the amino acid sequence of SEQ ID NO: 576. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 577. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 578. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 577 and a light chain having the amino acid sequence of SEQ ID NO: 578. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 575. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 576. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 575, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 576. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 577. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 578. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 577 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 578, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 579, 580, and 581, respectively, and (ii) amino acids of SEQ ID NOs: 582, 583, and 584, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 585, 586, and 587, respectively, and (ii) amino acids of SEQ ID NOs: 588, 589, and 590, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 591, 592, and 593, respectively, and (ii) amino acids of SEQ ID NOs: 594, 595, and 596, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 597, 598, and 599, respectively, and (ii) amino acids of SEQ ID NOs: 600, 601, and 602, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 603, 604, and 605, respectively, and (ii) amino acids of SEQ ID NOs: 606, 607, and 608, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 609, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 610, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 609. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 610. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 609, and a VL having the amino acid sequence of SEQ ID NO: 610. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 611. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 612. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 611 and a light chain having the amino acid sequence of SEQ ID NO: 612. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 609. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 610. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 609, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 610. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 611. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 612. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 611 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 612, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 613, 614, and 615, respectively, and (ii) amino acids of SEQ ID NOs: 616, 617, and 618, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 619, 620, and 621, respectively, and (ii) amino acids of SEQ ID NOs: 622, 523, and 624, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 625, 626, and 627, respectively, and (ii) amino acids of SEQ ID NOs: 628, 629, and 630, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 631, 632, and 633, respectively, and (ii) amino acids of SEQ ID NOs: 634, 635, and 636, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 637, 638, and 639, respectively, and (ii) amino acids of SEQ ID NOs: 640, 641, and 642, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 643, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 644, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 643. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 644. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 643, and a VL having the amino acid sequence of SEQ ID NO: 644. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 645. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 646. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 645 and a light chain having the amino acid sequence of SEQ ID NO: 646. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 643. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 644. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 643, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 644. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 645. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 646. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 645 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 646, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 647, 648, and 649, respectively, and (ii) amino acids of SEQ ID NOs: 650, 651, and 652, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 653, 654, and 655, respectively, and (ii) amino acids of SEQ ID NOs: 656, 657, and 658, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 659, 660, and 661, respectively, and (ii) amino acids of SEQ ID NOs: 662, 663, and 664, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 665, 666, and 667, respectively, and (ii) amino acids of SEQ ID NOs: 668, 669, and 670, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 671, 672, and 673, respectively, and (ii) amino acids of SEQ ID NOs: 674, 675, and 676, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 677, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 678, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 677. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 678. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 677, and a VL having the amino acid sequence of SEQ ID NO: 678. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 679. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 680. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 679 and a light chain having the amino acid sequence of SEQ ID NO: 680. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 677. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 678. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 677, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 678. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 679. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 680. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 679 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 680, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 681, 682, and 683, respectively, and (ii) amino acids of SEQ ID NOs: 684, 685, and 686, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 687, 688, and 689, respectively, and (ii) amino acids of SEQ ID NOs: 690, 691, and 692, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 693, 694, and 695, respectively, and (ii) amino acids of SEQ ID NOs: 696, 697, and 698, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 699, 700, and 701, respectively, and (ii) amino acids of SEQ ID NOs: 702, 703, and 704, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 705, 706, and 707, respectively, and (ii) amino acids of SEQ ID NOs: 708, 709, and 710, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 711, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 712, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 711. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 712. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 711, and a VL having the amino acid sequence of SEQ ID NO: 712. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 713. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 714. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 713 and a light chain having the amino acid sequence of SEQ ID NO: 714. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 711. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 712. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 711, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 712. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 713. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 714. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 713 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 714, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 715, 716, and 717, respectively, and (ii) amino acids of SEQ ID NOs: 718, 719, and 720, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 721, 722, and 723, respectively, and (ii) amino acids of SEQ ID NOs: 724, 725, and 726, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 727, 728, and 729, respectively, and (ii) amino acids of SEQ ID NOs: 730, 731, and 732, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 733, 734, and 735, respectively, and (ii) amino acids of SEQ ID NOs: 736, 737, and 738, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 739, 740, and 741, respectively, and (ii) amino acids of SEQ ID NOs: 742, 743, and 744, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 745, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 746, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 745. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 746. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 745, and a VL having the amino acid sequence of SEQ ID NO: 746. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 747. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 748. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 747 and a light chain having the amino acid sequence of SEQ ID NO: 748. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 745. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 746. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 745, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 746. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 747. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 748. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 747 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 748, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 749, 750, and 751, respectively, and (ii) amino acids of SEQ ID NOs: 752, 753, and 754, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 755, 756, and 757, respectively, and (ii) amino acids of SEQ ID NOs: 758, 759, and 760, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 761, 762, and 763, respectively, and (ii) amino acids of SEQ ID NOs: 764, 765, and 766, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 767, 768, and 769, respectively, and (ii) amino acids of SEQ ID NOs: 770, 771, and 772, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 773, 774, and 775, respectively, and (ii) amino acids of SEQ ID NOs: 776, 777, and 778, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 779, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 780, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 779. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 780. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 779, and a VL having the amino acid sequence of SEQ ID NO: 780. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 781. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 782. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 781 and a light chain having the amino acid sequence of SEQ ID NO: 782. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 779. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 780. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 779, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 780. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 781. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 782. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 781 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 782, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 783, 784, and 785, respectively, and (ii) amino acids of SEQ ID NOs: 786, 787, and 788, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 789, 790, and 791, respectively, and (ii) amino acids of SEQ ID NOs: 792, 793, and 794, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 795, 796, and 797, respectively, and (ii) amino acids of SEQ ID NOs: 798, 799, and 800, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 801, 802, and 803, respectively, and (ii) amino acids of SEQ ID NOs: 804, 805, and 806, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 807, 808, and 809, respectively, and (ii) amino acids of SEQ ID NOs: 810, 811, and 812, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 813, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 814, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 813. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 814. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 813, and a VL having the amino acid sequence of SEQ ID NO: 814. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 815. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 816. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 815 and a light chain having the amino acid sequence of SEQ ID NO: 816. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 813. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 814. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 813, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 814. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 815. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 816. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 815 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 816, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 817, 818, and 819, respectively, and (ii) amino acids of SEQ ID NOs: 820, 821, and 822, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 823, 824, and 825, respectively, and (ii) amino acids of SEQ ID NOs: 826, 827, and 828, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 829, 830, and 831, respectively, and (ii) amino acids of SEQ ID NOs: 832, 833, and 834, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 835, 836, and 837, respectively, and (ii) amino acids of SEQ ID NOs: 838, 839, and 840, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 841, 842, and 843, respectively, and (ii) amino acids of SEQ ID NOs: 844, 845, and 846, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 847, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 848, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 847. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 848. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 847, and a VL having the amino acid sequence of SEQ ID NO: 848. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 849. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 850. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 849 and a light chain having the amino acid sequence of SEQ ID NO: 850. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 847. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 848. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 847, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 848. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 849. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 850. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 849 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 850, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 851, 852, and 853, respectively, and (ii) amino acids of SEQ ID NOs: 854, 855, and 856, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 857, 858, and 859, respectively, and (ii) amino acids of SEQ ID NOs: 860, 861, and 862, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 863, 864, and 865, respectively, and (ii) amino acids of SEQ ID NOs: 866, 867, and 868, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 869, 870, and 871, respectively, and (ii) amino acids of SEQ ID NOs: 872, 873, and 874, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 875, 876, and 877, respectively, and (ii) amino acids of SEQ ID NOs: 878, 879, and 880, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 881, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 882, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 881. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 882. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 881, and a VL having the amino acid sequence of SEQ ID NO: 882. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 883. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 884. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 883 and a light chain having the amino acid sequence of SEQ ID NO: 884. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 881. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 882. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 881, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 882. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 883. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 884. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 883 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 884, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 885, 886, and 887, respectively, and (ii) amino acids of SEQ ID NOs: 888, 889, and 890, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 891, 892, and 893, respectively, and (ii) amino acids of SEQ ID NOs: 894, 895, and 896, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 897, 898, and 899, respectively, and (ii) amino acids of SEQ ID NOs: 900, 901, and 902, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 903, 904, and 905, respectively, and (ii) amino acids of SEQ ID NOs: 906, 907, and 908, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 909, 910, and 911, respectively, and (ii) amino acids of SEQ ID NOs: 912, 913, and 914, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 915, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 916, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 915. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 916. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 915, and a VL having the amino acid sequence of SEQ ID NO: 916. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 917. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 918. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 917 and a light chain having the amino acid sequence of SEQ ID NO: 918. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 915. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 916. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 915, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 916. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 917. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 918. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 917 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 918, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 919, 920, and 921, respectively, and (ii) amino acids of SEQ ID NOs: 922, 923, and 924, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 925, 926, and 927, respectively, and (ii) amino acids of SEQ ID NOs: 928, 929, and 930, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 931, 932, and 933, respectively, and (ii) amino acids of SEQ ID NOs: 934, 935, and 936, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 937, 938, and 939, respectively, and (ii) amino acids of SEQ ID NOs: 940, 941, and 942, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 943, 944, and 945, respectively, and (ii) amino acids of SEQ ID NOs: 946, 947, and 948, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 949, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 950, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 949. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 950. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 949, and a VL having the amino acid sequence of SEQ ID NO: 950. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 951. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 952. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 951 and a light chain having the amino acid sequence of SEQ ID NO: 952. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 949. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 950. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 949, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 950. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 951. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 952. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 951 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 952, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 953, 954, and 955, respectively, and (ii) amino acids of SEQ ID NOs: 956, 957, and 958, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 959, 960, and 961, respectively, and (ii) amino acids of SEQ ID NOs: 962, 963, and 964, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 965, 966, and 967, respectively, and (ii) amino acids of SEQ ID NOs: 968, 969, and 970, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 971, 972, and 973, respectively, and (ii) amino acids of SEQ ID NOs: 974, 975, and 976, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 977, 978, and 979, respectively, and (ii) amino acids of SEQ ID NOs: 980, 981, and 982, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 983, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 984, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 983. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 984. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 983, and a VL having the amino acid sequence of SEQ ID NO: 984. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 985. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 986. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 985 and a light chain having the amino acid sequence of SEQ ID NO: 986. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 983. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 984. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 983, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 984. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 985. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 986. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 985 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 986, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 987, 988, and 989, respectively, and (ii) amino acids of SEQ ID NOs: 990, 991, and 992, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 993, 994, and 995, respectively, and (ii) amino acids of SEQ ID NOs: 996, 997, and 998, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 999, 1000, and 1001, respectively, and (ii) amino acids of SEQ ID NOs: 1002, 1003, and 1004, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1005, 1006, and 1007, respectively, and (ii) amino acids of SEQ ID NOs: 1008, 1009, and 1010, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1011, 1012, and 1013, respectively, and (ii) amino acids of SEQ ID NOs: 1014, 1015, and 1016, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1017, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1018, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1017. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1018. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1017, and a VL having the amino acid sequence of SEQ ID NO: 1018. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1019. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1020. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1019 and a light chain having the amino acid sequence of SEQ ID NO: 1020. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1017. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1018. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1017, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1018. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1019. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1020. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1019 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1020, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1021, 1022, and 1023, respectively, and (ii) amino acids of SEQ ID NOs: 1024, 1025, and 1026, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1027, 1028, and 1029, respectively, and (ii) amino acids of SEQ ID NOs: 1030, 1031, and 1032, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1033, 1034, and 1035, respectively, and (ii) amino acids of SEQ ID NOs: 1036, 1037, and 1038, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1039, 1040, and 1041, respectively, and (ii) amino acids of SEQ ID NOs: 1042, 1043, and 1044, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1045, 1046, and 1047, respectively, and (ii) amino acids of SEQ ID NOs: 1048, 1049, and 1050, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1051, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1052, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1051. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1052. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1051, and a VL having the amino acid sequence of SEQ ID NO: 1052. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1053. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1054. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1053 and a light chain having the amino acid sequence of SEQ ID NO: 1054. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1051. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1052. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1051, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1052. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1053. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1054. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1053 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1054, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1055, 1056, and 1057, respectively, and (ii) amino acids of SEQ ID NOs: 1058, 1059, and 1060, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1061, 1062, and 1063, respectively, and (ii) amino acids of SEQ ID NOs: 1064, 1065, and 1066, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1067, 1068, and 1069, respectively, and (ii) amino acids of SEQ ID NOs: 1070, 1071, and 1072, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1073, 1074, and 1075, respectively, and (ii) amino acids of SEQ ID NOs: 1076, 1077, and 1078, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1079, 1080, and 1081, respectively, and (ii) amino acids of SEQ ID NOs: 1082, 1083, and 1084, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1085, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1086, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1085. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1086. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1085, and a VL having the amino acid sequence of SEQ ID NO: 1086. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1087. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1088. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1087 and a light chain having the amino acid sequence of SEQ ID NO: 1088. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1085. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1086. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1085, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1086. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1087. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1088. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1087 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1088, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1089, 1090, and 1091, respectively, and (ii) amino acids of SEQ ID NOs: 1092, 1093, and 1094, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1095, 1096, and 1097, respectively, and (ii) amino acids of SEQ ID NOs: 1098, 1099, and 1100, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1101, 1102, and 1103, respectively, and (ii) amino acids of SEQ ID NOs: 1104, 1105, and 1106, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1107, 1108, and 1109, respectively, and (ii) amino acids of SEQ ID NOs: 1110, 1111, and 1112, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1113, 1114, and 1115, respectively, and (ii) amino acids of SEQ ID NOs: 1116, 1117, and 1118, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1119, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1120, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1119. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1120. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1119, and a VL having the amino acid sequence of SEQ ID NO: 1120. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1121. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1122. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1121 and a light chain having the amino acid sequence of SEQ ID NO: 1122. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1119. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1120. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1119, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1120. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1121. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1122. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1121 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1122, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1123, 1124, and 1125, respectively, and (ii) amino acids of SEQ ID NOs: 1126, 1127, and 1128, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1129, 1130, and 1131, respectively, and (ii) amino acids of SEQ ID NOs: 1132, 1133, and 1134, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1135, 1136, and 1137, respectively, and (ii) amino acids of SEQ ID NOs: 1138, 1139, and 1140, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1141, 1142, and 1143, respectively, and (ii) amino acids of SEQ ID NOs: 1144, 1145, and 1146, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1147, 1148, and 1149, respectively, and (ii) amino acids of SEQ ID NOs: 1150, 1151, and 1152, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1153, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1154, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1153. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1154. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1153, and a VL having the amino acid sequence of SEQ ID NO: 1154. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1155. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1156. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1155 and a light chain having the amino acid sequence of SEQ ID NO: 1156. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1153. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1154. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1153, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1154. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1155. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1156. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1155 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1156, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1157, 1158, and 1159, respectively, and (ii) amino acids of SEQ ID NOs: 1160, 1161, and 1162, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1163, 1164, and 1165, respectively, and (ii) amino acids of SEQ ID NOs: 1166, 1167, and 1168, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1169, 1170, and 1171, respectively, and (ii) amino acids of SEQ ID NOs: 1172, 1173, and 1174, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1175, 1176, and 1177, respectively, and (ii) amino acids of SEQ ID NOs: 1178, 1179, and 1180, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1181, 1182, and 1183, respectively, and (ii) amino acids of SEQ ID NOs: 1184, 1185, and 1186, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1187, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1188, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1187. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1188. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1187, and a VL having the amino acid sequence of SEQ ID NO: 1188. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1189. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1190. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1189 and a light chain having the amino acid sequence of SEQ ID NO: 1190. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1187. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1188. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1187, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1188. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1189. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1190. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1189 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1190, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1191, 1192, and 1193, respectively, and (ii) amino acids of SEQ ID NOs: 1194, 1195, and 1196, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1197, 1198, and 1199, respectively, and (ii) amino acids of SEQ ID NOs: 1200, 1201, and 1202, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1203, 1204, and 1205, respectively, and (ii) amino acids of SEQ ID NOs: 1206, 1207, and 1208, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1209, 1210, and 1211, respectively, and (ii) amino acids of SEQ ID NOs: 1212, 1213, and 1214, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1215, 1216, and 1217, respectively, and (ii) amino acids of SEQ ID NOs: 1218, 1219, and 1220, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1221, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1222, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1221. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1222. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1221, and a VL having the amino acid sequence of SEQ ID NO: 1222. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1223. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1224. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1223 and a light chain having the amino acid sequence of SEQ ID NO: 1224. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1221. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1222. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1221, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1222. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1223. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1224. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1223 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1224, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1225, 1226, and 1227, respectively, and (ii) amino acids of SEQ ID NOs: 1228, 1229, and 1230, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1231, 1232, and 1233, respectively, and (ii) amino acids of SEQ ID NOs: 1234, 1235, and 1236, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1237, 1238, and 1239, respectively, and (ii) amino acids of SEQ ID NOs: 1240, 1241, and 1242, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1243, 1244, and 1245, respectively, and (ii) amino acids of SEQ ID NOs: 1246, 1247, and 1248, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1249, 1250, and 1251, respectively, and (ii) amino acids of SEQ ID NOs: 1252, 1253, and 1254, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1255, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1256, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1255. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1256. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1255, and a VL having the amino acid sequence of SEQ ID NO: 1256. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1257. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1258. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1257 and a light chain having the amino acid sequence of SEQ ID NO: 1258. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1255. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1256. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1255, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1256. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1257. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1258. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1257 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1258, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1259, 1260, and 1261, respectively, and (ii) amino acids of SEQ ID NOs: 1262, 1263, and 1264, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1265, 1266, and 1267, respectively, and (ii) amino acids of SEQ ID NOs: 1268, 1269, and 1270, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1271, 1272, and 1273, respectively, and (ii) amino acids of SEQ ID NOs: 1274, 1275, and 1276, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1277, 1278, and 1279, respectively, and (ii) amino acids of SEQ ID NOs: 1280, 1281, and 1282, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1283, 1284, and 1285, respectively, and (ii) amino acids of SEQ ID NOs: 1286, 1287, and 1288, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1289, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1290, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1289. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1290. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1289, and a VL having the amino acid sequence of SEQ ID NO: 1290. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1291. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1292. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1291 and a light chain having the amino acid sequence of SEQ ID NO: 1292. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1289. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1290. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1289, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1290. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1291. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1292. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1291 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1292, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1293, 1294, and 1295, respectively, and (ii) amino acids of SEQ ID NOs: 1296, 1297, and 1298, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1299, 1300, and 1301, respectively, and (ii) amino acids of SEQ ID NOs: 1302, 1303, and 1304, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1305, 1306, and 1307, respectively, and (ii) amino acids of SEQ ID NOs: 1308, 1309, and 1310, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1311, 1312, and 1313, respectively, and (ii) amino acids of SEQ ID NOs: 1314, 1315, and 1316, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1317, 1318, and 1319, respectively, and (ii) amino acids of SEQ ID NOs: 1320, 1321, and 1322, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1323, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1324, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1323. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1324. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1323, and a VL having the amino acid sequence of SEQ ID NO: 1324. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1325. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1326. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1325 and a light chain having the amino acid sequence of SEQ ID NO: 1326. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1323. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1324. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1323, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1324. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1325. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1326. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1325 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1326, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1327, 1328, and 1329, respectively, and (ii) amino acids of SEQ ID NOs: 1330, 1331, and 1332, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1333, 1334, and 1335, respectively, and (ii) amino acids of SEQ ID NOs: 1336, 1337, and 1338, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1339, 1340, and 1341, respectively, and (ii) amino acids of SEQ ID NOs: 1342, 1343, and 1344, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1345, 1346, and 1347, respectively, and (ii) amino acids of SEQ ID NOs: 1348, 1349, and 1350, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1351, 1352, and 1353, respectively, and (ii) amino acids of SEQ ID NOs: 1354, 1355, and 1356, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1357, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1358, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1357. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1358. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1357, and a VL having the amino acid sequence of SEQ ID NO: 1358. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1359. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1360. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1359 and a light chain having the amino acid sequence of SEQ ID NO: 1360. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1357. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1358. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1357, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1358. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1359. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1360. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1359 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1360, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1361, 1362, and 1363, respectively, and (ii) amino acids of SEQ ID NOs: 1364, 1365, and 1366, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1367, 1368, and 1369, respectively, and (ii) amino acids of SEQ ID NOs: 1370, 1371, and 1372, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1373, 1374, and 1375, respectively, and (ii) amino acids of SEQ ID NOs: 1376, 1377, and 1378, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1379, 1380, and 1381, respectively, and (ii) amino acids of SEQ ID NOs: 1382, 1383, and 1384, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1385, 1386, and 1387, respectively, and (ii) amino acids of SEQ ID NOs: 1388, 1389, and 1390, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1391, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1392, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1391. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1392. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1391, and a VL having the amino acid sequence of SEQ ID NO: 1392. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1393. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1394. In one aspect, provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1393 and a light chain having the amino acid sequence of SEQ ID NO: 1394. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1391. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1392. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1391, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1392. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1393. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1394. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1393 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1394, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1395, 1396, and 1397, respectively, and (ii) amino acids of SEQ ID NOs: 1398, 1399, and 1400, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1401, 1402, and 1403, respectively, and (ii) amino acids of SEQ ID NOs: 1404, 1405, and 1406, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1407, 1408, and 1409, respectively, and (ii) amino acids of SEQ ID NOs: 1410, 1411, and 1412, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1413, 1414, and 1415, respectively, and (ii) amino acids of SEQ ID NOs: 1416, 1417, and 1418, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1419, 1420, and 1421, respectively, and (ii) amino acids of SEQ ID NOs: 1422, 1423, and 1424, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1425, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1426, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1425. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1426. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1425, and a VL having the amino acid sequence of SEQ ID NO: 1426. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1427. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1428. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1427 and a light chain having the amino acid sequence of SEQ ID NO: 1428. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1425. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1426. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1425, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1426. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1427. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1428. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1427 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1428, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1429, 1430, and 1431, respectively, and (ii) amino acids of SEQ ID NOs: 1432, 1433, and 1434, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1435, 1436, and 1437, respectively, and (ii) amino acids of SEQ ID NOs: 1438, 1439, and 1440, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1441, 1442, and 1443, respectively, and (ii) amino acids of SEQ ID NOs: 1444, 1445, and 1446, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1447, 1448, and 1449, respectively, and (ii) amino acids of SEQ ID NOs: 1450, 1451, and 1452, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1453, 1454, and 1455, respectively, and (ii) amino acids of SEQ ID NOs: 1456, 1457, and 1458, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1459, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1460, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1459. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1460. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1459, and a VL having the amino acid sequence of SEQ ID NO: 1460. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1461. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1462. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1461 and a light chain having the amino acid sequence of SEQ ID NO: 1462. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1459. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1460. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1459, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1460. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1461. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1462. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1461 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1462, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1463, 1464, and 1465, respectively, and (ii) amino acids of SEQ ID NOs: 1466, 1467, and 1468, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1469, 1470, and 1471, respectively, and (ii) amino acids of SEQ ID NOs: 1472, 1473, and 1474, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1475, 1476, and 1477, respectively, and (ii) amino acids of SEQ ID NOs: 1478, 1479, and 1480, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1481, 1482, and 1483, respectively, and (ii) amino acids of SEQ ID NOs: 1484, 1485, and 1486, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1487, 1488, and 1489, respectively, and (ii) amino acids of SEQ ID NOs: 1490, 1491, and 1492, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1493, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1494, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1493. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1494. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1493, and a VL having the amino acid sequence of SEQ ID NO: 1494. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1495. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1496. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1495 and a light chain having the amino acid sequence of SEQ ID NO: 1496. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1493. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1494. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1493, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1494. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1495. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1496. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1495 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1496, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1497, 1498, and 1499, respectively, and (ii) amino acids of SEQ ID NOs: 1500, 1501, and 1502, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1503, 1504, and 1505, respectively, and (ii) amino acids of SEQ ID NOs: 1506, 1507, and 1508, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1509, 1510, and 1511, respectively, and (ii) amino acids of SEQ ID NOs: 1512, 1513, and 1514, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1515, 1516, and 1517, respectively, and (ii) amino acids of SEQ ID NOs: 1518, 1519, and 1520, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1521, 1522, and 1523, respectively, and (ii) amino acids of SEQ ID NOs: 1524, 1525, and 1526, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1527, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1528, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1527. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1528. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1527, and a VL having the amino acid sequence of SEQ ID NO: 1528. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1529. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1530. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1529 and a light chain having the amino acid sequence of SEQ ID NO: 1530. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1527. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1528. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1527, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1528. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1529. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1530. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1529 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1530, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1531, 1532, and 1533, respectively, and (ii) amino acids of SEQ ID NOs: 1534, 1535, and 1536, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1537, 1538, and 1539, respectively, and (ii) amino acids of SEQ ID NOs: 1540, 1541, and 1542, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1543, 1544, and 1545, respectively, and (ii) amino acids of SEQ ID NOs: 1546, 1547, and 1548, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1549, 1550, and 1551, respectively, and (ii) amino acids of SEQ ID NOs: 1552, 1553, and 1554, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1555, 1556, and 1557, respectively, and (ii) amino acids of SEQ ID NOs: 1558, 1559, and 1560, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1561, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1562, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1561. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1562. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1561, and a VL having the amino acid sequence of SEQ ID NO: 1562. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1563. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1564. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1563 and a light chain having the amino acid sequence of SEQ ID NO: 1564. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1561. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1562. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1561, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1562. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1563. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1564. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1563 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1564, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1565, 1566, and 1567, respectively, and (ii) amino acids of SEQ ID NOs: 1568, 1569, and 1570, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1571, 1572, and 1573, respectively, and (ii) amino acids of SEQ ID NOs: 1574, 1575, and 1576, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1577, 1578, and 1579, respectively, and (ii) amino acids of SEQ ID NOs: 1580, 1581, and 1582, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1583, 1584, and 1585, respectively, and (ii) amino acids of SEQ ID NOs: 1586, 1587, and 1588, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1589, 1590, and 1591, respectively, and (ii) amino acids of SEQ ID NOs: 1592, 1593, and 1594, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1595, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1596, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1595. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1596. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1595, and a VL having the amino acid sequence of SEQ ID NO: 1596. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1597. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1598. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1597 and a light chain having the amino acid sequence of SEQ ID NO: 1598. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1595. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1596. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1595, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1596. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1597. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1598. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1597 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1598, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1599, 1600, and 1601, respectively, and (ii) amino acids of SEQ ID NOs: 1602, 1603, and 1604, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1605, 1606, and 1607, respectively, and (ii) amino acids of SEQ ID NOs: 1608, 1609, and 1610, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1611, 1612, and 1613, respectively, and (ii) amino acids of SEQ ID NOs: 1614, 1615, and 1616, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1617, 1618, and 1619, respectively, and (ii) amino acids of SEQ ID NOs: 1620, 1621, and 1622, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1623, 1624, and 1625, respectively, and (ii) amino acids of SEQ ID NOs: 1626, 1627, and 1628, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1629, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1630, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1629. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1630. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1629, and a VL having the amino acid sequence of SEQ ID NO: 1630. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1631. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1632. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1631 and a light chain having the amino acid sequence of SEQ ID NO: 1632. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1629. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1630. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1629, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1630. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1631. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1632. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1631 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1632, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1633, 1634, and 1635, respectively, and (ii) amino acids of SEQ ID NOs: 1636, 1637, and 1638, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1639, 1640, and 1641, respectively, and (ii) amino acids of SEQ ID NOs: 1642, 1643, and 1644, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1645, 1646, and 1647, respectively, and (ii) amino acids of SEQ ID NOs: 1648, 1649, and 1650, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1651, 1652, and 1653, respectively, and (ii) amino acids of SEQ ID NOs: 1654, 1655, and 1656, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1657, 1658, and 1659, respectively, and (ii) amino acids of SEQ ID NOs: 1660, 1661, and 1662, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1663, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1664, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1663. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1664. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1663, and a VL having the amino acid sequence of SEQ ID NO: 1664. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1665. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1666. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1665 and a light chain having the amino acid sequence of SEQ ID NO: 1666. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1663. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1664. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1663, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1664. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1665. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1666. In one aspect, herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1665 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1666, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1667, 1668, and 1669, respectively, and (ii) amino acids of SEQ ID NOs: 1670, 1671, and 1672, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1673, 1674, and 1675, respectively, and (ii) amino acids of SEQ ID NOs: 1676, 1677, and 1678, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1679, 1680, and 1681, respectively, and (ii) amino acids of SEQ ID NOs: 1682, 1683, and 1684, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1685, 1686, and 1687, respectively, and (ii) amino acids of SEQ ID NOs: 1688, 1689, and 1690, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1691, 1692, and 1693, respectively, and (ii) amino acids of SEQ ID NOs: 1694, 1695, and 1696, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1697, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1698, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1697. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1698. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1697, and a VL having the amino acid sequence of SEQ ID NO: 1698. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1699. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1700. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1699 and a light chain having the amino acid sequence of SEQ ID NO: 1700. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1697. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1698. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1697, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1698. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1699. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1700. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1699 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1700, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1701, 1702, and 1703, respectively, and (ii) amino acids of SEQ ID NOs: 1704, 1705, and 1706, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1707, 1708, and 1709, respectively, and (ii) amino acids of SEQ ID NOs: 1710, 1711, and 1712, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1713, 1714, and 1715, respectively, and (ii) amino acids of SEQ ID NOs: 1716, 1717, and 1718, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1719, 1720, and 1721, respectively, and (ii) amino acids of SEQ ID NOs: 1722, 1723, and 1724, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1725, 1726, and 1727, respectively, and (ii) amino acids of SEQ ID NOs: 1728, 1729, and 1730, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1731, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1732, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1731. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1732. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1731, and a VL having the amino acid sequence of SEQ ID NO: 1732. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1733. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1734. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1733 and a light chain having the amino acid sequence of SEQ ID NO: 1734. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1731. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1732. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1731, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1732. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1733. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1734. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1733 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1734, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1735, 1736, and 1737, respectively, and (ii) amino acids of SEQ ID NOs: 1738, 1739, and 1740, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1741, 1742, and 1743, respectively, and (ii) amino acids of SEQ ID NOs: 1744, 1745, and 1746, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1747, 1748, and 1749, respectively, and (ii) amino acids of SEQ ID NOs: 1750, 1751, and 1752, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1753, 1754, and 1755, respectively, and (ii) amino acids of SEQ ID NOs: 1756, 1757, and 1758, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1759, 1760, and 1761, respectively, and (ii) amino acids of SEQ ID NOs: 1762, 1763, and 1764, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1765, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1766, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1765. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1766. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1765, and a VL having the amino acid sequence of SEQ ID NO: 1766. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1767. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1768. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1767 and a light chain having the amino acid sequence of SEQ ID NO: 1768. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1765. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1766. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1765, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1766. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1767. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1768. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1767 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1768, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1769, 1770, and 1771, respectively, and (ii) amino acids of SEQ ID NOs: 1772, 1773, and 1774, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1775, 1776, and 1777, respectively, and (ii) amino acids of SEQ ID NOs: 1778, 1779, and 1780, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1781, 1782, and 1783, respectively, and (ii) amino acids of SEQ ID NOs: 1784, 1785, and 1786, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1787, 1788, and 1789, respectively, and (ii) amino acids of SEQ ID NOs: 1790, 1791, and 1792, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1793, 1794, and 1795, respectively, and (ii) amino acids of SEQ ID NOs: 1796, 1797, and 1798, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1799, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1800, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1799. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1800. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1799, and a VL having the amino acid sequence of SEQ ID NO: 1800. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1801. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1802. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1801 and a light chain having the amino acid sequence of SEQ ID NO: 1802. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1799. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1800. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1799, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1800. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1801. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1802. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1801 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1802, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1803, 1804, and 1805, respectively, and (ii) amino acids of SEQ ID NOs: 1806, 1807, and 1808, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1809, 1810, and 1811, respectively, and (ii) amino acids of SEQ ID NOs: 1812, 1813, and 1814, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1815, 1816, and 1817, respectively, and (ii) amino acids of SEQ ID NOs: 1818, 1819, and 1820, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1821, 1822, and 1823, respectively, and (ii) amino acids of SEQ ID NOs: 1824, 1825, and 1826, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1827, 1828, and 1829, respectively, and (ii) amino acids of SEQ ID NOs: 1830, 1831, and 1832, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1833, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1834, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1833. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1834. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1833, and a VL having the amino acid sequence of SEQ ID NO: 1834. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1835. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1836. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1835 and a light chain having the amino acid sequence of SEQ ID NO: 1836. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1833. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1834. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1833, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1834. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1835. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1836. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1835 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1836, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1837, 1838, and 1839, respectively, and (ii) amino acids of SEQ ID NOs: 1840, 1841, and 1842, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1843, 1844, and 1845, respectively, and (ii) amino acids of SEQ ID NOs: 1846, 1847, and 1848, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1849, 1850, and 1851, respectively, and (ii) amino acids of SEQ ID NOs: 1852, 1853, and 1854, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1855, 1856, and 1857, respectively, and (ii) amino acids of SEQ ID NOs: 1858, 1859, and 1860, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1861, 1862, and 1863, respectively, and (ii) amino acids of SEQ ID NOs: 1864, 1865, and 1866, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1867, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1868, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1867. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1868. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1867, and a VL having the amino acid sequence of SEQ ID NO: 1868. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1869. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1870. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1869 and a light chain having the amino acid sequence of SEQ ID NO: 1870. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1867. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1868. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1867, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1868. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1869. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1870. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1869 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1870, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1871, 1872, and 1873, respectively, and (ii) amino acids of SEQ ID NOs: 1874, 1875, and 1876, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1877, 1878, and 1879, respectively, and (ii) amino acids of SEQ ID NOs: 1880, 1881, and 1882, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1883, 1884, and 1885, respectively, and (ii) amino acids of SEQ ID NOs: 1886, 1887, and 1888, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1889, 1890, and 1891, respectively, and (ii) amino acids of SEQ ID NOs: 1892, 1893, and 1894, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1895, 1896, and 1897, respectively, and (ii) amino acids of SEQ ID NOs: 1898, 1899, and 1900, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1901, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1902, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1901. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1902. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1901, and a VL having the amino acid sequence of SEQ ID NO: 1902. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1903. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1904. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1903 and a light chain having the amino acid sequence of SEQ ID NO: 1904. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1901. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1902. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1901, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1902. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1903. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1904. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1903 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1904, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1905, 1906, and 1907, respectively, and (ii) amino acids of SEQ ID NOs: 1908, 1909, and 1910, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1911, 1912, and 1913, respectively, and (ii) amino acids of SEQ ID NOs: 1914, 1915, and 1916, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1917, 1918, and 1919, respectively, and (ii) amino acids of SEQ ID NOs: 1920, 1921, and 1922, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1923, 1924, and 1925, respectively, and (ii) amino acids of SEQ ID NOs: 1926, 1927, and 1928, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1929, 1930, and 1931, respectively, and (ii) amino acids of SEQ ID NOs: 1932, 1933, and 1934, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1935, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1936, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1935. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1936. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1935, and a VL having the amino acid sequence of SEQ ID NO: 1936. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1937. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1938. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1937 and a light chain having the amino acid sequence of SEQ ID NO: 1938. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1935. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1936. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1935, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1936. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1937. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1938. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1937 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1938, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1939, 1940, and 1941, respectively, and (ii) amino acids of SEQ ID NOs: 1942, 1943, and 1944, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1945, 1946, and 1947, respectively, and (ii) amino acids of SEQ ID NOs: 1948, 1949, and 1950, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1951, 1952, and 1953, respectively, and (ii) amino acids of SEQ ID NOs: 1954, 1955, and 1956, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1957, 1958, and 1959, respectively, and (ii) amino acids of SEQ ID NOs: 1960, 1961, and 1962, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1963, 1964, and 1965, respectively, and (ii) amino acids of SEQ ID NOs: 1966, 1967, and 1968, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 1969, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 1970, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1969. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 1970. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 1969, and a VL having the amino acid sequence of SEQ ID NO: 1970. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1971. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 1972. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1971 and a light chain having the amino acid sequence of SEQ ID NO: 1972. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1969. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1970. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1969, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1970. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1971. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1972. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1971 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1972, Antibodies that bind TRGV9 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1973, 1974, and 1975, respectively, and (ii) amino acids of SEQ ID NOs: 1976, 1977, and 1978, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1979, 1980, and 1981, respectively, and (ii) amino acids of SEQ ID NOs: 1982, 1983, and 1984, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 1985, 1986, and 1987, respectively, and (ii) amino acids of SEQ ID NOs: 1988, 1989, and 1990, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1991, 1992, and 1993, respectively, and (ii) amino acids of SEQ ID NOs: 1994, 1995, and 1996, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 1997, 1998, and 1999, respectively, and (ii) amino acids of SEQ ID NOs: 2000, 2001, and 2002, respectively Provided herein are antibodies that bind TRGV9, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2003, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2004, respectively. do. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 2003. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having the amino acid sequence of SEQ ID NO: 2004. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having the amino acid sequence of SEQ ID NO: 2003, and a VL having the amino acid sequence of SEQ ID NO: 2004. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2005. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having the amino acid sequence of SEQ ID NO: 2006. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2005 and a light chain having the amino acid sequence of SEQ ID NO: 2006. In one aspect provided herein is an antibody that binds TRGV9 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2003. In one aspect provided herein is an antibody that binds TRGV9 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2004. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2003, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2004. An antibody that binds to TRGV9 is provided. In one aspect provided herein is an antibody that binds TRGV9 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2005. In one aspect provided herein is an antibody that binds TRGV9 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2006. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2005 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2006, Antibodies that bind TRGV9 are provided.

In one aspect, provided herein are antibodies that bind TRGV9. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 31, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 32, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 31, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 32, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 65, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 66, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 65, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 66, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 99, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 100, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 99, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 100, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 133, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 134, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 133, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 134, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 167, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 168, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 167, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 168, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 201, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 202, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 201, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 202, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 235, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 236, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 235, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 236, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 269, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 270, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 269, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 270, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 303, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 304, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 303, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 304, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 337, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 338, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 337, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 338, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 371, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 372, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 371, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 372, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 405, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 406, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 405, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 406, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 439, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 440, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 439, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 440, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 473, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 474, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 473, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 474, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 507, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 508, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 507, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 508, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 541, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 542, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 541, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 542, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 575, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 576, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 575, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 576, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 609, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 610, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 609, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 610, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 643, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 644, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 643, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 644, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 677, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 678, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 677, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 678, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 711, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 712, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 711, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 712, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 745, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 746, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 745, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 746, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 779, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 780, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 779, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 780, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 813, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 814, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 813, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 814, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 847, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 848, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 847, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 848, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 881, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 882, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 881, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 882, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 915, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 916, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 915, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 916, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 949, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 950, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 949, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 950, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH comprising the VH having the amino acid sequence of SEQ ID NO: 983, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 984, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 983, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 984, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1017, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1018, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1017, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1018, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1051, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1052, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1051, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1052, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1085, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1086, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1085, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1086, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1119, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1120, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1119, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1120, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1153, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1154, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1153, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1154, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1187, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1188, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1187, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1188, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1221, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1222, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1221, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1222, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1255, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1256, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1255, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1256, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1289, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1290, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1289, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1290, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1323, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1324, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1323, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1324, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1357, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1358, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1357, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1358, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1391, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1392, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1391, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1392, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1425, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1426, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1425, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1426, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1459, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1460, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1459, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1460, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1493, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1494, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1493, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1494, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1527, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1528, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1527, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1528, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1561, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1562, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1561, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1562, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1595, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1596, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1595, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1596, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1629, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1630, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1629, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1630, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1663, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1664, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1663, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1664, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1697, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1698, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1697, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1698, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1731, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1732, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1731, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1732, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1765, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1766, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1765, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1766, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1799, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1800, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1799, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1800, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1833, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1834, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1833, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1834, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1867, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1868, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1867, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1868, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1901, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1902, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1901, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1902, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1935, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1936, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1935, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1936, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1969, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 1970, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 1969, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1970, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2003, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGV9 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2004, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGV9 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2003, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2004, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In some embodiments, the TRGV9 antibody is a multispecific antibody. In some embodiments, the TRGV9 antibody is a bispecific antibody. In some embodiments, the TRGV9 antibody is a trispecific antibody. In some embodiments, the TRGV9 antibody is a tetraspecific antibody.

In one aspect, the VH CDR1 having the amino acid sequence of SEQ ID NO: 25, wherein the third amino acid is A or T; VH CDR2 having the amino acid sequence of SEQ ID NO: 26, wherein the second amino acid is G or S, the fourth amino acid is S or T, and the sixth amino acid is D or S; and the first amino acid is A, G, or V, the second amino acid is K, R, or T, the fourth amino acid is D, H, or G, and the fifth amino acid is D, E, or V, and six The amino acid sequence of SEQ ID NO: 27, wherein the ninth amino acid is F, L, or Y, the eighth amino acid is A, G, P, or V, the ninth amino acid is F or L, and the third amino acid is V or I. Provided herein are antibodies that bind to TRGV9, comprising a VH CDR3 having In one aspect, the VL CDR1 having the amino acid sequence of SEQ ID NO: 28, wherein the third amino acid is I or V and the fourth amino acid is R or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 29, wherein the first amino acid is A, P, or S; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 30, wherein the third amino acid is F or Y. In one aspect, the VH CDR1 having the amino acid sequence of SEQ ID NO: 25, wherein the third amino acid is A or T; VH CDR2 having the amino acid sequence of SEQ ID NO: 26, wherein the second amino acid is G or S, the fourth amino acid is S or T, and the sixth amino acid is D or S; and the first amino acid is A, G, or V, the second amino acid is K, R, or T, the fourth amino acid is D, H, or G, and the fifth amino acid is D, E, or V, and six The amino acid sequence of SEQ ID NO: 27, wherein the ninth amino acid is F, L, or Y, the eighth amino acid is A, G, P, or V, the ninth amino acid is F or L, and the third amino acid is V or I. VH CDR3 with; VL CDR1 having the amino acid sequence of SEQ ID NO: 28, wherein the third amino acid is I or V and the fourth amino acid is R or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 29, wherein the first amino acid is A, P, or S; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 30, wherein the third amino acid is F or Y.

In one aspect, the VH CDR1 having the amino acid sequence of SEQ ID NO: 93; VH CDR2 having the amino acid sequence of SEQ ID NO: 94; and a VH CDR3 having the amino acid sequence of SEQ ID NO:95. In one aspect, the VL CDR1 having the amino acid sequence of SEQ ID NO: 96; VL CDR2 having the amino acid sequence of SEQ ID NO: 97; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 98, wherein the third amino acid is A or Y, the fourth is N or S, the sixth is F or W, and the eighth is R or W. Antibodies that bind are provided herein. In one aspect, the VH CDR1 having the amino acid sequence of SEQ ID NO: 93; VH CDR2 having the amino acid sequence of SEQ ID NO: 94; and VH CDR3 having the amino acid sequence of SEQ ID NO: 95; VL CDR1 having the amino acid sequence of SEQ ID NO: 96; VL CDR2 having the amino acid sequence of SEQ ID NO: 97; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 98, wherein the third amino acid is A or Y, the fourth is N or S, the sixth is F or W, and the eighth is R or W. Antibodies that bind are provided herein.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 127, wherein the first amino acid is G or R, the fourth amino acid is F or L, and the fifth amino acid is R or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 128, wherein the second amino acid is S or T, the third amino acid is S or T, the fourth amino acid is S or T, and the sixth amino acid is G, S, or Y; the fourth amino acid is L or R, the sixth amino acid is I or V, the seventh amino acid is A, G, or R, the eighth amino acid is G or B, and the ninth amino acid is A, T, or V; , wherein the 10th amino acid is D or G, the 11th amino acid is D or Y, and the 16th amino acid is L or M; Provided. In one aspect, the VL CDR1 having the amino acid sequence of SEQ ID NO: 130; VL CDR2 having the amino acid sequence of SEQ ID NO: 131; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 132; provided herein is an antibody that binds to TRGV9. In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 127, wherein the first amino acid is G or R, the fourth amino acid is F or L, and the fifth amino acid is R or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 128, wherein the second amino acid is S or T, the third amino acid is S or T, the fourth amino acid is S or T, and the sixth amino acid is G, S, or Y; the fourth amino acid is L or R, the sixth amino acid is I or V, the seventh amino acid is A, G, or R, the eighth amino acid is G or B, and the ninth amino acid is A, T, or V; , VH CDR3 having the amino acid sequence of SEQ ID NO: 129, wherein the 10th amino acid is D or G, the 11th amino acid is D or Y, and the 16th amino acid is L or M; VL CDR1 having the amino acid sequence of SEQ ID NO: 130; VL CDR2 having the amino acid sequence of SEQ ID NO: 131; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 132; provided herein is an antibody that binds to TRGV9.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 297, wherein the fifth amino acid is N or S and the sixth amino acid is N or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 298; The fourth amino acid is R or V, the sixth amino acid is I or V, the seventh amino acid is G or T, the eighth amino acid is G or T, the twelfth amino acid is S or Y, and the 14th amino acid is A Or G, an antibody that binds to TRGV9 comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 299. In one aspect, the VL CDR1 having the amino acid sequence of SEQ ID NO: 300, wherein the fourth amino acid is A or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 301; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 302; provided herein is an antibody that binds to TRGV9. In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 297, wherein the fifth amino acid is N or S and the sixth amino acid is N or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 298; The fourth amino acid is R or V, the sixth amino acid is I or V, the seventh amino acid is G or T, the eighth amino acid is G or T, the twelfth amino acid is S or Y, and the 14th amino acid is A or VH CDR3 having the amino acid sequence of SEQ ID NO: 299, which is G; VL CDR1 having the amino acid sequence of SEQ ID NO: 300, wherein the fourth amino acid is A or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 301; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 302; provided herein is an antibody that binds to TRGV9.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 569; VH CDR2 having the amino acid sequence of SEQ ID NO: 570; and a VH CDR3 having the amino acid sequence of SEQ ID NO: 571, wherein an antibody that binds to TRGV9 is provided herein. In one embodiment, the second amino acid is G or N, the third amino acid is I or V, the fourth amino acid is A or S, the fifth amino acid is S, or no amino acid is added at the fifth position and the sequence is VL CDR1 having the amino acid sequence of SEQ ID NO: 572, continuing to the sixth position; VL CDR2 having the amino acid sequence of SEQ ID NO: 573, wherein the first amino acid is A or G and the third amino acid is C or S; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 574, wherein the second amino acid is K or Q, the fourth amino acid is G or N, the sixth amino acid is A or S, and the ninth amino acid is Y or W. , antibodies that bind to TRGV9 are provided herein. In one aspect, the VH CDR1 having the amino acid sequence of SEQ ID NO: 569; VH CDR2 having the amino acid sequence of SEQ ID NO: 570; VH CDR3 having the amino acid sequence of SEQ ID NO: 571; The second amino acid is G or N, the third amino acid is I or V, the fourth amino acid is A or S, the fifth amino acid is S, or no amino acid is added at the fifth position and the sequence extends through to the sixth position. continued, VL CDR1 having the amino acid sequence of SEQ ID NO: 572; VL CDR2 having the amino acid sequence of SEQ ID NO: 573, wherein the first amino acid is A or G and the third amino acid is C or S; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 574, wherein the second amino acid is K or Q, the fourth amino acid is G or N, the sixth amino acid is A or S, and the ninth amino acid is Y or W. , antibodies that bind to TRGV9 are provided herein.

In one aspect, the VH CDR1 having the amino acid sequence of SEQ ID NO: 739; VH CDR2 having the amino acid sequence of SEQ ID NO: 740; and the third amino acid is D or E, the fourth amino acid is I or L, the sixth amino acid is I or V, the 11th amino acid is M or Y, the 12th amino acid is D or Y, and the 13th amino acid is Q or Provided herein is an antibody that binds TRGV9 comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 741, wherein the amino acid sequence is Y and the 14th amino acid is D or Y. In one aspect, a VL CDR1 having the amino acid sequence of SEQ ID NO: 742, wherein the third amino acid is F or V and the sixth amino acid is N or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 743; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 744. In one aspect, the VH CDR1 having the amino acid sequence of SEQ ID NO: 739; VH CDR2 having the amino acid sequence of SEQ ID NO: 740; and the third amino acid is D or E, the fourth amino acid is I or L, the sixth amino acid is I or V, the 11th amino acid is M or Y, the 12th amino acid is D or Y, and the 13th amino acid is Q or Y, and the 14th amino acid is D or Y, VH CDR3 having the amino acid sequence of SEQ ID NO: 741; VL CDR1 having the amino acid sequence of SEQ ID NO: 742, wherein the third amino acid is F or V and the sixth amino acid is N or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 743; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 744.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 1181, wherein the fifth amino acid is G or S and the sixth amino acid is A or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 1182, wherein the third amino acid is S or T; The amino acid of SEQ ID NO: 1183, wherein the sixth amino acid is I or M, the seventh amino acid is L or V, the eighth amino acid is A or S, the ninth amino acid is P or T, and the 11th amino acid is K or R. Antibodies that bind TRGV9 comprising a VH CDR3 having the sequence are provided herein. In one embodiment, a VL CDR1 having the amino acid sequence of SEQ ID NO: 1184, wherein the fifth amino acid is D or N and the eighth amino acid is A or D; VL CDR2 having the amino acid sequence of SEQ ID NO: 1185; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 1186. In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 1181, wherein the fifth amino acid is G or S and the sixth amino acid is A or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 1182, wherein the third amino acid is S or T; The amino acid of SEQ ID NO: 1183, wherein the sixth amino acid is I or M, the seventh amino acid is L or V, the eighth amino acid is A or S, the ninth amino acid is P or T, and the 11th amino acid is K or R. VH CDR3 having the sequence; VL CDR1 having the amino acid sequence of SEQ ID NO: 1184, wherein the fifth amino acid is D or N and the eighth amino acid is A or D; VL CDR2 having the amino acid sequence of SEQ ID NO: 1185; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 1186.

In one aspect, provided herein are antibodies that bind TRDV2. In some embodiments, an antibody comprises a heavy chain variable region and a light chain variable region. In some embodiments, the TRDV2 antibody is a humanized antibody.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2007, 2008, and 2009, respectively, and (ii) amino acids of SEQ ID NOs: 2010, 2011, and 2012, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2013, 2014, and 2015, respectively, and (ii) amino acids of SEQ ID NOs: 2016, 2017, and 2018, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2019, 2020, and 2021, respectively, and (ii) amino acids of SEQ ID NOs: 2022, 2023, and 2024, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2025, 2026, and 2027, respectively, and (ii) amino acids of SEQ ID NOs: 2028, 2029, and 2030, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2031, 2032, and 2033, respectively, and (ii) amino acids of SEQ ID NOs: 2034, 2035, and 2036, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2037, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2038, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2037. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2038. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2037, and a VL having the amino acid sequence of SEQ ID NO: 2038. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2039. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2040. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2039 and a light chain having the amino acid sequence of SEQ ID NO: 2040. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2037. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2038. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2037, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2038. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2039. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2040. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2039, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2040. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2041, 2042, and 2043, respectively, and (ii) amino acids of SEQ ID NOs: 2044, 2045, and 2046, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2047, 2048, and 2049, respectively, and (ii) amino acids of SEQ ID NOs: 2050, 2051, and 2052, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2053, 2054, and 2055, respectively, and (ii) amino acids of SEQ ID NOs: 2056, 2057, and 2058, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2059, 2060, and 2061, respectively, and (ii) amino acids of SEQ ID NOs: 2062, 2063, and 2064, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2065, 2066, and 2067, respectively, and (ii) amino acids of SEQ ID NOs: 2068, 2069, and 2070, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2071, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2072, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2071. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2072. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2071, and a VL having the amino acid sequence of SEQ ID NO: 2072. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2073. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2074. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2073 and a light chain having the amino acid sequence of SEQ ID NO: 2074. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2071. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2072. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2071, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2072. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2073. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2074. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2073, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2074. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2075, 2076, and 2077, respectively, and (ii) amino acids of SEQ ID NOs: 2078, 2079, and 2080, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2081, 2082, and 2083, respectively, and (ii) amino acids of SEQ ID NOs: 2084, 2085, and 2086, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2087, 2088, and 2089, respectively, and (ii) amino acids of SEQ ID NOs: 2090, 2091, and 2092, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2093, 2094, and 2095, respectively, and (ii) amino acids of SEQ ID NOs: 2096, 2097, and 2098, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2099, 2100, and 2101, respectively, and (ii) amino acids of SEQ ID NOs: 2102, 2103, and 2104, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2105, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2106, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2105. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2106. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2105, and a VL having the amino acid sequence of SEQ ID NO: 2106. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2107. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2108. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2107 and a light chain having the amino acid sequence of SEQ ID NO: 2108. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2105. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2106. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2105, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2106. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2107. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2108. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2107, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2108. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2109, 2110, and 2111, respectively, and (ii) amino acids of SEQ ID NOs: 2112, 2113, and 2114, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2115, 2116, and 2117, respectively, and (ii) amino acids of SEQ ID NOs: 2118, 2119, and 2120, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2121, 2122, and 2123, respectively, and (ii) amino acids of SEQ ID NOs: 2124, 2125, and 2126, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2127, 2128, and 2129, respectively, and (ii) amino acids of SEQ ID NOs: 2130, 2131, and 2132, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2133, 2134, and 2135, respectively, and (ii) amino acids of SEQ ID NOs: 2136, 2137, and 2138, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2139, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2140, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2139. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2140. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2139, and a VL having the amino acid sequence of SEQ ID NO: 2140. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2141. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2142. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2141 and a light chain having the amino acid sequence of SEQ ID NO: 2142. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2139. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2140. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2139, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2140. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2141. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2142. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2141 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2142 Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2143, 2144, and 2145, respectively, and (ii) amino acids of SEQ ID NOs: 2146, 2147, and 2148, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2149, 2150, and 2151, respectively, and (ii) amino acids of SEQ ID NOs: 2152, 2153, and 2154, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2155, 2156, and 2157, respectively, and (ii) amino acids of SEQ ID NOs: 2158, 2159, and 2160, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2161, 2162, and 2163, respectively, and (ii) amino acids of SEQ ID NOs: 2164, 2165, and 2166, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2167, 2168, and 2169, respectively, and (ii) amino acids of SEQ ID NOs: 2170, 2171, and 2172, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2173, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2174, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2173. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2174. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2173, and a VL having the amino acid sequence of SEQ ID NO: 2174. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2175. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2176. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2175 and a light chain having the amino acid sequence of SEQ ID NO: 2176. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2173. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2174. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2173, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2174. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2175. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2176. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2175, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2176. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2177, 2178, and 2179, respectively, and (ii) amino acids of SEQ ID NOs: 2180, 2181, and 2182, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2183, 2184, and 2185, respectively, and (ii) amino acids of SEQ ID NOs: 2186, 2187, and 2188, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2189, 2190, and 2191, respectively, and (ii) amino acids of SEQ ID NOs: 2192, 2193, and 2194, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2195, 2196, and 2197, respectively, and (ii) amino acids of SEQ ID NOs: 2198, 2199, and 2200, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2201, 2202, and 2203, respectively, and (ii) amino acids of SEQ ID NOs: 2204, 2205, and 2206, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2207, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2208, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2207. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2208. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2207, and a VL having the amino acid sequence of SEQ ID NO: 2208. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2209. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2210. In one aspect provided herein is an antibody that binds to TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2209 and a light chain having the amino acid sequence of SEQ ID NO: 2210. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2207. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2208. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2207, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2208. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2209. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2210. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2209, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2210. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2211, 2212, and 2213, respectively, and (ii) amino acids of SEQ ID NOs: 2214, 2215, and 2216, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2217, 2218, and 2219, respectively, and (ii) amino acids of SEQ ID NOs: 2220, 2221, and 2222, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2223, 2224, and 2225, respectively, and (ii) amino acids of SEQ ID NOs: 2226, 2227, and 2228, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2229, 2230, and 2231, respectively, and (ii) amino acids of SEQ ID NOs: 2232, 2233, and 2234, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2235, 2236, and 2237, respectively, and (ii) amino acids of SEQ ID NOs: 2238, 2239, and 2240, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2241, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2242, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2241. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2242. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2241, and a VL having the amino acid sequence of SEQ ID NO: 2242. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2243. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2244. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2243 and a light chain having the amino acid sequence of SEQ ID NO: 2244. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2241. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2242. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2241, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2242. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2243. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2244. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2243, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2244. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2245, 2246, and 2247, respectively, and (ii) amino acids of SEQ ID NOs: 2248, 2249, and 2250, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2251, 2252, and 2253, respectively, and (ii) amino acids of SEQ ID NOs: 2254, 2255, and 2256, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2257, 2258, and 2259, respectively, and (ii) amino acids of SEQ ID NOs: 2260, 2261, and 2262, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2263, 2264, and 2265, respectively, and (ii) amino acids of SEQ ID NOs: 2266, 2267, and 2268, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2269, 2270, and 2271, respectively, and (ii) amino acids of SEQ ID NOs: 2272, 2273, and 2274, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2275, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2276, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2275. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2276. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2275, and a VL having the amino acid sequence of SEQ ID NO: 2276. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2277. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2278. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2277 and a light chain having the amino acid sequence of SEQ ID NO: 2278. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2275. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2276. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2275, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2276. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2277. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2278. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2277, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2278. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2279, 2280, and 2281, respectively, and (ii) amino acids of SEQ ID NOs: 2282, 2283, and 2284, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2285, 2286, and 2287, respectively, and (ii) amino acids of SEQ ID NOs: 2288, 2289, and 2290, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2291, 2292, and 2293, respectively, and (ii) amino acids of SEQ ID NOs: 2294, 2295, and 2296, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2297, 2298, and 2299, respectively, and (ii) amino acids of SEQ ID NOs: 2300, 2301, and 2302, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2303, 2304, and 2305, respectively, and (ii) amino acids of SEQ ID NOs: 2306, 2307, and 2308, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2309, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2310, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2309. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2310. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2309, and a VL having the amino acid sequence of SEQ ID NO: 2310. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2311. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2312. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2311 and a light chain having the amino acid sequence of SEQ ID NO: 2312. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2309. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2310. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2309, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2310. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2311. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2312. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2311 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2312 Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2313, 2314, and 2315, respectively, and (ii) amino acids of SEQ ID NOs: 2316, 2317, and 2318, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2319, 2320, and 2321, respectively, and (ii) amino acids of SEQ ID NOs: 2322, 2323, and 2324, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2325, 2326, and 2327, respectively, and (ii) amino acids of SEQ ID NOs: 2328, 2329, and 2330, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2331, 2332, and 2333, respectively, and (ii) amino acids of SEQ ID NOs: 2334, 2335, and 2336, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2337, 2338, and 2339, respectively, and (ii) amino acids of SEQ ID NOs: 2340, 2341, and 2342, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2343, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2344, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2343. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2344. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2343, and a VL having the amino acid sequence of SEQ ID NO: 2344. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2345. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2346. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2345 and a light chain having the amino acid sequence of SEQ ID NO: 2346. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2343. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2344. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2343, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2344. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2345. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2346. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2345, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2346. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2347, 2348, and 2349, respectively, and (ii) amino acids of SEQ ID NOs: 2350, 2351, and 2352, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2353, 2354, and 2355, respectively, and (ii) amino acids of SEQ ID NOs: 2356, 2357, and 2358, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2359, 2360, and 2361, respectively, and (ii) amino acids of SEQ ID NOs: 2362, 2363, and 2364, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2365, 2366, and 2367, respectively, and (ii) amino acids of SEQ ID NOs: 2368, 2369, and 2370, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2371, 2372, and 2373, respectively, and (ii) amino acids of SEQ ID NOs: 2374, 2375, and 2376, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2377, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2378, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2377. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2378. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2377, and a VL having the amino acid sequence of SEQ ID NO: 2378. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2379. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2380. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2379 and a light chain having the amino acid sequence of SEQ ID NO: 2380. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2377. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2378. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2377, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2378. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2379. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2380. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2379, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2380. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2381, 2382, and 2383, respectively, and (ii) amino acids of SEQ ID NOs: 2384, 2385, and 2386, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2387, 2388, and 2389, respectively, and (ii) amino acids of SEQ ID NOs: 2390, 2391, and 2392, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2393, 2394, and 2395, respectively, and (ii) amino acids of SEQ ID NOs: 2396, 2397, and 2398, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2399, 2400, and 2401, respectively, and (ii) amino acids of SEQ ID NOs: 2402, 2403, and 2404, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2405, 2406, and 2407, respectively, and (ii) amino acids of SEQ ID NOs: 2408, 2409, and 2410, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2411, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2412, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2411. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2412. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2411, and a VL having the amino acid sequence of SEQ ID NO: 2412. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2413. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2414. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2413 and a light chain having the amino acid sequence of SEQ ID NO: 2414. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2411. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2412. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2411, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2412. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2413. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2414. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2413, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2414. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2415, 2416, and 2417, respectively, and (ii) amino acids of SEQ ID NOs: 2418, 2419, and 2420, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2421, 2422, and 2423, respectively, and (ii) amino acids of SEQ ID NOs: 2424, 2425, and 2426, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2427, 2428, and 2429, respectively, and (ii) amino acids of SEQ ID NOs: 2430, 2431, and 2432, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2433, 2434, and 2435, respectively, and (ii) amino acids of SEQ ID NOs: 2436, 2437, and 2438, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2439, 2440, and 2441, respectively, and (ii) amino acids of SEQ ID NOs: 2442, 2443, and 2444, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2445, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2446, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2445. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2446. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2445, and a VL having the amino acid sequence of SEQ ID NO: 2446. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2447. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2448. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2447 and a light chain having the amino acid sequence of SEQ ID NO: 2448. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2445. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2446. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2445, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2446. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2447. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2448. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2447, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2448. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2449, 2450, and 2451, respectively, and (ii) amino acids of SEQ ID NOs: 2452, 2453, and 2454, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2455, 2456, and 2457, respectively, and (ii) amino acids of SEQ ID NOs: 2458, 2459, and 2460, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2461, 2462, and 2463, respectively, and (ii) amino acids of SEQ ID NOs: 2464, 2465, and 2466, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2467, 2468, and 2469, respectively, and (ii) amino acids of SEQ ID NOs: 2470, 2471, and 2472, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2473, 2474, and 2475, respectively, and (ii) amino acids of SEQ ID NOs: 2476, 2477, and 2478, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2479, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2480, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2479. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2480. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2479, and a VL having the amino acid sequence of SEQ ID NO: 2480. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2481. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2482. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2481 and a light chain having the amino acid sequence of SEQ ID NO: 2482. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2479. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2480. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2479, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2480. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2481. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2482. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2481 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2482. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2483, 2484, and 2485, respectively, and (ii) amino acids of SEQ ID NOs: 2486, 2487, and 2488, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2489, 2490, and 2491, respectively, and (ii) amino acids of SEQ ID NOs: 2492, 2493, and 2494, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2495, 2496, and 2497, respectively, and (ii) amino acids of SEQ ID NOs: 2498, 2499, and 2500, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2501, 2502, and 2503, respectively, and (ii) amino acids of SEQ ID NOs: 2504, 2505, and 2506, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2507, 2508, and 2509, respectively, and (ii) amino acids of SEQ ID NOs: 2510, 2511, and 2512, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2513, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2514, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2513. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2514. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2513, and a VL having the amino acid sequence of SEQ ID NO: 2514. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2515. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2516. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2515 and a light chain having the amino acid sequence of SEQ ID NO: 2516. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2513. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2514. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2513, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2514. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2515. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2516. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2515, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2516. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2517, 2518, and 2519, respectively, and (ii) amino acids of SEQ ID NOs: 2520, 2521, and 2522, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2523, 2524, and 2525, respectively, and (ii) amino acids of SEQ ID NOs: 2526, 2527, and 2528, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2529, 2530, and 2531, respectively, and (ii) amino acids of SEQ ID NOs: 2532, 2533, and 2534, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2535, 2536, and 2537, respectively, and (ii) amino acids of SEQ ID NOs: 2538, 2539, and 2540, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2541, 2542, and 2543, respectively, and (ii) amino acids of SEQ ID NOs: 2544, 2545, and 2546, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2547, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2548, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2547. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2548. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2547, and a VL having the amino acid sequence of SEQ ID NO: 2548. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2549. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2550. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2549 and a light chain having the amino acid sequence of SEQ ID NO: 2550. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2547. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2548. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2547, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2548. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2549. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2550. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2549, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2550. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2551, 2552, and 2553, respectively, and (ii) amino acids of SEQ ID NOs: 2554, 2555, and 2556, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2557, 2558, and 2559, respectively, and (ii) amino acids of SEQ ID NOs: 2560, 2561, and 2562, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2563, 2564, and 2565, respectively, and (ii) amino acids of SEQ ID NOs: 2566, 2567, and 2568, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2569, 2570, and 2571, respectively, and (ii) amino acids of SEQ ID NOs: 2572, 2573, and 2574, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2575, 2576, and 2577, respectively, and (ii) amino acids of SEQ ID NOs: 2578, 2579, and 2580, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2581, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2582, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2581. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2582. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2581, and a VL having the amino acid sequence of SEQ ID NO: 2582. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2583. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2584. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2583 and a light chain having the amino acid sequence of SEQ ID NO: 2584. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2581. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2582. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2581, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2582. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2583. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2584. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2583, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2584. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2585, 2586, and 2587, respectively, and (ii) amino acids of SEQ ID NOs: 2588, 2589, and 2590, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2591, 2592, and 2593, respectively, and (ii) amino acids of SEQ ID NOs: 2594, 2595, and 2596, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2597, 2598, and 2599, respectively, and (ii) amino acids of SEQ ID NOs: 2600, 2601, and 2602, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2603, 2604, and 2605, respectively, and (ii) amino acids of SEQ ID NOs: 2606, 2607, and 2608, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2609, 2610, and 2611, respectively, and (ii) amino acids of SEQ ID NOs: 2612, 2613, and 2614, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2615, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2616, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2615. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2616. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2615, and a VL having the amino acid sequence of SEQ ID NO: 2616. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2617. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2618. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2617 and a light chain having the amino acid sequence of SEQ ID NO: 2618. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2615. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2616. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2615, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2616. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2617. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2618. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2617 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2618 Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2619, 2620, and 2621, respectively, and (ii) amino acids of SEQ ID NOs: 2622, 2623, and 2624, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2625, 2626, and 2627, respectively, and (ii) amino acids of SEQ ID NOs: 2628, 2629, and 2630, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2631, 2632, and 2633, respectively, and (ii) amino acids of SEQ ID NOs: 2634, 2635, and 2636, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2637, 2638, and 2639, respectively, and (ii) amino acids of SEQ ID NOs: 2640, 2641, and 2642, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2643, 2644, and 2645, respectively, and (ii) amino acids of SEQ ID NOs: 2646, 2647, and 2648, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2649, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2650, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2649. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2650. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2649, and a VL having the amino acid sequence of SEQ ID NO: 2650. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2651. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2652. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2651 and a light chain having the amino acid sequence of SEQ ID NO: 2652. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2649. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2650. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2649, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2650. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2651. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2652. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2651 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2652 Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2653, 2654, and 2655, respectively, and (ii) amino acids of SEQ ID NOs: 2656, 2657, and 2658, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2659, 2660, and 2661, respectively, and (ii) amino acids of SEQ ID NOs: 2662, 2663, and 2664, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2665, 2666, and 2667, respectively, and (ii) amino acids of SEQ ID NOs: 2668, 2669, and 2670, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2671, 2672, and 2673, respectively, and (ii) amino acids of SEQ ID NOs: 2674, 2675, and 2676, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2677, 2678, and 2679, respectively, and (ii) amino acids of SEQ ID NOs: 2680, 2681, and 2682, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2683, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2684, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2683. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2684. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2683, and a VL having the amino acid sequence of SEQ ID NO: 2684. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2685. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2686. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2685 and a light chain having the amino acid sequence of SEQ ID NO: 2686. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2683. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2684. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2683, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2684. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2685. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2686. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2685, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 266. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2687, 2688, and 2689, respectively, and (ii) amino acids of SEQ ID NOs: 2690, 2691, and 2692, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2693, 2694, and 2695, respectively, and (ii) amino acids of SEQ ID NOs: 2696, 2697, and 2698, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2699, 2700, and 2701, respectively, and (ii) amino acids of SEQ ID NOs: 2702, 2703, and 2704, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2705, 2706, and 2707, respectively, and (ii) amino acids of SEQ ID NOs: 2708, 2709, and 2710, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2711, 2712, and 2713, respectively, and (ii) amino acids of SEQ ID NOs: 2714, 2715, and 2716, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2717, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2718, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2717. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2718. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2717, and a VL having the amino acid sequence of SEQ ID NO: 2718. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2719. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2720. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2719 and a light chain having the amino acid sequence of SEQ ID NO: 2720. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2717. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2718. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2717, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2718. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2719. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2720. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2719, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2720. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2721, 2722, and 2723, respectively, and (ii) amino acids of SEQ ID NOs: 2724, 2725, and 2726, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2727, 2728, and 2729, respectively, and (ii) amino acids of SEQ ID NOs: 2730, 2731, and 2732, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2733, 2734, and 2735, respectively, and (ii) amino acids of SEQ ID NOs: 2736, 2737, and 2738, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2739, 2740, and 2741, respectively, and (ii) amino acids of SEQ ID NOs: 2742, 2743, and 2744, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2745, 2746, and 2747, respectively, and (ii) amino acids of SEQ ID NOs: 2748, 2749, and 2750, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2751, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2752, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2751. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2752. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2751, and a VL having the amino acid sequence of SEQ ID NO: 2752. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2753. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2754. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2753 and a light chain having the amino acid sequence of SEQ ID NO: 2754. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2751. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2752. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2751, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2752. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2753. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2754. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2753, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2754. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2755, 2756, and 2757, respectively, and (ii) amino acids of SEQ ID NOs: 2758, 2759, and 2760, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2761, 2762, and 2763, respectively, and (ii) amino acids of SEQ ID NOs: 2764, 2765, and 2766, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2767, 2768, and 2769, respectively, and (ii) amino acids of SEQ ID NOs: 2770, 2771, and 2772, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2773, 2774, and 2775, respectively, and (ii) amino acids of SEQ ID NOs: 2776, 2777, and 2778, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2779, 2780, and 2781, respectively, and (ii) amino acids of SEQ ID NOs: 2782, 2783, and 2784, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2785, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2786, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2785. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2786. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2785, and a VL having the amino acid sequence of SEQ ID NO: 2786. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2787. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2788. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2787 and a light chain having the amino acid sequence of SEQ ID NO: 2788. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2785. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2786. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2785, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2786. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2787. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2788. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2787, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2788. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2789, 2790, and 2791, respectively, and (ii) amino acids of SEQ ID NOs: 2792, 2793, and 2794, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2795, 2796, and 2797, respectively, and (ii) amino acids of SEQ ID NOs: 2798, 2799, and 2800, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2801, 2802, and 2803, respectively, and (ii) amino acids of SEQ ID NOs: 2804, 2805, and 2806, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2807, 2808, and 2809, respectively, and (ii) amino acids of SEQ ID NOs: 2810, 2811, and 2812, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2813, 2814, and 2815, respectively, and (ii) amino acids of SEQ ID NOs: 2816, 2817, and 2818, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2819, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2820, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2819. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2820. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2819, and a VL having the amino acid sequence of SEQ ID NO: 2820. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2821. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2822. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2821 and a light chain having the amino acid sequence of SEQ ID NO: 2822. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2819. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2820. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2819, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2820. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2821. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2822. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2821, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2822. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2823, 2824, and 2825, respectively, and (ii) amino acids of SEQ ID NOs: 2826, 2827, and 2828, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2829, 2830, and 2831, respectively, and (ii) amino acids of SEQ ID NOs: 2832, 2833, and 2834, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2835, 2836, and 2837, respectively, and (ii) amino acids of SEQ ID NOs: 2838, 2839, and 2840, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2841, 2842, and 2843, respectively, and (ii) amino acids of SEQ ID NOs: 2844, 2845, and 2846, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2847, 2848, and 2849, respectively, and (ii) amino acids of SEQ ID NOs: 2850, 2851, and 2852, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2853, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2854, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2853. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2854. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2853, and a VL having the amino acid sequence of SEQ ID NO: 2854. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2855. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2856. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2855 and a light chain having the amino acid sequence of SEQ ID NO: 2856. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2853. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2854. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2853, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2854. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2855. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2856. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2855, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2856. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2857, 2858, and 2859, respectively, and (ii) amino acids of SEQ ID NOs: 2860, 2861, and 2862, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2863, 2864, and 2865, respectively, and (ii) amino acids of SEQ ID NOs: 2866, 2867, and 2868, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2869, 2870, and 2871, respectively, and (ii) amino acids of SEQ ID NOs: 2872, 2873, and 2874, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2875, 2876, and 2877, respectively, and (ii) amino acids of SEQ ID NOs: 2878, 2879, and 2880, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2881, 2882, and 2883, respectively, and (ii) amino acids of SEQ ID NOs: 2884, 2885, and 2886, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2887, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2888, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2887. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2888. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2887, and a VL having the amino acid sequence of SEQ ID NO: 2888. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2889. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2890. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2889 and a light chain having the amino acid sequence of SEQ ID NO: 2890. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2887. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2888. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2887, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2888. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2889. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2890. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2889, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2890. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2891, 2892, and 2893, respectively, and (ii) amino acids of SEQ ID NOs: 2894, 2895, and 2896, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2897, 2898, and 2899, respectively, and (ii) amino acids of SEQ ID NOs: 2900, 2901, and 2902, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2903, 2904, and 2905, respectively, and (ii) amino acids of SEQ ID NOs: 2906, 2907, and 2908, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2909, 2910, and 2911, respectively, and (ii) amino acids of SEQ ID NOs: 2912, 2913, and 2914, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2915, 2916, and 2917, respectively, and (ii) amino acids of SEQ ID NOs: 2918, 2919, and 2920, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2921, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2922, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2921. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2922. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2921, and a VL having the amino acid sequence of SEQ ID NO: 2922. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2923. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2924. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2923 and a light chain having the amino acid sequence of SEQ ID NO: 2924. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2921. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2922. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2921, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2922. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2923. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2924. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2923, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2924. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2925, 2926, and 2927, respectively, and (ii) amino acids of SEQ ID NOs: 2928, 2929, and 2930, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2931, 2932, and 2933, respectively, and (ii) amino acids of SEQ ID NOs: 2934, 2935, and 2936, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2937, 2938, and 2939, respectively, and (ii) amino acids of SEQ ID NOs: 2940, 2941, and 2942, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2943, 2944, and 2945, respectively, and (ii) amino acids of SEQ ID NOs: 2946, 2947, and 2948, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2949, 2950, and 2951, respectively, and (ii) amino acids of SEQ ID NOs: 2952, 2953, and 2954, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2955, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2956, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2955. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2956. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2955, and a VL having the amino acid sequence of SEQ ID NO: 2956. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2957. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2958. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2957 and a light chain having the amino acid sequence of SEQ ID NO: 2958. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2955. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2956. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2955, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2956. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2957. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2958. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2957, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2958. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2959, 2960, and 2961, respectively, and (ii) amino acids of SEQ ID NOs: 2962, 2963, and 2964, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2965, 2966, and 2967, respectively, and (ii) amino acids of SEQ ID NOs: 2968, 2969, and 2970, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2971, 2972, and 2973, respectively, and (ii) amino acids of SEQ ID NOs: 2974, 2975, and 2976, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2977, 2978, and 2979, respectively, and (ii) amino acids of SEQ ID NOs: 2980, 2981, and 2982, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2983, 2984, and 2985, respectively, and (ii) amino acids of SEQ ID NOs: 2986, 2987, and 2988, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 2989, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 2990, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2989. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 2990. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 2989, and a VL having the amino acid sequence of SEQ ID NO: 2990. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2991. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 2992. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 2991 and a light chain having the amino acid sequence of SEQ ID NO: 2992. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2989. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2990. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2989, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2990. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2991. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2992. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2991 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2992. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 2993, 2994, and 2995, respectively, and (ii) amino acids of SEQ ID NOs: 2996, 2997, and 2998, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 2999, 3000, and 3001, respectively, and (ii) amino acids of SEQ ID NOs: 3002, 3003, and 3004, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3005, 3006, and 3007, respectively, and (ii) amino acids of SEQ ID NOs: 3008, 3009, and 3010, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3011, 3012, and 3013, respectively, and (ii) amino acids of SEQ ID NOs: 3014, 3015, and 3016, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3017, 3018, and 3019, respectively, and (ii) amino acids of SEQ ID NOs: 3020, 3021, and 3022, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3023, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3024, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3023. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3024. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3023, and a VL having the amino acid sequence of SEQ ID NO: 3024. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3025. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3026. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3025 and a light chain having the amino acid sequence of SEQ ID NO: 3026. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3023. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3024. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3023, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3024. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3025. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3026. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3025 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3026 Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3027, 3028, and 3029, respectively, and (ii) amino acids of SEQ ID NOs: 3030, 3031, and 3032, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3033, 3034, and 3035, respectively, and (ii) amino acids of SEQ ID NOs: 3036, 3037, and 3038, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3039, 3040, and 3041, respectively, and (ii) amino acids of SEQ ID NOs: 3042, 3043, and 3044, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3045, 3046, and 3047, respectively, and (ii) amino acids of SEQ ID NOs: 3048, 3049, and 3050, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3051, 3052, and 3053, respectively, and (ii) amino acids of SEQ ID NOs: 3054, 3055, and 3056, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3057, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3058, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3057. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3058. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3057, and a VL having the amino acid sequence of SEQ ID NO: 3058. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3059. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3060. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3059 and a light chain having the amino acid sequence of SEQ ID NO: 3060. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3057. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3058. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3057, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3058. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3059. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3060. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3059, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3060. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3061, 3062, and 3063, respectively, and (ii) amino acids of SEQ ID NOs: 3064, 3065, and 3066, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3067, 3068, and 3069, respectively, and (ii) amino acids of SEQ ID NOs: 3070, 3071, and 3072, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3073, 3074, and 3075, respectively, and (ii) amino acids of SEQ ID NOs: 3076, 3077, and 3078, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3079, 3080, and 3081, respectively, and (ii) amino acids of SEQ ID NOs: 3082, 3083, and 3084, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3085, 3086, and 3087, respectively, and (ii) amino acids of SEQ ID NOs: 3088, 3089, and 3090, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3091, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3092, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3091. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3092. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3091, and a VL having the amino acid sequence of SEQ ID NO: 3092. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3093. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3094. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3093 and a light chain having the amino acid sequence of SEQ ID NO: 3094. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3091. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3092. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3091, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3092. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3093. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3094. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3093, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3094. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3095, 3096, and 3097, respectively, and (ii) amino acids of SEQ ID NOs: 3098, 3099, and 3100, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3101, 3102, and 3103, respectively, and (ii) amino acids of SEQ ID NOs: 3104, 3105, and 3106, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3107, 3108, and 3109, respectively, and (ii) amino acids of SEQ ID NOs: 3110, 3111, and 3112, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3113, 3114, and 3115, respectively, and (ii) amino acids of SEQ ID NOs: 3116, 3117, and 3118, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3119, 3120, and 3121, respectively, and (ii) amino acids of SEQ ID NOs: 3122, 3123, and 3124, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3125, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3126, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3125. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3126. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3125, and a VL having the amino acid sequence of SEQ ID NO: 3126. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3127. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3128. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3127 and a light chain having the amino acid sequence of SEQ ID NO: 3128. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3125. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3126. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3125, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3126. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3127. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3128. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3127, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3128. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3129, 3130, and 3131, respectively, and (ii) amino acids of SEQ ID NOs: 3132, 3133, and 3134, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3135, 3136, and 3137, respectively, and (ii) amino acids of SEQ ID NOs: 3138, 3139, and 3140, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3141, 3142, and 3143, respectively, and (ii) amino acids of SEQ ID NOs: 3144, 3145, and 3146, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3147, 3148, and 3149, respectively, and (ii) amino acids of SEQ ID NOs: 3150, 3151, and 3152, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3153, 3154, and 3155, respectively, and (ii) amino acids of SEQ ID NOs: 3156, 3157, and 3158, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3159, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3160, respectively. do. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3159. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3160. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3159, and a VL having the amino acid sequence of SEQ ID NO: 3160. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3161. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3162. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3161 and a light chain having the amino acid sequence of SEQ ID NO: 3162. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3159. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3160. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3159, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3160. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3161. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3162. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3161, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3162. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3163, 3164, and 3165, respectively, and (ii) amino acids of SEQ ID NOs: 3166, 3167, and 3168, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3169, 3170, and 3171, respectively, and (ii) amino acids of SEQ ID NOs: 3172, 3173, and 3174, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3175, 3176, and 3177, respectively, and (ii) amino acids of SEQ ID NOs: 3178, 3179, and 3180, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3181, 3182, and 3183, respectively, and (ii) amino acids of SEQ ID NOs: 3184, 3185, and 3186, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3187, 3188, and 3189, respectively, and (ii) amino acids of SEQ ID NOs: 3190, 3191, and 3192, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3193, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3194, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3193. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3194. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3193, and a VL having the amino acid sequence of SEQ ID NO: 3194. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3195. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3196. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3195 and a light chain having the amino acid sequence of SEQ ID NO: 3196. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3193. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3194. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3193, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3194. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3195. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3196. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3195 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3196 Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3197, 3198, and 3199, respectively, and (ii) amino acids of SEQ ID NOs: 3200, 3201, and 3202, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3203, 3204, and 3205, respectively, and (ii) amino acids of SEQ ID NOs: 3206, 3207, and 3208, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3209, 3210, and 3211, respectively, and (ii) amino acids of SEQ ID NOs: 3212, 3213, and 3214, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3215, 3216, and 3217, respectively, and (ii) amino acids of SEQ ID NOs: 3218, 3219, and 3220, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3221, 3222, and 3223, respectively, and (ii) amino acids of SEQ ID NOs: 3224, 3225, and 3226, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3227, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3228, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3227. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3228. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3227, and a VL having the amino acid sequence of SEQ ID NO: 3228. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3229. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3230. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3229 and a light chain having the amino acid sequence of SEQ ID NO: 3230. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3227. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3228. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3227, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3228. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3229. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3230. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3229, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3230. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3231, 3232, and 3233, respectively, and (ii) amino acids of SEQ ID NOs: 3234, 3235, and 3236, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3237, 3238, and 3239, respectively, and (ii) amino acids of SEQ ID NOs: 3240, 3241, and 3242, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3243, 3244, and 3245, respectively, and (ii) amino acids of SEQ ID NOs: 3246, 3247, and 3248, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3249, 3250, and 3251, respectively, and (ii) amino acids of SEQ ID NOs: 3252, 3253, and 3254, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3255, 3256, and 3257, respectively, and (ii) amino acids of SEQ ID NOs: 3258, 3259, and 3260, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3261, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3262, respectively. do. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3261. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3262. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3261, and a VL having the amino acid sequence of SEQ ID NO: 3262. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3263. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3264. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3263 and a light chain having the amino acid sequence of SEQ ID NO: 3264. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3261. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3262. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3261, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3262. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3263. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3264. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3263, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3264. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3265, 3266, and 3267, respectively, and (ii) amino acids of SEQ ID NOs: 3268, 3269, and 3270, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3271, 3272, and 3273, respectively, and (ii) amino acids of SEQ ID NOs: 3274, 3275, and 3276, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3277, 3278, and 3279, respectively, and (ii) amino acids of SEQ ID NOs: 3280, 3281, and 3282, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3283, 3284, and 3285, respectively, and (ii) amino acids of SEQ ID NOs: 3286, 3287, and 3288, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3289, 3290, and 3291, respectively, and (ii) amino acids of SEQ ID NOs: 3292, 3293, and 3294, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3295, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3296, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3295. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3296. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3295, and a VL having the amino acid sequence of SEQ ID NO: 3296. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3297. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3298. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3297 and a light chain having the amino acid sequence of SEQ ID NO: 3298. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3295. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3296. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3295, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3296. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3297. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3298. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3297, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3298. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3299, 3300, and 3301, respectively, and (ii) amino acids of SEQ ID NOs: 3302, 3303, and 3304, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3305, 3306, and 3307, respectively, and (ii) amino acids of SEQ ID NOs: 3308, 3309, and 3310, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3311, 3312, and 3313, respectively, and (ii) amino acids of SEQ ID NOs: 3314, 3315, and 3316, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3317, 3318, and 3319, respectively, and (ii) amino acids of SEQ ID NOs: 3320, 3321, and 3322, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3323, 3324, and 3325, respectively, and (ii) amino acids of SEQ ID NOs: 3326, 3327, and 3328, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3329, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3330, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3329. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3330. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3329, and a VL having the amino acid sequence of SEQ ID NO: 3330. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3331. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3332. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3331 and a light chain having the amino acid sequence of SEQ ID NO: 3332. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3329. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3330. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3329, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3330. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3331. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3332. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3331 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3332 Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3333, 3334, and 3335, respectively, and (ii) amino acids of SEQ ID NOs: 3336, 3337, and 3338, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3339, 3340, and 3341, respectively, and (ii) amino acids of SEQ ID NOs: 3342, 3343, and 3344, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3345, 3346, and 3347, respectively, and (ii) amino acids of SEQ ID NOs: 3348, 3349, and 3350, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3351, 3352, and 3353, respectively, and (ii) amino acids of SEQ ID NOs: 3354, 3355, and 3356, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3357, 3358, and 3359, respectively, and (ii) amino acids of SEQ ID NOs: 3360, 3361, and 3362, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3363, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3364, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3363. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3364. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3363, and a VL having the amino acid sequence of SEQ ID NO: 3364. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3365. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3366. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3365 and a light chain having the amino acid sequence of SEQ ID NO: 3366. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3363. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3364. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3363, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3364. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3365. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3366. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3365, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3366. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3367, 3368, and 3369, respectively, and (ii) amino acids of SEQ ID NOs: 3370, 3371, and 3372, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3373, 3374, and 3375, respectively, and (ii) amino acids of SEQ ID NOs: 3376, 3377, and 3378, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3379, 3380, and 3381, respectively, and (ii) amino acids of SEQ ID NOs: 3382, 3383, and 3384, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3385, 3386, and 3387, respectively, and (ii) amino acids of SEQ ID NOs: 3388, 3389, and 3390, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3391, 3392, and 3393, respectively, and (ii) amino acids of SEQ ID NOs: 3394, 3395, and 3396, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3397, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3398, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3397. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3398. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3397, and a VL having the amino acid sequence of SEQ ID NO: 3398. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3399. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3400. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3399 and a light chain having the amino acid sequence of SEQ ID NO: 3400. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3397. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3398. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3397, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3398. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3399. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3400. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3399, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3400. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3401, 3402, and 3403, respectively, and (ii) amino acids of SEQ ID NOs: 3404, 3405, and 3406, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3407, 3408, and 3409, respectively, and (ii) amino acids of SEQ ID NOs: 3410, 3411, and 3412, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3413, 3414, and 3415, respectively, and (ii) amino acids of SEQ ID NOs: 3416, 3417, and 3418, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3419, 3420, and 3421, respectively, and (ii) amino acids of SEQ ID NOs: 3422, 3423, and 3424, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3425, 3426, and 3427, respectively, and (ii) amino acids of SEQ ID NOs: 3428, 3429, and 3430, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3431, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3432, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3431. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3432. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3431, and a VL having the amino acid sequence of SEQ ID NO: 3432. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3433. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3434. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3433 and a light chain having the amino acid sequence of SEQ ID NO: 3434. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3431. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3432. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3431, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3432. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3433. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3434. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3433, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3434. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3435, 3436, and 3437, respectively, and (ii) amino acids of SEQ ID NOs: 3438, 3439, and 3440, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3441, 3442, and 3443, respectively, and (ii) amino acids of SEQ ID NOs: 3444, 3445, and 3446, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3447, 3448, and 3449, respectively, and (ii) amino acids of SEQ ID NOs: 3450, 3451, and 3452, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3453, 3454, and 3455, respectively, and (ii) amino acids of SEQ ID NOs: 3456, 3457, and 3458, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3459, 3460, and 3461, respectively, and (ii) amino acids of SEQ ID NOs: 3462, 3463, and 3464, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3465, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3466, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3465. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3466. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3465, and a VL having the amino acid sequence of SEQ ID NO: 3466. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3467. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3468. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3467 and a light chain having the amino acid sequence of SEQ ID NO: 3468. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3465. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3466. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3465, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3466. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3467. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3468. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3467, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3468. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3469, 3470, and 3471, respectively, and (ii) amino acids of SEQ ID NOs: 3472, 3473, and 3474, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3475, 3476, and 3477, respectively, and (ii) amino acids of SEQ ID NOs: 3478, 3479, and 3480, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3481, 3482, and 3483, respectively, and (ii) amino acids of SEQ ID NOs: 3484, 3485, and 3486, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3487, 3488, and 3489, respectively, and (ii) amino acids of SEQ ID NOs: 3490, 3491, and 3492, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3493, 3494, and 3495, respectively, and (ii) amino acids of SEQ ID NOs: 3496, 3497, and 3498, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3499, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3500, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3499. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3500. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3499, and a VL having the amino acid sequence of SEQ ID NO: 3500. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3501. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3502. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3501 and a light chain having the amino acid sequence of SEQ ID NO: 3502. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3499. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3500. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3499, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3500. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3501. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3502. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3501, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3502. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3503, 3504, and 3505, respectively, and (ii) amino acids of SEQ ID NOs: 3506, 3507, and 3508, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3509, 3510, and 3511, respectively, and (ii) amino acids of SEQ ID NOs: 3512, 3513, and 3514, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3515, 3516, and 3517, respectively, and (ii) amino acids of SEQ ID NOs: 3518, 3519, and 3520, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3521, 3522, and 3523, respectively, and (ii) amino acids of SEQ ID NOs: 3524, 3525, and 3526, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3527, 3528, and 3529, respectively, and (ii) amino acids of SEQ ID NOs: 3530, 3531, and 3532, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3533, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3534, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3533. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3534. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3533, and a VL having the amino acid sequence of SEQ ID NO: 3534. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3535. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3536. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3535 and a light chain having the amino acid sequence of SEQ ID NO: 3536. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3533. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3534. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3533, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3534. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3535. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3536. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3535, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3536. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3537, 3538, and 3539, respectively, and (ii) amino acids of SEQ ID NOs: 3540, 3541, and 3542, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3543, 3544, and 3545, respectively, and (ii) amino acids of SEQ ID NOs: 3546, 3547, and 3548, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3549, 3550, and 3551, respectively, and (ii) amino acids of SEQ ID NOs: 3552, 3553, and 3554, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3555, 3556, and 3557, respectively, and (ii) amino acids of SEQ ID NOs: 3558, 3559, and 3560, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3561, 3562, and 3563, respectively, and (ii) amino acids of SEQ ID NOs: 3564, 3565, and 3566, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3567, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3568, respectively. do. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3567. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3568. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3567, and a VL having the amino acid sequence of SEQ ID NO: 3568. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3569. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3570. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3569 and a light chain having the amino acid sequence of SEQ ID NO: 3570. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3567. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3568. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3567, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3568. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3569. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3570. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3569, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3570. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3571, 3572, and 3573, respectively, and (ii) amino acids of SEQ ID NOs: 3574, 3575, and 3576, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3577, 3578, and 3579, respectively, and (ii) amino acids of SEQ ID NOs: 3580, 3581, and 3582, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3583, 3584, and 3585, respectively, and (ii) amino acids of SEQ ID NOs: 3586, 3587, and 3588, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3589, 3590, and 3591, respectively, and (ii) amino acids of SEQ ID NOs: 3592, 3593, and 3594, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3595, 3596, and 3597, respectively, and (ii) amino acids of SEQ ID NOs: 3598, 3599, and 3600, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3601, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3602, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3601. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3602. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3601, and a VL having the amino acid sequence of SEQ ID NO: 3602. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3603. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3604. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3603 and a light chain having the amino acid sequence of SEQ ID NO: 3604. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3601. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3602. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3601, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3602. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3603. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3604. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3603, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3604. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3605, 3606, and 3607, respectively, and (ii) amino acids of SEQ ID NOs: 3608, 3609, and 3610, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3611, 3612, and 3613, respectively, and (ii) amino acids of SEQ ID NOs: 3614, 3615, and 3616, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3617, 3618, and 3619, respectively, and (ii) amino acids of SEQ ID NOs: 3620, 3621, and 3622, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3623, 3624, and 3625, respectively, and (ii) amino acids of SEQ ID NOs: 3626, 3627, and 3628, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3629, 3630, and 3631, respectively, and (ii) amino acids of SEQ ID NOs: 3632, 3633, and 3634, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3635, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3636, respectively. do. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3635. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3636. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3635, and a VL having the amino acid sequence of SEQ ID NO: 3636. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3637. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3638. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3637 and a light chain having the amino acid sequence of SEQ ID NO: 3638. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3635. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3636. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3635, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3636. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3637. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3638. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3637, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3638. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3639, 3640, and 3641, respectively, and (ii) amino acids of SEQ ID NOs: 3642, 3643, and 3644, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3645, 3646, and 3647, respectively, and (ii) amino acids of SEQ ID NOs: 3648, 3649, and 3650, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3651, 3652, and 3653, respectively, and (ii) amino acids of SEQ ID NOs: 3654, 3655, and 3656, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3657, 3658, and 3659, respectively, and (ii) amino acids of SEQ ID NOs: 3660, 3661, and 3662, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3663, 3664, and 3665, respectively, and (ii) amino acids of SEQ ID NOs: 3666, 3667, and 3668, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3669, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3670, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3669. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3670. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3669, and a VL having the amino acid sequence of SEQ ID NO: 3670. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3671. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3672. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3671 and a light chain having the amino acid sequence of SEQ ID NO: 3672. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3669. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3670. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3669, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3670. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3671. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3672. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3671 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3672. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3673, 3674, and 3675, respectively, and (ii) amino acids of SEQ ID NOs: 3676, 3677, and 3678, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3679, 3680, and 3681, respectively, and (ii) amino acids of SEQ ID NOs: 3682, 3683, and 3684, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3685, 3686, and 3687, respectively, and (ii) amino acids of SEQ ID NOs: 3688, 3689, and 3690, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3691, 3692, and 3693, respectively, and (ii) amino acids of SEQ ID NOs: 3694, 3695, and 3696, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3697, 3698, and 3699, respectively, and (ii) amino acids of SEQ ID NOs: 3700, 3701, and 3702, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3703, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3704, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3703. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3704. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3703, and a VL having the amino acid sequence of SEQ ID NO: 3704. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3705. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3706. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3705 and a light chain having the amino acid sequence of SEQ ID NO: 3706. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3703. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3704. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3703, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3704. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3705. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3706. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3705, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3706. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3707, 3708, and 3709, respectively, and (ii) amino acids of SEQ ID NOs: 3710, 3711, and 3712, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3713, 3714, and 3715, respectively, and (ii) amino acids of SEQ ID NOs: 3716, 3717, and 3718, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3719, 3720, and 3721, respectively, and (ii) amino acids of SEQ ID NOs: 3722, 3723, and 3724, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3725, 3726, and 3727, respectively, and (ii) amino acids of SEQ ID NOs: 3728, 3729, and 3730, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3731, 3732, and 3733, respectively, and (ii) amino acids of SEQ ID NOs: 3734, 3735, and 3736, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3737, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3738, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3737. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3738. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3737, and a VL having the amino acid sequence of SEQ ID NO: 3738. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3739. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3740. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3739 and a light chain having the amino acid sequence of SEQ ID NO: 3740. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3737. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3738. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3737, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3738. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3739. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3740. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3739, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3740. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3741, 3742, and 3743, respectively, and (ii) amino acids of SEQ ID NOs: 3744, 3745, and 3746, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3747, 3748, and 3749, respectively, and (ii) amino acids of SEQ ID NOs: 3750, 3751, and 3752, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3753, 3754, and 3755, respectively, and (ii) amino acids of SEQ ID NOs: 3756, 3757, and 3758, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3759, 3760, and 3761, respectively, and (ii) amino acids of SEQ ID NOs: 3762, 3763, and 3764, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3765, 3766, and 3767, respectively, and (ii) amino acids of SEQ ID NOs: 3768, 3769, and 3770, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3771, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3772, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3771. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3772. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3771, and a VL having the amino acid sequence of SEQ ID NO: 3772. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3773. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3774. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3773 and a light chain having the amino acid sequence of SEQ ID NO: 3774. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3771. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3772. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3771, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3772. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3773. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3774. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3773, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3774. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3775, 3776, and 3777, respectively, and (ii) amino acids of SEQ ID NOs: 3778, 3779, and 3780, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3781, 3782, and 3783, respectively, and (ii) amino acids of SEQ ID NOs: 3784, 3785, and 3786, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3787, 3788, and 3789, respectively, and (ii) amino acids of SEQ ID NOs: 3790, 3791, and 3792, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3793, 3794, and 3795, respectively, and (ii) amino acids of SEQ ID NOs: 3796, 3797, and 3798, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3799, 3800, and 3801, respectively, and (ii) amino acids of SEQ ID NOs: 3802, 3803, and 3804, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3805, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3806, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3805. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3806. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3805, and a VL having the amino acid sequence of SEQ ID NO: 3806. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3807. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3808. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3807 and a light chain having the amino acid sequence of SEQ ID NO: 3808. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3805. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3806. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3805, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3806. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3807. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3808. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3807, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3808. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3809, 3810, and 3811, respectively, and (ii) amino acids of SEQ ID NOs: 3812, 3813, and 3814, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3815, 3816, and 3817, respectively, and (ii) amino acids of SEQ ID NOs: 3818, 3819, and 3820, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3821, 3822, and 3823, respectively, and (ii) amino acids of SEQ ID NOs: 3824, 3825, and 3826, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3827, 3828, and 3829, respectively, and (ii) amino acids of SEQ ID NOs: 3830, 3831, and 3832, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3833, 3834, and 3835, respectively, and (ii) amino acids of SEQ ID NOs: 3836, 3837, and 3838, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3839, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3840, respectively. do. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3839. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3840. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3839, and a VL having the amino acid sequence of SEQ ID NO: 3840. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3841. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3842. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3841 and a light chain having the amino acid sequence of SEQ ID NO: 3842. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3839. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3840. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3839, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3840. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3841. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3842. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3841 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3842 Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3843, 3844, and 3845, respectively, and (ii) amino acids of SEQ ID NOs: 3846, 3847, and 3848, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3849, 3850, and 3851, respectively, and (ii) amino acids of SEQ ID NOs: 3852, 3853, and 3854, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3855, 3856, and 3857, respectively, and (ii) amino acids of SEQ ID NOs: 3858, 3859, and 3860, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3861, 3862, and 3863, respectively, and (ii) amino acids of SEQ ID NOs: 3864, 3865, and 3866, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3867, 3868, and 3869, respectively, and (ii) amino acids of SEQ ID NOs: 3870, 3871, and 3872, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3873, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3874, respectively. do. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3873. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3874. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3873, and a VL having the amino acid sequence of SEQ ID NO: 3874. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3875. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3876. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3875 and a light chain having the amino acid sequence of SEQ ID NO: 3876. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3873. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3874. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3873, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3874. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3875. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3876. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3875, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3876. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3877, 3878, and 3879, respectively, and (ii) amino acids of SEQ ID NOs: 3880, 3881, and 3882, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3883, 3884, and 3885, respectively, and (ii) amino acids of SEQ ID NOs: 3886, 3887, and 3888, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3889, 3890, and 3891, respectively, and (ii) amino acids of SEQ ID NOs: 3892, 3893, and 3894, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3895, 3896, and 3897, respectively, and (ii) amino acids of SEQ ID NOs: 3898, 3899, and 3900, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3901, 3902, and 3903, respectively, and (ii) amino acids of SEQ ID NOs: 3904, 3905, and 3906, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3907, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3908, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3907. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3908. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3907, and a VL having the amino acid sequence of SEQ ID NO: 3908. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3909. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3910. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3909 and a light chain having the amino acid sequence of SEQ ID NO: 3910. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3907. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3908. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3907, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3908. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3909. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3910. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3909, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3910. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3911, 3912, and 3913, respectively, and (ii) amino acids of SEQ ID NOs: 3914, 3915, and 3916, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3917, 3918, and 3919, respectively, and (ii) amino acids of SEQ ID NOs: 3920, 3921, and 3922, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3923, 3924, and 3925, respectively, and (ii) amino acids of SEQ ID NOs: 3926, 3927, and 3928, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3929, 3930, and 3931, respectively, and (ii) amino acids of SEQ ID NOs: 3932, 3933, and 3934, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3935, 3936, and 3937, respectively, and (ii) amino acids of SEQ ID NOs: 3938, 3939, and 3940, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3941, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3942, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3941. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3942. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3941, and a VL having the amino acid sequence of SEQ ID NO: 3942. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3943. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3944. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3943 and a light chain having the amino acid sequence of SEQ ID NO: 3944. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3941. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3942. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3941, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3942. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3943. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3944. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3943, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3944. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3945, 3946, and 3947, respectively, and (ii) amino acids of SEQ ID NOs: 3948, 3949, and 3950, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3951, 3952, and 3953, respectively, and (ii) amino acids of SEQ ID NOs: 3954, 3955, and 3956, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3957, 3958, and 3959, respectively, and (ii) amino acids of SEQ ID NOs: 3960, 3961, and 3962, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3963, 3964, and 3965, respectively, and (ii) amino acids of SEQ ID NOs: 3966, 3967, and 3968, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3969, 3970, and 3971, respectively, and (ii) amino acids of SEQ ID NOs: 3972, 3973, and 3974, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 3975, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 3976, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3975. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 3976. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 3975, and a VL having the amino acid sequence of SEQ ID NO: 3976. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3977. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 3978. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 3977 and a light chain having the amino acid sequence of SEQ ID NO: 3978. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3975. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3976. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3975, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3976. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3977. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3978. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3977 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3978 Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3979, 3980, and 3981, respectively, and (ii) amino acids of SEQ ID NOs: 3982, 3983, and 3984, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3985, 3986, and 3987, respectively, and (ii) amino acids of SEQ ID NOs: 3988, 3989, and 3990, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 3991, 3992, and 3993, respectively, and (ii) amino acids of SEQ ID NOs: 3994, 3995, and 3996, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 3997, 3998, and 3999, respectively, and (ii) amino acids of SEQ ID NOs: 4000, 4001, and 4002, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4003, 4004, and 4005, respectively, and (ii) amino acids of SEQ ID NOs: 4006, 4007, and 4008, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4009, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4010, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 4009. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 4010. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 4009, and a VL having the amino acid sequence of SEQ ID NO: 4010. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4011. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 4012. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4011 and a light chain having the amino acid sequence of SEQ ID NO: 4012. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4009. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4010. In one aspect, provided herein, a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4009, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4010. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4011. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4012. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4011 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4012 Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4013, 4014, and 4015, respectively, and (ii) amino acids of SEQ ID NOs: 4016, 4017, and 4018, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 4019, 4020, and 4021, respectively, and (ii) amino acids of SEQ ID NOs: 4022, 4023, and 4024, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4025, 4026, and 4027, respectively, and (ii) amino acids of SEQ ID NOs: 4028, 4029, and 4030, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 4031, 4032, and 4033, respectively, and (ii) amino acids of SEQ ID NOs: 4034, 4035, and 4036, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4037, 4038, and 4039, respectively, and (ii) amino acids of SEQ ID NOs: 4040, 4041, and 4042, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4043, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4044, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 4043. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 4044. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 4043, and a VL having the amino acid sequence of SEQ ID NO: 4044. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4045. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 4046. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4045 and a light chain having the amino acid sequence of SEQ ID NO: 4046. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4043. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4044. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4043, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4044. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4045. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4046. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4045, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4046. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4047, 4048, and 4049, respectively, and (ii) amino acids of SEQ ID NOs: 4050, 4051, and 4052, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4053, 4054, and 4055, respectively, and (ii) amino acids of SEQ ID NOs: 4056, 4057, and 4058, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 4059, 4060, and 4061, respectively, and (ii) amino acids of SEQ ID NOs: 4062, 4063, and 4064, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4065, 4066, and 4067, respectively, and (ii) amino acids of SEQ ID NOs: 4068, 4069, and 4070, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4071, 4072, and 4073, respectively, and (ii) amino acids of SEQ ID NOs: 4074, 4075, and 4076, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4077, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4078, respectively. do. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 4077. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 4078. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 4077, and a VL having the amino acid sequence of SEQ ID NO: 4078. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4079. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 4080. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4079 and a light chain having the amino acid sequence of SEQ ID NO: 4080. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4077. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4078. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4077, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4078. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4079. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4080. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4079, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4080. Antibodies that bind to TRDV2 are provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4081, 4082, and 4083, respectively, and (ii) amino acids of SEQ ID NOs: 4084, 4085, and 4086, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4087, 4088, and 4089, respectively, and (ii) amino acids of SEQ ID NOs: 4090, 4091, and 4092, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4093, 4094, and 4095, respectively, and (ii) amino acids of SEQ ID NOs: 4096, 4097, and 4098, respectively Provided herein are antibodies that bind to TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4099, 4100, and 4101, respectively, and (ii) amino acids of SEQ ID NOs: 4102, 4103, and 4104, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4105, 4106, and 4107, respectively, and (ii) amino acids of SEQ ID NOs: 4108, 4109, and 4110, respectively Provided herein are antibodies that bind TRDV2, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4111, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4112, respectively. do. In one aspect provided herein is an antibody that binds to TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 4111. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having the amino acid sequence of SEQ ID NO: 4112. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having the amino acid sequence of SEQ ID NO: 4111, and a VL having the amino acid sequence of SEQ ID NO: 4112. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4113. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having the amino acid sequence of SEQ ID NO: 4114. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4113 and a light chain having the amino acid sequence of SEQ ID NO: 4114. In one aspect provided herein is an antibody that binds TRDV2 comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4111. In one aspect provided herein is an antibody that binds TRDV2 comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4112. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4111, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4112. Antibodies that bind to TRDV2 are provided. In one aspect provided herein is an antibody that binds TRDV2 comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4113. In one aspect provided herein is an antibody that binds TRDV2 comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4114. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4113, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4114. Antibodies that bind to TRDV2 are provided.

In one aspect, antibodies that bind TRDV2 are provided herein. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2037, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2038, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2037, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2038, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2071, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2072, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2071, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2072, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2105, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2106, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2105, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2106, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2139, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2140, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2139, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2140, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2173, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL comprising the VL having the amino acid sequence of SEQ ID NO: 2174, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2173, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2174, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2207, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2208, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2207, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2208, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2241, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2242, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2241, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2242, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2275, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2276, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2275, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2276, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2309, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2310, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2309, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2310, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2343, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2344, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2343, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2344, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2377, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2378, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2377, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2378, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2411, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2412, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2411, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2412, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2445, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2446, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2445, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2446, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2479, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2480, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2479, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2480, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2513, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2514, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2513, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2514, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2547, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2548, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2547, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2548, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2581, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2582, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2581, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2582, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2615, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2616, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2615, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2616, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2649, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2650, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2649, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2650, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2683, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2684, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2683, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2684, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2717, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2718, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2717, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2718, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2751, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2752, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2751, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2752, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2785, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2786, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2785, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2786, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2819, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2820, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2819, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2820, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2853, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2854, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2853, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2854, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2887, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2888, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2887, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2888, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2921, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2922, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2921, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2922, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2955, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2956, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2955, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2956, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2989, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 2990, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 2989, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2990, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3023, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3024, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3023, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3024, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3057, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3058, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3057, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3058, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3091, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3092, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3091, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3092, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3125, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3126, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3125, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3126, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3159, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3160, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3159, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3160, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3193, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL comprising the VL having the amino acid sequence of SEQ ID NO: 3194, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3193, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3194, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3227, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3228, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3227, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3228, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3261, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3262, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3261, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL CDR1 having the amino acid sequence of SEQ ID NO: 3262, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3295, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3296, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3295, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3296, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3329, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3330, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3329, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3330, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3363, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3364, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3363, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3364, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3397, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3398, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3397, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3398, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3431, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3432, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3431, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3432, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3465, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3466, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3465, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3466, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3499, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3500, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3499, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3500, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3533, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3534, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3533, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3534, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3567, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3568, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3567, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3568, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3601, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3602, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3601, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3602, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3635, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3636, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3635, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3636, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3669, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3670, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3669, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3670, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3703, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3704, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3703, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3704, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3737, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3738, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3737, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3738, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3771, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3772, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3771, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3772, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3805, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3806, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3805, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3806, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3839, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3840, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3839, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3840, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3873, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3874, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3873, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3874, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3907, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3908, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3907, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3908, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3941, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3942, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3941, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3942, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3975, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 3976, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 3975, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3976, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4009, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4010, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4009, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4010, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4043, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4044, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4043, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4044, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4077, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4078, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4077, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4078, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRDV2 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4111, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRDV2 antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4112, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4111, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4112, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In some embodiments, the TRDV2 antibody is a multispecific antibody. In some embodiments, the TRDV2 antibody is a bispecific antibody. In some embodiments, the TRDV2 antibody is a trispecific antibody. In some embodiments, the TRDV2 antibody is a tetraspecific antibody.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 2031, wherein the fifth amino acid is R or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 2032; and a VH CDR3 having the amino acid sequence of SEQ ID NO: 2033, wherein the sixth amino acid is F or Y. In one aspect, the VL CDR1 having the amino acid sequence of SEQ ID NO: 2034; VL CDR2 having the amino acid sequence of SEQ ID NO: 2035, wherein the third amino acid is S or T; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2036, wherein the sixth amino acid is R or S, the seventh amino acid is L or M, and the eighth amino acid is S or T. . In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 2031, wherein the fifth amino acid is R or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 2032; VH CDR3 having the amino acid sequence of SEQ ID NO: 2033, wherein the sixth amino acid is F or Y; VL CDR1 having the amino acid sequence of SEQ ID NO: 2034; VL CDR2 having the amino acid sequence of SEQ ID NO: 2035, wherein the third amino acid is S or T; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2036, wherein the sixth amino acid is R or S, the seventh amino acid is L or M, and the eighth amino acid is S or T. .

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 2099, wherein the fifth amino acid is S or T; VH CDR2 having the amino acid sequence of SEQ ID NO: 2100, wherein the fourth amino acid is D or S and the sixth amino acid is I or S; The third amino acid is D or E, the fourth amino acid is R or S, the sixth amino acid is Y, or no amino acid is added at the sixth position and the sequence continues to the seventh position, and the eighth amino acid is G or V and a VH CDR3 having the amino acid sequence of SEQ ID NO: 2101, wherein the ninth amino acid is P or S. In one aspect, the VL CDR1 having the amino acid sequence of SEQ ID NO: 2102; VL CDR2 having the amino acid sequence of SEQ ID NO: 2103; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2104. In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 2099, wherein the fifth amino acid is S or T; VH CDR2 having the amino acid sequence of SEQ ID NO: 2100, wherein the fourth amino acid is D or S and the sixth amino acid is I or S; The third amino acid is D or E, the fourth amino acid is R or S, the sixth amino acid is Y, or no amino acid is added at the sixth position and the sequence continues to the seventh position, and the eighth amino acid is G or V and a VH CDR3 having the amino acid sequence of SEQ ID NO: 2101, wherein the ninth amino acid is P or S; VL CDR1 having the amino acid sequence of SEQ ID NO: 2102; VL CDR2 having the amino acid sequence of SEQ ID NO: 2103; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2104.

In one aspect, the amino acid sequence of SEQ ID NO: 2133, wherein the second amino acid is D or G, the fifth amino acid is N, S, or T, the sixth amino acid is N or S, and the seventh amino acid is H or Y VH CDR1 with; VH CDR2 having the amino acid sequence of SEQ ID NO: 2134, wherein the first amino acid is I or V, the fourth amino acid is N or S, and the sixth amino acid is N or S; Provided herein is an antibody that binds TRDV2 comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 2135, wherein the seventh amino acid is E or V and the tenth amino acid is G or T. In one aspect, the VL CDR1 having the amino acid sequence of SEQ ID NO: 2136; VL CDR2 having the amino acid sequence of SEQ ID NO: 2137; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2138 wherein the ninth amino acid is G or S. In one aspect, the amino acid sequence of SEQ ID NO: 2133, wherein the second amino acid is D or G, the fifth amino acid is N, S, or T, the sixth amino acid is N or S, and the seventh amino acid is H or Y VH CDR1 with; VH CDR2 having the amino acid sequence of SEQ ID NO: 2134, wherein the first amino acid is I or V, the fourth amino acid is N or S, and the sixth amino acid is N or S; VH CDR3 having the amino acid sequence of SEQ ID NO: 2135, wherein the seventh amino acid is E or V and the tenth amino acid is G or T; VL CDR1 having the amino acid sequence of SEQ ID NO: 2136; VL CDR2 having the amino acid sequence of SEQ ID NO: 2137; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2138, wherein the ninth amino acid is G or S.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 2269, wherein the first amino acid is G or S and the fifth amino acid is S or T; VH CDR2 having the amino acid sequence of SEQ ID NO: 2270; and a VH CDR3 having the amino acid sequence of SEQ ID NO: 2271, wherein the seventh amino acid is D or E, the ninth amino acid is D or S, and the 18th amino acid is G or N. Provided. In one aspect, the VL CDR1 having the amino acid sequence of SEQ ID NO: 2272; VL CDR2 having the amino acid sequence of SEQ ID NO: 2273; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2274, wherein the third amino acid is F or Y and the sixth amino acid is A or T. In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 2269, wherein the first amino acid is G or S and the fifth amino acid is S or T; VH CDR2 having the amino acid sequence of SEQ ID NO: 2270; and VH CDR3 having the amino acid sequence of SEQ ID NO: 2271, wherein the seventh amino acid is D or E, the ninth amino acid is D or S, and the 18th amino acid is G or N; VL CDR1 having the amino acid sequence of SEQ ID NO: 2272; VL CDR2 having the amino acid sequence of SEQ ID NO: 2273; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2274, wherein the third amino acid is F or Y and the sixth amino acid is A or T.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 2337, wherein the first amino acid is G or N, the fifth amino acid is N or S, and the sixth amino acid is G, N or Y; VH CDR2 having the amino acid sequence of SEQ ID NO: 2338, wherein the second amino acid is F or Y; A VH CDR3 having the amino acid sequence of SEQ ID NO: 2339, wherein the second amino acid is K or R, the third amino acid is E or L, the 10th amino acid is S or T, and the 11th amino acid is A or T. Antibodies that bind TRDV2 are provided herein. In one embodiment, a VL CDR1 having the amino acid sequence of SEQ ID NO: 2340, wherein the first amino acid is S or T, the fifth amino acid is E or G, and the seventh amino acid is D or N; VL CDR2 having the amino acid sequence of SEQ ID NO: 2341; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2342, wherein the first amino acid is A or T. In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 2337, wherein the first amino acid is G or N, the fifth amino acid is N or S, and the sixth amino acid is G, N, or Y; VH CDR2 having the amino acid sequence of SEQ ID NO: 2338, wherein the second amino acid is F or Y; VH CDR3 having the amino acid sequence of SEQ ID NO: 2339, wherein the second amino acid is K or R, the third amino acid is E or L, the tenth amino acid is S or T, and the eleventh amino acid is A or T; VL CDR1 having the amino acid sequence of SEQ ID NO: 2340, wherein the first amino acid is S or T, the fifth amino acid is E or G, and the seventh amino acid is D or N; VL CDR2 having the amino acid sequence of SEQ ID NO: 2341; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2342, wherein the first amino acid is A or T.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 3017, wherein the sixth amino acid is S or T; VH CDR2 having the amino acid sequence of SEQ ID NO: 3018; and a VH CDR3 having the amino acid sequence of SEQ ID NO: 3019, wherein the eighth amino acid is S or T. In one aspect, the VL CDR1 having the amino acid sequence of SEQ ID NO: 3020, the second amino acid being dl G or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 3021; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 3022, wherein the first amino acid is I or M. In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 3017, wherein the sixth amino acid is S or T; VH CDR2 having the amino acid sequence of SEQ ID NO: 3018; and VH CDR3 having the amino acid sequence of SEQ ID NO: 3019, wherein the eighth amino acid is S or T; VL CDR1 having the amino acid sequence of SEQ ID NO: 3020, the second amino acid being dl G or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 3021; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 3022, wherein the first amino acid is I or M.

In one aspect, the VH CDR1 having the amino acid sequence of SEQ ID NO: 2983; VH CDR2 having the amino acid sequence of SEQ ID NO: 2984, wherein the third amino acid is P or S; Provided herein is an antibody that binds to TRDV2, comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 2985, wherein the fourth amino acid is M or V, the sixth amino acid is T or V, and the 11th amino acid is A or D. do. In one aspect, the VL CDR1 having the amino acid sequence of SEQ ID NO: 2986; VL CDR2 having the amino acid sequence of SEQ ID NO: 2987; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2988. In one aspect, the VH CDR1 having the amino acid sequence of SEQ ID NO: 2983; VH CDR2 having the amino acid sequence of SEQ ID NO: 2984, wherein the third amino acid is P or S; VH CDR3 having the amino acid sequence of SEQ ID NO: 2985, wherein the fourth amino acid is M or V, the sixth amino acid is T or V, and the 11th amino acid is A or D; VL CDR1 having the amino acid sequence of SEQ ID NO: 2986; VL CDR2 having the amino acid sequence of SEQ ID NO: 2987; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 2988.

In one aspect, antibodies that bind TRGDC are provided herein. In some embodiments, an antibody comprises a heavy chain variable region and a light chain variable region. In some embodiments, the TRGDC antibody is a humanized antibody.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4115, 4116, and 4117, respectively, and (ii) amino acids of SEQ ID NOs: 4118, 4119, and 4120, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4121, 4122, and 4123, respectively, and (ii) amino acids of SEQ ID NOs: 4124, 4125, and 4126, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4127, 4128, and 4129, respectively, and (ii) amino acids of SEQ ID NOs: 4130, 4131, and 4132, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4133, 4134, and 4135, respectively, and (ii) amino acids of SEQ ID NOs: 4136, 4137, and 4138, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4139, 4140, and 4141, respectively, and (ii) amino acids of SEQ ID NOs: 4142, 4143, and 4144, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4145, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4146, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4145. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4146. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4145, and a VL having the amino acid sequence of SEQ ID NO: 4146. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4147. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4148. In one aspect, provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4147 and a light chain having the amino acid sequence of SEQ ID NO: 4148. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4145. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4146. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4145, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4146. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4147. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4148. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4147, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4148. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4149, 4150, and 4151, respectively, and (ii) amino acids of SEQ ID NOs: 4152, 4153, and 4154, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4155, 4156, and 4157, respectively, and (ii) amino acids of SEQ ID NOs: 4158, 4159, and 4160, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4161, 4162, and 4163, respectively, and (ii) amino acids of SEQ ID NOs: 4164, 4165, and 4166, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4167, 4168, and 4169, respectively, and (ii) amino acids of SEQ ID NOs: 4170, 4171, and 4172, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4173, 4174, and 4175, respectively, and (ii) amino acids of SEQ ID NOs: 4176, 4177, and 4178, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4179, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4180, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4179. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4180. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4179, and a VL having the amino acid sequence of SEQ ID NO: 4180. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4181. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4182. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4181 and a light chain having the amino acid sequence of SEQ ID NO: 4182. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4179. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4180. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4179, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4180. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4181. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4182. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4181 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4182. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4183, 4184, and 4185, respectively, and (ii) amino acids of SEQ ID NOs: 4186, 4187, and 4188, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4189, 4190, and 4191, respectively, and (ii) amino acids of SEQ ID NOs: 4192, 4193, and 4194, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4195, 4196, and 4197, respectively, and (ii) amino acids of SEQ ID NOs: 4198, 4199, and 4200, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 4201, 4202, and 4203, respectively, and (ii) amino acids of SEQ ID NOs: 4204, 4205, and 4206, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 4207, 4208, and 4209, respectively, and (ii) amino acids of SEQ ID NOs: 4210, 4211, and 4212, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4213, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4214, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4213. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4214. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4213, and a VL having the amino acid sequence of SEQ ID NO: 4214. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4215. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4216. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4215 and a light chain having the amino acid sequence of SEQ ID NO: 4216. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4213. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4214. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4213, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4214. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4215. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4216. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4215, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4216. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4217, 4218, and 4219, respectively, and (ii) amino acids of SEQ ID NOs: 4220, 4221, and 4222, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4223, 4224, and 4225, respectively, and (ii) amino acids of SEQ ID NOs: 4226, 4227, and 4228, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4229, 4230, and 4231, respectively, and (ii) amino acids of SEQ ID NOs: 4232, 4233, and 4234, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4235, 4236, and 4237, respectively, and (ii) amino acids of SEQ ID NOs: 4238, 4239, and 4240, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4241, 4242, and 4243, respectively, and (ii) amino acids of SEQ ID NOs: 4244, 4245, and 4246, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4247, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4248, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4247. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4248. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4247, and a VL having the amino acid sequence of SEQ ID NO: 4248. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4249. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4250. In one aspect, provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4249 and a light chain having the amino acid sequence of SEQ ID NO: 4250. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4247. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4248. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4247, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4248. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4249. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4250. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4249, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4250. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4251, 4252, and 4253, respectively, and (ii) amino acids of SEQ ID NOs: 4254, 4255, and 4256, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4257, 4258, and 4259, respectively, and (ii) amino acids of SEQ ID NOs: 4260, 4261, and 4262, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4263, 4264, and 4265, respectively, and (ii) amino acids of SEQ ID NOs: 4266, 4267, and 4268, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 4269, 4270, and 4271, respectively, and (ii) amino acids of SEQ ID NOs: 4272, 4273, and 4274, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4275, 4276, and 4277, respectively, and (ii) amino acids of SEQ ID NOs: 4278, 4279, and 4280, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4281, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4282, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4281. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4282. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4281, and a VL having the amino acid sequence of SEQ ID NO: 4282. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4283. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4284. In one aspect, provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4283 and a light chain having the amino acid sequence of SEQ ID NO: 4284. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4281. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4282. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4281, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4282. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4283. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4284. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4283, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4284. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4285, 4286, and 4287, respectively, and (ii) amino acids of SEQ ID NOs: 4288, 4289, and 4290, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4291, 4292, and 4293, respectively, and (ii) amino acids of SEQ ID NOs: 4294, 4295, and 4296, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4297, 4298, and 4299, respectively, and (ii) amino acids of SEQ ID NOs: 4300, 4301, and 4302, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4303, 4304, and 4305, respectively, and (ii) amino acids of SEQ ID NOs: 4306, 4307, and 4308, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4309, 4310, and 4311, respectively, and (ii) amino acids of SEQ ID NOs: 4312, 4313, and 4314, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4315, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4316, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4315. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4316. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4315, and a VL having the amino acid sequence of SEQ ID NO: 4316. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4317. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4318. In one aspect, provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4317 and a light chain having the amino acid sequence of SEQ ID NO: 4318. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4315. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4316. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4315, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4316. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4317. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4318. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4317, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4318. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4319, 4320, and 4321, respectively, and (ii) amino acids of SEQ ID NOs: 4322, 4323, and 4324, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4325, 4326, and 4327, respectively, and (ii) amino acids of SEQ ID NOs: 4328, 4329, and 4330, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4331, 4332, and 4333, respectively, and (ii) amino acids of SEQ ID NOs: 4334, 4335, and 4336, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4337, 4338, and 4339, respectively, and (ii) amino acids of SEQ ID NOs: 4340, 4341, and 4342, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4343, 4344, and 4345, respectively, and (ii) amino acids of SEQ ID NOs: 4346, 4347, and 4348, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4349, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4350, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4349. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4350. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4349, and a VL having the amino acid sequence of SEQ ID NO: 4350. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4351. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4352. In one aspect, provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4351 and a light chain having the amino acid sequence of SEQ ID NO: 4352. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4349. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4350. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4349, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4350. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4351. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4352. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4351, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4352. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4353, 4354, and 4355, respectively, and (ii) amino acids of SEQ ID NOs: 4356, 4357, and 4358, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4359, 4360, and 4361, respectively, and (ii) amino acids of SEQ ID NOs: 4362, 4363, and 4364, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4365, 4366, and 4367, respectively, and (ii) amino acids of SEQ ID NOs: 4368, 4369, and 4370, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4371, 4372, and 4373, respectively, and (ii) amino acids of SEQ ID NOs: 4374, 4375, and 4376, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4377, 4378, and 4379, respectively, and (ii) amino acids of SEQ ID NOs: 4380, 4381, and 4382, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4383, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4384, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4383. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4384. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4383, and a VL having the amino acid sequence of SEQ ID NO: 4384. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4385. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4386. In one aspect, provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4385 and a light chain having the amino acid sequence of SEQ ID NO: 4386. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4383. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4384. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4383, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4384. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4385. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4386. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4385, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4386. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4387, 4388, and 4389, respectively, and (ii) amino acids of SEQ ID NOs: 4390, 4391, and 4392, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4393, 4394, and 4395, respectively, and (ii) amino acids of SEQ ID NOs: 4396, 4397, and 4398, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4399, 4400, and 4401, respectively, and (ii) amino acids of SEQ ID NOs: 4402, 4403, and 4404, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4405, 4406, and 4407, respectively, and (ii) amino acids of SEQ ID NOs: 4408, 4409, and 4410, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4411, 4412, and 4413, respectively, and (ii) amino acids of SEQ ID NOs: 4414, 4415, and 4416, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4417, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4418, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4417. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4418. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4417, and a VL having the amino acid sequence of SEQ ID NO: 4418. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4419. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4420. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4419 and a light chain having the amino acid sequence of SEQ ID NO: 4420. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4417. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4418. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4417, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4418. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4419. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4420. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4419, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4420. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4421, 4422, and 4423, respectively, and (ii) amino acids of SEQ ID NOs: 4424, 4425, and 4426, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4427, 4428, and 4429, respectively, and (ii) amino acids of SEQ ID NOs: 4430, 4431, and 4432, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4433, 4434, and 4435, respectively, and (ii) amino acids of SEQ ID NOs: 4436, 4437, and 4438, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4439, 4440, and 4441, respectively, and (ii) amino acids of SEQ ID NOs: 4442, 4443, and 4444, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4445, 4446, and 4447, respectively, and (ii) amino acids of SEQ ID NOs: 4448, 4449, and 4450, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4451, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4452, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4451. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4452. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4451, and a VL having the amino acid sequence of SEQ ID NO: 4452. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4453. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4454. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4453 and a light chain having the amino acid sequence of SEQ ID NO: 4454. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4451. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4452. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4451, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4452. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4453. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4454. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4453, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4454. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4455, 4456, and 4457, respectively, and (ii) amino acids of SEQ ID NOs: 4458, 4459, and 4460, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 4461, 4462, and 4463, respectively, and (ii) amino acids of SEQ ID NOs: 4464, 4465, and 4466, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4467, 4468, and 4469, respectively, and (ii) amino acids of SEQ ID NOs: 4470, 4471, and 4472, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4473, 4474, and 4475, respectively, and (ii) amino acids of SEQ ID NOs: 4476, 4477, and 4478, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4479, 4480, and 4481, respectively, and (ii) amino acids of SEQ ID NOs: 4482, 4483, and 4484, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4485, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4486, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4485. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4486. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4485, and a VL having the amino acid sequence of SEQ ID NO: 4486. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4487. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4488. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4487 and a light chain having the amino acid sequence of SEQ ID NO: 4488. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4485. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4486. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4485, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4486. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4487. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4488. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4487, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4488. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4489, 4490, and 4491, respectively, and (ii) amino acids of SEQ ID NOs: 4492, 4493, and 4494, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4495, 4496, and 4497, respectively, and (ii) amino acids of SEQ ID NOs: 4498, 4499, and 4500, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4501, 4502, and 4503, respectively, and (ii) amino acids of SEQ ID NOs: 4504, 4505, and 4506, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4507, 4508, and 4509, respectively, and (ii) amino acids of SEQ ID NOs: 4510, 4511, and 4512, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4513, 4514, and 4515, respectively, and (ii) amino acids of SEQ ID NOs: 4516, 4517, and 4518, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4519, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4520, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4519. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4520. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4519, and a VL having the amino acid sequence of SEQ ID NO: 4520. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4521. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4522. In one aspect, provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4521 and a light chain having the amino acid sequence of SEQ ID NO: 4522. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4519. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4520. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4519, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4520. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4521. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4522. In one aspect herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4521 and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4522. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4523, 4524, and 4525, respectively, and (ii) amino acids of SEQ ID NOs: 4526, 4527, and 4528, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4529, 4530, and 4531, respectively, and (ii) amino acids of SEQ ID NOs: 4532, 4533, and 4534, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4535, 4536, and 4537, respectively, and (ii) amino acids of SEQ ID NOs: 4538, 4539, and 4540, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4541, 4542, and 4543, respectively, and (ii) amino acids of SEQ ID NOs: 4544, 4545, and 4546, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4547, 4548, and 4549, respectively, and (ii) amino acids of SEQ ID NOs: 4550, 4551, and 4552, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4553, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4554, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4553. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4554. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4553, and a VL having the amino acid sequence of SEQ ID NO: 4554. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4555. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4556. In one aspect, provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4555 and a light chain having the amino acid sequence of SEQ ID NO: 4556. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4553. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4554. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4553, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4554. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4555. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4556. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4555, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4556. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4557, 4558, and 4559, respectively, and (ii) amino acids of SEQ ID NOs: 4560, 4561, and 4562, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4563, 4564, and 4565, respectively, and (ii) amino acids of SEQ ID NOs: 4566, 4567, and 4568, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4569, 4570, and 4571, respectively, and (ii) amino acids of SEQ ID NOs: 4572, 4573, and 4574, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4575, 4576, and 4577, respectively, and (ii) amino acids of SEQ ID NOs: 4578, 4579, and 4580, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4581, 4582, and 4583, respectively, and (ii) amino acids of SEQ ID NOs: 4584, 4585, and 4586, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4587, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4588, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4587. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4588. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4587, and a VL having the amino acid sequence of SEQ ID NO: 4588. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4589. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4590. In one aspect, provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4589 and a light chain having the amino acid sequence of SEQ ID NO: 4590. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4587. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4588. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4587, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4588. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4589. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4590. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4589, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4590. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4591, 4592, and 4593, respectively, and (ii) amino acids of SEQ ID NOs: 4594, 4595, and 4596, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4597, 4598, and 4599, respectively, and (ii) amino acids of SEQ ID NOs: 4600, 4601, and 4602, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4603, 4604, and 4605, respectively, and (ii) amino acids of SEQ ID NOs: 4606, 4607, and 4608, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 4609, 4610, and 4611, respectively, and (ii) amino acids of SEQ ID NOs: 4612, 4613, and 4614, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4615, 4616, and 4617, respectively, and (ii) amino acids of SEQ ID NOs: 4618, 4619, and 4620, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4621, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4622, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4621. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4622. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4621, and a VL having the amino acid sequence of SEQ ID NO: 4622. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4623. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4624. In one aspect, provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4623 and a light chain having the amino acid sequence of SEQ ID NO: 4624. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4621. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4622. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4621, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4622. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4623. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4624. In one aspect, provided herein is a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4623, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4624. An antibody that binds to TRGDC is provided.

In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4625, 4626, and 4627, respectively, and (ii) amino acids of SEQ ID NOs: 4628, 4629, and 4630, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 4631, 4632, and 4633, respectively, and (ii) amino acids of SEQ ID NOs: 4634, 4635, and 4636, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4637, 4638, and 4639, respectively, and (ii) amino acids of SEQ ID NOs: 4640, 4641, and 4642, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NOs: 4643, 4644, and 4645, respectively, and (ii) amino acids of SEQ ID NOs: 4646, 4647, and 4648, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequences of SEQ ID NOs: 4649, 4650, and 4651, respectively, and (ii) amino acids of SEQ ID NOs: 4652, 4653, and 4654, respectively Provided herein are antibodies that bind TRGDC, comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the sequence. In one aspect, (i) a VH having the amino acid sequence of SEQ ID NO: 4655, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of SEQ ID NO: 4656, respectively. do. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4655. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having the amino acid sequence of SEQ ID NO: 4656. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having the amino acid sequence of SEQ ID NO: 4655, and a VL having the amino acid sequence of SEQ ID NO: 4656. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4657. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having the amino acid sequence of SEQ ID NO: 4658. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having the amino acid sequence of SEQ ID NO: 4657 and a light chain having the amino acid sequence of SEQ ID NO: 4658. In one aspect provided herein is an antibody that binds TRGDC comprising a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4655. In one aspect provided herein is an antibody that binds TRGDC comprising a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4656. In one aspect, provided herein is a VH having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4655, and a VL having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4656. An antibody that binds to TRGDC is provided. In one aspect provided herein is an antibody that binds TRGDC comprising a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4657. In one aspect provided herein is an antibody that binds TRGDC comprising a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4658. In one aspect, provided herein, a heavy chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4657, and a light chain having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4658. An antibody that binds to TRGDC is provided.

In one aspect, provided herein are antibodies that bind TRGDC. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4145, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4146, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4145, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4146, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4179, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4180, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4179, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4180, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4213, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4214, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4213, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4214, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4247, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4248, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4247, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4248, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4281, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4282, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4281, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4282, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4315, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4316, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4315, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4316, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4349, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4350, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4349, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4350, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4383, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4384, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4383, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4384, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4417, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4418, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4417, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4418, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4451, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4452, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4451, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4452, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4485, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4486, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4485, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4486, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH comprising the VH having the amino acid sequence of SEQ ID NO: 4519, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4520, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4519, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4520, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4553, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4554, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4553, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4554, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4587, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4588, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4587, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4588, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4621, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4622, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4621, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4622, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4655, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. . In one embodiment, the TRGDC antibody comprises a VL having the amino acid sequence of SEQ ID NO: 4656, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. do. In one embodiment, the TRGDC antibody comprises a VH having the amino acid sequence of SEQ ID NO: 4655, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4656, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In some embodiments, the TRGDC antibody is a multispecific antibody. In some embodiments, the TRGDC antibody is a bispecific antibody. In some embodiments, the TRGDC antibody is a trispecific antibody. In some embodiments, the TRGDC antibody is a tetraspecific antibody.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 4139, wherein the eighth amino acid is R or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 4140; and of SEQ ID NO: 4141, wherein the third amino acid is D or G, the fourth amino acid is E or L, the sixth amino acid is E or G, the ninth amino acid is E or D, and the 11th amino acid is C or F. Antibodies that bind TRGDC comprising a VH CDR3 having an amino acid sequence are provided herein. In one aspect, a VL CDR1 having the amino acid sequence of SEQ ID NO: 4142, wherein the fourth amino acid is H or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 4143; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 4144, wherein the eighth amino acid is F or W. In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 4139, wherein the eighth amino acid is R or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 4140; and of SEQ ID NO: 4141, wherein the third amino acid is D or G, the fourth amino acid is E or L, the sixth amino acid is E or G, the ninth amino acid is E or D, and the 11th amino acid is C or F. VH CDR3 having the amino acid sequence; VL CDR1 having the amino acid sequence of SEQ ID NO: 4142, wherein the fourth amino acid is H or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 4143; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 4144, wherein the eighth amino acid is F or W.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 4173, wherein the first amino acid is G or R, the fourth amino acid is F or L, and the sixth amino acid is N or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 4174; The amino acid sequence of SEQ ID NO: 4175, wherein the fourth amino acid is R or V, the seventh amino acid is G or T, the eighth amino acid is G or T, the ninth amino acid is absent or T, and the 16th amino acid is L or M. Provided herein are antibodies that bind to TRGDC, comprising a VH CDR3 with In one aspect, a VL CDR1 having the amino acid sequence of SEQ ID NO: 4176, wherein the fourth amino acid is A or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 4177; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 4178. In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 4173, wherein the first amino acid is G or R, the fourth amino acid is F or L, and the sixth amino acid is N or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 4174; The amino acid sequence of SEQ ID NO: 4175, wherein the fourth amino acid is R or V, the seventh amino acid is G or T, the eighth amino acid is G or T, the ninth amino acid is absent or T, and the 16th amino acid is L or M. VH CDR3 having; VL CDR1 having the amino acid sequence of SEQ ID NO: 4176, wherein the fourth amino acid is A or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 4177; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 4178.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 4479, wherein the third amino acid is S or T and the sixth amino acid is N or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 4480, wherein the fourth amino acid is I or F, the sixth amino acid is G or S, the seventh amino acid is A or T, and the eighth amino acid is A, G, or P; The first amino acid is S or there is no amino acid at this position, the second amino acid is S, T or there is no amino acid at this position, the third amino acid is A, G, or S, and the fourth amino acid is G, N, or T wherein the fifth amino acid is A, G, or S, the sixth amino acid is G, T, or Y, the seventh amino acid is G, T, or V, and the eighth amino acid is D, T, or Y; Provided herein is an antibody that binds TRGDC comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 4481, wherein the ninth amino acid is T or Y, the 15th amino acid is I or M, and the 16th amino acid is D or N. do. In one aspect, the VL CDR1 having the amino acid sequence of SEQ ID NO: 4482; VL CDR2 having the amino acid sequence of SEQ ID NO: 4483, wherein the first amino acid is E or K and the third amino acid is F or S; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 4484, wherein the fifth amino acid is E or Q. In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 4479, wherein the third amino acid is S or T and the sixth amino acid is N or S; VH CDR2 having the amino acid sequence of SEQ ID NO: 4480, wherein the fourth amino acid is I or F, the sixth amino acid is G or S, the seventh amino acid is A or T, and the eighth amino acid is A, G, or P; The first amino acid is S or there is no amino acid at this position, the second amino acid is S, T or there is no amino acid at this position, the third amino acid is A, G, or S, and the fourth amino acid is G, N, or T wherein the fifth amino acid is A, G, or S, the sixth amino acid is G, T, or Y, the seventh amino acid is G, T, or V, and the eighth amino acid is D, T, or Y; VH CDR3 having the amino acid sequence of SEQ ID NO: 4481, wherein the ninth amino acid is T or Y, the 15th amino acid is I or M, and the 16th amino acid is D or N; VL CDR1 having the amino acid sequence of SEQ ID NO: 4482; VL CDR2 having the amino acid sequence of SEQ ID NO: 4483, wherein the first amino acid is E or K and the third amino acid is F or S; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 4484, wherein the fifth amino acid is E or Q.

In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 4241; VH CDR2 having the amino acid sequence of SEQ ID NO: 4242, wherein the seventh amino acid is A or Y; Provided herein is an antibody that binds TRGDC comprising a VH CDR3 having the amino acid sequence of SEQ ID NO: 4243, wherein the third amino acid is E or L and the ninth amino acid is I or V. In one aspect, a VL CDR1 having the amino acid sequence of SEQ ID NO: 4244, wherein the first amino acid is N or S and the fourth amino acid is N or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 4245; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 4246, wherein the fifth amino acid is N or S and the tenth amino acid is V or W. In one aspect, a VH CDR1 having the amino acid sequence of SEQ ID NO: 4241; VH CDR2 having the amino acid sequence of SEQ ID NO: 4242, wherein the seventh amino acid is A or Y; VH CDR3 having the amino acid sequence of SEQ ID NO: 4243, wherein the third amino acid is E or L and the ninth amino acid is I or V; VL CDR1 having the amino acid sequence of SEQ ID NO: 4244, wherein the first amino acid is N or S and the fourth amino acid is N or S; VL CDR2 having the amino acid sequence of SEQ ID NO: 4245; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 4246, wherein the fifth amino acid is N or S and the tenth amino acid is V or W.

In another aspect, provided herein are multispecific antibodies that bind TRGV9. In some embodiments, the multispecific antibody is a bispecific antibody. In some embodiments, the multispecific antibody is a trispecific antibody. In some embodiments, the multispecific antibody is a tetraspecific antibody. In one embodiment, the multispecific TRGV9 antibody comprises (a) a first binding domain that binds TRGV9, and (b) a second binding domain that binds a second target. In one embodiment, the multispecific TRGV9 antibody comprises (a) a first binding domain that binds TRGV9, and (b) a second binding domain that binds a second target, and (c) a third binding domain that binds a third target. contains the domain In one embodiment, the multispecific TRGV9 antibody comprises (a) a first binding domain that binds TRGV9, and (b) a second binding domain that binds a second target, (c) a third binding domain that binds a third target. , and (d) a fourth binding domain that binds a fourth target.

In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 31, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 is VL having the amino acid sequence of SEQ ID NO: 32, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 31, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 32, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 65, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 66, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 65, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 66, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 99, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 100, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 99, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 100, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 133, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 134, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 133, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 134, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 167, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 168, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 167, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 168, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 201, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 202, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 201, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 202, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 235, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 236, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 235, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 236, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 269, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 270, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 269, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 270, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 303, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 304, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 303, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 304, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 337, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 338, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 337, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 338, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 371, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 372, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 371, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 372, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 405, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 406, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 405, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 406, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 439, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 is VL having the amino acid sequence of SEQ ID NO: 440, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 439, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 440, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 473, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 474, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 473, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 474, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 507, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 508, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 507, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 508, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 541, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 542, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 541, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 542, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 575, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 576, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 575, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 576, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 609, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 610, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 609, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 610, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 643, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 644, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 643, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 644, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 677, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 678, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 677, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 678, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 711, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 712, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 711, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 712, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 745, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 746, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 745, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 746, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 779, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 780, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 779, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 780, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 813, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 814, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 813, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 814, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 847, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 848, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 847, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 848, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 881, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 882, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 881, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 882, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 915, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 916, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 915, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 916, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 949, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 950, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 949, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 950, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 983, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 984, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 983, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 984, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1017, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1018, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1017, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1018, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1051, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1052, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1051, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1052, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1085, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1086, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1085, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1086, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1119, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1120, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1119, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1120, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1153, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1154, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1153, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1154, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1187, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1188, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1187, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1188, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1221, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1222, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1221, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1222, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1255, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1256, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1255, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1256, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1289, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1290, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1289, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1290, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1323, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1324, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1323, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1324, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1357, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1358, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1357, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1358, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1391, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1392, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1391, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1392, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1425, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1426, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1425, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1426, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1459, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 is VL having the amino acid sequence of SEQ ID NO: 1460, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1459, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1460, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1493, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1494, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1493, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1494, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1527, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1528, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1527, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1528, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1561, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1562, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1561, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1562, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1595, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 is VL having the amino acid sequence of SEQ ID NO: 1596, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1595, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1596, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1629, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1630, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1629, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1630, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1663, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1664, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1663, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1664, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1697, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1698, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1697, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1698, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1731, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1732, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1731, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1732, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1765, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1766, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1765, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1766, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1799, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1800, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1799, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1800, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1833, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1834, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1833, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1834, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1867, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1868, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1867, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1868, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1901, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1902, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1901, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1902, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1935, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1936, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1935, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1936, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1969, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 1970, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 1969, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 1970, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises VH having the amino acid sequence of SEQ ID NO: 2003, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGV9 comprises VL having the amino acid sequence of SEQ ID NO: 2004, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGV9 comprises a VH having the amino acid sequence of SEQ ID NO: 2003, a VH CDR1 having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3, respectively. , VH including VH CDR2, and VH CDR3; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2004, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively.

In another aspect, provided herein are multispecific antibodies that bind TRDV2. In some embodiments, the multispecific antibody is a bispecific antibody. In some embodiments, the multispecific antibody is a trispecific antibody. In some embodiments, the multispecific antibody is a tetraspecific antibody. In one embodiment, the multispecific TRDV2 antibody comprises (a) a first binding domain that binds TRDV2, and (b) a second binding domain that binds a second target. In one embodiment, the multispecific TRDV2 antibody comprises (a) a first binding domain that binds TRDV2, and (b) a second binding domain that binds a second target, and (c) a third binding domain that binds a third target. contains the domain In one embodiment, the multispecific TRDV2 antibody comprises (a) a first binding domain that binds TRDV2, and (b) a second binding domain that binds a second target, (c) a third binding domain that binds a third target. , and (d) a fourth binding domain that binds to a fourth target.

In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2037, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2038, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2037, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2038, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2071, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 2072, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2071, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2072, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2105, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2106, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2105, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2106, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 2139, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2140, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2139, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2140, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2173, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2174, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 2173, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR3, respectively. VH containing; and a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL having the amino acid sequence of SEQ ID NO: 2174, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2207, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 2208, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2207, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2208, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2241, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 2242, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2241, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2242, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2275, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 2276, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2275, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2276, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2309, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2310, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2309, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2310, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2343, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2344, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2343, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2344, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2377, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2378, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2377, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2378, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2411, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2412, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2411, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2412, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2445, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 2446, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2445, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2446, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2479, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 2480, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2479, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2480, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2513, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 2514, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2513, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2514, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2547, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2548, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2547, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2548, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2581, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2582, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2581, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2582, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2615, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2616, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2615, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2616, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2649, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2650, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2649, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2650, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2683, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 2684, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2683, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2684, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2717, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 2718, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2717, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2718, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2751, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2752, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2751, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2752, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2785, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2786, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2785, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2786, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2819, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2820, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2819, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2820, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2853, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 2854, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2853, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2854, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2887, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2888, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2887, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2888, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 2921, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2922, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2921, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2922, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2955, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2956, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2955, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2956, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 2989, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 2990, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 2989, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 2990, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3023, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3024, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3023, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3024, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 3057, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3058, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3057, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3058, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3091, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3092, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3091, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3092, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 3125, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3126, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3125, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3126, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3159, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3160, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3159, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3160, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3193, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3194, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3193, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3194, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3227, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3228, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3227, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3228, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3261, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 3262, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3261, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL CDR1 having the amino acid sequence of SEQ ID NO: 3262, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 3295, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3296, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3295, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3296, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3329, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3330, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3329, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3330, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3363, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3364, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3363, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3364, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 3397, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3398, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3397, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3398, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3431, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 3432, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3431, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3432, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3465, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3466, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3465, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3466, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 3499, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3500, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3499, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3500, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3533, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3534, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3533, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3534, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3567, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3568, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3567, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3568, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 3601, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3602, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3601, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3602, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3635, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3636, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3635, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3636, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3669, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3670, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3669, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3670, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 3703, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3704, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3703, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3704, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3737, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3738, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3737, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3738, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3771, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3772, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3771, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3772, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3805, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 3806, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3805, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3806, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 3839, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3840, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3839, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3840, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3873, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3874, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3873, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3874, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3907, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 3908, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3907, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3908, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 3941, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3942, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3941, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3942, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 is VH having the amino acid sequence of SEQ ID NO: 3975, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 3976, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 3975, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 3976, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 4009, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 4010, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 4009, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4010, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 4043, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 4044, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 4043, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4044, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 4077, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 comprises VL having the amino acid sequence of SEQ ID NO: 4078, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 4077, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4078, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises VH having the amino acid sequence of SEQ ID NO: 4111, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRDV2 is VL having the amino acid sequence of SEQ ID NO: 4112, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRDV2 comprises a VH having the amino acid sequence of SEQ ID NO: 4111, a VH CDR1 having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3, respectively. , VH including VH CDR2, and VH CDR3; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4112, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively.

In another aspect, provided herein are multispecific antibodies that bind TRGDC. In some embodiments, the multispecific antibody is a bispecific antibody. In some embodiments, the multispecific antibody is a trispecific antibody. In some embodiments, the multispecific antibody is a tetraspecific antibody. In one embodiment, the multispecific TRGDC antibody comprises (a) a first binding domain that binds TRGDC, and (b) a second binding domain that binds a second target. In one embodiment, the multispecific TRGDC antibody comprises (a) a first binding domain that binds TRGDC, and (b) a second binding domain that binds a second target, and (c) a third binding domain that binds a third target. contains the domain In one embodiment, the multispecific TRGDC antibody comprises (a) a first binding domain that binds TRGDC, and (b) a second binding domain that binds a second target, (c) a third binding domain that binds a third target. , and (d) a fourth binding domain that binds a fourth target.

In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4145, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4146, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4145, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4146, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4179, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4180, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4179, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4180, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4213, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4214, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4213, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4214, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4247, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4248, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4247, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4248, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4281, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4282, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4281, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4282, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4315, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4316, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4315, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4316, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4349, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4350, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4349, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4350, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4383, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC is VL having the amino acid sequence of SEQ ID NO: 4384, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4383, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4384, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4417, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4418, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4417, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4418, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4451, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4452, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4451, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4452, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4485, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4486, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4485, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4486, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4519, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4520, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4519, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4520, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4553, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4554, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4553, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4554, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4587, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4588, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4587, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4588, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4621, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4622, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. It includes a VL containing In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4621, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4622, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4655, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. Including VH containing. In one embodiment, the first binding domain that binds TRGDC comprises VL having the amino acid sequence of SEQ ID NO: 4656, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. Including VL containing. In one embodiment, the first binding domain that binds TRGDC comprises VH having the amino acid sequence of SEQ ID NO: 4655, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively. VH containing; and a VL comprising VL having the amino acid sequence of SEQ ID NO: 4656, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively.

In some embodiments, a multispecific antibody provided herein is a diabody, cross-body, or multispecific antibody obtained through controlled Fab arm exchange as those described herein.

In some embodiments, the multispecific antibody is an IgG-like molecule having complementary CH3 domains that promote heterodimerization; recombinant IgG-like dual targeting molecules, wherein each of the two sides of the molecule comprises Fab fragments or portions of Fab fragments of at least two different antibodies; IgG fusion molecules, in which a full-length IgG antibody is fused to an extra Fab fragment or part of a Fab fragment; Fc fusion molecules, wherein single-chain Fv molecules or stabilized diabodies are fused to heavy-chain constant domains, Fc-regions, or parts thereof; Fab fusion molecules, in which different Fab-fragments are fused together; ScFv-based and diabody-based heavy chain antibodies in which different single chain Fv molecules or different diabodies or different heavy chain antibodies (eg domain antibodies, nanobodies) are fused to each other or to another protein or carrier molecule ( eg domain antibodies, nanobodies).

In some embodiments, IgG-like molecules with complementary CH3 domain molecules are Triomab/Quadroma (Trion Pharma/Fresenius Biotech), Knob-into-Hole (Genentech), CrossMAb (Roche) and electrostatic Electrostatically-matched (Amgen), LUZ-Y (Genentech), Strand Exchange Engineered Domain body (SEEDbody) (EMD Serono), Biclonic (Merus) and DuoBody (Genmab A/ S) include.

In some embodiments, the recombinant IgG-like dual targeting molecule is Dual Targeting (DT)-Ig (GSK/Domantis), Two-in-one Antibody (Genentech), cross-linking Cross-linked Mab (Karmanos Cancer Center), mAb2 (F-Star) and CovX-body (CovX/Pfizer).

In some embodiments, the IgG fusion molecule is a dual variable domain (DVD)-Ig (Abbott), an IgG-like bispecific (ImClone/Eli Lilly), Ts2Ab (MedImmune/AZ) and BsAb (Zymogenetics), HERCULES (Biogen Idec) ) and TvAb (Roche).

In some embodiments, the Fc fusion molecule is a ScFv/Fc fusion (Academic Institution), SCORPION (Emergent BioSolutions/Trubion, Zymogenetics/BMS), Dual Affinity Retargeting Technology (Fc-DART) (MacroGenics) and Dual (ScFv) ₂ -Fab (National Research Center for Antibody Medicine--China).

In some embodiments, the Fab fusion bispecific antibody is F(ab) ₂ (Medarex/AMGEN), Dual-Action or Bis-Fab (Genentech), Dock-and-Lock (DNL) -Lock) (ImmunoMedics), Bivalent Bispecific (Biotecnol) and Fab-Fv (UCB-Celltech). ScFv-, diabody-based and domain antibodies include bispecific T cell engager (BiTE) (Micromet), tandem diabodies (Tandab) (Affimed), dual affinity retargeting technology (DART) (MacroGenics), single chain diabodies body (Academic), TCR-like antibodies (AIT, ReceptorLogics), human serum albumin ScFv fusions (Merrimack) and COMBODY (Epigen Biotech), dual targeting nanobodies (Ablynx), dual targeting heavy chain single domain antibodies. don't

Full-length bispecific antibodies provided herein can be generated using, for example, Fab arm exchange (or half molecule exchange) between two monospecific bivalent antibodies, either using coexpression or in a cell-free environment. in vitro by introducing substitutions at the heavy chain CH3 interface within each half molecule to favor the formation of heterodimers of the two antibody half molecules with distinct specificities. The Fab arm exchange reaction is the result of a disulfide-bond isomerization reaction and dissociation-association of the CH3 domains. Heavy chain disulfide bonds in the hinge region of the parental monospecific antibody are reduced. The resulting free cysteine of one of the parental monospecific antibodies forms an inter-heavy chain disulfide bond with a cysteine residue of a second parental monospecific antibody molecule, simultaneously releasing and re-associating the CH3 domain of the parental antibody by dissociation-association. is formed The CH3 domain of the Fab arm can be engineered to favor heterodimerization over homodimerization. The resulting product is a bispecific antibody with two Fab arms or half molecules, each binding a distinct epitope, eg, an epitope on CD8 and an epitope on CD4. Other methods of making multispecific antibodies are known and contemplated.

As used herein, “homodimerization” refers to the interaction of two heavy chains with identical CH3 amino acid sequences. As used herein, "homodimer" refers to an antibody having two heavy chains with identical CH3 amino acid sequences.

As used herein, “heterodimerization” refers to the interaction of two heavy chains with unequal CH3 amino acid sequences. As used herein, “heterodimer” refers to an antibody having two heavy chains with unequal CH3 amino acid sequences.

A “knob-in-hole” strategy (see, eg, International Patent Application Publication No. WO2006/028936) can be used to generate full-length bispecific antibodies. Briefly, selected amino acids forming the interface of the CH3 domains in human IgG can be mutated at positions that affect CH3 domain interactions to promote heterodimer formation. An amino acid with a small side chain (hole) is introduced into the heavy chain of an antibody that specifically binds to a first antigen, and an amino acid with a large side chain (knob) is introduced into the heavy chain of an antibody that specifically binds to a second antigen. After coexpression of the two antibodies, heterodimers are formed as a result of the preferential interaction of heavy chains with "holes" and heavy chains with "knobs". Exemplary CH3 substitution pairs forming knobs and holes are as follows (expressed as modified position in 1st CH3 domain of first heavy chain/modified position in 2nd CH3 domain of second heavy chain): T366Y/F405A, T366W / F405W, F405W/Y407A, T394W/Y407T, T394S/Y407A, T366W/T394S, F405W/T394S, and T366W/T366S_L368A_Y407V.

Other strategies can be used, such as using electrostatic interactions to promote heavy chain heterodimerization by substituting a positively charged residue on one CH3 surface and a negatively charged residue on a second CH3 surface, which is a US patent application. Publication No. US2010/0015133; US Patent Application Publication No. US2009/0182127; US Patent Application Publication No. US2010/028637; or as described in published US patent application US2011/0123532. In another strategy, as described in US Patent Application Publication No. US2012/0149876 or US Patent Application Publication No. US2013/0195849, the following substitution (modified position in the first CH3 domain of the first heavy chain/the second CH3 of the second heavy chain) expressed as modified positions within the domain) can promote heterodimerization by: K409F, L351Y_Y407A/T366V K409F Y407A/T366A_K409F, or T350V_L351Y_F405A Y407V/T350V_T366L_K392L_T394W.

In addition to the methods described above, the bispecific antibodies provided herein introduce asymmetric mutations in the CH3 regions of the two monospecific homodimeric antibodies and, under reducing conditions to allow disulfide bond isomerization, the bispecific antibodies of the two parental monospecific antibodies. By forming bispecific heterodimeric antibodies from homodimeric antibodies, they can be produced in vitro in a cell-free environment according to methods described in International Patent Application Publication No. WO2011/131746. In these methods, the first monospecific bivalent antibody and the second monospecific bivalent antibody are engineered to have specific substitutions in the CH3 domain that promote heterodimer stability; The antibodies are incubated together under reducing conditions sufficient to cause the cysteines of the hinge region to undergo disulfide bond isomerization; This results in bispecific antibodies by Fab arm exchange. Incubation conditions can optionally be restored to non-reducing conditions. Exemplary reducing agents that may be used include 2-mercaptoethylamine (2-MEA), dithiothreitol (DTT), dithioerythritol (DTE), glutathione, tris(2-carboxyethyl)phosphine (TCEP), L-cysteine and beta-mercaptoethanol, preferably a reducing agent selected from the group consisting of 2-mercaptoethylamine, dithiothreitol and tris(2-carboxyethyl)phosphine. for example at pH 5 to 8, for example at pH 7.0 or pH 7.4 in the presence of at least 25 mM 2-MEA or in the presence of at least 0.5 mM dithiothreitol at least at a temperature of at least 20°C. Incubation for 90 minutes may be used.

In some embodiments, the TRGV9 antibody comprises a single chain antibody. In some embodiments, the TRGV9 antibody comprises a single domain antibody. In some embodiments, a TRGV9 antibody comprises a Nanobody. In certain embodiments, the TRGV9 antibody includes a VHH antibody. In certain embodiments, TRGV9 antibodies include llama antibodies. In some embodiments, the TRGV9 antibody does not comprise a single chain antibody. In some embodiments, the TRGV9 antibody does not comprise a single domain antibody. In certain embodiments, the TRGV9 antibody does not comprise a Nanobody. In certain embodiments, the TRGV9 antibody does not include a VHH antibody. In certain embodiments, the TRGV9 antibody does not include a llama antibody.

In some embodiments, the TRGV9 multispecific antibody comprises a single chain antibody. In some embodiments, the TRGV9 multispecific antibody comprises a single domain antibody. In certain embodiments, the TRGV9 multispecific antibody comprises a Nanobody. In certain embodiments, the TRGV9 multispecific antibody comprises a VHH antibody. In certain embodiments, the TRGV9 multispecific antibody comprises a llama antibody. In some embodiments, the TRGV9 multispecific antibody does not comprise a single chain antibody. In some embodiments, the TRGV9 multispecific antibody does not comprise a single domain antibody. In certain embodiments, the TRGV9 multispecific antibody does not comprise a Nanobody. In certain embodiments, the TRGV9 multispecific antibody does not include a VHH antibody. In certain embodiments, the TRGV9 multispecific antibody does not include llama antibodies.

According to another specific embodiment, provided herein is a TRGV9 antibody or antigen-binding fragment thereof that induces antibody-dependent cell-mediated cytotoxicity (ADCC). Antibodies or antigen-binding fragments thereof can, for example, induce ADCC in vitro.

In certain embodiments, the antibody or antigen-binding fragment thereof exhibits T cell dependent cytotoxicity of a second cell in vitro with an EC ₅₀ of less than about 160 pM when assessed in vitro at an effector to target cell ratio of 1:1. induce

In some embodiments, TRGV9 is on the surface of a T cell. In some embodiments, TRGV9 is on the surface of a T cell and the second target antigen is on the surface of a second cell. In some embodiments, the second cell is killed when the multispecific antibody binds TRGV9 on the surface of the T cell and a second target antigen on the surface of the second cell.

In some embodiments, the TRDV2 antibody comprises a single chain antibody. In some embodiments, a TRDV2 antibody comprises a single domain antibody. In some embodiments, a TRDV2 antibody comprises a Nanobody. In certain embodiments, TRDV2 antibodies include VHH antibodies. In certain embodiments, TRDV2 antibodies include llama antibodies. In some embodiments, the TRDV2 antibody does not comprise a single chain antibody. In some embodiments, the TRDV2 antibody does not comprise a single domain antibody. In certain embodiments, the TRDV2 antibody does not comprise a Nanobody. In certain embodiments, the TRDV2 antibody does not include a VHH antibody. In certain embodiments, TRDV2 antibodies do not include llama antibodies.

In some embodiments, the TRDV2 multispecific antibody comprises a single chain antibody. In some embodiments, the TRDV2 multispecific antibody comprises a single domain antibody. In certain embodiments, the TRDV2 multispecific antibody comprises a Nanobody. In certain embodiments, the TRDV2 multispecific antibody comprises a VHH antibody. In certain embodiments, TRDV2 multispecific antibodies include llama antibodies. In some embodiments, the TRDV2 multispecific antibody does not comprise a single chain antibody. In some embodiments, the TRDV2 multispecific antibody does not comprise a single domain antibody. In certain embodiments, the TRDV2 multispecific antibody does not comprise a Nanobody. In certain embodiments, the TRDV2 multispecific antibody does not include a VHH antibody. In certain embodiments, the TRDV2 multispecific antibody does not include llama antibodies.

According to another specific embodiment, provided herein is a TRDV2 antibody or antigen-binding fragment thereof that induces antibody-dependent cell-mediated cytotoxicity (ADCC). Antibodies or antigen-binding fragments thereof can, for example, induce ADCC in vitro.

In certain embodiments, the antibody or antigen-binding fragment thereof exhibits T cell dependent cytotoxicity of a second cell in vitro with an EC ₅₀ of less than about 160 pM when assessed in vitro at an effector to target cell ratio of 1:1. induce

In some embodiments, TRDV2 is on the surface of a T cell. In some embodiments, TRDV2 is on the surface of a T cell and the second target antigen is on the surface of a second cell. In some embodiments, the second cell is killed when the multispecific antibody binds TRDV2 on the surface of the T cell and an antigen on the surface of the second cell.

In some embodiments, a TRGDC antibody comprises a single chain antibody. In some embodiments, a TRGDC antibody comprises a single domain antibody. In certain embodiments, a TRGDC antibody comprises a Nanobody. In certain embodiments, TRGDC antibodies include VHH antibodies. In certain embodiments, TRGDC antibodies include llama antibodies. In some embodiments, the TRGDC antibody does not comprise a single chain antibody. In some embodiments, the TRGDC antibody does not comprise a single domain antibody. In certain embodiments, the TRGDC antibody does not comprise a Nanobody. In certain embodiments, the TRGDC antibody does not include a VHH antibody. In certain embodiments, the TRGDC antibody does not include a llama antibody.

In some embodiments, the TRGDC multispecific antibody comprises a single chain antibody. In some embodiments, the TRGDC multispecific antibody comprises a single domain antibody. In certain embodiments, the TRGDC multispecific antibody comprises a Nanobody. In certain embodiments, the TRGDC multispecific antibody comprises a VHH antibody. In certain embodiments, the TRGDC multispecific antibody comprises a llama antibody. In some embodiments, the TRGDC multispecific antibody does not comprise a single chain antibody. In some embodiments, the TRGDC multispecific antibody does not comprise a single domain antibody. In certain embodiments, the TRGDC multispecific antibody does not comprise a Nanobody. In certain embodiments, the TRGDC multispecific antibody does not include a VHH antibody. In certain embodiments, the TRGDC multispecific antibody does not include a llama antibody.

According to another specific embodiment, provided herein is a TRGDC antibody or antigen-binding fragment thereof that induces antibody-dependent cell-mediated cytotoxicity (ADCC). Antibodies or antigen-binding fragments thereof can, for example, induce ADCC in vitro.

In certain embodiments, the antibody or antigen-binding fragment thereof exhibits T cell dependent cytotoxicity of a second cell in vitro with an EC ₅₀ of less than about 160 pM when assessed in vitro at an effector to target cell ratio of 1:1. induce

In some embodiments, TRGDCs are on the surface of T cells. In some embodiments, the TRGDC is on the surface of a T cell and the second target antigen is on the surface of a second cell. In some embodiments, the second cell is killed when the multispecific antibody binds the TRGDC on the surface of the T cell and the antigen on the surface of the second cell.

In some embodiments, the multispecific antibody induces T cell dependent cytotoxicity of a second cell in vitro with an EC ₅₀ of less than about 500 pM. In some embodiments, the multispecific antibody induces T cell dependent cytotoxicity of a second cell in vitro with an EC ₅₀ of less than about 300 pM. In some embodiments, the multispecific antibody induces γδ T cell dependent cytotoxicity of the second cell in vitro with an EC ₅₀ of less than about 160 pM. In some embodiments, the EC ₅₀ is assessed using a mixture of γδ T effector cells and target cells expressing the second target antigen. In some embodiments, the ratio of effector cells to target cells is between about 0.01:1 and about 5:1. In some embodiments, the ratio of effector cells to target cells is between about 0.1:1 and about 2:1. In some embodiments, the ratio of effector cells to target cells is about 1:1.

In certain embodiments, the EC ₅₀ is less than about 1000 pM, less than about 900 pM, less than about 800 pM, less than about 700 pM, less than about 600 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 less than about 190 pM, less than about 180 pM, less than about 170 pM, less than about 160 pM, less than about 150 pM, less than about 140 pM, less than about 130 pM, less than about 120 pM, less than about 110 pM, about 100 less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, less than about 50 pM, less than about 40 pM, less than about 30 pM, less than about 20 pM, or less than about 10 pM.

In certain embodiments, the effector to target cell ratio is, for example, 0.01:1, 0.02:1, 0.03:1, 0.04:1, 0.05:1, 0.06:1, 0.07:1, 0.08:1, 0.09: 1, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or 10:1. In certain embodiments, the effector to target cell ratio may be, for example, 0.01:1 to 10:1. In certain embodiments, the concentration of the multispecific antibody or antigen-binding fragment thereof is about 0.000005 ng/mL, about 0.00005 ng/mL, about 0.0005, about 0.005 ng/mL, about 0.01 ng/mL, about 0.02 ng/mL, About 0.03 ng/mL, about 0.04 ng/mL, about 0.05 ng/mL, about 0.06 ng/mL, about 0.07 ng/mL, about 0.08 ng/mL, about 0.09 ng/mL, about 0.1 ng/mL, about 0.5 ng/mL, about 1.0 ng/mL, about 10 ng/mL, about 20 ng/mL about, about 30 ng/mL about 40 ng/mL, about 50 ng/mL, about 60 ng/mL, about 70 ng/mL mL, about 80 ng/mL, about 90 ng/mL, about 100 ng/mL, or about 1000 ng/mL. In certain embodiments, the concentration of the multispecific antibody or antigen-binding fragment thereof is between about 0.000005 ng/mL and about 1000 ng/mL.

In another aspect, provided herein are antibodies that compete with any of the TRGV9 antibodies described herein for binding to TRGV9. In another aspect, provided herein are antibodies that bind to the same epitope as any of the TRGV9 antibodies described herein. In another aspect, a TRGV9 antibody that binds an epitope on TRGV9 that overlaps an epitope on TRGV9 bound by a TRGV9 antibody described herein is provided. In some embodiments, a TRGV9 antibody comprises VH CDR1, VH CDR2, and VH CDR3 of a TRGV9 antibody provided herein. In some embodiments, a TRGV9 antibody comprises VL CDR1, VL CDR2, and VL CDR3 of a TRGV9 antibody provided herein. In some embodiments, a TRGV9 antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRGV9 antibody provided herein. In some embodiments, a TRGV9 antibody comprises a VH of a TRGV9 antibody provided herein. In some embodiments, a TRGV9 antibody comprises a VL of a TRGV9 antibody provided herein. In some embodiments, a TRGV9 antibody comprises a VH and a VL of a TRGV9 antibody provided herein. In some embodiments, a TRGV9 antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRGV9 antibody provided herein. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Kabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody conform to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody are according to a contact numbering scheme. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody conform to the IMGT numbering system. In certain embodiments, the TRGV9 antibody is a multispecific antibody. In some embodiments, the TRGV9 antibody is a bispecific antibody.

In another aspect, an antibody that competes with a TRGV9 reference antibody for binding to TRGV9 is provided. In another aspect, a TRGV9 antibody that binds to the same TRGV9 epitope as a TRGV9 reference antibody is provided. In another aspect, a TRGV9 antibody that binds to an epitope on TRGV9 that overlaps an epitope on TRGV9 bound by a TRGV9 reference antibody is provided. In some embodiments, a TRGV9 reference antibody comprises VH CDR1, VH CDR2, and VH CDR3 of a TRGV9 reference antibody provided herein. In some embodiments, a TRGV9 reference antibody comprises VL CDR1, VL CDR2, and VL CDR3 of a TRGV9 reference antibody provided herein. In some embodiments, a TRGV9 reference antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRGV9 reference antibody provided herein. In some embodiments, a TRGV9 reference antibody comprises a VH of a TRGV9 reference antibody provided herein. In some embodiments, a TRGV9 reference antibody comprises a VL of a TRGV9 reference antibody provided herein. In some embodiments, a TRGV9 reference antibody comprises a VH and a VL of a TRGV9 reference antibody provided herein. In some embodiments, a TRGV9 reference antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRGV9 reference antibody provided herein. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 reference antibody are according to the Kabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 reference antibody are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 reference antibody conform to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 reference antibody are according to a contact numbering scheme. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 reference antibody conform to the IMGT numbering system. In certain embodiments, the antibody is a multispecific antibody. In some embodiments, the antibody is a bispecific antibody. In certain embodiments, the TRGV9 reference antibody is a multispecific antibody. In some embodiments, the TRGV9 reference antibody is a bispecific antibody.

In another aspect, provided herein are antibodies that compete with any of the TRDV2 antibodies described herein for binding to TRDV2. In another aspect, provided herein are antibodies that bind to the same epitope as any of the TRDV2 antibodies described herein. In another aspect, a TRDV2 antibody that binds an epitope on TRDV2 that overlaps an epitope on TRDV2 bound by a TRDV2 antibody described herein is provided. In some embodiments, a TRDV2 antibody comprises VH CDR1, VH CDR2, and VH CDR3 of a TRDV2 antibody provided herein. In some embodiments, a TRDV2 antibody comprises VL CDR1, VL CDR2, and VL CDR3 of a TRDV2 antibody provided herein. In some embodiments, a TRDV2 antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRDV2 antibody provided herein. In some embodiments, a TRDV2 antibody comprises a VH of a TRDV2 antibody provided herein. In some embodiments, a TRDV2 antibody comprises a VL of a TRDV2 antibody provided herein. In some embodiments, a TRDV2 antibody comprises a VH and a VL of a TRDV2 antibody provided herein. In some embodiments, a TRDV2 antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRDV2 antibody provided herein. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 antibody are according to the Kabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 antibody are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 antibody conform to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 antibody are according to a contact numbering scheme. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 antibody conform to the IMGT numbering system. In certain embodiments, the TRDV2 antibody is a multispecific antibody. In some embodiments, the TRDV2 antibody is a bispecific antibody.

In another aspect, an antibody that competes with a TRDV2 reference antibody for binding to TRDV2 is provided. In another aspect, a TRDV2 antibody that binds to the same TRDV2 epitope as a TRDV2 reference antibody is provided. In another aspect, a TRDV2 antibody that binds to an epitope on TRDV2 that overlaps an epitope on TRDV2 bound by a TRDV2 reference antibody is provided. In some embodiments, a TRDV2 reference antibody comprises VH CDR1, VH CDR2, and VH CDR3 of a TRDV2 reference antibody provided herein. In some embodiments, a TRDV2 reference antibody comprises VL CDR1, VL CDR2, and VL CDR3 of a TRDV2 reference antibody provided herein. In some embodiments, a TRDV2 reference antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRDV2 reference antibody provided herein. In some embodiments, a TRDV2 reference antibody comprises a VH of a TRDV2 reference antibody provided herein. In some embodiments, a TRDV2 reference antibody comprises a VL of a TRDV2 reference antibody provided herein. In some embodiments, a TRDV2 reference antibody comprises a VH and a VL of a TRDV2 reference antibody provided herein. In some embodiments, a TRDV2 reference antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRDV2 reference antibody provided herein. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 reference antibody are according to the Kabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 reference antibody are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 reference antibody conform to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 reference antibody are according to a contact numbering scheme. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRDV2 reference antibody conform to the IMGT numbering system. In certain embodiments, the antibody is a multispecific antibody. In some embodiments, the antibody is a bispecific antibody. In certain embodiments, the TRDV2 reference antibody is a multispecific antibody. In some embodiments, the TRDV2 reference antibody is a bispecific antibody.

In another aspect, provided herein are antibodies that compete with any of the TRGDC antibodies described herein for binding to TRGDC. In another aspect, provided herein are antibodies that bind to the same epitope as any of the TRGDC antibodies described herein. In another aspect, a TRGDC antibody that binds an epitope on TRGDC that overlaps an epitope on TRGDC bound by a TRGDC antibody described herein is provided. In some embodiments, a TRGDC antibody comprises VH CDR1, VH CDR2, and VH CDR3 of a TRGDC antibody provided herein. In some embodiments, a TRGDC antibody comprises VL CDR1, VL CDR2, and VL CDR3 of a TRGDC antibody provided herein. In some embodiments, a TRGDC antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRGDC antibody provided herein. In some embodiments, a TRGDC antibody comprises a VH of a TRGDC antibody provided herein. In some embodiments, a TRGDC antibody comprises a VL of a TRGDC antibody provided herein. In some embodiments, a TRGDC antibody comprises a VH and a VL of a TRGDC antibody provided herein. In some embodiments, a TRGDC antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRGDC antibody provided herein. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC antibody are according to the Kabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC antibody are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC antibody conform to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC antibody are according to a contact numbering scheme. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC antibody conform to the IMGT numbering system. In certain embodiments, the TRGDC antibody is a multispecific antibody. In some embodiments, the TRGDC antibody is a bispecific antibody.

In another aspect, an antibody that competes with a TRGDC reference antibody for binding to TRGDC is provided. In another aspect, a TRGDC antibody that binds to the same TRGDC epitope as a TRGDC reference antibody is provided. In another aspect, a TRGDC antibody that binds to an epitope on TRGDC that overlaps an epitope on TRGDC bound by a TRGDC reference antibody is provided. In some embodiments, a TRGDC reference antibody comprises VH CDR1, VH CDR2, and VH CDR3 of a TRGDC reference antibody provided herein. In some embodiments, a TRGDC reference antibody comprises VL CDR1, VL CDR2, and VL CDR3 of a TRGDC reference antibody provided herein. In some embodiments, a TRGDC reference antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRGDC reference antibody provided herein. In some embodiments, a TRGDC reference antibody comprises a VH of a TRGDC reference antibody provided herein. In some embodiments, a TRGDC reference antibody comprises a VL of a TRGDC reference antibody provided herein. In some embodiments, a TRGDC reference antibody comprises a VH and a VL of a TRGDC reference antibody provided herein. In some embodiments, a TRGDC reference antibody comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRGDC reference antibody provided herein. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC reference antibody are according to the Kabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC reference antibody are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC reference antibody conform to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC reference antibody are according to a contact numbering scheme. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGDC reference antibody conform to the IMGT numbering system. In certain embodiments, the antibody is a multispecific antibody. In some embodiments, the antibody is a bispecific antibody. In certain embodiments, the TRGDC reference antibody is a multispecific antibody. In some embodiments, the TRGDC reference antibody is a bispecific antibody.

In some embodiments described herein, the immune effector properties of antibodies provided herein can be enhanced or subdued through Fc modification by techniques known to those skilled in the art. For example, Fc effector functions such as Clq binding, complement dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), cell surface receptors (e.g. For example, down-regulation of the B cell receptor (BCR), etc., can be provided and/or controlled by modifying residues within the Fc responsible for these activities.

“Antibody-dependent cell-mediated cytotoxicity” or “ADCC” refers to the expression of non-specific cytotoxic cells (eg, natural killer (NK) cells, neutrophils, and macrophages) that express Fc receptors (FcR) on target cells. Refers to a cell-mediated reaction that recognizes bound antibodies and subsequently causes lysis of target cells.

The ability of an antibody to induce ADCC can be enhanced by engineering its oligosaccharide component. Human IgG1 or IgG3 is N-glycosylated at Asn297 by most of the glycans of the well-known biantennary GO, GOF, G1, G1F, G2 or G2F type. Antibodies produced by unengineered CHO cells typically have a glycan fucose content of at least about 85%. Removal of core fucose from biantennary complex-type oligosaccharides attached to the Fc region enhances ADCC of antibodies through improved FcγRIIIa binding without altering antigen binding or CDC activity . These Abs have been reported to lead to the successful expression of relatively highly afucosylated antibodies carrying biantennary complexes of Fc oligosaccharides in a variety of ways, such as control of culture osmolality (Konno et al. , Cytotechnology 64:249-65, 2012), variant CHO strain Lec13 as host cell line (see Shields et al. , J Biol Chem 277:26733-26740, 2002), variant CHO strain EB66 as host Application as a cell line (see Olivier et al. , MAbs; 2(4), 2010; Epub advance of print; PMID: 20562582), application of the rat hybridoma cell line YB2/0 as a host cell line (Shinkawa et al . al. , J Biol Chem 278:3466-3473, 2003), and specifically introduced small interfering RNA against the α-1,6-fucosyltransferase (FUT8) gene (Mori et al. , Biotechnol Bioeng 88:901-908, 2004), or β-1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II or kifunensine, a potent alpha-mannosidase I inhibitor. Co-expression (Ferrara et al. , J Biol Chem 281:5032-5036, 2006; Ferrara et al. , Biotechnol Bioeng 93:851-861, 2006; Xhou et al. , Biotechnol Bioeng 99:652-65, 2008 ]).

In some embodiments described herein, ADCC induced by antibodies provided herein may also be enhanced by certain substitutions within the antibody Fc. Exemplary substitutions are amino acid positions 256, 290, 298, 312, 356, 330, 333, 334, 360, 378 or 430 (residue numbering according to EU index) as described, for example, in US Pat. No. 6,737,056. is a substitution in

In some embodiments, a TRGV9 antibody provided herein is chimeric. In some embodiments, a TRGV9 antibody provided herein is human. In some embodiments, a TRGV9 antibody provided herein is humanized. In certain embodiments, a TRGV9 antibody provided herein is an isolated TRGV9 antibody. In some embodiments, a TRGV9 antigen-binding fragment provided herein is chimeric. In some embodiments, a TRGV9 antigen-binding fragment provided herein is human. In some embodiments, a TRGV9 antigen-binding fragment provided herein is humanized. In certain embodiments, a TRGV9 antigen-binding fragment provided herein is an isolated TRGV9 antigen-binding fragment. In some embodiments, a TRGV9 antibody provided herein is an IgG antibody. In some embodiments, the IgG antibody is an IgG1 antibody. In some embodiments, the IgG antibody is an IgG2 antibody. In some embodiments, the IgG antibody is an IgG3 antibody. In some embodiments, the IgG antibody is an IgG4 antibody. In some embodiments, a TRGV9 antibody provided herein is multivalent. In some embodiments, an antibody is capable of binding at least three antigens. In some embodiments, a TRGV9 antibody provided herein is multivalent. In some embodiments, an antibody is capable of binding at least 4 antigens. In some embodiments, an antibody is capable of binding at least 5 antigens.

In some embodiments, the TRGV9 multispecific antibodies provided herein are chimeric. In some embodiments, a TRGV9 multispecific antibody provided herein is human. In some embodiments, TRGV9 multispecific antibodies provided herein are humanized. In some embodiments, a TRGV9 multispecific antibody provided herein is an isolated TRGV9 multispecific antibody. In some embodiments, a TRGV9 multispecific antibody comprising a TRGV9 antigen-binding fragment provided herein is chimeric. In some embodiments, a TRGV9 multispecific antibody comprising a TRGV9 antigen-binding fragment provided herein is human. In some embodiments, TRGV9 multispecific antibodies comprising TRGV9 antigen-binding fragments provided herein are humanized. In some embodiments, a TRGV9 multispecific antibody comprising a TRGV9 antigen-binding fragment provided herein is an isolated TRGV9 multispecific antibody.

In some embodiments of the TRGV9 multispecific antibodies provided herein, the first binding domain is human. In some embodiments, the second binding domain is human. In some embodiments of the TRGV9 multispecific antibodies provided herein, both the first binding domain and the second binding domain are human. In some embodiments of the TRGV9 multispecific antibodies provided herein, the first binding domain is humanized. In some embodiments of the TRGV9 multispecific antibodies provided herein, the second binding domain is humanized. In some embodiments of the TRGV9 multispecific antibodies provided herein, both the first binding domain and the second binding domain are humanized. In some embodiments of the TRGV9 multispecific antibodies provided herein, the first binding domain is human and the second binding domain is humanized. In some embodiments of the TRGV9 multispecific antibodies provided herein, the first binding domain is humanized and the second binding domain is human.

In some embodiments, TRGV9 multispecific antibodies provided herein are multivalent. In some embodiments, the multispecific antibody is capable of binding at least three antigens. In some embodiments, the multispecific antibody is capable of binding at least 5 antigens. In certain embodiments, the multispecific antibody is a multispecific antibody. In some embodiments, a TRGV9 multispecific antibody provided herein is an IgG antibody. In some embodiments, the IgG antibody is an IgG1 antibody. In some embodiments, the IgG antibody is an IgG2 antibody. In some embodiments, the IgG antibody is an IgG3 antibody. In some embodiments, the IgG antibody is an IgG4 antibody.

In certain embodiments, an antibody provided herein is part of a multispecific antibody. In some embodiments, the multispecific antibody comprises a first binding domain that binds a TRGV9 antigen. In some embodiments, the multispecific antibody, as provided herein, comprises a first binding domain that binds a TRGV9 antigen and comprises a second binding domain that binds a second target antigen. In certain embodiments, the multispecific antibody binds a TRGV9 antigen, a second target antigen, and one or more additional antigens. In some embodiments of the various antibodies provided herein, the antibody binds an epitope of a given antigen.

In some embodiments, a TRDV2 antibody provided herein is chimeric. In some embodiments, a TRDV2 antibody provided herein is human. In some embodiments, a TRDV2 antibody provided herein is humanized. In certain embodiments, a TRDV2 antibody provided herein is an isolated TRDV2 antibody. In some embodiments, a TRDV2 antigen-binding fragment provided herein is chimeric. In some embodiments, a TRDV2 antigen-binding fragment provided herein is human. In some embodiments, a TRDV2 antigen-binding fragment provided herein is humanized. In certain embodiments, a TRDV2 antigen-binding fragment provided herein is an isolated TRDV2 antigen-binding fragment. In some embodiments, a TRDV2 antibody provided herein is an IgG antibody. In some embodiments, the IgG antibody is an IgG1 antibody. In some embodiments, the IgG antibody is an IgG2 antibody. In some embodiments, the IgG antibody is an IgG3 antibody. In some embodiments, the IgG antibody is an IgG4 antibody. In some embodiments, TRDV2 antibodies provided herein are multivalent. In some embodiments, an antibody is capable of binding at least three antigens. In some embodiments, an antibody is capable of binding at least 4 antigens. In some embodiments, an antibody is capable of binding at least 5 antigens.

In some embodiments, TRDV2 multispecific antibodies provided herein are chimeric. In some embodiments, TRDV2 multispecific antibodies provided herein are human. In some embodiments, TRDV2 multispecific antibodies provided herein are humanized. In some embodiments, a TRDV2 multispecific antibody provided herein is an isolated TRDV2 multispecific antibody. In some embodiments, a TRDV2 multispecific antibody comprising a TRDV2 antigen-binding fragment provided herein is chimeric. In some embodiments, a TRDV2 multispecific antibody comprising a TRDV2 antigen-binding fragment provided herein is human. In some embodiments, a TRDV2 multispecific antibody comprising a TRDV2 antigen-binding fragment provided herein is humanized. In some embodiments, a TRDV2 multispecific antibody comprising a TRDV2 antigen-binding fragment provided herein is an isolated TRDV2 multispecific antibody.

In some embodiments of the TRDV2 multispecific antibodies provided herein, the first binding domain is human. In some embodiments, the second binding domain is human. In some embodiments of the TRDV2 multispecific antibodies provided herein, both the first binding domain and the second binding domain are human. In some embodiments of the TRDV2 multispecific antibodies provided herein, the first binding domain is humanized. In some embodiments of the TRDV2 multispecific antibodies provided herein, the second binding domain is humanized. In some embodiments of the TRDV2 multispecific antibodies provided herein, both the first binding domain and the second binding domain are humanized. In some embodiments of the TRDV2 multispecific antibodies provided herein, the first binding domain is human and the second binding domain is humanized. In some embodiments of the TRDV2 multispecific antibodies provided herein, the first binding domain is humanized and the second binding domain is human.

In some embodiments, TRDV2 multispecific antibodies provided herein are multivalent. In some embodiments, the multispecific antibody is capable of binding at least three antigens. In some embodiments, the multispecific antibody is capable of binding at least 5 antigens. In certain embodiments, the multispecific antibody is a multispecific antibody. In some embodiments, a TRDV2 multispecific antibody provided herein is an IgG antibody. In some embodiments, the IgG antibody is an IgG1 antibody. In some embodiments, the IgG antibody is an IgG2 antibody. In some embodiments, the IgG antibody is an IgG3 antibody. In some embodiments, the IgG antibody is an IgG4 antibody.

In certain embodiments, an antibody provided herein is part of a multispecific antibody. In some embodiments, the multispecific antibody comprises a first binding domain that binds a TRDV2 antigen. In some embodiments, the multispecific antibody, as provided herein, comprises a first binding domain that binds a TRDV2 antigen and comprises a second binding domain that binds a second target antigen. In certain embodiments, the multispecific antibody binds a TRDV2 antigen, a second target antigen, and one or more additional antigens. In some embodiments of the various antibodies provided herein, the antibody binds an epitope of a given antigen.

In some embodiments, a TRGDC antibody provided herein is chimeric. In some embodiments, a TRGDC antibody provided herein is human. In some embodiments, a TRGDC antibody provided herein is humanized. In some embodiments, a TRGDC antibody provided herein is an isolated TRGDC antibody. In some embodiments, a TRGDC antigen-binding fragment provided herein is chimeric. In some embodiments, a TRGDC antigen-binding fragment provided herein is human. In some embodiments, a TRGDC antigen-binding fragment provided herein is humanized. In certain embodiments, a TRGDC antigen-binding fragment provided herein is an isolated TRGDC antigen-binding fragment. In some embodiments, the TRGDC antibody is an IgG antibody. In some embodiments, the IgG antibody is an IgG1 antibody. In some embodiments, the IgG antibody is an IgG2 antibody. In some embodiments, the IgG antibody is an IgG3 antibody. In some embodiments, the IgG antibody is an IgG4 antibody. In some embodiments, a TRGDC antibody provided herein is multivalent. In some embodiments, an antibody is capable of binding at least three antigens. In some embodiments, an antibody is capable of binding at least 4 antigens. In some embodiments, an antibody is capable of binding at least 5 antigens.

In some embodiments, the TRGDC multispecific antibodies provided herein are chimeric. In some embodiments, TRGDC multispecific antibodies provided herein are human. In some embodiments, TRGDC multispecific antibodies provided herein are humanized. In some embodiments, a TRGDC multispecific antibody provided herein is an isolated TRGDC multispecific antibody. In some embodiments, a TRGDC multispecific antibody comprising a TRGDC antigen-binding fragment provided herein is chimeric. In some embodiments, a TRGDC multispecific antibody comprising a TRGDC antigen-binding fragment provided herein is human. In some embodiments, a TRGDC multispecific antibody comprising a TRGDC antigen-binding fragment provided herein is humanized. In some embodiments, a TRGDC multispecific antibody comprising a TRGDC antigen-binding fragment provided herein is an isolated TRGDC multispecific antibody.

In some embodiments of the TRGDC multispecific antibodies provided herein, the first binding domain is human. In some embodiments, the second binding domain is human. In some embodiments of the TRGDC multispecific antibodies provided herein, both the first binding domain and the second binding domain are human. In some embodiments of the TRGDC multispecific antibodies provided herein, the first binding domain is humanized. In some embodiments of the TRGDC multispecific antibodies provided herein, the second binding domain is humanized. In some embodiments of the TRGDC multispecific antibodies provided herein, both the first binding domain and the second binding domain are humanized. In some embodiments of the TRGDC multispecific antibodies provided herein, the first binding domain is human and the second binding domain is humanized. In some embodiments of the TRGDC multispecific antibodies provided herein, the first binding domain is humanized and the second binding domain is human.

In some embodiments, TRGDC multispecific antibodies provided herein are multivalent. In some embodiments, the multispecific antibody is capable of binding at least three antigens. In some embodiments, the multispecific antibody is capable of binding at least 5 antigens. In certain embodiments, the multispecific antibody is a multispecific antibody. In some embodiments, a TRGDC multispecific antibody provided herein is an IgG antibody. In some embodiments, the IgG antibody is an IgG1 antibody. In some embodiments, the IgG antibody is an IgG2 antibody. In some embodiments, the IgG antibody is an IgG3 antibody. In some embodiments, the IgG antibody is an IgG4 antibody.

In certain embodiments, an antibody provided herein is part of a multispecific antibody. In some embodiments, the multispecific antibody comprises a first binding domain that binds a TRGDC antigen. In some embodiments, the multispecific antibody, as provided herein, comprises a first binding domain that binds a TRGDC antigen and comprises a second binding domain that binds a second target antigen. In certain embodiments, the multispecific antibody binds a TRGDC antigen, a second target antigen, and one or more additional antigens. In some embodiments of the various antibodies provided herein, the antibody binds an epitope of a given antigen.

Also provided are nucleic acid sequences encoding the antibodies provided herein. In another general aspect, a vector comprising an isolated nucleic acid sequence encoding an antibody provided herein is provided. In another general aspect, a vector comprising an isolated nucleic acid sequence encoding an antibody provided herein is provided. Also provided are vectors comprising nucleic acid sequences encoding the antibodies provided herein. Also provided are host cells comprising vectors comprising nucleic acid sequences encoding the antibodies provided herein. Also provided are kits comprising vectors comprising nucleic acid sequences encoding the antibodies provided herein and packaging therefor. In another general aspect, provided herein is an isolated nucleic acid sequence encoding a monoclonal antibody or antigen-binding fragment thereof provided herein. In certain embodiments, the antibody is a TRGV9 antibody. In certain embodiments, the antibody is a TRDV2 antibody. In certain embodiments, the antibody is a TRGDC antibody.

It will be appreciated by those of skill in the art that it is possible to change the coding sequence of a protein (eg, make a substitution, deletion, insertion, etc.) without changing the amino acid sequence of the protein. Thus, one skilled in the art will appreciate that alterations may be made to the nucleic acid sequence encoding the antibodies provided herein without altering the amino acid sequence of the protein.

In view of this disclosure, any vector known to one of ordinary skill in the art may be used, such as a plasmid, cosmid, phage vector, or viral vector. In some embodiments, the vector is a recombinant expression vector, such as a plasmid. A vector may include any elements for establishing the normal function of an expression vector, such as promoters, ribosome binding elements, terminators, enhancers, selectable markers, and origins of replication. A promoter may be a constitutive, inducible, or repressive promoter. A number of expression vectors capable of delivering nucleic acids to cells are known in the art and can be used herein for the production of antibodies or antigen-binding fragments thereof in cells. Conventional cloning techniques or artificial gene synthesis may be used to generate recombinant expression vectors according to certain embodiments. Such techniques are well known to those skilled in the art in light of this disclosure.

Also provided are host cells comprising an isolated nucleic acid sequence encoding an antibody provided herein. Also provided are host cells comprising an isolated nucleic acid sequence encoding an antigen-binding fragment provided herein. Any host cell known to one of ordinary skill in the art in light of this disclosure can be used for recombinant expression of an antibody or antigen-binding fragment thereof provided herein. In some embodiments, the host cells are E. coli TG1 or BL21 cells (eg, for expression of scFv or Fab antibodies), CHO-DG44 or CHO-K1 cells, or HEK293 cells (eg, for expression of full-length IgG antibodies). for expression). According to certain embodiments, the recombinant expression vector is transformed into a host cell by conventional methods, such as chemical transfection, heat shock, or electroporation, wherein it is stably integrated into the host cell genome such that the recombinant nucleic acid sequence is effectively expressed. do.

Also provided are methods of generating the antibodies disclosed herein. The method comprises culturing a cell comprising a nucleic acid encoding the antibody under conditions that produce the antibody, and recovering the antibody from the cell or cell culture (eg, supernatant). The expressed antibody can be harvested from the cells and purified according to conventional techniques known in the art and as described in this disclosure.

pharmaceutical composition

In another general aspect, a pharmaceutical composition comprising a TRGV9 antibody provided herein and a pharmaceutically acceptable carrier is provided. In another general aspect, a pharmaceutical composition comprising a TRDV2 antibody provided herein and a pharmaceutically acceptable carrier is provided. In another general aspect, a pharmaceutical composition comprising a TRGDC antibody provided herein and a pharmaceutically acceptable carrier is provided. In certain embodiments, the antibody is isolated. Also provided is a method of preparing the pharmaceutical composition comprising combining the antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

In another aspect, provided herein is a pharmaceutical composition comprising (a) a first binding domain that binds TRGV9 and (b) a second binding domain that binds a second target, and a pharmaceutically acceptable carrier includes In another aspect, provided herein is a pharmaceutical composition comprising (a) a first binding domain that binds TRDV2 and (b) a second binding domain that binds a second target, and a pharmaceutically acceptable carrier includes In another aspect, provided herein is a pharmaceutical composition comprising (a) a first binding domain that binds TRGDC and (b) a second binding domain that binds a second target, and a pharmaceutically acceptable carrier includes Any multispecific antibody provided herein is contemplated in a pharmaceutical composition.

As used herein, the term “pharmaceutical composition” refers to a product comprising an antibody provided herein together with a pharmaceutically acceptable carrier. The antibodies provided herein and compositions comprising them are also useful in the manufacture of medicaments for therapeutic applications.

As used herein, the term "carrier" refers to any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid-containing vesicle, microsphere, liposomal encapsulation, or pharmaceutical formulation. refers to other materials well known in the art for It will be appreciated that the nature of the carrier, excipient, or diluent will depend on the route of administration for the particular application. As used herein, the term "pharmaceutically acceptable carrier" refers to a non-toxic material that does not interfere with the effectiveness of the compositions provided herein, or the biological activity of the compositions provided herein. According to certain embodiments, in view of the present disclosure, any pharmaceutically acceptable carrier suitable for use in antibody pharmaceutical compositions may be used herein.

Formulations of pharmaceutically active ingredients containing pharmaceutically acceptable carriers are known in the art, for example, in Remington: The Science and Practice of Pharmacy (eg, 21st edition (2005) and subsequent publications therein). edition)]. Non-limiting examples of additional ingredients include buffers, diluents, solvents, tonicity adjusting agents, preservatives, stabilizers, and chelating agents. One or more pharmaceutically acceptable carriers may be used in formulating the pharmaceutical compositions provided herein.

In one embodiment, the pharmaceutical composition is a liquid formulation. Preferred examples of liquid formulations are aqueous formulations, ie formulations containing water. Liquid formulations may include solutions, suspensions, emulsions, microemulsions, gels, and the like. Aqueous formulations typically contain at least 50% w/w water, or at least 60%, 70%, 75%, 80%, 85%, 90%, or at least 95% w/w water.

In one embodiment, the pharmaceutical composition may be formulated as an injectable, for example injectable via an injection device (eg, syringe or infusion pump). Injections can be delivered, for example, subcutaneously, intramuscularly, intraperitoneally, intravitreally, or intravenously.

In another embodiment, the pharmaceutical composition is a solid formulation, such as a freeze-dried or spray-dried composition, which may be used as is or to which a physician or patient adds solvents and/or diluents prior to use. Solid dosage forms may include tablets, such as compressed tablets, and/or coated tablets, and capsules (eg, hard or soft gelatin capsules). The pharmaceutical composition may also be in the form of, for example, sachets, dragees, powders, granules, lozenges, or powders for reconstitution.

The dosage form may be immediate release (in which case the dosage form may contain a water-soluble or water-dispersible carrier), or delayed-release, sustained-release, or controlled-release (in which case the dosage form may be in the gastrointestinal tract or under the skin). may contain a water-insoluble polymer that controls the dissolution rate).

In other embodiments, the pharmaceutical composition can be delivered intranasally, intrabuccally, or sublingually.

The pH in the aqueous formulation may be between pH 3 and pH 10. In one embodiment, the pH of the formulation is from about 7.0 to about 9.5. In another embodiment, the pH of the formulation is from about 3.0 to about 7.0.

In another embodiment, the pharmaceutical composition includes a buffering agent. Non-limiting examples of buffering agents include arginine, aspartic acid, bicine, citrate, disodium hydrogen phosphate, fumaric acid, glycine, glycylglycine, histidine, lysine, maleic acid, malic acid, sodium acetate, sodium carbonate, sodium dihydrogen phosphate, phosphoric acid sodium, succinate, tartaric acid, tricine, and tris(hydroxymethyl)-aminomethane, and mixtures thereof. Buffers may be present individually or in aggregate at a concentration of about 0.01 mg/ml to about 50 mg/ml, for example about 0.1 mg/ml to about 20 mg/ml. A pharmaceutical composition comprising each of these specific buffering agents constitutes an alternative embodiment.

In another embodiment, the pharmaceutical composition includes a preservative. Non-limiting examples of preservatives include benzethonium chloride, benzoic acid, benzyl alcohol, bronopol, butyl 4-hydroxybenzoate, chlorobutanol, chlorocresol, chlorhexidine, chlorphenesin, o-cresol, m-cresol, p-cresol, ethyl 4-hydroxybenzoate, imidurea, methyl 4-hydroxybenzoate, phenol, 2-phenoxyethanol, 2-phenylethanol, propyl 4-hydroxybenzoate, sodium dehydroacetate, thiomerosal, and mixtures thereof. The preservatives may be present individually or in aggregate at a concentration of about 0.01 mg/ml to about 50 mg/ml, for example about 0.1 mg/ml to about 20 mg/ml. A pharmaceutical composition comprising each of these specific preservatives constitutes an alternative embodiment.

In another embodiment, the pharmaceutical composition includes an isotonic agent. Non-limiting examples of isotonic agents include salts (eg, sodium chloride), amino acids (eg, glycine, histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, and threonine), alditols (eg, glycerol, 1,2- propanediol (propylene glycol, 1,3-propanediol, and 1,3-butanediol), polyethylene glycol (eg, PEG400), and mixtures thereof. Another example of an isotonic agent includes a sugar. Non-limiting examples of sugars include monosaccharides, disaccharides, or polysaccharides, or water-soluble glucans (e.g., fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, including dextrins, cyclodextrins, alpha and beta-HPCD, soluble starch, hydroxyethyl starch, and sodium carboxymethyl-cellulose). Another example of an isotonic agent is a sugar alcohol, wherein the term “sugar alcohol” is defined as a C(4-8) hydrocarbon having at least one —OH group. Non-limiting examples of sugar alcohols include mannitol, sorbitol, inositol, galactitol, dulcitol, xylitol, and arabitol. Isotonic agents may be present individually or in aggregate at a concentration of about 0.01 mg/ml to about 50 mg/ml, for example about 0.1 mg/ml to about 20 mg/ml. A pharmaceutical composition comprising each of these particular isotonic agents constitutes an alternative embodiment.

In another embodiment, the pharmaceutical composition includes a chelating agent. Non-limiting examples of chelating agents include citric acid, aspartic acid, salts of ethylenediaminetetraacetic acid (EDTA), and mixtures thereof. The chelating agent may be present individually or in aggregate at a concentration of about 0.01 mg/ml to about 50 mg/ml, for example about 0.1 mg/ml to about 20 mg/ml. A pharmaceutical composition comprising each of these specific chelating agents constitutes an alternative embodiment.

In another embodiment, the pharmaceutical composition includes a stabilizer. Non-limiting examples of stabilizers include one or more aggregation inhibitors, one or more oxidation inhibitors, one or more surfactants, and/or one or more protease inhibitors.

In another embodiment, the pharmaceutical composition comprises a stabilizer, which stabilizer is carboxy-/hydroxycellulose and its derivatives (eg HPC, HPC-SL, HPC-L and HPMC), cyclodextrin, 2-methylthioethanol , polyethylene glycol (eg PEG 3350), polyvinyl alcohol (PVA), polyvinyl pyrrolidone, a salt (eg sodium chloride), a sulfur-containing material such as monothioglycerol), or thioglycolic acid. Stabilizers may be present individually or in aggregate at a concentration of about 0.01 mg/ml to about 50 mg/ml, for example about 0.1 mg/ml to about 20 mg/ml. A pharmaceutical composition comprising each of these specific stabilizers constitutes an alternative embodiment.

In a further embodiment, the pharmaceutical composition comprises one or more surfactants, preferably certain surfactants, at least one surfactant, or two different surfactants. The term “surfactant” refers to any molecule or ion composed of a water-soluble (hydrophilic) part and an oil-soluble (lipophilic) part. The surfactant may be selected from the group consisting of, for example, anionic surfactants, cationic surfactants, nonionic surfactants, and/or zwitterionic surfactants. The surfactants may be present individually or in aggregate at a concentration of about 0.1 mg/ml to about 20 mg/ml. A pharmaceutical composition comprising each of these specific surfactants constitutes an alternative embodiment.

In a further embodiment, the pharmaceutical composition includes one or more protease inhibitors, such as EDTA, and/or benzamidine hydrochloride (HCl). The protease inhibitors may be present individually or in aggregate at a concentration of about 0.1 mg/ml to about 20 mg/ml. A pharmaceutical composition comprising each of these specific protease inhibitors constitutes an alternative embodiment.

In another general aspect, provided herein is a method for preparing a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof provided herein, wherein the method comprises combining the antibody or antigen-binding fragment thereof with a pharmaceutically acceptable carrier. combining to obtain a pharmaceutical composition.

How to use

Functional activity of the antibodies provided herein can be characterized by methods known in the art and as described herein. Methods for characterizing antibodies and antigen-binding fragments thereof include affinity and specificity assays including Biacore, ELISA, and OctetRed assays; a binding assay to detect binding of the antibody to target cells by FACS; Binding assays to detect binding of an antibody to a target antigen on a cell include, but are not limited to. According to certain embodiments, methods for characterizing antibodies and antigen-binding fragments thereof include those described below. In certain embodiments, the antibody is a TRGV9 antibody. In certain embodiments, the antibody is a TRDV2 antibody. In certain embodiments, the antibody is a TRGDC antibody.

In one aspect, a method of activating a T cell expressing TRGV9 is provided, the method comprising contacting the T cell with a TRGV9 antibody provided herein. In some embodiments, the contacting results in increased expression of CD69, CD25, and/or granzyme B as compared to control T cells expressing TRGV9.

In another general aspect, a method of inactivating a T cell expressing TRGV9 is provided, the method comprising contacting the T cell with an antibody provided herein that binds TRGV9. In another general aspect, a method of blocking activation of a T cell expressing TRGV9 is provided, the method comprising contacting the T cell with an antibody provided herein that binds TRGV9. In another general aspect, a method of modulating activation of a T cell expressing TRGV9 is provided, the method comprising contacting the T cell with an antibody provided herein that binds TRGV9.

In another aspect, provided herein is a method of directing a T cell expressing TRGV9 to a target cell, the method comprising contacting the T cell with a multispecific TRGV9 antibody provided herein. In another aspect, provided herein is a method of inducing a T cell expressing TRGV9 into a target cell, the method comprising contacting the T cell with a pharmaceutical composition comprising a multispecific TRGV9 antibody provided herein . In some embodiments, the contacting directs the T cell to the target cell. Also provided is a method of targeting an antigen on the surface of a target cell, the method comprising exposing the target cell to a multispecific TRGV9 antibody provided herein. Also provided is a method of targeting an antigen on the surface of a target cell, the method comprising exposing the target cell to a pharmaceutical composition comprising a multispecific TRGV9 antibody provided herein. In another general aspect, a method of targeting an antigen on the surface of a target cell is provided, the method comprising exposing the target cell to a multispecific TRGV9 antibody provided herein. In another general aspect, a method of targeting an antigen on the surface of a target cell is provided, the method comprising exposing the target cell to a pharmaceutical composition comprising a multispecific TRGV9 antibody provided herein.

Also provided herein is a method of treating a disease or disorder in a subject comprising administering to the subject a TRGV9 antibody provided herein. Also provided herein are methods of treating a disease or disorder in a subject comprising administering to the subject a TRGV9 antigen-binding fragment provided herein. Also provided herein is a method of treating a disease or disorder in a subject comprising administering to the subject a pharmaceutical composition comprising a TRGV9 antibody provided herein. Also provided are methods of treating a disease or disorder in a subject comprising administering to the subject a pharmaceutical composition comprising a TRGV9 antigen-binding fragment provided herein. In certain embodiments, the disease or disorder is caused in whole or in part by target cells expressing the second target.

In some embodiments, methods of directing γδ T cells to target cells are also provided, the methods comprising contacting the γδ T cells with a multispecific TRGV9 antibody provided herein. In some embodiments, use of the TRGV9 antibodies provided herein to direct γδ T cells to target cells is also provided. In some embodiments, use of the TRGV9 multispecific antibodies provided herein in the manufacture of a medicament for directing γδ T cells to target cells is also provided. In certain embodiments, the target cell expresses a second target. In some embodiments, the contacting step directs the γδ T cells to the target cells.

In some embodiments, a method of inhibiting growth or proliferation of a target cell is also provided, the method comprising contacting the target cell with a multispecific TRGV9 antibody provided herein. In some embodiments, use of the TRGV9 multispecific antibodies provided herein to inhibit growth or proliferation of target cells is also provided. In some embodiments, use of the TRGV9 multispecific antibodies provided herein in the manufacture of a medicament for inhibiting the growth or proliferation of a target cell is also provided. In certain embodiments, the target cell expresses a second target on the cell surface. In certain embodiments, contacting a target cell with the multispecific TRGV9 antibody inhibits growth or proliferation of the target cell. In some embodiments, the target cell is in the presence of T cells expressing TRGV9 while in contact with the multispecific antibody. In certain embodiments, the T cells expressing TRGV9 are γδ T cells.

In some embodiments, a method of depleting a target cell in a subject is also provided, the method comprising administering to the subject an effective amount of a multispecific TRGV9 antibody provided herein. In some embodiments, use of the multispecific TRGV9 antibodies provided herein to eliminate target cells in a subject is also provided. In some embodiments, use of the TRGV9 multispecific antibodies provided herein in the manufacture of a medicament for depleting target cells in a subject is also provided. In some embodiments, the target cell expresses a second target on the cell surface. In certain embodiments, the target cell is in the presence of T cells expressing TRGV9 in the subject. In certain embodiments, the T cells expressing TRGV9 are γδ T cells. In certain embodiments, the subject is one in need thereof.

In some embodiments, a method of treating a disease caused in whole or in part by target cells in a subject is also provided, the method comprising administering to the subject an effective amount of a multispecific TRGV9 antibody provided herein. In some embodiments, use of the multispecific TRGV9 antibody in the treatment of a disease caused in whole or in part by target cells in a subject is also provided. In some embodiments, use of the multispecific TRGV9 antibodies provided herein in the manufacture of a medicament for treating a disease caused in whole or in part by target cells in a subject is also provided. In some embodiments, the target cell expresses a second target on the cell surface. In certain embodiments, the target cell is in the presence of T cells expressing TRGV9 in the subject. In certain embodiments, the T cells expressing TRGV9 are γδ T cells. In certain embodiments, the subject is one in need thereof. In some embodiments, the second target is a cancer antigen. In some embodiments, the second target is a tumor-associated antigen.

Also provided is a method of activating a T cell that expresses TRDV2, the method comprising contacting the T cell with a TRDV2 antibody provided herein. In some embodiments, the contacting results in increased expression of CD69, CD25, and/or granzyme B as compared to control T cells expressing TRDV2.

In another general aspect, a method of inactivating a T cell expressing TRDV2 is provided, the method comprising contacting the T cell with an antibody that binds TRDV2 provided herein. In another general aspect, a method of blocking activation of a T cell expressing TRDV2 is provided, the method comprising contacting the T cell with an antibody that binds TRDV2 provided herein. In another general aspect, a method of modulating activation of a T cell expressing TRDV2 is provided, the method comprising contacting the T cell with an antibody that binds TRDV2 provided herein.

In another aspect, provided herein is a method of directing a T cell expressing TRDV2 to a target cell, the method comprising contacting the T cell with a multispecific TRDV2 antibody provided herein. In another aspect, provided herein is a method of directing a T cell expressing TRDV2 to a target cell, the method comprising contacting the T cell with a pharmaceutical composition comprising a multispecific TRDV2 antibody provided herein . In some embodiments, the contacting directs the T cell to the target cell. Also provided is a method of targeting an antigen on the surface of a target cell, the method comprising exposing the target cell to a TRDV2 multispecific antibody provided herein. Also provided is a method of targeting an antigen on the surface of a target cell, the method comprising exposing the target cell to a pharmaceutical composition comprising a TRDV2 multispecific antibody provided herein. In another general aspect, a method of targeting an antigen on the surface of a target cell is provided, the method comprising exposing the target cell to a TRDV2 multispecific antibody provided herein. In another general aspect, a method of targeting an antigen on the surface of a target cell is provided, the method comprising exposing the target cell to a pharmaceutical composition comprising a TRDV2 multispecific antibody provided herein.

Also provided herein are methods of treating a disease or disorder in a subject comprising administering to the subject a TRDV2 antibody provided herein. Also provided herein are methods of treating a disease or disorder in a subject comprising administering to the subject a TRDV2 antigen-binding fragment provided herein. Also provided herein is a method of treating a disease or disorder in a subject comprising administering to the subject a pharmaceutical composition comprising a TRDV2 antibody provided herein. Also provided are methods of treating a disease or disorder in a subject comprising administering to the subject a pharmaceutical composition comprising a TRDV2 antigen-binding fragment provided herein. In certain embodiments, the disease or disorder is caused in whole or in part by target cells expressing the second target.

In some embodiments, methods of directing γδ T cells to target cells are also provided, the methods comprising contacting the γδ T cells with a multispecific TRDV2 antibody provided herein. In some embodiments, use of a TRDV2 antibody provided herein to direct γδ T cells to target cells is also provided. In some embodiments, use of the TRDV2 multispecific antibodies provided herein in the manufacture of a medicament for directing γδ T cells to target cells is also provided. In certain embodiments, the target cell expresses a second target. In some embodiments, the contacting step directs the γδ T cells to the target cells.

In some embodiments, a method of inhibiting growth or proliferation of a target cell is also provided, the method comprising contacting the target cell with a multispecific TRDV2 antibody provided herein. In some embodiments, use of the TRDV2 multispecific antibodies provided herein to inhibit growth or proliferation of target cells is also provided. In some embodiments, use of the TRDV2 multispecific antibodies provided herein in the manufacture of a medicament for inhibiting the growth or proliferation of a target cell is also provided. In certain embodiments, the target cell expresses a second target on the cell surface. In certain embodiments, contacting a target cell with the multispecific TRDV2 antibody inhibits growth or proliferation of the target cell. In some embodiments, the target cell is in the presence of T cells expressing TRDV2 while in contact with the multispecific antibody. In certain embodiments, the T cells expressing TRDV2 are γδ T cells.

In some embodiments, a method of depleting a target cell in a subject is also provided, the method comprising administering to the subject an effective amount of a multispecific TRDV2 antibody provided herein. In some embodiments, use of the multispecific TRDV2 antibodies provided herein to deplete target cells in a subject is also provided. In some embodiments, use of the TRDV2 multispecific antibodies provided herein in the manufacture of a medicament for depleting target cells in a subject is also provided. In some embodiments, the target cell expresses a second target on the cell surface. In certain embodiments, the target cell is in the presence of T cells expressing TRDV2 in the subject. In certain embodiments, the T cells expressing TRDV2 are γδ T cells. In certain embodiments, the subject is one in need thereof.

In some embodiments, a method of treating a disease caused in whole or in part by target cells in a subject is also provided, the method comprising administering to the subject an effective amount of a multispecific TRDV2 antibody provided herein. In some embodiments, use of the multispecific TRDV2 antibody in the treatment of a disease caused in whole or in part by target cells in a subject is also provided. In some embodiments, use of the multispecific TRDV2 antibodies provided herein in the manufacture of a medicament for treating a disease caused in whole or in part by target cells in a subject is also provided. In some embodiments, the target cell expresses a second target on the cell surface. In certain embodiments, the target cell is in the presence of T cells expressing TRDV2 in the subject. In certain embodiments, the T cells expressing TRDV2 are γδ T cells. In certain embodiments, the subject is one in need thereof. In some embodiments, the second target is a cancer antigen. In some embodiments, the second target is a tumor-associated antigen.

Also provided is a method of activating a T cell expressing TRGDC, the method comprising contacting the T cell with a TRGDC antibody provided herein. In some embodiments, the contacting results in increased expression of CD69, CD25, and/or granzyme B as compared to control T cells expressing TRGDC.

In another general aspect, a method of inactivating a T cell expressing TRGDC is provided, the method comprising contacting the T cell with an antibody that binds TRGDC provided herein. In another general aspect, a method of blocking activation of a T cell expressing TRGDC is provided, the method comprising contacting the T cell with an antibody provided herein that binds TRGDC. In another general aspect, a method of modulating activation of a T cell expressing TRGDC is provided, the method comprising contacting the T cell with an antibody that binds TRGDC provided herein.

In another aspect, provided herein is a method of directing a T cell expressing TRGDC to a target cell, the method comprising contacting the T cell with a multispecific TRGDC antibody provided herein. In another aspect, provided herein is a method of directing a T cell expressing TRGDC to a target cell, the method comprising contacting the T cell with a pharmaceutical composition comprising a multispecific TRGDC antibody provided herein . In some embodiments, the contacting directs the T cell to the target cell. Also provided is a method of targeting an antigen on the surface of a target cell, the method comprising exposing the target cell to a TRGDC multispecific antibody provided herein. Also provided is a method of targeting an antigen on the surface of a target cell, the method comprising exposing the target cell to a pharmaceutical composition comprising a TRGDC multispecific antibody provided herein. In another general aspect, a method of targeting an antigen on the surface of a target cell is provided, the method comprising exposing the target cell to a TRGDC multispecific antibody provided herein. In another general aspect, a method of targeting an antigen on the surface of a target cell is provided, the method comprising exposing the target cell to a pharmaceutical composition comprising a TRGDC multispecific antibody provided herein.

Also provided herein is a method of treating a disease or disorder in a subject comprising administering to the subject a TRGDC antibody provided herein. Also provided herein are methods of treating a disease or disorder in a subject comprising administering to the subject a TRGDC antigen-binding fragment provided herein. Also provided herein is a method of treating a disease or disorder in a subject comprising administering to the subject a pharmaceutical composition comprising a TRGDC antibody provided herein. Also provided is a method of treating a disease or disorder in a subject comprising administering to the subject a pharmaceutical composition comprising a TRGDC antigen-binding fragment provided herein. In certain embodiments, the disease or disorder is caused in whole or in part by target cells expressing the second target.

In some embodiments, methods of directing γδ T cells to target cells are also provided, the methods comprising contacting the γδ T cells with a multispecific TRGDC antibody provided herein. In some embodiments, use of the TRGDC antibodies provided herein to direct γδ T cells to target cells is also provided. In some embodiments, use of the TRGDC multispecific antibodies provided herein in the manufacture of a medicament for directing γδ T cells to target cells is also provided. In certain embodiments, the target cell expresses a second target. In some embodiments, the contacting step directs the γδ T cells to the target cells.

In some embodiments, a method of inhibiting growth or proliferation of a target cell is also provided, the method comprising contacting the target cell with a multispecific TRGDC antibody provided herein. In some embodiments, use of the TRGDC multispecific antibodies provided herein to inhibit growth or proliferation of target cells is also provided. In some embodiments, use of the TRGDC multispecific antibodies provided herein in the manufacture of a medicament for inhibiting the growth or proliferation of a target cell is also provided. In certain embodiments, the target cell expresses a second target on the cell surface. In certain embodiments, contacting a target cell with the multispecific TRGDC antibody inhibits growth or proliferation of the target cell. In some embodiments, the target cell is in the presence of T cells expressing TRGDC while in contact with the multispecific antibody. In certain embodiments, the T cells expressing TRGDC are γδ T cells.

In some embodiments, a method of depleting a target cell in a subject is also provided, the method comprising administering to the subject an effective amount of a multispecific TRGDC antibody provided herein. In some embodiments, use of the multispecific TRGDC antibodies provided herein to deplete target cells in a subject is also provided. In some embodiments, use of the TRGDC multispecific antibodies provided herein in the manufacture of a medicament for depleting target cells in a subject is also provided. In some embodiments, the target cell expresses a second target on the cell surface. In some embodiments, the target cell is in the presence of T cells expressing TRGDC in the subject. In certain embodiments, the T cells expressing TRGDC are γδ T cells. In certain embodiments, the subject is one in need thereof.

In some embodiments, a method of treating a disease caused in whole or in part by target cells in a subject is also provided, the method comprising administering to the subject an effective amount of a multispecific TRGDC antibody provided herein. In some embodiments, use of the multispecific TRGDC antibody in the treatment of a disease caused in whole or in part by target cells in a subject is also provided. In another aspect, use of the TRGDC multispecific antibodies provided herein in the manufacture of a medicament for treating a disease caused in whole or in part by target cells in a subject is also provided. In some embodiments, the target cell expresses a second target on the cell surface. In some embodiments, the target cell is in the presence of T cells expressing TRGDC in the subject. In certain embodiments, the T cells expressing TRGDC are γδ T cells. In certain embodiments, the subject is one in need thereof. In some embodiments, the second target is a cancer antigen. In some embodiments, the second target is a tumor-associated antigen.

In some embodiments, the subject is a subject in need thereof. In some embodiments, the subject is a human. In certain embodiments, an effective amount is administered to a subject.

As used herein, the term “effective amount” refers to an active ingredient or amount of ingredients that elicits a desired biological or medical response in a subject.

According to certain embodiments, an effective amount refers to an amount of therapy sufficient to achieve one, two, three, four, or more of the following effects: (i) the disease, disorder, or condition being treated, or symptoms associated therewith; the effect of reducing or alleviating the severity of; (ii) shortening the duration of the disease, disorder, or condition being treated, or symptoms associated therewith; (iii) preventing progression of the disease, disorder or condition being treated, or symptoms associated therewith; (iv) effects that cause regression of the disease, disorder or condition being treated, or symptoms associated therewith; (v) preventing the occurrence or onset of the disease, disorder or condition being treated, or symptoms associated therewith; (vi) preventing recurrence of the disease, disorder or condition being treated, or symptoms associated therewith; (vii) reducing hospitalization of a subject having the disease, disorder or condition being treated, or symptoms related thereto; (viii) reducing the length of hospitalization of a subject having the disease, disorder or condition being treated, or symptoms related thereto; (ix) increasing the survival rate of a subject having the disease, disorder or condition being treated, or symptoms related thereto; (xi) inhibiting or reducing the disease, disorder or condition being treated, or symptoms associated therewith, in a subject; and/or (xii) enhancing or ameliorating the prophylactic or therapeutic effect(s) of another therapy.

The effective amount or dosage depends on a variety of factors, such as the disease, disorder or condition being treated, the means of administration, the target site, the physiological condition of the subject (including, for example, age, weight, health), whether the subject is a human or an animal. awareness, other drugs administered, and whether the treatment is prophylactic or therapeutic. The therapeutic dose is optimally titrated to optimize safety and efficacy.

According to certain embodiments, the compositions described herein are formulated to be compatible with their intended route of administration to a subject. For example, compositions described herein may be formulated to be suitable for intravenous, subcutaneous, or intramuscular administration.

As used herein, the terms "treat," "treating," and "treatment" are all intended to refer to an improvement or reversal of at least one measurable physical parameter associated with cancer, which is necessarily identifiable in a subject. but not identifiable in the subject. The terms “treat,” “treating,” and “treatment” can also refer to causing regression or preventing the progression, or at least slowing the progression, of a disease, disorder, or condition. In certain embodiments, "treat," "treating," and "treatment" refer to the alleviation, development, or prevention of onset of, or more preferably, one or more symptoms associated with a disease, disorder, or condition, such as a tumor or cancer. Refers to a decrease in duration. In certain embodiments, “treat,” “treating,” and “treatment” refer to preventing recurrence of a disease, disorder, or condition. In certain embodiments, “treat,” “treating,” and “treatment” refer to increasing the survival rate of a subject having a disease, disorder, or condition. In certain embodiments, “treat,” “treating,” and “treatment” refer to the elimination of a disease, disorder, or condition in a subject.

In some embodiments, the TRGV9 antibodies provided herein are used in combination with supplemental therapy. In some embodiments, TRDV2 antibodies provided herein are used in combination with supplemental therapy.

In some embodiments, TRGDC antibodies provided herein are used in combination with supplemental therapy.

As used herein, with reference to administration of two or more therapies to a subject, the term “in combination” refers to the use of more than one therapies. The use of the term “in combination” does not limit the order in which the therapies are administered to a subject. For example, prior to administration of the second therapy to the subject (eg, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours , 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks ago), concurrently with, or after (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, After 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks) the first therapy (eg, a composition described herein) may be administered.

The TRGV9 antibodies provided herein can also be used as agents for detecting TRGV9-expressing cells. Accordingly, in another method, a method of detecting a cell expressing TRGV9 is provided, the method comprising contacting the cell with a TRGV9 antibody provided herein. In certain embodiments, detection is by ELISA. In some embodiments, detection is by FACS analysis. Also provided are kits comprising the TRGV9 antibodies provided herein and instructions for use.

TRDV2 antibodies provided herein can also be used as agents to detect TRDV2-expressing cells. Accordingly, in another method, a method of detecting a cell expressing TRDV2 is provided, the method comprising contacting the cell with a TRDV2 antibody provided herein. In certain embodiments, detection is by ELISA. In some embodiments, detection is by FACS analysis. Also provided are kits comprising the TRDV2 antibodies provided herein and instructions for use.

The TRGDC antibodies provided herein can also be used as agents to detect TRGDC-expressing cells. Accordingly, in another method, a method of detecting a cell expressing TRGDC is provided, the method comprising contacting the cell with a TRGDC antibody provided herein. In certain embodiments, detection is by ELISA. In some embodiments, detection is by FACS analysis. Also provided are kits comprising the TRGDC antibodies provided herein and instructions for use.

Enrichment and detection methods

In one aspect, a TRGV9 antibody provided herein is used as an agent to detect TRGV9-expressing cells. Accordingly, in another method, a method of detecting a cell expressing TRGV9 is provided, the method comprising contacting the cell with a TRGV9 antibody provided herein. In certain embodiments, detection is by ELISA. In some embodiments, detection is by FACS analysis. Also provided are kits comprising the TRGV9 antibodies provided herein and instructions for use.

Enrichment, isolation, separation, purification, sorting, selection, capture or detection, or any combination thereof, can be done using known techniques such as beads, microfluidics, solid supports, columns, and the like. For example, TRGV9 cells can be isolated or visualized using known methods when bound to a TRGV9 antibody provided herein.

TRGV9 antibodies or multispecific TRGV9 antibodies provided herein can be used to selectively enrich, isolate, isolate, purify, sort, select, capture or detect TRGV9-expressing cells. A TRGV9 antibody or multispecific TRGV9 antibody provided herein is in a bispecific format comprising, e.g., a first antigen binding domain that specifically binds TRGV9 and a second antigen binding domain that specifically binds a second target. can be used as In another embodiment, the multispecific TRGV9 antibodies provided herein can be used in a format that further incorporates a third antigen binding domain that specifically binds a third antigen (eg, in a trispecific antibody). In another embodiment, the multispecific TRGV9 antibodies provided herein can be used in a format that further incorporates a fourth antigen binding domain that specifically binds a fourth antigen (eg, as a quadrispecific antibody).

In one aspect, provided herein is a method of enriching TRGV9-expressing cells, the method comprising providing a sample comprising TRGV9-expressing cells; contacting the sample with a TRGV9 antibody provided herein; and enriching the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of isolating TRGV9-expressing cells, the method comprising providing a sample comprising TRGV9-expressing cells; contacting the sample with a TRGV9 antibody provided herein; and isolating the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of isolating TRGV9-expressing cells, the method comprising providing a sample comprising TRGV9-expressing cells; contacting the sample with a TRGV9 antibody provided herein; and isolating the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of purifying TRGV9-expressing cells, the method comprising providing a sample comprising TRGV9-expressing cells; contacting the sample with a TRGV9 antibody provided herein; and purifying the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of sorting TRGV9-expressing cells, the method comprising providing a sample comprising TRGV9-expressing cells; contacting the sample with a TRGV9 antibody provided herein; and sorting the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of selecting TRGV9-expressing cells, the method comprising providing a sample comprising TRGV9-expressing cells; contacting the sample with a TRGV9 antibody provided herein; and selecting the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of capturing TRGV9-expressing cells, the method comprising providing a sample comprising TRGV9-expressing cells; contacting the sample with a TRGV9 antibody provided herein; and capturing the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of detecting TRGV9-expressing cells, the method comprising providing a sample comprising TRGV9-expressing cells; contacting the sample with a TRGV9 antibody provided herein; and detecting the TRGV9-expressing cells bound to the TRGV9 antibody.

In one aspect, provided herein is a method of enriching TRGV9-expressing cells, comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and enriching the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of isolating a TRGV9-expressing cell, the method comprising contacting the TRGV9-expressing cell with a TRGV9 antibody provided herein; and isolating the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of isolating a TRGV9-expressing cell, comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and isolating the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of purifying a TRGV9-expressing cell, the method comprising contacting the TRGV9-expressing cell with a TRGV9 antibody provided herein; and purifying the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of sorting a TRGV9-expressing cell, the method comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and sorting the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of selecting a TRGV9-expressing cell comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and selecting the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of capturing a TRGV9-expressing cell comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and capturing the TRGV9-expressing cells bound to the TRGV9 antibody. In one aspect, provided herein is a method of detecting a TRGV9-expressing cell, comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and detecting the TRGV9-expressing cells bound to the TRGV9 antibody.

In one aspect, provided herein is a method of enriching TRGV9-expressing cells, comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and enriching the TRGV9-expressing cells based on the binding of the TRGV9-expressing cells to the TRGV9 antibody. In one aspect, provided herein is a method of isolating a TRGV9-expressing cell, the method comprising contacting the TRGV9-expressing cell with a TRGV9 antibody provided herein; and isolating the TRGV9-expressing cell based on the binding of the TRGV9-expressing cell to the TRGV9 antibody. In one aspect, provided herein is a method of isolating a TRGV9-expressing cell, comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and isolating the TRGV9-expressing cells based on binding of the TRGV9-expressing cells to the TRGV9 antibody. In one aspect, provided herein is a method of purifying a TRGV9-expressing cell, the method comprising contacting the TRGV9-expressing cell with a TRGV9 antibody provided herein; and purifying the TRGV9-expressing cells based on binding of the TRGV9-expressing cells to the TRGV9 antibody. In one aspect, provided herein is a method of sorting a TRGV9-expressing cell, the method comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and sorting the TRGV9-expressing cells based on binding of the TRGV9-expressing cells to the TRGV9 antibody. In one aspect, provided herein is a method of selecting a TRGV9-expressing cell comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and selecting the TRGV9-expressing cell based on the binding of the TRGV9-expressing cell to the TRGV9 antibody. In one aspect, provided herein is a method of capturing a TRGV9-expressing cell comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and capturing the TRGV9-expressing cell based on binding of the TRGV9-expressing cell to the TRGV9 antibody. In one aspect, provided herein is a method of detecting a TRGV9-expressing cell, comprising contacting a TRGV9-expressing cell with a TRGV9 antibody provided herein; and detecting the TRGV9-expressing cell based on binding of the TRGV9-expressing cell to the TRGV9 antibody.

In certain embodiments of the above methods, the TRGV9-expressing cell is a T cell. In some embodiments of the above methods, the TRGV9-expressing cells are present in a population of cells. In some embodiments of the above methods, the TRGV9-expressing cell is within a population of lymphocytes. In some embodiments of the above methods, the TRGV9-expressing cells are within a T cell population. In some embodiments of the above methods, the TRGV9-expressing cells are provided as a cell population. In some embodiments of the above methods, the TRGV9-expressing cells are provided as a population of lymphocytes. In some embodiments of the above methods, the TRGV9-expressing cells are provided as a T cell population. In some embodiments of the above methods, TRGV9-expressing cells are provided as a sample comprising a population of cells. In some embodiments of the above methods, TRGV9-expressing cells are provided as a sample comprising a population of lymphocytes. In some embodiments of the above methods, TRGV9-expressing cells are provided as a sample comprising a T cell population. In some embodiments of the above methods, the sample is a blood sample. In some embodiments of the above methods, the sample is a tissue sample. In some embodiments of the above methods, the sample is a tissue culture sample.

In some embodiments of the above methods, the TRGV9 antibody is a multispecific TRGV9 antibody provided herein. In some embodiments of the above methods, the TRGV9 antibody is a bispecific TRGV9 antibody provided herein. In some embodiments of the above methods, the TRGV9 antibody is a trispecific TRGV9 antibody provided herein. In some embodiments of the above methods, the TRGV9 antibody is a quadspecific TRGV9 antibody provided herein. In certain embodiments, the TRGV9 antibody specifically binds TRGV9. In one embodiment, the multispecific TRGV9 antibody comprises (a) a first binding domain that binds TRGV9, and (b) a second binding domain that binds a second target. In one embodiment, the multispecific TRGV9 antibody comprises (a) a first binding domain that binds TRGV9, and (b) a second binding domain that binds a second target, and (c) a third binding domain that binds a third target. contains the domain In one embodiment, the multispecific TRGV9 antibody comprises (a) a first binding domain that binds TRGV9, and (b) a second binding domain that binds a second target, (c) a third binding domain that binds a third target. , and (d) a fourth binding domain that binds to a fourth target. In one embodiment, the multispecific TRGV9 antibody comprises (a) a first binding domain that specifically binds TRGV9, and (b) a second binding domain that specifically binds a second target. In one embodiment, the multispecific TRGV9 antibody comprises (a) a first binding domain that specifically binds TRGV9, and (b) a second binding domain that specifically binds a second target, and (c) a third target. It includes a third binding domain that specifically binds to. In one embodiment, the multispecific TRGV9 antibody comprises (a) a first binding domain that specifically binds to TRGV9, and (b) a second binding domain that specifically binds to a second target, (c) a third binding domain that binds to a third target. a third binding domain that specifically binds, and (d) a fourth binding domain that specifically binds to a fourth target.

In a specific embodiment of the methods provided herein, the method uses multi-marker detection. In some embodiments, multi-marker detection uses a multispecific TRGV9 antibody provided herein. In some embodiments, multi-marker detection uses a bispecific TRGV9 antibody provided herein. In some embodiments, multi-marker detection uses a trispecific TRGV9 antibody provided herein. In some embodiments, multi-marker detection uses a quadspecific TRGV9 antibody provided herein.

In certain embodiments of the methods provided herein, the methods are included as steps in a T cell manufacturing process. In certain embodiments, the cell is a CAR-T cell. In certain embodiments of the methods provided herein, the methods are included as steps in a T cell transformation process.

In certain embodiments of the methods provided herein, the methods are included as steps in a diagnostic method. In certain embodiments of the methods provided herein, the methods are included as steps in a method of quantifying TRGV9-expressing T cells.

In certain embodiments of the methods provided herein, the method further comprises amplifying the enriched, isolated, separated, purified, sorted, selected, captured or detected TRGV9-expressing cells. In certain embodiments, amplification is performed in vitro. In certain embodiments, amplification is performed in vivo. In certain embodiments of the methods provided herein, the method further comprises growing the enriched, isolated, separated, purified, sorted, selected, captured or detected TRGV9-expressing cells. In certain embodiments, growth is in vitro. In certain embodiments, growth is in vivo. In certain embodiments of the methods provided herein, the method further comprises quantifying the enriched, isolated, separated, purified, sorted, selected, captured or detected TRGV9-expressing cells.

In one aspect, a TRDV2 antibody provided herein is used as an agent to detect TRDV2-expressing cells. Accordingly, in another method, a method of detecting a cell expressing TRDV2 is provided, the method comprising contacting the cell with a TRDV2 antibody provided herein. In certain embodiments, detection is by ELISA. In some embodiments, detection is by FACS analysis. Also provided are kits comprising the TRDV2 antibodies provided herein and instructions for use.

Enrichment, isolation, separation, purification, sorting, selection, capture or detection, or any combination thereof, can be done using known techniques such as beads, microfluidics, solid supports, columns, and the like. For example, TRDV2 cells can be isolated or visualized using known methods when bound to a TRDV2 antibody provided herein.

TRDV2 antibodies or multispecific TRDV2 antibodies provided herein can be used to selectively enrich, isolate, isolate, purify, sort, select, capture or detect TRDV2-expressing cells. A TRDV2 antibody or multispecific TRDV2 antibody provided herein is a dual antibody comprising, e.g., a first antigen-binding domain that specifically binds TRDV2 and a second antigen-binding domain that specifically binds a second target. Can be used in a specific format. In another embodiment, the multispecific TRDV2 antibodies provided herein may be used in a format that further incorporates a third antigen-binding domain that specifically binds a third antigen (eg, in a trispecific antibody). In another embodiment, the multispecific TRDV2 antibodies provided herein may be used in a format that further incorporates a fourth antigen-binding domain that specifically binds a fourth antigen (eg, as a quadrispecific antibody).

In one aspect, provided herein is a method of enriching TRDV2-expressing cells, the method comprising providing a sample comprising TRDV2-expressing cells; contacting the sample with a TRDV2 antibody provided herein; and enriching the TRDV2-expressing cells bound to the TRDV2 antibody. In one aspect, provided herein is a method of isolating TRDV2-expressing cells, the method comprising providing a sample comprising TRDV2-expressing cells; contacting the sample with a TRDV2 antibody provided herein; and isolating the TRDV2-expressing cells bound to the TRDV2 antibody. In one aspect, provided herein is a method of isolating TRDV2-expressing cells, the method comprising providing a sample comprising TRDV2-expressing cells; contacting the sample with a TRDV2 antibody provided herein; and isolating the TRDV2-expressing cells bound to the TRDV2 antibody. In one aspect, provided herein is a method of purifying TRDV2-expressing cells, the method comprising providing a sample comprising TRDV2-expressing cells; contacting the sample with a TRDV2 antibody provided herein; and purifying the TRDV2-expressing cells bound to the TRDV2 antibody. In one aspect, provided herein is a method of sorting TRDV2-expressing cells, the method comprising providing a sample comprising TRDV2-expressing cells; contacting the sample with a TRDV2 antibody provided herein; and sorting the TRDV2-expressing cells bound to the TRDV2 antibody. In one aspect, provided herein is a method of selecting TRDV2-expressing cells, the method comprising providing a sample comprising TRDV2-expressing cells; contacting the sample with a TRDV2 antibody provided herein; and selecting the TRDV2-expressing cells that bind to the TRDV2 antibody. In one aspect, provided herein is a method of capturing TRDV2-expressing cells, the method comprising providing a sample comprising TRDV2-expressing cells; contacting the sample with a TRDV2 antibody provided herein; and capturing the TRDV2-expressing cell bound to the TRDV2 antibody. In one aspect, provided herein is a method of detecting TRDV2-expressing cells, the method comprising providing a sample comprising TRDV2-expressing cells; contacting the sample with a TRDV2 antibody provided herein; and detecting the TRDV2-expressing cell bound to the TRDV2 antibody.

In one aspect, provided herein is a method of enriching a TRDV2-expressing cell, comprising contacting a TRDV2-expressing cell with a TRDV2 antibody provided herein; and enriching the TRDV2-expressing cells bound to the TRDV2 antibody. In one aspect, provided herein is a method of isolating a TRDV2-expressing cell, the method comprising contacting the TRDV2-expressing cell with a TRDV2 antibody provided herein; and isolating the TRDV2-expressing cells bound to the TRDV2 antibody. In one aspect, provided herein is a method of isolating a TRDV2-expressing cell comprising contacting a TRDV2-expressing cell with a TRDV2 antibody provided herein; and isolating the TRDV2-expressing cells bound to the TRDV2 antibody. In one aspect, provided herein is a method of purifying a TRDV2-expressing cell, the method comprising contacting the TRDV2-expressing cell with a TRDV2 antibody provided herein; and purifying the TRDV2-expressing cells bound to the TRDV2 antibody. In one aspect, provided herein is a method of sorting a TRDV2-expressing cell, comprising contacting a TRDV2-expressing cell with a TRDV2 antibody provided herein; and sorting the TRDV2-expressing cells bound to the TRDV2 antibody. In one aspect, provided herein is a method of selecting a TRDV2-expressing cell comprising contacting a TRDV2-expressing cell with a TRDV2 antibody provided herein; and selecting the TRDV2-expressing cells that bind to the TRDV2 antibody. In one aspect, provided herein is a method of capturing a TRDV2-expressing cell, comprising contacting the TRDV2-expressing cell with a TRDV2 antibody provided herein; and capturing the TRDV2-expressing cell bound to the TRDV2 antibody. In one aspect, provided herein is a method of detecting a TRDV2-expressing cell, comprising contacting a TRDV2-expressing cell with a TRDV2 antibody provided herein; and detecting the TRDV2-expressing cell bound to the TRDV2 antibody.

In one aspect, provided herein is a method of enriching a TRDV2-expressing cell, comprising contacting a TRDV2-expressing cell with a TRDV2 antibody provided herein; and enriching the TRDV2-expressing cells based on binding of the TRDV2-expressing cells to the TRDV2 antibody. In one aspect, provided herein is a method of isolating a TRDV2-expressing cell, the method comprising contacting the TRDV2-expressing cell with a TRDV2 antibody provided herein; and isolating the TRDV2-expressing cell based on binding of the TRDV2-expressing cell to the TRDV2 antibody. In one aspect, provided herein is a method of isolating a TRDV2-expressing cell, comprising contacting a TRDV2-expressing cell with a TRDV2 antibody provided herein; and isolating the TRDV2-expressing cells based on binding of the TRDV2-expressing cells to the TRDV2 antibody. In one aspect, provided herein is a method of purifying a TRDV2-expressing cell, the method comprising contacting the TRDV2-expressing cell with a TRDV2 antibody provided herein; and purifying the TRDV2-expressing cells based on the binding of the TRDV2-expressing cells to the TRDV2 antibody. In one aspect, provided herein is a method of sorting a TRDV2-expressing cell, comprising contacting a TRDV2-expressing cell with a TRDV2 antibody provided herein; and sorting the TRDV2-expressing cells based on the binding of the TRDV2-expressing cells to the TRDV2 antibody. In one aspect, provided herein is a method of selecting a TRDV2-expressing cell comprising contacting a TRDV2-expressing cell with a TRDV2 antibody provided herein; and selecting the TRDV2-expressing cell based on the binding of the TRDV2-expressing cell to the TRDV2 antibody. In one aspect, provided herein is a method of capturing a TRDV2-expressing cell, the method comprising contacting the TRDV2-expressing cell with a TRDV2 antibody provided herein; and capturing the TRDV2-expressing cell based on binding of the TRDV2-expressing cell to the TRDV2 antibody. In one aspect, provided herein is a method of detecting a TRDV2-expressing cell, comprising contacting a TRDV2-expressing cell with a TRDV2 antibody provided herein; and detecting the TRDV2-expressing cell based on the binding of the TRDV2-expressing cell to the TRDV2 antibody.

In certain embodiments of the above methods, the TRDV2-expressing cell is a T cell. In some embodiments of the above methods, the TRDV2-expressing cells are present in a population of cells. In some embodiments of the above methods, the TRDV2-expressing cell is within a population of lymphocytes. In some embodiments of the above methods, the TRDV2-expressing cells are within a T cell population. In some embodiments of the above methods, the TRDV2-expressing cells are provided as a cell population. In some embodiments of the above methods, the TRDV2-expressing cells are provided as a population of lymphocytes. In some embodiments of the above methods, TRDV2-expressing cells are provided as a T cell population. In some embodiments of the above methods, TRDV2-expressing cells are provided as a sample comprising a population of cells. In some embodiments of the above methods, TRDV2-expressing cells are provided as a sample comprising a population of lymphocytes. In some embodiments of the above methods, TRDV2-expressing cells are provided as a sample comprising a T cell population. In some embodiments of the above methods, the sample is a blood sample. In some embodiments of the above methods, the sample is a tissue sample. In some embodiments of the above methods, the sample is a tissue culture sample.

In some embodiments of the above methods, the TRDV2 antibody is a multispecific TRDV2 antibody provided herein. In some embodiments of the above methods, the TRDV2 antibody is a bispecific TRDV2 antibody provided herein. In some embodiments of the above methods, the TRDV2 antibody is a trispecific TRDV2 antibody provided herein. In some embodiments of the above methods, the TRDV2 antibody is a quadspecific TRDV2 antibody provided herein. In certain embodiments, the TRDV2 antibody specifically binds TRDV2. In one embodiment, the multispecific TRDV2 antibody comprises (a) a first binding domain that binds TRDV2, and (b) a second binding domain that binds a second target. In one embodiment, the multispecific TRDV2 antibody comprises (a) a first binding domain that binds TRDV2, and (b) a second binding domain that binds a second target, and (c) a third binding domain that binds a third target. contains the domain In one embodiment, the multispecific TRDV2 antibody comprises (a) a first binding domain that binds TRDV2, and (b) a second binding domain that binds a second target, (c) a third binding domain that binds a third target. , and (d) a fourth binding domain that binds a fourth target. In one embodiment, the multispecific TRDV2 antibody comprises (a) a first binding domain that specifically binds TRDV2, and (b) a second binding domain that specifically binds a second target. In one embodiment, the multispecific TRDV2 antibody comprises (a) a first binding domain that specifically binds TRDV2, and (b) a second binding domain that specifically binds a second target, and (c) a third target. It includes a third binding domain that specifically binds to. In one embodiment, the multispecific TRDV2 antibody comprises (a) a first binding domain that specifically binds to TRDV2, and (b) a second binding domain that specifically binds to a second target, (c) a third binding domain that binds to a third target. a third binding domain that specifically binds, and (d) a fourth binding domain that specifically binds to a fourth target.

In a specific embodiment of the methods provided herein, the method uses multi-marker detection. In some embodiments, multi-marker detection uses a multispecific TRDV2 antibody provided herein. In some embodiments, multi-marker detection uses a bispecific TRDV2 antibody provided herein. In some embodiments, multi-marker detection uses a trispecific TRDV2 antibody provided herein. In some embodiments, multi-marker detection uses a quadspecific TRDV2 antibody provided herein.

In certain embodiments of the methods provided herein, the methods are included as steps in a T cell manufacturing process. In certain embodiments, the cell is a CAR-T cell. In certain embodiments of the methods provided herein, the methods are included as steps in a T cell transformation process.

In certain embodiments of the methods provided herein, the methods are included as steps in a diagnostic method. In certain embodiments of the methods provided herein, the methods are included as a step in a method of quantifying TRDV2-expressing T cells.

In certain embodiments of the methods provided herein, the method further comprises amplifying the enriched, isolated, separated, purified, sorted, selected, captured or detected TRDV2-expressing cells. In certain embodiments, amplification is performed in vitro. In certain embodiments, amplification is performed in vivo. In certain embodiments of the methods provided herein, the method further comprises growing the enriched, isolated, separated, purified, sorted, selected, captured or detected TRDV2-expressing cells. In certain embodiments, growth is in vitro. In certain embodiments, growth is in vivo. In certain embodiments of the methods provided herein, the method further comprises quantifying the enriched, isolated, separated, purified, sorted, selected, captured or detected TRDV2-expressing cells.

In one aspect, a TRGDC antibody provided herein is used as an agent to detect TRGDC-expressing cells. Accordingly, in another method, a method of detecting a cell expressing TRGDC is provided, the method comprising contacting the cell with a TRGDC antibody provided herein. In certain embodiments, detection is by ELISA. In some embodiments, detection is by FACS analysis. Also provided are kits comprising the TRGDC antibodies provided herein and instructions for use.

Enrichment, isolation, separation, purification, sorting, selection, capture or detection, or any combination thereof, can be done using known techniques such as beads, microfluidics, solid supports, columns, and the like. For example, TRGDC cells can be isolated or visualized using known methods when bound to the TRGDC antibodies provided herein.

TRGDC antibodies or multispecific TRGDC antibodies provided herein can be used to selectively enrich, isolate, isolate, purify, sort, select, capture or detect TRGDC-expressing cells. A TRGDC antibody or multispecific TRGDC antibody provided herein is in a bispecific format comprising, e.g., a first antigen binding domain that specifically binds TRGDC and a second antigen binding domain that specifically binds a second target. can be used as In another embodiment, the multispecific TRGDC antibodies provided herein may be used in a format that further incorporates a third antigen-binding domain that specifically binds a third antigen (eg, in a trispecific antibody). In another embodiment, the multispecific TRGDC antibodies provided herein can be used in a format that further incorporates a fourth antigen-binding domain that specifically binds to a fourth antigen (eg, as a tetraspecific antibody).

In one aspect, provided herein is a method of enriching TRGDC-expressing cells, the method comprising providing a sample comprising TRGDC-expressing cells: contacting the sample with a TRGDC antibody provided herein; and enriching the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of isolating TRGDC-expressing cells, the method comprising providing a sample comprising TRGDC-expressing cells: contacting the sample with a TRGDC antibody provided herein; and isolating the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of isolating TRGDC-expressing cells, the method comprising providing a sample comprising TRGDC-expressing cells: contacting the sample with a TRGDC antibody provided herein; and isolating the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of purifying TRGDC-expressing cells, the method comprising providing a sample comprising TRGDC-expressing cells: contacting the sample with a TRGDC antibody provided herein; and purifying the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of sorting TRGDC-expressing cells, the method comprising providing a sample comprising TRGDC-expressing cells: contacting the sample with a TRGDC antibody provided herein; and sorting the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of selecting TRGDC-expressing cells, the method comprising providing a sample comprising TRGDC-expressing cells: contacting the sample with a TRGDC antibody provided herein; and selecting the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of capturing TRGDC-expressing cells, the method comprising providing a sample comprising TRGDC-expressing cells: contacting the sample with a previously provided TRGDC antibody; and capturing the TRGDC-expressing cell bound to the TRGDC antibody. In one aspect, provided herein is a method of detecting TRGDC-expressing cells, the method comprising providing a sample comprising TRGDC-expressing cells: contacting the sample with a TRGDC antibody provided herein; and detecting the TRGDC-expressing cell bound to the TRGDC antibody.

In one aspect, provided herein is a method of enriching TRGDC-expressing cells, comprising contacting a TRGDC-expressing cell with a TRGDC antibody provided herein; and enriching the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of isolating a TRGDC-expressing cell, the method comprising contacting the TRGDC-expressing cell with a TRGDC antibody provided herein; and isolating the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of isolating a TRGDC-expressing cell, the method comprising contacting a TRGDC-expressing cell with a TRGDC antibody provided herein; and isolating the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of purifying a TRGDC-expressing cell, the method comprising contacting the TRGDC-expressing cell with a TRGDC antibody provided herein; and purifying the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of sorting a TRGDC-expressing cell, the method comprising contacting the TRGDC-expressing cell with a TRGDC antibody provided herein; and sorting the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of selecting a TRGDC-expressing cell, the method comprising contacting the TRGDC-expressing cell with a TRGDC antibody provided herein; and selecting the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of capturing a TRGDC-expressing cell, the method comprising contacting the TRGDC-expressing cell with a TRGDC antibody provided herein; and capturing the TRGDC-expressing cells bound to the TRGDC antibody. In one aspect, provided herein is a method of detecting a TRGDC-expressing cell, comprising contacting a TRGDC-expressing cell with a TRGDC antibody provided herein; and detecting the TRGDC-expressing cell bound to the TRGDC antibody.

In one aspect, provided herein is a method of enriching TRGDC-expressing cells, comprising contacting a TRGDC-expressing cell with a TRGDC antibody provided herein; and enriching the TRGDC-expressing cells based on binding of the TRGDC-expressing cells to the TRGDC antibody. In one aspect, provided herein is a method of isolating a TRGDC-expressing cell, the method comprising contacting the TRGDC-expressing cell with a TRGDC antibody provided herein; and isolating the TRGDC-expressing cell based on binding of the TRGDC-expressing cell to the TRGDC antibody. In one aspect, provided herein is a method of isolating a TRGDC-expressing cell, the method comprising contacting a TRGDC-expressing cell with a TRGDC antibody provided herein; and isolating the TRGDC-expressing cells based on the binding of the TRGDC-expressing cells to the TRGDC antibody. In one aspect, provided herein is a method of purifying a TRGDC-expressing cell, the method comprising contacting the TRGDC-expressing cell with a TRGDC antibody provided herein; and purifying the TRGDC-expressing cells based on the binding of the TRGDC-expressing cells to the TRGDC antibody. In one aspect, provided herein is a method of sorting a TRGDC-expressing cell, the method comprising contacting the TRGDC-expressing cell with a TRGDC antibody provided herein; and sorting the TRGDC-expressing cells based on the binding of the TRGDC-expressing cells to the TRGDC antibody. In one aspect, provided herein is a method of selecting a TRGDC-expressing cell, the method comprising contacting the TRGDC-expressing cell with a TRGDC antibody provided herein; and selecting the TRGDC-expressing cell based on the binding of the TRGDC-expressing cell to the TRGDC antibody. In one aspect, provided herein is a method of capturing a TRGDC-expressing cell, the method comprising contacting the TRGDC-expressing cell with a TRGDC antibody provided herein; and capturing the TRGDC-expressing cell based on binding of the TRGDC-expressing cell to the TRGDC antibody. In one aspect, provided herein is a method of detecting a TRGDC-expressing cell, comprising contacting a TRGDC-expressing cell with a TRGDC antibody provided herein; and detecting the TRGDC-expressing cell based on binding of the TRGDC-expressing cell to the TRGDC antibody.

In certain embodiments of the above methods, the TRGDC-expressing cell is a T cell. In some embodiments of the above methods, the TRGDC-expressing cells are present in a population of cells. In some embodiments of the above methods, the TRGDC-expressing cell is within a population of lymphocytes. In some embodiments of the above methods, the TRGDC-expressing cells are within a T cell population. In some embodiments of the above methods, the TRGDC-expressing cells are provided as a cell population. In some embodiments of the above methods, the TRGDC-expressing cells are provided as a population of lymphocytes. In some embodiments of the above methods, the TRGDC-expressing cells are provided as a T cell population. In some embodiments of the above methods, TRGDC-expressing cells are provided as a sample comprising a population of cells. In some embodiments of the above methods, TRGDC-expressing cells are provided as a sample comprising a population of lymphocytes. In some embodiments of the above methods, TRGDC-expressing cells are provided as a sample comprising a T cell population. In some embodiments of the above methods, the sample is a blood sample. In some embodiments of the above methods, the sample is a tissue sample. In some embodiments of the above methods, the sample is a tissue culture sample.

In some embodiments of the above methods, the TRGDC antibody is a multispecific TRGDC antibody provided herein. In some embodiments of the methods above, the TRGDC antibody is a bispecific TRGDC antibody provided herein. In some embodiments of the above methods, the TRGDC antibody is a trispecific TRGDC antibody provided herein. In some embodiments of the above methods, the TRGDC antibody is a quadspecific TRGDC antibody provided herein. In certain embodiments, the TRGDC antibody specifically binds TRGDC. In one embodiment, the multispecific TRGDC antibody comprises (a) a first binding domain that binds TRGDC, and (b) a second binding domain that binds a second target. In one embodiment, the multispecific TRGDC antibody comprises (a) a first binding domain that binds TRGDC, and (b) a second binding domain that binds a second target, and (c) a third binding domain that binds a third target. contains the domain In one embodiment, the multispecific TRGDC antibody comprises (a) a first binding domain that binds TRGDC, and (b) a second binding domain that binds a second target, (c) a third binding domain that binds a third target. , and (d) a fourth binding domain that binds a fourth target. In one embodiment, the multispecific TRGDC antibody comprises (a) a first binding domain that specifically binds TRGDC, and (b) a second binding domain that specifically binds a second target. In one embodiment, the multispecific TRGDC antibody comprises (a) a first binding domain that specifically binds TRGDC, and (b) a second binding domain that specifically binds a second target, and (c) a third target. It includes a third binding domain that specifically binds to. In one embodiment, the multispecific TRGDC antibody comprises (a) a first binding domain that specifically binds to TRGDC, and (b) a second binding domain that specifically binds to a second target, (c) a third binding domain that binds to a third target. a third binding domain that specifically binds, and (d) a fourth binding domain that specifically binds to a fourth target.

In a specific embodiment of the methods provided herein, the method uses multi-marker detection. In some embodiments, multi-marker detection uses multispecific TRGDC antibodies provided herein. In some embodiments, multi-marker detection uses a bispecific TRGDC antibody provided herein. In some embodiments, multi-marker detection uses a trispecific TRGDC antibody provided herein. In some embodiments, multi-marker detection uses a quadspecific TRGDC antibody provided herein.

In certain embodiments of the methods provided herein, the methods are included as steps in a T cell manufacturing process. In certain embodiments, the cell is a CAR-T cell. In certain embodiments of the methods provided herein, the methods are included as steps in a T cell transformation process.

In certain embodiments of the methods provided herein, the methods are included as steps in a diagnostic method. In certain embodiments of the methods provided herein, the methods are included as steps in a method of quantifying TRGDC-expressing T cells.

In certain embodiments of the methods provided herein, the method further comprises amplifying the enriched, isolated, separated, purified, sorted, selected, captured or detected TRGDC-expressing cells. In certain embodiments, amplification is performed in vitro. In certain embodiments, amplification is performed in vivo. In certain embodiments of the methods provided herein, the method further comprises growing the enriched, isolated, separated, purified, sorted, selected, captured or detected TRGDC-expressing cells. In certain embodiments, growth is in vitro. In certain embodiments, growth is in vivo. In certain embodiments of the methods provided herein, the method further comprises quantifying the enriched, isolated, separated, purified, sorted, selected, captured, or detected TRGDC-expressing cells. .

embodiment

The present invention provides the following non-limiting embodiments.

In one set of embodiments, the following are provided:

A1. Antibodies that bind T cell receptor (TCR) Vγ9 (TRGV9), including:

(One) (i) a VH comprising VH having the amino acid sequence of SEQ ID NO: 31, VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 32, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(2) (i) a VH having the amino acid sequence of SEQ ID NO: 65, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 66, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(3) (i) a VH having the amino acid sequence of SEQ ID NO: 99, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 100, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(4) (i) a VH having the amino acid sequence of SEQ ID NO: 133, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 134, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(5) (i) a VH having the amino acid sequence of SEQ ID NO: 167, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 168, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(6) (i) a VH having the amino acid sequence of SEQ ID NO: 201, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 202, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(7) (i) a VH having the amino acid sequence of SEQ ID NO: 235, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 236, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(8) (i) a VH having the amino acid sequence of SEQ ID NO: 269, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 270, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(9) (i) a VH having the amino acid sequence of SEQ ID NO: 303, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 304, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(10) (i) a VH having the amino acid sequence of SEQ ID NO: 337, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 338, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(11) (i) a VH having the amino acid sequence of SEQ ID NO: 371, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 372, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(12) (i) a VH having the amino acid sequence of SEQ ID NO: 405, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 406, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(13) (i) a VH having the amino acid sequence of SEQ ID NO: 439, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 440, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(14) (i) a VH having the amino acid sequence of SEQ ID NO: 473, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 474, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(15) (i) a VH having the amino acid sequence of SEQ ID NO: 507, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 508, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(16) (i) a VH having the amino acid sequence of SEQ ID NO: 541, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 542, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(17) (i) a VH having the amino acid sequence of SEQ ID NO: 575, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 576, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(18) (i) a VH having the amino acid sequence of SEQ ID NO: 609, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 610, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(19) (i) a VH having the amino acid sequence of SEQ ID NO: 643, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 644, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(20) (i) a VH having the amino acid sequence of SEQ ID NO: 677, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 678, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(21) (i) a VH having the amino acid sequence of SEQ ID NO: 711, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 712, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(22) (i) a VH having the amino acid sequence of SEQ ID NO: 745, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 746, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(23) (i) a VH having the amino acid sequence of SEQ ID NO: 779, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 780, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(24) (i) a VH having the amino acid sequence of SEQ ID NO: 813, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 814, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(25) (i) a VH having the amino acid sequence of SEQ ID NO: 847, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 848, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(26) (i) a VH having the amino acid sequence of SEQ ID NO: 881, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 882, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(27) (i) a VH having the amino acid sequence of SEQ ID NO: 915, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 916, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(28) (i) a VH having the amino acid sequence of SEQ ID NO: 949, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 950, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(29) (i) a VH having the amino acid sequence of SEQ ID NO: 983, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 984, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(30) (i) a VH having the amino acid sequence of SEQ ID NO: 1017, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1018, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(31) (i) a VH having the amino acid sequence of SEQ ID NO: 1051, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1052, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(32) (i) a VH having the amino acid sequence of SEQ ID NO: 1085, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1086, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(33) (i) a VH having the amino acid sequence of SEQ ID NO: 1119, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1120, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(34) (i) a VH having the amino acid sequence of SEQ ID NO: 1153, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1154, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(35) (i) a VH having the amino acid sequence of SEQ ID NO: 1187, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1188, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(36) (i) a VH having the amino acid sequence of SEQ ID NO: 1221, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1222, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(37) (i) a VH having the amino acid sequence of SEQ ID NO: 1255, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1256, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(38) (i) a VH having the amino acid sequence of SEQ ID NO: 1289, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1290, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(39) (i) a VH having the amino acid sequence of SEQ ID NO: 1323, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1324, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(40) (i) a VH having the amino acid sequence of SEQ ID NO: 1357, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1358, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(41) (i) a VH having the amino acid sequence of SEQ ID NO: 1391, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1392, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(42) (i) a VH having the amino acid sequence of SEQ ID NO: 1425, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1426, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(43) (i) a VH having the amino acid sequence of SEQ ID NO: 1459, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1460, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(44) (i) a VH having the amino acid sequence of SEQ ID NO: 1493, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1494, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(45) (i) a VH having the amino acid sequence of SEQ ID NO: 1527, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1528, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(46) (i) a VH having the amino acid sequence of SEQ ID NO: 1561, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1562, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(47) (i) a VH having the amino acid sequence of SEQ ID NO: 1595, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1596, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(48) (i) a VH having the amino acid sequence of SEQ ID NO: 1629, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1630, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(49) (i) a VH having the amino acid sequence of SEQ ID NO: 1663, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1664, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(50) (i) a VH having the amino acid sequence of SEQ ID NO: 1697, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1698, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(51) (i) a VH having the amino acid sequence of SEQ ID NO: 1731, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1732, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(52) (i) a VH having the amino acid sequence of SEQ ID NO: 1765, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1766, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(53) (i) a VH having the amino acid sequence of SEQ ID NO: 1799, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1800, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(54) (i) a VH having the amino acid sequence of SEQ ID NO: 1833, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1834, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(55) (i) a VH having the amino acid sequence of SEQ ID NO: 1867, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1868, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(56) (i) a VH having the amino acid sequence of SEQ ID NO: 1901, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1902, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(57) (i) a VH having the amino acid sequence of SEQ ID NO: 1935, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1936, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(58) (i) a VH having the amino acid sequence of SEQ ID NO: 1969, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1970, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively; or

(59) (i) a VH having the amino acid sequence of SEQ ID NO: 2003, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2004, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively.

A2. The antibody of embodiment A1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the Kabat numbering system.

A3. The antibody of embodiment A1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the Chothia numbering system.

A4. The antibody of embodiment A1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the AbM numbering system.

A5. The antibody of embodiment A1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the Contact numbering system.

A6. The antibody of embodiment A1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the IMGT numbering system.

A7. The antibody of any one of Embodiments A1 to A6 wherein the antibody is a humanized antibody.

A8. The antibody of any one of Embodiments A1 to A7 wherein the antibody is an IgG antibody.

A9. The antibody of embodiment A8, wherein the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.

A10. The antibody of any one of Embodiments A1-A9, wherein the antibody comprises a kappa light chain.

A11. The antibody of any one of Embodiments A1 to A9, wherein the antibody comprises a lambda light chain.

A12. The antibody of any one of Embodiments A1 to A11, wherein the antibody is a monoclonal antibody.

A13. The antibody of any one of Embodiments A1 to A12, wherein the antibody binds to the TRGV9 antigen.

A14. The antibody of any one of Embodiments A1-A12, wherein the antibody binds to a TRGV9 epitope.

A15. The antibody of any one of Embodiments A1-A14, wherein the antibody specifically binds to TRGV9.

A16. The antibody of any one of Embodiments A1 to A15, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an antigen of TRGV9.

A17. The antibody of any one of Embodiments A1 to A15, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an epitope of TRGV9.

A18. The antibody of any one of Embodiments A1 to A17, wherein TRGV9 is present on the surface of a T cell.

A19. The antibody of any one of Embodiments A1 to A18 wherein the antibody is multivalent.

A20. The antibody of embodiment A19, wherein the antibody is capable of binding at least three antigens.

A21. The antibody of embodiment A19, wherein the antibody is capable of binding at least 5 antigens.

A22. The antibody of any one of Embodiments A1-A21, wherein the antibody is a multispecific antibody.

A23. The antibody of embodiment A22 wherein the antibody is a bispecific antibody.

A24. A nucleic acid sequence encoding the antibody of any one of embodiments A1-A23.

A25. A vector comprising the nucleic acid sequence of embodiment A24.

A26. A host cell comprising the vector of embodiment A25.

A27. A kit comprising the vector of embodiment A25 and packaging therefor.

A28. A kit comprising the antibody of any one of embodiments A1-A23 and packaging therefor.

A29. A pharmaceutical composition comprising the antibody of any one of embodiments A1-A23 and a pharmaceutically acceptable carrier.

A30. A method of preparing the pharmaceutical composition of embodiment A29 comprising combining the antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

A31. A method of activating a T cell expressing TRGV9 comprising contacting the T cell with the antibody of any one of embodiments A1-A23.

A32. The method of embodiment A31, wherein the contacting results in increased expression of CD69, CD25, and/or Granzyme B as compared to control T cells expressing TRGV9.

B1. Antibodies that bind to TCR Vδ2 (TRDV2), including:

(One) (i) a VH having the amino acid sequence of SEQ ID NO: 2037, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2038, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(2) (i) a VH having the amino acid sequence of SEQ ID NO: 2071, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2072, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(3) (i) a VH having the amino acid sequence of SEQ ID NO: 2105, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2106, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(4) (i) a VH having the amino acid sequence of SEQ ID NO: 2139, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2140, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(5) (i) a VH having the amino acid sequence of SEQ ID NO: 2173, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2174, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(6) (i) a VH having the amino acid sequence of SEQ ID NO: 2207, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2208, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(7) (i) a VH having the amino acid sequence of SEQ ID NO: 2241, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2242, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(8) (i) a VH having the amino acid sequence of SEQ ID NO: 2275, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2276, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(9) (i) a VH having the amino acid sequence of SEQ ID NO: 2309, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2310, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(10) (i) a VH having the amino acid sequence of SEQ ID NO: 2343, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2344, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(11) (i) a VH having the amino acid sequence of SEQ ID NO: 2377, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2378, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(12) (i) a VH having the amino acid sequence of SEQ ID NO: 2411, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2412, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(13) (i) a VH having the amino acid sequence of SEQ ID NO: 2445, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2446, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(14) (i) a VH having the amino acid sequence of SEQ ID NO: 2479, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2480, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(15) (i) a VH having the amino acid sequence of SEQ ID NO: 2513, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2514, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(16) (i) a VH having the amino acid sequence of SEQ ID NO: 2547, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2548, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(17) (i) a VH having the amino acid sequence of SEQ ID NO: 2581, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2582, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(18) (i) a VH having the amino acid sequence of SEQ ID NO: 2615, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2616, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(19) (i) a VH having the amino acid sequence of SEQ ID NO: 2649, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2650, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(20) (i) a VH having the amino acid sequence of SEQ ID NO: 2683, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2684, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(21) (i) a VH having the amino acid sequence of SEQ ID NO: 2717, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2718, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(22) (i) a VH having the amino acid sequence of SEQ ID NO: 2751, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2752, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(23) (i) a VH having the amino acid sequence of SEQ ID NO: 2785, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2786, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(24) (i) a VH having the amino acid sequence of SEQ ID NO: 2819, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2820, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(25) (i) a VH having the amino acid sequence of SEQ ID NO: 2853, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2854, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(26) (i) a VH having the amino acid sequence of SEQ ID NO: 2887, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2888, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(27) (i) a VH having the amino acid sequence of SEQ ID NO: 2921, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2922, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(28) (i) a VH having the amino acid sequence of SEQ ID NO: 2955, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2956, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(29) (i) a VH having the amino acid sequence of SEQ ID NO: 2989, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2990, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(30) (i) a VH having the amino acid sequence of SEQ ID NO: 3023, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3024, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(31) (i) a VH having the amino acid sequence of SEQ ID NO: 3057, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3058, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(32) (i) a VH having the amino acid sequence of SEQ ID NO: 3091, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3092, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(33) (i) a VH having the amino acid sequence of SEQ ID NO: 3125, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3126, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(34) (i) a VH having the amino acid sequence of SEQ ID NO: 3159, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3160, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(35) (i) a VH having the amino acid sequence of SEQ ID NO: 3193, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3194, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(36) (i) a VH having the amino acid sequence of SEQ ID NO: 3227, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3228, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(37) (i) a VH having the amino acid sequence of SEQ ID NO: 3261, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3262, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(38) (i) a VH having the amino acid sequence of SEQ ID NO: 3295, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3296, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(39) (i) a VH having the amino acid sequence of SEQ ID NO: 3329, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3330, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(40) (i) a VH having the amino acid sequence of SEQ ID NO: 3363, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3364, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(41) (i) a VH having the amino acid sequence of SEQ ID NO: 3397, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3398, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(42) (i) a VH having the amino acid sequence of SEQ ID NO: 3431, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3432, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(43) (i) a VH having the amino acid sequence of SEQ ID NO: 3465, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3466, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(44) (i) a VH having the amino acid sequence of SEQ ID NO: 3499, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3500, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(45) (i) a VH having the amino acid sequence of SEQ ID NO: 3533, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3534, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(46) (i) a VH having the amino acid sequence of SEQ ID NO: 3567, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3568, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(47) (i) a VH having the amino acid sequence of SEQ ID NO: 3601, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3602, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(48) (i) a VH having the amino acid sequence of SEQ ID NO: 3635, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3636, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(49) (i) a VH having the amino acid sequence of SEQ ID NO: 3669, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3670, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(50) (i) a VH having the amino acid sequence of SEQ ID NO: 3703, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3704, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(51) (i) a VH having the amino acid sequence of SEQ ID NO: 3737, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3738, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(52) (i) a VH having the amino acid sequence of SEQ ID NO: 3771, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3772, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(53) (i) a VH having the amino acid sequence of SEQ ID NO: 3805, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3806, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(54) (i) a VH having the amino acid sequence of SEQ ID NO: 3839, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3840, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(55) (i) a VH having the amino acid sequence of SEQ ID NO: 3873, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3874, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(56) (i) a VH having the amino acid sequence of SEQ ID NO: 3907, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3908, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(57) (i) a VH having the amino acid sequence of SEQ ID NO: 3941, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3942, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(58) (i) a VH having the amino acid sequence of SEQ ID NO: 3975, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3976, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(59) (i) a VH having the amino acid sequence of SEQ ID NO: 4009, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4010, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(60) (i) a VH having the amino acid sequence of SEQ ID NO: 4043, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4044, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(61) (i) a VH having the amino acid sequence of SEQ ID NO: 4077, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4078, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively; or

(62) (i) a VH having the amino acid sequence of SEQ ID NO: 4111, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4112, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively.

B2. The antibody of embodiment B1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the Kabat numbering system.

B3. The antibody of embodiment B1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the Chothia numbering system.

B4. The antibody of embodiment B1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the AbM numbering system.

B5. The antibody of embodiment B1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the contact numbering scheme.

B6. The antibody of embodiment B1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the IMGT numbering system.

B7. The antibody of any one of Embodiments B1 to B6 wherein the antibody is a humanized antibody.

B8. The antibody of any one of Embodiments B1 to B7 wherein the antibody is an IgG antibody.

B9. The antibody of embodiment B8, wherein the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.

B10. The antibody of any one of Embodiments B1-B9, wherein the antibody comprises a kappa light chain.

B11. The antibody of any one of Embodiments B1 to B9, wherein the antibody comprises a lambda light chain.

B12. The antibody of any one of Embodiments B1 to B11, wherein the antibody is a monoclonal antibody.

B13. The antibody of any one of Embodiments B1 to B12, wherein the antibody binds to the TRDV2 antigen.

B14. The antibody of any one of Embodiments B1 to B12, wherein the antibody binds to a TRDV2 epitope.

B15. The antibody of any one of Embodiments B1 to B14, wherein the antibody specifically binds to TRDV2.

B16. The antibody of any one of Embodiments B1 to B15, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an antigen of TRDV2.

B17. The antibody of any one of Embodiments B1 to B15, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an epitope of TRDV2.

B18. The antibody of any one of Embodiments B1 to B17, wherein TRDV2 is present on the surface of a T cell.

B19. The antibody of any one of Embodiments B1 to B18 wherein the antibody is multivalent.

B20. The antibody of embodiment B19, wherein the antibody is capable of binding at least three antigens.

B21. The antibody of embodiment B19, wherein the antibody is capable of binding at least 5 antigens.

B22. The antibody of any one of Embodiments B1 to B21 wherein the antibody is a multispecific antibody.

B23. The antibody of embodiment B22 wherein the antibody is a bispecific antibody.

B24. A nucleic acid sequence encoding the antibody of any one of embodiments B1-B23.

B25. A vector comprising the nucleic acid sequence of embodiment B24.

B26. A host cell comprising the vector of embodiment B25.

B27. A kit comprising the vector of embodiment B25 and packaging therefor.

B28. A kit comprising the antibody of any one of embodiments B1-B23 and packaging therefor.

B29. A pharmaceutical composition comprising the antibody of any one of embodiments B1-B23 and a pharmaceutically acceptable carrier.

B30. A method of preparing the pharmaceutical composition of embodiment B29 comprising combining the antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

B31. A method of activating a T cell expressing TRDV2 comprising contacting the T cell with the antibody of any one of embodiments B1-B23.

B32. The method of embodiment B31, wherein the contacting results in increased expression of CD69, CD25, and/or granzyme B as compared to control T cells expressing TRDV2.

C1. Antibodies that bind to the TCR gamma delta constant region (TRGDC), including:

(One) (i) a VH having the amino acid sequence of SEQ ID NO: 4145, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4146, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(2) (i) a VH having the amino acid sequence of SEQ ID NO: 4179, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4180, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(3) (i) a VH having the amino acid sequence of SEQ ID NO: 4213, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4214, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(4) (i) a VH having the amino acid sequence of SEQ ID NO: 4247, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4248, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(5) (i) a VH having the amino acid sequence of SEQ ID NO: 4281, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4282, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(6) (i) a VH having the amino acid sequence of SEQ ID NO: 4315, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4316, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(7) (i) a VH having the amino acid sequence of SEQ ID NO: 4349, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4350, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(8) (i) a VH having the amino acid sequence of SEQ ID NO: 4383, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4384, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(9) (i) a VH having the amino acid sequence of SEQ ID NO: 4417, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4418, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(10) (i) a VH having the amino acid sequence of SEQ ID NO: 4451, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4452, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(11) (i) a VH having the amino acid sequence of SEQ ID NO: 4485, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4486, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(12) (i) a VH having the amino acid sequence of SEQ ID NO: 4519, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4520, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(13) (i) a VH having the amino acid sequence of SEQ ID NO: 4553, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4554, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(14) (i) a VH having the amino acid sequence of SEQ ID NO: 4587, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4588, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;

(15) (i) a VH having the amino acid sequence of SEQ ID NO: 4621, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4622, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively; or

(16) (i) a VH having the amino acid sequence of SEQ ID NO: 4655, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4656, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively.

C2. The antibody of embodiment C1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the Kabat numbering system.

C3. The antibody of embodiment C1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the Chothia numbering system.

C4. The antibody of embodiment C1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the AbM numbering system.

C5. The antibody of embodiment C1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the contact numbering scheme.

C6. The antibody of embodiment C1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the IMGT numbering system.

C7. The antibody of any one of Embodiments C1 to C6 wherein the antibody is a humanized antibody.

C8. The antibody of any one of Embodiments C1 to C7 wherein the antibody is an IgG antibody.

C9. The antibody of embodiment C8, wherein the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.

C10. The antibody of any one of embodiments C1 to C9, wherein the antibody comprises a kappa light chain.

C11. The antibody of any one of Embodiments C1 to C9, wherein the antibody comprises a lambda light chain.

C12. The antibody of any one of embodiments C1 to C11, wherein the antibody is a monoclonal antibody.

C13. The antibody of any one of embodiments C1 to C12, wherein the antibody binds to a TRGDC antigen.

C14. The antibody of any one of embodiments C1 to C12, wherein the antibody binds to a TRGDC epitope.

C15. The antibody of any one of Embodiments C1 to C14, wherein the antibody specifically binds to TRGDC.

C16. The antibody of any one of embodiments C1 to C15, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an antigen of TRGDC.

C17. The antibody of any one of embodiments C1 to C15, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an epitope of TRGDC.

C18. The antibody of any one of Embodiments C1 to C17, wherein the TRGDC is on the surface of a T cell.

C19. The antibody of any one of Embodiments C1 to C18, wherein the antibody is multivalent.

C20. The antibody of embodiment C19, wherein the antibody is capable of binding at least three antigens.

C21. The antibody of embodiment C19, wherein the antibody is capable of binding at least 5 antigens.

C22. The antibody of any one of Embodiments C1 to C21, wherein the antibody is a multispecific antibody.

C23. The antibody of embodiment C22 wherein the antibody is a bispecific antibody.

C24. A nucleic acid sequence encoding the antibody of any one of embodiments C1-C23.

C25. A vector comprising the nucleic acid sequence of embodiment C24.

C26. A host cell comprising the vector of embodiment C25.

C27. A kit comprising the vector of embodiment C25 and packaging therefor.

C28. A kit comprising the antibody of any one of embodiments C1-C23 and packaging therefor.

C29. A pharmaceutical composition comprising the antibody of any one of embodiments C1-C23 and a pharmaceutically acceptable carrier.

C30. A method of preparing the pharmaceutical composition of embodiment C29, comprising combining the antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

C31. A method of activating a T cell expressing TRGDC comprising contacting the T cell with the antibody of any one of embodiments C1-C23.

C32. The method of embodiment C31, wherein the contacting results in increased expression of CD69, CD25, and/or granzyme B as compared to control T cells expressing TRGDC.

Exemplary antibodies that bind TRGV9 are provided in the Examples herein. Exemplary antibodies that bind TRDV2 are also provided in the Examples herein. Exemplary antibodies that bind TRGDC are also provided in the Examples herein. Exemplary binders that bind TRGV9 are provided herein, eg, in Tables 2-7 as well as in the Examples. Exemplary binding agents that bind TRDV2 are provided herein, eg, in Tables 2-7 as well as in the Examples. Exemplary binding agents that bind TRGDC are provided herein, eg, in Tables 2-7 as well as in the Examples.

Certain embodiments of the present invention are described herein. Upon reading the foregoing description, variations of the disclosed embodiments may become apparent to those skilled in the art, and it is expected that those skilled in the art will be able to employ such variations as appropriate. Accordingly, this invention may be practiced in a manner other than as specifically described herein, and this invention covers all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. It is intended to include Furthermore, any combination of the above-described elements within all possible variations of the invention is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. A number of embodiments of the present invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the description in the Examples section is intended to illustrate the scope of the invention as set forth in the claims, but not to limit it.

Example

Example 1: Example 1: Generation of antibodies that bind to γδ T cells

1.1: Generation of MABS that bind to γδ T cell antigen

An animal (eg, mouse or rabbit) is immunized with an antigen or portion of an antigen specific for γδ T cells. To generate γδ T cell monoclonal antibodies, peripheral blood mononuclear cells are isolated from the whole blood of immunized animals and antigen-specific B cells are grown. B cells secreting antibodies reactive against the γδ T cell antigen are identified by antigen-binding ELISA screening of B cell culture supernatants. High binding ELISA plates are coated overnight with γδ T cell antigen. The ELISA plate is blocked and the diluted B cell culture supernatant is added to the plate. The plate is incubated at room temperature, and after incubation, a secondary antibody specific for recognizing the γδ T cell antigen antibody is added to the plate to determine whether the γδ T cell antigen antibody binds to the γδ T cell antigen. Binding of the antibody is determined by the reaction of the substrate on the secondary antibody.

After identifying a monoclonal antibody capable of binding to the γδ T cell antigen, the variable regions of the heavy and light chains of the γδ T cell antibody are sequenced. γδ T cell antibodies that bind to TRGV9, TRDV2, and TRGDC are generated. Constructs are created for expression of the heavy and light chains of the γδ T cell antibody. The construct is transfected into host cells to express the heavy and light chains, and γδ T cell antibodies are isolated from the supernatant.

1.2: Generation of TRGV9 Antibodies, TRDV2 Antibodies, and TRGDC Antibodies

immunogen. Recombinant human TCR Vγ9 x Vδ2 fused to human Fc was used as the immunogen and the sequence is listed in Table 1 .

[Table 1]

기기(GE Healthcare Life Sciences)를 사용하여, 7일 후의 상층액(1 L)을 인산염 완충 식염수(PBS)(pH 6.8)로 사전평형화된 10 mL의 컬럼 부피(CV)를 갖는 MABSELECT SURE(GE Life Sciences)에 5 mL/분의 유량으로 첨가하였다. 컬럼 물질에 결합한 비특이적 단백질을 500 mM NaCl로 보충된 PBS(pH 6.8)(5 CV)로 세척하였다. Fc-함유 면역원을 40 mM 소듐 아세테이트 pH 5.0(5 CV), pH 4.5(5 CV), pH 4.0(10 CV), pH 3.5(5 CV), 및 pH 3.0(5 CV)으로 단계적으로 용리시켰다. 분획을 풀링하고, PBS(pH 6.8)로 사전평형화된 HiLoad 16/600 SUPERDEX(GE Healthcare) 컬럼 상에 0.2 mL/분의 유량으로 적용하였다(5 mL). 표적 단백질을 용리시키고, 풀링하고, SDS-PAGE, 분석용 SEC, 및 질량 분석에 의한 온전한 질량에 의해 분석하였다. 순도는 99% 초과로 추정되었다. Protein production of immunogens . Expression plasmids encoding immunogens (see Table 1 ) were transfected into CHO cells at a DNA ratio of 1:1. The total amount of DNA for a 750 mL expression scale was 750 μg. The final expression volume was 1 L after two feeds and enhancer addition.

MABSELECT SURE (GE Life Sciences) at a flow rate of 5 mL/min. Non-specific proteins bound to the column material were washed with PBS (pH 6.8) supplemented with 500 mM NaCl (5 CV). The Fc-containing immunogen was eluted stepwise with 40 mM sodium acetate pH 5.0 (5 CV), pH 4.5 (5 CV), pH 4.0 (10 CV), pH 3.5 (5 CV), and pH 3.0 (5 CV). Fractions were pooled and applied (5 mL) at a flow rate of 0.2 mL/min onto a HiLoad 16/600 SUPERDEX (GE Healthcare) column pre-equilibrated with PBS pH 6.8. Target proteins were eluted, pooled, and analyzed by SDS-PAGE, analytical SEC, and intact mass by mass spectrometry. Purity was estimated to be greater than 99%.

Antibodies were generated using the ALIVAMAB transgenic mouse technology (Ablexis). ALIVAMAB mice were immunized with recombinant human Vγ9/Vδ2 TCR protein. Lymphocytes were extracted from organs of the secondary lymphoid system and fused with the FO mouse myeloma cell line for hybridoma generation or subjected to single cell sorting via FACS. Hybridoma supernatants were screened for binding to γδ T cells by FACS or by MSD electrochemiluminescence. Identified cell binders were classified into light chain isotypes by ELISA. Single cell sorted supernatants were screened by MSD electrochemiluminescence for binding to recombinant human Vγ9/Vδ2 protein. Several hits with the desired binding profile were selected and sequenced, as provided below.

The VH and VL sequences of certain TRGV9, TRDV2, and TRGDC antibodies are provided in Table 2 . The CDR sequences of certain TRGV9, TRDV2, and TRGDC antibodies are provided in Table 3 (Kabat), Table 4 (Chothia), Table 5 (AbM), Table 6 (Contact), and Table 7 (IMGT).

[Table 2]

[Table 3]

[Table 4]

[Table 5]

[Table 6]

[Table 7]

Variable region cloning. Both RNA and B cell lysates purified by the QIAGEN kit (RNEASY Plus Mini Kit) were used for cDNA synthesis using the Smarter cDNA synthesis kit (Clontech, Mount View, CA). To facilitate cDNA synthesis, reverse transcription was primed with oligodT followed by "5'capping" with Smarter IIA oligonucleotides. Subsequent amplification of the VH and VL fragments was performed using a two-step PCR amplification using a 5' primer targeting the SMARTER IIA cap and a 3' primer targeting the consensus region in CH1. Briefly, every 50 μl PCR reaction consisted of 20 μM forward and reverse primer mix, 25 μl PRIMESTAR MAX DNA polymerase premix (Clontech), 2 μl unpurified cDNA, and 21 μl double-distilled It consists of H2O. The cycling program started at 94°C for 3 minutes, followed by 35 cycles (30 seconds at 94°C, 1 minute at 55°C, 1 minute at 68°C) and ended at 72°C for 7 minutes. Second round PCR was performed with VL and VH second round primers, which contained 15 bp complementary extensions that "overlap" each region in each Lonza mother vector (VH and VL). Start the second round PCR with the following program: 94° C. for 3 min; 35 cycles (30 sec at 94°C, 1 min at 55°C, 1 min at 68°C); It was carried out with a program that terminated at 72 ° C. for 7 minutes. The IN-FUSION® HD cloning kit (Clonetech, USA) was used for directional cloning of the VL gene into the Lonza huIgK or lambda vector or the directional cloning of the VH gene into the Lonza huIgG1 vector. To facilitate IN-FUSION® HD cloning, PCR products were treated with cloning enhancer prior to IN-FUSION HD cloning. Cloning and transformation was performed according to the manufacturer's protocol (Clonetech, USA). Mini-prep DNA was subjected to Sanger sequencing to confirm that complete V-gene fragments were obtained.

1.3 Binding activity of TRGV9, TRDV2, and TRGDC antibodies to target cell lines.

Binding of antibodies to human γδ T cells or SKW cell lines expressing Vγ9/Vδ2, Vγ9/Vδ2, or Vγ5/Vδ2 was performed by flow cytometry. Briefly, cells were centrifuged at 300xg for 5 minutes and the pellet was resuspended in 34 ml fresh medium (RPMI + 10% FBS). 50 μL of cells were then plated in assay plates (44K cells/well). Samples were incubated for 1 hour at 37°C in a tissue culture (TC) incubator followed by a wash step by adding 100 μl FACS staining buffer. Add secondary capture antibody (1 ug/mL of AF488 anti-mouse CD3, A647 conjugated anti-human IgG Fc specific antibody with clone OKT3 (2 μg/mL)) to appropriate wells at 50 μL/well according to plate map did. After incubation for 60 minutes at 37° C. in the TC incubator, the cells were washed again as described above. Then, they were resuspended in 20 μL/well running buffer containing a 1:1000 dilution of Sytox blue dead cell stain and the plates were run on the iQue Screener.

Gating and Data Analysis : A human anti-human Vy9 antibody (VG9B2 mAb at 10 nM) was used to indicate the gating of the positive population. All cells were first gated for singlets in a SCS-A versus SCS-H dot plot, the CD3 positive population was followed by survival/death, and this subset of the CD3 positive population was screened for Vγ9 positive binding using a positive control mAb. gated on. Cells from the viable cell population were also evaluated by RL1(A647) Geomeans for cell binding of the control mAb. Magnification was calculated for background wells containing only secondary antibodies (designated as 'Background' in the ForeCyt settings) using advanced metrics and selecting the normalization metric. Results were exported to the GeneData screener to graph and summarize the results, which are shown in Table 8 .

[Table 8]

Cytokine and Effector Molecular Analysis . Cytokine and effector molecules were evaluated intracellularly and in cell culture supernatants. For intracellular cytokine and effector molecule evaluation by flow cytometry, cells were initially surface stained with the indicated monoclonal antibodies and washed twice with wash buffer. Stained cells were fixed and permeabilized using the BD Fix/Perm kit (BD Biosciences) according to the manufacturer's instructions. Permeabilized cells were probed with monoclonal antibodies against intracellular cytokines (TNFα, IFNγ) or effector molecules (granzyme B) for 30 minutes at 4°C. Cells were washed twice and acquired on a Novocyte flow cytometer. Gating for cytokines was established using a Fluorescence Minus One (FMO) control. To evaluate cytokines in cell culture supernatants, cell culture supernatants were collected at the indicated time points and quantified using a custom human magnetic Luminex assay 15 flex kit (R&D Systems, Minneapolis, USA) according to the manufacturer's instructions. . Quantification of cytokines was performed on a MAGPIX multiplex detection system with xPONENT software. The results are shown in Table 9 .

Activated T cell surface marker profile. Flow cytometry was used to assess the percentage of Vy9 T cells in the cell population as well as the percentage of Vy9+ cells expressing specific T cell activation markers, including CD25 and CD71 expression. Briefly, 48-well plates were coated with 200 μl of antibody (1 μg/ml) and control antibody (VG7A5 1 μg/ml) in PBS overnight at 40°C. PBMC were thawed and resuspended in RPMI + 10% FBS medium. They were then labeled with CTV dye to track proliferation. CTV-labeled PBMCs were plated 2×10 ⁶ in 250 μl medium per well of an antibody-coated plate and incubated at 37° C. for 2 days. Supernatants were collected on day 2 for Luminex analysis (IFNγ, TNFα, Granzyme B). Cells were spun, transferred to IL-2 containing medium (100 IU/ml), rested for 3 days and then stained for CD25, CD71, IFNγ, and granzyme B after 3 days. The results are shown in Table 9 .

[Table 9]

Those skilled in the art will recognize that changes may be made to the embodiments described above without departing from the broad inventive concept. It is therefore understood that this invention is not limited to the specific embodiments disclosed, but is intended to cover modifications within the spirit and scope of the invention as defined by this specification.

SEQUENCE LISTING <110> JANSSEN BIOTECH, INC. <120> COMPOSITIONS AND METHODS FOR MODULATING DELTA GAMMA CHAIN MEDIATED IMMUNITY <130> 14620-236-228 / JBI6395WOPCT1 <140> <141> <150> 63/106,703 <151> 2020-10-28 <160> 4660 <170> PatentIn version 3.5 <210> 1 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1 Ser Tyr Ser Leu Thr 1 5 <210> 2 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 3 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3 Asp Gly Glu Leu Gly Pro Phe Asp Tyr 1 5 <210> 4 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 5 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 5 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 6 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 6 Gln Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 7 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 7 Gly Phe Ala Phe Ser Ser Tyr 1 5 <210> 8 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 8 Ser Ser Ser Ser Ser Tyr 1 5 <210> 9 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 9 Asp Gly Glu Leu Gly Pro Phe Asp 1 5 <210> 10 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 10 Ser Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 11 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 11 Gly Ala Ser One <210> 12 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 12 Tyr Gly Arg Ser Pro Leu 1 5 <210> 13 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 13 Gly Phe Ala Phe Ser Ser Tyr Ser Leu Thr 1 5 10 <210> 14 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 14 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 15 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 15 Asp Gly Glu Leu Gly Pro Phe Asp Tyr 1 5 <210> 16 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 16 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 17 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 17 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 18 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 18 Gln Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 19 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 19 Ser Ser Tyr Ser Leu Thr 1 5 <210> 20 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 20 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 21 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 21 Ala Thr Asp Gly Glu Leu Gly Pro Phe Asp 1 5 10 <210> 22 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 22 Ser Ser Ser Tyr Leu Ala Trp Phe 1 5 <210> 23 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 23 Arg Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 24 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 24 Gln Gln Tyr Gly Arg Ser Pro Leu 1 5 <210> 25 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 25 Gly Phe Ala Phe Ser Ser Tyr Ser 1 5 <210> 26 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 26 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 27 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 27 Ala Thr Asp Gly Glu Leu Gly Pro Phe Asp Tyr 1 5 10 <210> 28 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 28 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 29 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 29 Gly Ala Ser One <210> 30 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 30 Gln Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 31 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 31 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Ser Tyr 20 25 30 Ser Leu Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Asp Gly Glu Leu Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 32 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 32 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Arg Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 33 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 33 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Ser Tyr 20 25 30 Ser Leu Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Asp Gly Glu Leu Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 34 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 34 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Arg Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 35 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 35 Asp Tyr Ala Met Asp 1 5 <210> 36 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 36 Ser Ile Ser Ser Thr Ser Asn Tyr Ile Phe Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 37 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 37 Ser Tyr Asn Trp Asn Tyr Gly Gly Ala Phe Asp Ile 1 5 10 <210> 38 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 38 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Phe Ala 1 5 10 <210> 39 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 39 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 40 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 40 Gln Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 41 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 41 Gly Phe Thr Phe Ser Asp Tyr 1 5 <210> 42 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 42 Ser Ser Thr Ser Asn Tyr 1 5 <210> 43 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 43 Ser Tyr Asn Trp Asn Tyr Gly Gly Ala Phe Asp 1 5 10 <210> 44 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 44 Ser Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 45 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 45 Gly Ala Ser One <210> 46 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 46 Tyr Gly Arg Ser Pro Leu 1 5 <210> 47 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 47 Gly Phe Thr Phe Ser Asp Tyr Ala Met Asp 1 5 10 <210> 48 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 48 Ser Ile Ser Ser Thr Ser Asn Tyr Ile Phe 1 5 10 <210> 49 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 49 Ser Tyr Asn Trp Asn Tyr Gly Gly Ala Phe Asp Ile 1 5 10 <210> 50 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 50 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Phe Ala 1 5 10 <210> 51 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 51 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 52 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 52 Gln Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 53 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 53 Ser Asp Tyr Ala Met Asp 1 5 <210> 54 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 54 Trp Ile Ser Ser Ile Ser Ser Thr Ser Asn Tyr Ile Phe 1 5 10 <210> 55 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 55 Ala Asn Ser Tyr Asn Trp Asn Tyr Gly Gly Ala Phe Asp 1 5 10 <210> 56 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 56 Ser Ser Ser Tyr Phe Ala Trp Tyr 1 5 <210> 57 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 57 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 58 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 58 Gln Gln Tyr Gly Arg Ser Pro Leu 1 5 <210> 59 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 59 Gly Phe Thr Phe Ser Asp Tyr Ala 1 5 <210> 60 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 60 Ile Ser Ser Thr Ser Asn Tyr Ile 1 5 <210> 61 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 61 Ala Asn Ser Tyr Asn Trp Asn Tyr Gly Gly Ala Phe Asp Ile 1 5 10 <210> 62 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 62 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 63 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 63 Gly Ala Ser One <210> 64 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 64 Gln Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 65 <211> 121 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 65 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Ala Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Ile 35 40 45 Ser Ser Ile Ser Ser Thr Ser Asn Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Val Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Asn Trp Asn Tyr Gly Gly Ala Phe Asp Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 66 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 66 Asp Ile Gln Met Thr Gln Ser Pro Gly Thr Leu Ser Ser Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 67 <211> 451 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 67 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Ala Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Ile 35 40 45 Ser Ser Ile Ser Ser Thr Ser Asn Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Val Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Asn Trp Asn Tyr Gly Gly Ala Phe Asp Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys 450 <210> 68 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 68 Asp Ile Gln Met Thr Gln Ser Pro Gly Thr Leu Ser Ser Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 69 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 69 Asn Tyr Asp Met Asn 1 5 <210> 70 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 70 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 71 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 71 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 72 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 72 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 73 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 73 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 74 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 74 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 75 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 75 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 76 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 76 Ser Ser Ser Ser Ser Tyr 1 5 <210> 77 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 77 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 78 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 78 Ser Gln Gly Ile Asn Ser Trp 1 5 <210> 79 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 79 Ala Ala Ser One <210> 80 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 80 Ala Asn Ser Phe Pro Trp 1 5 <210> 81 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 81 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 82 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 82 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 83 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 83 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 84 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 84 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 85 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 85 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 86 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 86 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 87 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 87 Ser Asn Tyr Asp Met Asn 1 5 <210> 88 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 88 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 89 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 89 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 90 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 90 Asn Ser Trp Leu Ala Trp Tyr 1 5 <210> 91 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 91 Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln 1 5 10 <210> 92 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 92 Gln Gln Ala Asn Ser Phe Pro Trp 1 5 <210> 93 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 93 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 94 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 94 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 95 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 96 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 96 Gln Gly Ile Asn Ser Trp 1 5 <210> 97 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 97 Ala Ala Ser One <210> 98 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 98 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 99 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 99 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 100 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 100 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 101 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 101 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 102 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 102 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 103 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 103 Ser Tyr Asp Met Asn 1 5 <210> 104 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 104 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 105 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 105 Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 15 <210> 106 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 106 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 107 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 107 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 108 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 108 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 109 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 109 Arg Phe Thr Leu Ser Ser Tyr 1 5 <210> 110 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 110 Ser Ser Ser Ser Ser Tyr 1 5 <210> 111 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 111 Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu Asp 1 5 10 15 <210> 112 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 112 Ser Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 113 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 113 Gly Ala Ser One <210> 114 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 114 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 115 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 115 Arg Phe Thr Leu Ser Ser Tyr Asp Met Asn 1 5 10 <210> 116 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 116 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 117 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 117 Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 15 <210> 118 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 118 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 119 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 119 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 120 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 120 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 121 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 121 Ser Ser Tyr Asp Met Asn 1 5 <210> 122 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 122 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 123 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 123 Ala Arg Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu 1 5 10 15 Asp <210> 124 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 124 Ser Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 125 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 125 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 126 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 126 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 127 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 127 Arg Phe Thr Leu Ser Ser Tyr Asp 1 5 <210> 128 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 128 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 129 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 129 Ala Arg Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu 1 5 10 15 Asp Val <210> 130 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 130 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 131 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 131 Gly Ala Ser One <210> 132 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 132 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 133 <211> 125 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 133 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Thr Leu Ser Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu 100 105 110 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 134 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 134 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 135 <211> 455 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 135 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Thr Leu Ser Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu 100 105 110 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr 115 120 125 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 130 135 140 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 145 150 155 160 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 165 170 175 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 180 185 190 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 195 200 205 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu 210 215 220 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 225 230 235 240 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 245 250 255 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 260 265 270 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 275 280 285 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 290 295 300 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 305 310 315 320 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 325 330 335 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 340 345 350 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 355 360 365 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 370 375 380 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 385 390 395 400 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 405 410 415 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 420 425 430 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 435 440 445 Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 136 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 136 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 137 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 137 Thr Tyr Ser Met Asn 1 5 <210> 138 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 138 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 139 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 139 Asp Gly Glu Leu Gly Val Phe Asp Tyr 1 5 <210> 140 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 140 Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 141 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 141 Gly Pro Ser Gly Arg Ala Thr 1 5 <210> 142 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 142 Gln Gln Phe Gly Arg Ser Pro Leu Thr 1 5 <210> 143 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 143 Gly Phe Thr Phe Ser Thr Tyr 1 5 <210> 144 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 144 Ser Ser Ser Ser Ser Tyr 1 5 <210> 145 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 145 Asp Gly Glu Leu Gly Val Phe Asp 1 5 <210> 146 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 146 Ser Gln Ser Ile Ser Ser Ser Tyr 1 5 <210> 147 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 147 Gly Pro Ser One <210> 148 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 148 Phe Gly Arg Ser Pro Leu 1 5 <210> 149 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 149 Gly Phe Thr Phe Ser Thr Tyr Ser Met Asn 1 5 10 <210> 150 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 150 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 151 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 151 Asp Gly Glu Leu Gly Val Phe Asp Tyr 1 5 <210> 152 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 152 Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 153 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 153 Gly Pro Ser Gly Arg Ala Thr 1 5 <210> 154 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 154 Gln Gln Phe Gly Arg Ser Pro Leu Thr 1 5 <210> 155 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 155 Ser Thr Tyr Ser Met Asn 1 5 <210> 156 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 156 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 157 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 157 Ala Lys Asp Gly Glu Leu Gly Val Phe Asp 1 5 10 <210> 158 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 158 Ser Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 159 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 159 Val Leu Ile Tyr Gly Pro Ser Gly Arg Ala 1 5 10 <210> 160 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 160 Gln Gln Phe Gly Arg Ser Pro Leu 1 5 <210> 161 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 161 Gly Phe Thr Phe Ser Thr Tyr Ser 1 5 <210> 162 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 162 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 163 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 163 Ala Lys Asp Gly Glu Leu Gly Val Phe Asp Tyr 1 5 10 <210> 164 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 164 Gln Ser Ile Ser Ser Ser Ser Tyr 1 5 <210> 165 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 165 Gly Pro Ser One <210> 166 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 166 Gln Gln Phe Gly Arg Ser Pro Leu Thr 1 5 <210> 167 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 167 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Ser Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Ile Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Val Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Glu Leu Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 168 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 168 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Ala Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Val Leu 35 40 45 Ile Tyr Gly Pro Ser Gly Arg Ala Thr Gly Ile Pro Asp Arg Phe Arg 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Gly Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 169 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 169 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Ser Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Ile Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Val Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Glu Leu Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 170 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 170 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Ala Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Val Leu 35 40 45 Ile Tyr Gly Pro Ser Gly Arg Ala Thr Gly Ile Pro Asp Arg Phe Arg 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Gly Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 171 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 171 Asn Tyr Asp Met Asn 1 5 <210> 172 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 172 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 173 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 173 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 174 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 174 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 175 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 175 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 176 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 176 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 177 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 177 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 178 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 178 Ser Ser Ser Ser Ser Tyr 1 5 <210> 179 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 179 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 180 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 180 Ser Gln Gly Ile Asn Ser Trp 1 5 <210> 181 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 181 Ala Ala Ser One <210> 182 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 182 Ala Asn Ser Phe Pro Trp 1 5 <210> 183 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 183 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 184 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 184 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 185 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 185 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 186 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 186 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 187 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 187 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 188 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 188 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 189 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 189 Ser Asn Tyr Asp Met Asn 1 5 <210> 190 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 190 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 191 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 191 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 192 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 192 Asn Ser Trp Leu Ala Trp Tyr 1 5 <210> 193 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 193 Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln 1 5 10 <210> 194 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 194 Gln Gln Ala Asn Ser Phe Pro Trp 1 5 <210> 195 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 195 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 196 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 196 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 197 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 197 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 198 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 198 Gln Gly Ile Asn Ser Trp 1 5 <210> 199 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 199 Ala Ala Ser One <210> 200 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 200 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 201 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 201 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 202 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 202 Glu Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 203 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 203 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 204 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 204 Glu Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 205 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 205 Pro Tyr Thr Met Asn 1 5 <210> 206 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 206 Ser Ile Ser Ser Ser Ser Ser Tyr Met Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 207 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 207 Asp Gly Asp Leu Val Gly Pro Thr Tyr Tyr Phe Asp Tyr 1 5 10 <210> 208 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 208 Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys 1 5 10 <210> 209 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 209 Gln His Asn Lys Arg Pro Ser 1 5 <210> 210 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 210 Gln Ala Trp Asp Ser Thr Thr Val Val 1 5 <210> 211 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 211 Gly Phe Thr Phe Ser Pro Tyr 1 5 <210> 212 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 212 Ser Ser Ser Ser Ser Tyr 1 5 <210> 213 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 213 Asp Gly Asp Leu Val Gly Pro Thr Tyr Tyr Phe Asp 1 5 10 <210> 214 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 214 Asp Lys Leu Gly Asp Lys Tyr 1 5 <210> 215 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 215 Gln His Asn One <210> 216 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 216 Trp Asp Ser Thr Thr Val 1 5 <210> 217 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 217 Gly Phe Thr Phe Ser Pro Tyr Thr Met Asn 1 5 10 <210> 218 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 218 Ser Ile Ser Ser Ser Ser Ser Ser Tyr Met Tyr 1 5 10 <210> 219 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 219 Asp Gly Asp Leu Val Gly Pro Thr Tyr Tyr Phe Asp Tyr 1 5 10 <210> 220 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 220 Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys 1 5 10 <210> 221 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 221 Gln His Asn Lys Arg Pro Ser 1 5 <210> 222 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 222 Gln Ala Trp Asp Ser Thr Thr Val Val 1 5 <210> 223 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 223 Ser Pro Tyr Thr Met Asn 1 5 <210> 224 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 224 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Met Tyr 1 5 10 <210> 225 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 225 Ala Arg Asp Gly Asp Leu Val Gly Pro Thr Tyr Tyr Phe Asp 1 5 10 <210> 226 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 226 Asp Lys Tyr Ala Cys Trp Tyr 1 5 <210> 227 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 227 Leu Val Ile Tyr Gln His Asn Lys Arg Pro 1 5 10 <210> 228 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 228 Gln Ala Trp Asp Ser Thr Thr Val 1 5 <210> 229 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 229 Gly Phe Thr Phe Ser Pro Tyr Thr 1 5 <210> 230 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 230 Ile Ser Ser Ser Ser Ser Ser Tyr Met 1 5 <210> 231 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 231 Ala Arg Asp Gly Asp Leu Val Gly Pro Thr Tyr Tyr Phe Asp Tyr 1 5 10 15 <210> 232 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 232 Lys Leu Gly Asp Lys Tyr 1 5 <210> 233 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 233 Gln His Asn One <210> 234 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 234 Gln Ala Trp Asp Ser Thr Thr Val Val 1 5 <210> 235 <211> 122 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 235 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Pro Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Met Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Asp Leu Val Gly Pro Thr Tyr Tyr Phe Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 236 <211> 106 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 236 Ser Tyr Glu Leu Met Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln His Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Lys Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Thr Thr Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 237 <211> 452 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 237 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Pro Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Met Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Asp Leu Val Gly Pro Thr Tyr Tyr Phe Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Lys 450 <210> 238 <211> 212 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 238 Ser Tyr Glu Leu Met Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln His Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Lys Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Thr Thr Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala 100 105 110 Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn 115 120 125 Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val 130 135 140 Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu 145 150 155 160 Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser 165 170 175 Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser 180 185 190 Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro 195 200 205 Thr Glu Cys Ser 210 <210> 239 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 239 Ser Tyr Asp Met Asn 1 5 <210> 240 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 240 Ser Ile Ser Thr Ser Ser Gly Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 241 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 241 Asp Arg Gly Ile Ala Val Ala Gly Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 242 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 242 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 243 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 243 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 244 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 244 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 245 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 245 Gly Phe Thr Phe Arg Ser Tyr 1 5 <210> 246 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 246 Ser Thr Ser Ser Gly Tyr 1 5 <210> 247 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 247 Asp Arg Gly Ile Ala Val Ala Gly Asp Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 248 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 248 Ser Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 249 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 249 Gly Ala Ser One <210> 250 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 250 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 251 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 251 Gly Phe Thr Phe Arg Ser Tyr Asp Met Asn 1 5 10 <210> 252 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 252 Ser Ile Ser Thr Ser Ser Gly Tyr Ile Tyr 1 5 10 <210> 253 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 253 Asp Arg Gly Ile Ala Val Ala Gly Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 254 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 254 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 255 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 255 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 256 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 256 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 257 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 257 Arg Ser Tyr Asp Met Asn 1 5 <210> 258 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 258 Trp Val Ser Ser Ile Ser Thr Ser Ser Gly Tyr Ile Tyr 1 5 10 <210> 259 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 259 Ala Arg Asp Arg Gly Ile Ala Val Ala Gly Asp Tyr Tyr Tyr Gly Met 1 5 10 15 Asp <210> 260 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 260 Ser Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 261 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 261 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 262 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 262 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 263 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 263 Gly Phe Thr Phe Arg Ser Tyr Asp 1 5 <210> 264 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 264 Ile Ser Thr Ser Ser Gly Tyr Ile 1 5 <210> 265 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 265 Ala Arg Asp Arg Gly Ile Ala Val Ala Gly Asp Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 266 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 266 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 267 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 267 Gly Ala Ser One <210> 268 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 268 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 269 <211> 125 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 269 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Arg Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Thr Ser Ser Gly Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Ser 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Phe Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Ile Ala Val Ala Gly Asp Tyr Tyr Tyr Gly Met 100 105 110 Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 270 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 270 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Ala Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 271 <211> 455 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 271 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Arg Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Thr Ser Ser Gly Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Ser 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Phe Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Ile Ala Val Ala Gly Asp Tyr Tyr Tyr Gly Met 100 105 110 Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr 115 120 125 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 130 135 140 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 145 150 155 160 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 165 170 175 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 180 185 190 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 195 200 205 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu 210 215 220 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 225 230 235 240 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 245 250 255 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 260 265 270 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 275 280 285 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 290 295 300 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 305 310 315 320 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 325 330 335 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 340 345 350 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 355 360 365 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 370 375 380 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 385 390 395 400 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 405 410 415 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 420 425 430 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 435 440 445 Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 272 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 272 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Ala Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 273 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 273 Asn Tyr Asp Met Asn 1 5 <210> 274 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 274 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 275 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 275 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 276 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 276 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 277 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 277 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 278 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 278 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 279 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 279 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 280 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 280 Ser Ser Ser Ser Ser Tyr 1 5 <210> 281 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 281 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 282 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 282 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 283 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 283 Gly Ala Ser One <210> 284 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 284 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 285 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 285 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 286 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 286 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 287 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 287 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 288 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 288 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 289 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 289 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 290 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 290 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 291 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 291 Ser Asn Tyr Asp Met Asn 1 5 <210> 292 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 292 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 293 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 293 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 294 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 294 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 295 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 295 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 296 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 296 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 297 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 297 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 298 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 298 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 299 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 299 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 300 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 300 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 301 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 301 Gly Ala Ser One <210> 302 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 302 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 303 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 303 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 304 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 304 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 305 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 305 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 306 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 306 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 307 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 307 Ile Asn Ser Met Asn 1 5 <210> 308 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 308 Ser Ile Ser Ser Thr Ser Asp Tyr Ile Phe Asn Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 309 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 309 Asp Asp Val Phe Gly Ala Phe Asp Ile 1 5 <210> 310 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 310 Arg Thr Ser Gln Ser Val Ser Arg Ser Tyr Leu Gly 1 5 10 <210> 311 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 311 Gly Ser Ser Ser Arg Ala Thr 1 5 <210> 312 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 312 Gln Gln Tyr Ser Arg Ser Pro Leu Thr 1 5 <210> 313 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 313 Gly Phe Thr Phe Ser Ile Asn 1 5 <210> 314 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 314 Ser Ser Thr Ser Asp Tyr 1 5 <210> 315 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 315 Asp Asp Val Phe Gly Ala Phe Asp 1 5 <210> 316 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 316 Ser Gln Ser Val Ser Arg Ser Tyr 1 5 <210> 317 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 317 Gly Ser Ser One <210> 318 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 318 Tyr Ser Arg Ser Pro Leu 1 5 <210> 319 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 319 Gly Phe Thr Phe Ser Ile Asn Ser Met Asn 1 5 10 <210> 320 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 320 Ser Ile Ser Ser Thr Ser Asp Tyr Ile Phe 1 5 10 <210> 321 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 321 Asp Asp Val Phe Gly Ala Phe Asp Ile 1 5 <210> 322 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 322 Arg Thr Ser Gln Ser Val Ser Arg Ser Tyr Leu Gly 1 5 10 <210> 323 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 323 Gly Ser Ser Ser Arg Ala Thr 1 5 <210> 324 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 324 Gln Gln Tyr Ser Arg Ser Pro Leu Thr 1 5 <210> 325 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 325 Ser Ile Asn Ser Met Asn 1 5 <210> 326 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 326 Trp Val Ser Ser Ile Ser Ser Thr Ser Asp Tyr Ile Phe 1 5 10 <210> 327 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 327 Val Arg Asp Asp Val Phe Gly Ala Phe Asp 1 5 10 <210> 328 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 328 Ser Arg Ser Tyr Leu Gly Trp Tyr 1 5 <210> 329 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 329 Leu Leu Ile Phe Gly Ser Ser Ser Arg Ala 1 5 10 <210> 330 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 330 Gln Gln Tyr Ser Arg Ser Pro Leu 1 5 <210> 331 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 331 Gly Phe Thr Phe Ser Ile Asn Ser 1 5 <210> 332 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 332 Ile Ser Ser Thr Ser Asp Tyr Ile 1 5 <210> 333 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 333 Val Arg Asp Asp Val Phe Gly Ala Phe Asp Ile 1 5 10 <210> 334 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 334 Gln Ser Val Ser Arg Ser Tyr 1 5 <210> 335 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 335 Gly Ser Ser One <210> 336 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 336 Gln Gln Tyr Ser Arg Ser Pro Leu Thr 1 5 <210> 337 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 337 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Ile Asn 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Thr Ser Asp Tyr Ile Phe Asn Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Arg Asp Asp Val Phe Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 338 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 338 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Gln Ser Val Ser Arg Ser 20 25 30 Tyr Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu 35 40 45 Ile Phe Gly Ser Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 <210> 339 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 339 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Ile Asn 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Thr Ser Asp Tyr Ile Phe Asn Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Arg Asp Asp Val Phe Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 340 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 340 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Gln Ser Val Ser Arg Ser 20 25 30 Tyr Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu 35 40 45 Ile Phe Gly Ser Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 341 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 341 Asn Tyr Asp Met Asn 1 5 <210> 342 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 342 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 343 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 343 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 344 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 344 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 345 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 345 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 346 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 346 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 347 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 347 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 348 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 348 Ser Ser Ser Ser Ser Tyr 1 5 <210> 349 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 349 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 350 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 350 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 351 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 351 Gly Ala Ser One <210> 352 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 352 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 353 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 353 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 354 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 354 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 355 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 355 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 356 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 356 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 357 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 357 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 358 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 358 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 359 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 359 Ser Asn Tyr Asp Met Asn 1 5 <210> 360 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 360 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 361 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 361 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 362 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 362 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 363 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 363 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 364 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 364 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 365 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 365 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 366 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 366 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 367 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 367 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 368 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 368 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 369 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 369 Gly Ala Ser One <210> 370 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 370 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 371 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 371 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 372 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 372 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 373 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 373 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 374 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 374 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 375 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 375 Ser Tyr Asp Ile Asn 1 5 <210> 376 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 376 Ser Ile Thr Ser Ser Ser Tyr Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 377 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 377 Asp Leu Gly Val Arg Gly Val Asp Tyr Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 15 <210> 378 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 378 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 379 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 379 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 380 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 380 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 381 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 381 Gly Phe Thr Phe Ser Ser Tyr 1 5 <210> 382 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 382 Thr Ser Ser Ser Tyr Tyr 1 5 <210> 383 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 383 Asp Leu Gly Val Arg Gly Val Asp Tyr Tyr Tyr Tyr Gly Leu Asp 1 5 10 15 <210> 384 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 384 Ser Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 385 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 385 Gly Ala Ser One <210> 386 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 386 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 387 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 387 Gly Phe Thr Phe Ser Ser Tyr Asp Ile Asn 1 5 10 <210> 388 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 388 Ser Ile Thr Ser Ser Ser Tyr Tyr Ile Tyr 1 5 10 <210> 389 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 389 Asp Leu Gly Val Arg Gly Val Asp Tyr Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 15 <210> 390 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 390 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 391 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 391 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 392 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 392 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 393 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 393 Ser Ser Tyr Asp Ile Asn 1 5 <210> 394 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 394 Trp Val Ser Ser Ile Thr Ser Ser Ser Tyr Tyr Ile Tyr 1 5 10 <210> 395 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 395 Ala Arg Asp Leu Gly Val Arg Gly Val Asp Tyr Tyr Tyr Tyr Gly Leu 1 5 10 15 Asp <210> 396 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 396 Ser Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 397 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 397 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 398 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 398 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 399 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 399 Gly Phe Thr Phe Ser Ser Tyr Asp 1 5 <210> 400 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 400 Ile Thr Ser Ser Ser Tyr Tyr Ile 1 5 <210> 401 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 401 Ala Arg Asp Leu Gly Val Arg Gly Val Asp Tyr Tyr Tyr Tyr Gly Leu 1 5 10 15 Asp Val <210> 402 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 402 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 403 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 403 Gly Ala Ser One <210> 404 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 404 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 405 <211> 125 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 405 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Thr Ser Ser Ser Tyr Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Leu Gly Val Arg Gly Val Asp Tyr Tyr Tyr Tyr Gly Leu 100 105 110 Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 406 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 406 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 407 <211> 455 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 407 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Thr Ser Ser Ser Tyr Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Leu Gly Val Arg Gly Val Asp Tyr Tyr Tyr Tyr Gly Leu 100 105 110 Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr 115 120 125 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 130 135 140 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 145 150 155 160 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 165 170 175 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 180 185 190 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 195 200 205 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu 210 215 220 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 225 230 235 240 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 245 250 255 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 260 265 270 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 275 280 285 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 290 295 300 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 305 310 315 320 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 325 330 335 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 340 345 350 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 355 360 365 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 370 375 380 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 385 390 395 400 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 405 410 415 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 420 425 430 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 435 440 445 Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 408 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 408 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 409 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 409 Asn Tyr Asp Met Asn 1 5 <210> 410 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 410 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 411 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 411 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 412 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 412 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 413 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 413 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 414 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 414 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 415 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 415 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 416 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 416 Ser Ser Ser Ser Ser Tyr 1 5 <210> 417 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 417 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 418 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 418 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 419 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 419 Gly Ala Ser One <210> 420 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 420 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 421 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 421 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 422 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 422 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 423 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 423 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 424 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 424 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 425 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 425 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 426 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 426 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 427 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 427 Ser Asn Tyr Asp Met Asn 1 5 <210> 428 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 428 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 429 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 429 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 430 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 430 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 431 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 431 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 432 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 432 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 433 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 433 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 434 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 434 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 435 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 435 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 436 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 436 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 437 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 437 Gly Ala Ser One <210> 438 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 438 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 439 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 439 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 440 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 440 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 441 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 441 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 442 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 442 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 443 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 443 Val Tyr Ser Met Asn 1 5 <210> 444 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 444 Ser Ile Gly Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 445 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 445 Asp His Asp Tyr Gly Gly Leu Asp Tyr 1 5 <210> 446 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 446 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 447 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 447 Gly Pro Ser Asn Arg Ala Thr 1 5 <210> 448 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 448 Gln Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 449 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 449 Gly Phe Thr Phe Ser Val Tyr 1 5 <210> 450 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 450 Gly Ser Ser Ser Ser Tyr 1 5 <210> 451 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 451 Asp His Asp Tyr Gly Gly Leu Asp 1 5 <210> 452 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 452 Ser Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 453 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 453 Gly Pro Ser One <210> 454 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 454 Tyr Gly Arg Ser Pro Leu 1 5 <210> 455 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 455 Gly Phe Thr Phe Ser Val Tyr Ser Met Asn 1 5 10 <210> 456 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 456 Ser Ile Gly Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 457 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 457 Asp His Asp Tyr Gly Gly Leu Asp Tyr 1 5 <210> 458 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 458 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 459 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 459 Gly Pro Ser Asn Arg Ala Thr 1 5 <210> 460 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 460 Gln Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 461 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 461 Ser Val Tyr Ser Met Asn 1 5 <210> 462 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 462 Trp Val Ser Ser Ile Gly Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 463 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 463 Gly Arg Asp His Asp Tyr Gly Gly Leu Asp 1 5 10 <210> 464 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 464 Ser Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 465 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 465 Leu Leu Ile Tyr Gly Pro Ser Asn Arg Ala 1 5 10 <210> 466 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 466 Gln Gln Tyr Gly Arg Ser Pro Leu 1 5 <210> 467 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 467 Gly Phe Thr Phe Ser Val Tyr Ser 1 5 <210> 468 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 468 Ile Gly Ser Ser Ser Ser Tyr Ile 1 5 <210> 469 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 469 Gly Arg Asp His Asp Tyr Gly Gly Leu Asp Tyr 1 5 10 <210> 470 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 470 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 471 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 471 Gly Pro Ser One <210> 472 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 472 Gln Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 473 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 473 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Val Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Gly Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Gly Arg Asp His Asp Tyr Gly Gly Leu Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 474 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 474 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Pro Ser Asn Arg Ala Thr Asp Ile Pro Asp Arg Phe Ser 50 55 60 Gly Thr Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 475 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 475 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Val Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Gly Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Gly Arg Asp His Asp Tyr Gly Gly Leu Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 476 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 476 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Pro Ser Asn Arg Ala Thr Asp Ile Pro Asp Arg Phe Ser 50 55 60 Gly Thr Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 477 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 477 Ser Ile Tyr Trp Ser 1 5 <210> 478 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 478 Arg Ile Tyr Thr Thr Asp Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 479 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 479 Asn Gly Tyr Ser Tyr Gly Gly Phe Asn Tyr 1 5 10 <210> 480 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 480 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 481 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 481 Gly Asp Ser Tyr Arg Pro Ser 1 5 <210> 482 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 482 Gln Ser Tyr Asp Ser Ser Leu Ser Val Val Val 1 5 10 <210> 483 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 483 Gly Asp Ser Ile Ser Ser Ile 1 5 <210> 484 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 484 Tyr Thr Thr Asp Ile 1 5 <210> 485 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 485 Asn Gly Tyr Ser Tyr Gly Gly Phe Asn 1 5 <210> 486 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 486 Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp 1 5 10 <210> 487 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 487 Gly Asp Ser One <210> 488 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 488 Tyr Asp Ser Ser Leu Ser Val Val 1 5 <210> 489 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 489 Gly Asp Ser Ile Ser Ser Ile Tyr Trp Ser 1 5 10 <210> 490 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 490 Arg Ile Tyr Thr Thr Asp Ile Thr Asn 1 5 <210> 491 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 491 Asn Gly Tyr Ser Tyr Gly Gly Phe Asn Tyr 1 5 10 <210> 492 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 492 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 493 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 493 Gly Asp Ser Tyr Arg Pro Ser 1 5 <210> 494 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 494 Gln Ser Tyr Asp Ser Ser Leu Ser Val Val Val 1 5 10 <210> 495 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 495 Ser Ser Ile Tyr Trp Ser 1 5 <210> 496 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 496 Trp Ile Gly Arg Ile Tyr Thr Thr Asp Ile Thr Asn 1 5 10 <210> 497 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 497 Ala Lys Asn Gly Tyr Ser Tyr Gly Gly Phe Asn 1 5 10 <210> 498 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 498 Ile Gly Ala Gly Tyr Asp Val His Trp Tyr 1 5 10 <210> 499 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 499 Leu Leu Ile Tyr Gly Asp Ser Tyr Arg Pro 1 5 10 <210> 500 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 500 Gln Ser Tyr Asp Ser Ser Leu Ser Val Val 1 5 10 <210> 501 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 501 Gly Asp Ser Ile Ser Ser Ile Tyr 1 5 <210> 502 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 502 Ile Tyr Thr Thr Asp Ile Thr 1 5 <210> 503 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 503 Ala Lys Asn Gly Tyr Ser Tyr Gly Gly Phe Asn Tyr 1 5 10 <210> 504 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 504 Ser Ser Asn Ile Gly Ala Gly Tyr Asp 1 5 <210> 505 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 505 Gly Asp Ser One <210> 506 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 506 Gln Ser Tyr Asp Ser Ser Leu Ser Val Val Val 1 5 10 <210> 507 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 507 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ile 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Ser Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Thr Thr Asp Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Ala Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Lys Asn Gly Tyr Ser Tyr Gly Gly Phe Asn Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 508 <211> 111 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 508 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Arg Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asp Ser Tyr Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Val Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 509 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 509 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ile 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Ser Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Thr Thr Asp Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Ala Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Lys Asn Gly Tyr Ser Tyr Gly Gly Phe Asn Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 510 <211> 217 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 510 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Arg Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asp Ser Tyr Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Val Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 511 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 511 Asn Tyr Asp Met Asn 1 5 <210> 512 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 512 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 513 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 513 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 514 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 514 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 515 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 515 Thr Asn Thr Gln Arg Pro Ser 1 5 <210> 516 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 516 Ala Ala Trp Asp Asp Ser Leu Asn Ala Trp Val 1 5 10 <210> 517 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 517 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 518 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 518 Ser Ser Ser Ser Ser Tyr 1 5 <210> 519 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 519 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 520 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 520 Ser Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 521 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 521 Thr Asn Thr One <210> 522 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 522 Trp Asp Asp Ser Leu Asn Ala Trp 1 5 <210> 523 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 523 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 524 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 524 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 525 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 525 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 526 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 526 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 527 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 527 Thr Asn Thr Gln Arg Pro Ser 1 5 <210> 528 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 528 Ala Ala Trp Asp Asp Ser Leu Asn Ala Trp Val 1 5 10 <210> 529 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 529 Ser Asn Tyr Asp Met Asn 1 5 <210> 530 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 530 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 531 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 531 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 532 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 532 Ile Gly Ser Asn Thr Val Asn Trp Tyr 1 5 <210> 533 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 533 Leu Leu Ile Tyr Thr Asn Thr Gln Arg Pro 1 5 10 <210> 534 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 534 Ala Ala Trp Asp Asp Ser Leu Asn Ala Trp 1 5 10 <210> 535 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 535 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 536 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 536 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 537 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 537 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 538 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 538 Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 539 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 539 Thr Asn Thr One <210> 540 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 540 Ala Ala Trp Asp Asp Ser Leu Asn Ala Trp Val 1 5 10 <210> 541 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 541 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 542 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 542 Gln Pro Val Leu Thr Gln Ser Ser Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Thr Asn Thr Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Leu Val Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 543 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 543 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 544 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 544 Gln Pro Val Leu Thr Gln Ser Ser Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Thr Asn Thr Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Leu Val Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 545 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 545 His Tyr Asp Met Asn 1 5 <210> 546 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 546 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 547 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 547 Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly Leu Asp 1 5 10 15 Val <210> 548 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 548 Arg Ala Ser Gln Asn Val Ser Ser Thr Tyr Leu Ala 1 5 10 <210> 549 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 549 Gly Ala Cys Ser Arg Ala Thr 1 5 <210> 550 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 550 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 551 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 551 Gly Phe Thr Phe Ser His Tyr 1 5 <210> 552 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 552 Ser Ser Ser Ser Ser Tyr 1 5 <210> 553 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 553 Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly Leu Asp 1 5 10 15 <210> 554 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 554 Ser Gln Asn Val Ser Ser Thr Tyr 1 5 <210> 555 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 555 Gly Ala Cys One <210> 556 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 556 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 557 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 557 Gly Phe Thr Phe Ser His Tyr Asp Met Asn 1 5 10 <210> 558 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 558 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 559 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 559 Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly Leu Asp 1 5 10 15 Val <210> 560 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 560 Arg Ala Ser Gln Asn Val Ser Ser Thr Tyr Leu Ala 1 5 10 <210> 561 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 561 Gly Ala Cys Ser Arg Ala Thr 1 5 <210> 562 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 562 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 563 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 563 Ser His Tyr Asp Met Asn 1 5 <210> 564 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 564 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 565 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 565 Ala Arg Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly 1 5 10 15 Leu Asp <210> 566 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 566 Ser Ser Thr Tyr Leu Ala Trp Tyr 1 5 <210> 567 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 567 Leu Leu Ile Tyr Gly Ala Cys Ser Arg Ala 1 5 10 <210> 568 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 568 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 569 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 569 Gly Phe Thr Phe Ser His Tyr Asp 1 5 <210> 570 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 570 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 571 <211> 19 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 571 Ala Arg Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly 1 5 10 15 Leu Asp Val <210> 572 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 572 Gln Asn Val Ser Ser Thr Tyr 1 5 <210> 573 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 573 Gly Ala Cys One <210> 574 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 574 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 575 <211> 126 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 575 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Leu 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly 100 105 110 Leu Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 576 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 576 Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Val Ser Ser Thr 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Cys Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Tyr Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Arg Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 577 <211> 456 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 577 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Leu 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly 100 105 110 Leu Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser 115 120 125 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 130 135 140 Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 145 150 155 160 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 165 170 175 His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 180 185 190 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile 195 200 205 Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val 210 215 220 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 225 230 235 240 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 245 250 255 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 260 265 270 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 275 280 285 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 290 295 300 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 305 310 315 320 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 325 330 335 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 340 345 350 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 355 360 365 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 370 375 380 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 385 390 395 400 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 405 410 415 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 420 425 430 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 435 440 445 Ser Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 578 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 578 Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Val Ser Ser Thr 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Cys Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Tyr Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Arg Gly Thr Lys Leu Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 579 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 579 Asn Tyr Gly Met Asn 1 5 <210> 580 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 580 Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met Lys 1 5 10 15 Gly <210> 581 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 581 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 582 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 582 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 583 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 583 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 584 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 584 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 585 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 585 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 586 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 586 Ser Ser Gly Ser Ser Tyr 1 5 <210> 587 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 587 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 588 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 588 Ser Gln Gly Ile Asn Ser Trp 1 5 <210> 589 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 589 Ala Ala Ser One <210> 590 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 590 Ala Asn Ser Phe Pro Trp 1 5 <210> 591 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 591 Gly Phe Thr Phe Ser Asn Tyr Gly Met Asn 1 5 10 <210> 592 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 592 Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr 1 5 10 <210> 593 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 593 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 594 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 594 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 595 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 595 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 596 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 596 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 597 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 597 Ser Asn Tyr Gly Met Asn 1 5 <210> 598 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 598 Trp Val Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr 1 5 10 <210> 599 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 599 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 600 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 600 Asn Ser Trp Leu Ala Trp Tyr 1 5 <210> 601 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 601 Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln 1 5 10 <210> 602 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 602 Gln Gln Ala Asn Ser Phe Pro Trp 1 5 <210> 603 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 603 Gly Phe Thr Phe Ser Asn Tyr Gly 1 5 <210> 604 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 604 Ile Ser Ser Gly Ser Ser Tyr Lys 1 5 <210> 605 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 605 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 606 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 606 Gln Gly Ile Asn Ser Trp 1 5 <210> 607 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 607 Ala Ala Ser One <210> 608 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 608 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 609 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 609 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Leu Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Ser Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 610 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 610 Glu Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 611 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 611 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Leu Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Ser Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 612 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 612 Glu Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 613 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 613 Ser Tyr Asp Met Asn 1 5 <210> 614 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 614 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 615 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 615 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 616 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 616 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 617 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 617 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 618 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 618 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 619 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 619 Gly Phe Thr Phe Ser Ser Tyr 1 5 <210> 620 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 620 Ser Ser Ser Ser Ser Tyr 1 5 <210> 621 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 621 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 622 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 622 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 623 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 623 Gly Ala Ser One <210> 624 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 624 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 625 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 625 Gly Phe Thr Phe Ser Ser Tyr Asp Met Asn 1 5 10 <210> 626 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 626 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 627 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 627 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 628 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 628 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 629 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 629 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 630 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 630 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 631 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 631 Ser Ser Tyr Asp Met Asn 1 5 <210> 632 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 632 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 633 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 633 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 634 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 634 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 635 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 635 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 636 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 636 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 637 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 637 Gly Phe Thr Phe Ser Ser Tyr Asp 1 5 <210> 638 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 638 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 639 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 639 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 640 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 640 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 641 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 641 Gly Ala Ser One <210> 642 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 642 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 643 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 643 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 644 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 644 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 645 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 645 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 646 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 646 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 647 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 647 Asn Tyr Asp Met Asn 1 5 <210> 648 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 648 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 649 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 649 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 650 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 650 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 651 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 651 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 652 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 652 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 653 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 653 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 654 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 654 Ser Ser Ser Ser Ser Tyr 1 5 <210> 655 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 655 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 656 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 656 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 657 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 657 Gly Ala Ser One <210> 658 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 658 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 659 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 659 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 660 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 660 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 661 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 661 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 662 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 662 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 663 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 663 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 664 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 664 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 665 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 665 Ser Asn Tyr Asp Met Asn 1 5 <210> 666 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 666 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 667 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 667 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 668 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 668 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 669 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 669 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 670 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 670 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 671 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 671 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 672 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 672 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 673 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 673 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 674 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 674 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 675 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 675 Gly Ala Ser One <210> 676 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 676 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 677 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 677 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 678 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 678 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 679 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 679 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 680 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 680 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 681 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 681 Ser Tyr Ser Met Tyr 1 5 <210> 682 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 682 Ser Ile Gly Ser Ser Ser Thr Tyr Ile Phe Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 683 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 683 Asp Gly Glu Leu Gly Pro Phe Glu Tyr 1 5 <210> 684 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 684 Arg Ala Ser Gln Ser Val Ser Thr Ser Tyr Leu Ala 1 5 10 <210> 685 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 685 Gly Thr Ser Ser Arg Ala Thr 1 5 <210> 686 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 686 Leu Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 687 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 687 Gly Phe Thr Phe Ser Ser Tyr 1 5 <210> 688 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 688 Gly Ser Ser Ser Thr Tyr 1 5 <210> 689 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 689 Asp Gly Glu Leu Gly Pro Phe Glu 1 5 <210> 690 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 690 Ser Gln Ser Val Ser Thr Ser Tyr 1 5 <210> 691 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 691 Gly Thr Ser One <210> 692 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 692 Tyr Gly Arg Ser Pro Leu 1 5 <210> 693 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 693 Gly Phe Thr Phe Ser Ser Tyr Ser Met Tyr 1 5 10 <210> 694 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 694 Ser Ile Gly Ser Ser Ser Thr Tyr Ile Phe 1 5 10 <210> 695 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 695 Asp Gly Glu Leu Gly Pro Phe Glu Tyr 1 5 <210> 696 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 696 Arg Ala Ser Gln Ser Val Ser Thr Ser Tyr Leu Ala 1 5 10 <210> 697 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 697 Gly Thr Ser Ser Arg Ala Thr 1 5 <210> 698 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 698 Leu Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 699 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 699 Ser Ser Tyr Ser Met Tyr 1 5 <210> 700 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 700 Trp Val Ser Ser Ile Gly Ser Ser Ser Thr Tyr Ile Phe 1 5 10 <210> 701 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 701 Ala Arg Asp Gly Glu Leu Gly Pro Phe Glu 1 5 10 <210> 702 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 702 Ser Thr Ser Tyr Leu Ala Trp Phe 1 5 <210> 703 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 703 Leu Leu Ile Phe Gly Thr Ser Ser Arg Ala 1 5 10 <210> 704 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 704 Leu Gln Tyr Gly Arg Ser Pro Leu 1 5 <210> 705 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 705 Gly Phe Thr Phe Ser Ser Tyr Ser 1 5 <210> 706 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 706 Ile Gly Ser Ser Ser Thr Tyr Ile 1 5 <210> 707 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 707 Ala Arg Asp Gly Glu Leu Gly Pro Phe Glu Tyr 1 5 10 <210> 708 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 708 Gln Ser Val Ser Thr Ser Tyr 1 5 <210> 709 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 709 Gly Thr Ser One <210> 710 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 710 Leu Gln Tyr Gly Arg Ser Pro Leu Thr 1 5 <210> 711 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 711 Glu Val Gln Leu Val Gln Ser Gly Gly Asp Leu Val Lys Ser Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Gly Ser Ser Ser Thr Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Thr Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Arg Leu Gly Ala Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Glu Leu Gly Pro Phe Glu Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 712 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 712 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser 20 25 30 Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Phe Gly Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr His Cys Leu Gln Tyr Gly Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 <210> 713 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 713 Glu Val Gln Leu Val Gln Ser Gly Gly Asp Leu Val Lys Ser Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Gly Ser Ser Ser Thr Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Thr Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Arg Leu Gly Ala Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Glu Leu Gly Pro Phe Glu Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 714 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 714 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser 20 25 30 Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Phe Gly Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr His Cys Leu Gln Tyr Gly Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 715 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 715 Asn Tyr Asp Met Asn 1 5 <210> 716 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 716 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 717 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 717 Glu Ile Gly Val Thr Gly Thr Thr Tyr Tyr Gln Asp Tyr Gly Met Asp 1 5 10 15 Val <210> 718 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 718 Arg Ala Ser Gln Ser Phe Ser Ser Asn Tyr Leu Ala 1 5 10 <210> 719 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 719 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 720 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 720 Gln Gln Tyr Gly Ser Ser Pro Pro Phe Thr 1 5 10 <210> 721 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 721 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 722 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 722 Ser Ser Ser Ser Ser Tyr 1 5 <210> 723 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 723 Glu Ile Gly Val Thr Gly Thr Thr Tyr Tyr Gln Asp Tyr Gly Met Asp 1 5 10 15 <210> 724 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 724 Ser Gln Ser Phe Ser Ser Asn Tyr 1 5 <210> 725 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 725 Gly Ala Ser One <210> 726 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 726 Tyr Gly Ser Ser Pro Pro Phe 1 5 <210> 727 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 727 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 728 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 728 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 729 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 729 Glu Ile Gly Val Thr Gly Thr Thr Tyr Tyr Gln Asp Tyr Gly Met Asp 1 5 10 15 Val <210> 730 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 730 Arg Ala Ser Gln Ser Phe Ser Ser Asn Tyr Leu Ala 1 5 10 <210> 731 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 731 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 732 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 732 Gln Gln Tyr Gly Ser Ser Pro Pro Phe Thr 1 5 10 <210> 733 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 733 Ser Asn Tyr Asp Met Asn 1 5 <210> 734 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 734 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 735 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 735 Ala Arg Glu Ile Gly Val Thr Gly Thr Thr Tyr Tyr Gln Asp Tyr Gly 1 5 10 15 Met Asp <210> 736 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 736 Ser Ser Asn Tyr Leu Ala Trp Tyr 1 5 <210> 737 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 737 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 738 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 738 Gln Gln Tyr Gly Ser Ser Pro Pro Phe 1 5 <210> 739 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 739 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 740 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 740 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 741 <211> 19 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 741 Ala Arg Glu Ile Gly Val Thr Gly Thr Thr Tyr Tyr Gln Asp Tyr Gly 1 5 10 15 Met Asp Val <210> 742 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 742 Gln Ser Phe Ser Ser Asn Tyr 1 5 <210> 743 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 743 Gly Ala Ser One <210> 744 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 744 Gln Gln Tyr Gly Ser Ser Pro Pro Phe Thr 1 5 10 <210> 745 <211> 126 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 745 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Ser Leu Phe 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ile Gly Val Thr Gly Thr Thr Tyr Tyr Gln Asp Tyr Gly 100 105 110 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 746 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 746 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Phe Ser Ser Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 747 <211> 456 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 747 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Ser Leu Phe 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ile Gly Val Thr Gly Thr Thr Tyr Tyr Gln Asp Tyr Gly 100 105 110 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser 115 120 125 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 130 135 140 Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 145 150 155 160 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 165 170 175 His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 180 185 190 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile 195 200 205 Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val 210 215 220 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 225 230 235 240 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 245 250 255 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 260 265 270 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 275 280 285 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 290 295 300 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 305 310 315 320 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 325 330 335 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 340 345 350 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 355 360 365 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 370 375 380 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 385 390 395 400 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 405 410 415 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 420 425 430 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 435 440 445 Ser Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 748 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 748 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Phe Ser Ser Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 749 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 749 Asn Tyr Asp Met Asn 1 5 <210> 750 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 750 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 751 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 751 Asp Leu Gly Ile Thr Gly Thr Thr Met Asp Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 752 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 752 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 753 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 753 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 754 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 754 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 755 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 755 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 756 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 756 Ser Ser Ser Ser Ser Tyr 1 5 <210> 757 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 757 Asp Leu Gly Ile Thr Gly Thr Thr Met Asp Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 758 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 758 Ser Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 759 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 759 Gly Ala Ser One <210> 760 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 760 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 761 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 761 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 762 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 762 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 763 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 763 Asp Leu Gly Ile Thr Gly Thr Thr Met Asp Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 764 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 764 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 765 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 765 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 766 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 766 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 767 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 767 Ser Asn Tyr Asp Met Asn 1 5 <210> 768 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 768 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 769 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 769 Ala Arg Asp Leu Gly Ile Thr Gly Thr Thr Met Asp Tyr Tyr Tyr Gly 1 5 10 15 Met Asp <210> 770 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 770 Ser Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 771 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 771 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 772 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 772 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 773 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 773 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 774 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 774 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 775 <211> 19 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 775 Ala Arg Asp Leu Gly Ile Thr Gly Thr Thr Met Asp Tyr Tyr Tyr Gly 1 5 10 15 Met Asp Val <210> 776 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 776 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 777 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 777 Gly Ala Ser One <210> 778 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 778 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 779 <211> 126 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 779 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ala Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Leu Gly Ile Thr Gly Thr Thr Met Asp Tyr Tyr Tyr Gly 100 105 110 Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 780 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 780 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100 105 <210> 781 <211> 456 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 781 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ala Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Leu Gly Ile Thr Gly Thr Thr Met Asp Tyr Tyr Tyr Gly 100 105 110 Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser 115 120 125 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 130 135 140 Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 145 150 155 160 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 165 170 175 His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 180 185 190 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile 195 200 205 Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val 210 215 220 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 225 230 235 240 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 245 250 255 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 260 265 270 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 275 280 285 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 290 295 300 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 305 310 315 320 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 325 330 335 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 340 345 350 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 355 360 365 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 370 375 380 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 385 390 395 400 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 405 410 415 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 420 425 430 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 435 440 445 Ser Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 782 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 782 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 783 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 783 Ser Tyr Asp Met Asn 1 5 <210> 784 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 784 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 785 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 785 Asp Arg Gly Ile Gly Gly Asp Tyr Tyr Ser Tyr Ala Met Asp Val 1 5 10 15 <210> 786 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 786 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 787 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 787 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 788 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 788 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 789 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 789 Gly Phe Thr Phe Asn Ser Tyr 1 5 <210> 790 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 790 Ser Ser Ser Ser Ser Tyr 1 5 <210> 791 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 791 Asp Arg Gly Ile Gly Gly Asp Tyr Tyr Ser Tyr Ala Met Asp 1 5 10 <210> 792 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 792 Ser Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 793 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 793 Gly Ala Ser One <210> 794 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 794 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 795 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 795 Gly Phe Thr Phe Asn Ser Tyr Asp Met Asn 1 5 10 <210> 796 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 796 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 797 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 797 Asp Arg Gly Ile Gly Gly Asp Tyr Tyr Ser Tyr Ala Met Asp Val 1 5 10 15 <210> 798 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 798 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 799 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 799 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 800 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 800 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 801 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 801 Asn Ser Tyr Asp Met Asn 1 5 <210> 802 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 802 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 803 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 803 Ala Arg Asp Arg Gly Ile Gly Gly Asp Tyr Tyr Ser Tyr Ala Met Asp 1 5 10 15 <210> 804 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 804 Ser Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 805 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 805 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 806 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 806 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 807 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 807 Gly Phe Thr Phe Asn Ser Tyr Asp 1 5 <210> 808 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 808 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 809 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 809 Ala Arg Asp Arg Gly Ile Gly Gly Asp Tyr Tyr Ser Tyr Ala Met Asp 1 5 10 15 Val <210> 810 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 810 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 811 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 811 Gly Ala Ser One <210> 812 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 812 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 813 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 813 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Cys Thr Ile Ser Arg Asp Asn Ala Arg Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Ile Gly Gly Asp Tyr Tyr Ser Tyr Ala Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 814 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 814 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 815 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 815 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Cys Thr Ile Ser Arg Asp Asn Ala Arg Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Ile Gly Gly Asp Tyr Tyr Ser Tyr Ala Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 816 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 816 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 817 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 817 Asn Tyr Asp Met Asn 1 5 <210> 818 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 818 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 819 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 819 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 820 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 820 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 821 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 821 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 822 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 822 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 823 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 823 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 824 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 824 Ser Ser Ser Ser Ser Tyr 1 5 <210> 825 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 825 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 826 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 826 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 827 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 827 Gly Ala Ser One <210> 828 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 828 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 829 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 829 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 830 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 830 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 831 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 831 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 832 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 832 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 833 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 833 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 834 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 834 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 835 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 835 Ser Asn Tyr Asp Met Asn 1 5 <210> 836 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 836 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 837 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 837 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 838 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 838 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 839 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 839 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 840 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 840 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 841 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 841 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 842 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 842 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 843 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 843 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 844 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 844 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 845 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 845 Gly Ala Ser One <210> 846 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 846 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 847 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 847 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 848 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 848 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 849 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 849 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 850 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 850 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 851 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 851 Asn Tyr Asp Met Asn 1 5 <210> 852 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 852 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 853 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 853 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 854 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 854 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 855 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 855 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 856 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 856 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 857 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 857 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 858 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 858 Ser Ser Ser Ser Ser Tyr 1 5 <210> 859 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 859 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 860 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 860 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 861 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 861 Gly Ala Ser One <210> 862 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 862 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 863 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 863 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 864 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 864 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 865 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 865 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 866 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 866 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 867 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 867 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 868 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 868 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 869 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 869 Ser Asn Tyr Asp Met Asn 1 5 <210> 870 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 870 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 871 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 871 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 872 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 872 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 873 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 873 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 874 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 874 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 875 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 875 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 876 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 876 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 877 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 877 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 878 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 878 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 879 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 879 Gly Ala Ser One <210> 880 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 880 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 881 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 881 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 882 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 882 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 883 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 883 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 884 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 884 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 885 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 885 Asn Tyr Gly Met Asn 1 5 <210> 886 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 886 Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met Lys 1 5 10 15 Gly <210> 887 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 887 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 888 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 888 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 889 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 889 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 890 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 890 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 891 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 891 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 892 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 892 Ser Ser Gly Ser Ser Tyr 1 5 <210> 893 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 893 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 894 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 894 Ser Gln Gly Ile Asn Ser Trp 1 5 <210> 895 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 895 Ala Ala Ser One <210> 896 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 896 Ala Asn Ser Phe Pro Trp 1 5 <210> 897 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 897 Gly Phe Thr Phe Ser Asn Tyr Gly Met Asn 1 5 10 <210> 898 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 898 Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr 1 5 10 <210> 899 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 899 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 900 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 900 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 901 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 901 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 902 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 902 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 903 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 903 Ser Asn Tyr Gly Met Asn 1 5 <210> 904 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 904 Trp Val Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr 1 5 10 <210> 905 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 905 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 906 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 906 Asn Ser Trp Leu Ala Trp Tyr 1 5 <210> 907 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 907 Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln 1 5 10 <210> 908 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 908 Gln Gln Ala Asn Ser Phe Pro Trp 1 5 <210> 909 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 909 Gly Phe Thr Phe Ser Asn Tyr Gly 1 5 <210> 910 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 910 Ile Ser Ser Gly Ser Ser Tyr Lys 1 5 <210> 911 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 911 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 912 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 912 Gln Gly Ile Asn Ser Trp 1 5 <210> 913 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 913 Ala Ala Ser One <210> 914 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 914 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 915 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 915 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Leu Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Ser Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 916 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 916 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 917 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 917 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Leu Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Ser Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 918 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 918 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 919 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 919 Ser Ser Tyr Trp Thr 1 5 <210> 920 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 920 Tyr Met Phe Tyr Leu Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 921 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 921 Glu Arg Pro Val Leu Asp Ala Phe Asp Ile 1 5 10 <210> 922 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 922 Arg Ala Ser Gln Asp Ile Thr Asn Tyr Leu Ala 1 5 10 <210> 923 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 923 Ala Ala Ser Ser Leu Gln Gly 1 5 <210> 924 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 924 Leu Gln His Asp Thr Tyr Pro Tyr Thr 1 5 <210> 925 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 925 Gly Gly Ser Ile Lys Ser Ser 1 5 <210> 926 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 926 Phe Tyr Leu Gly Ser 1 5 <210> 927 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 927 Glu Arg Pro Val Leu Asp Ala Phe Asp 1 5 <210> 928 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 928 Ser Gln Asp Ile Thr Asn Tyr 1 5 <210> 929 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 929 Ala Ala Ser One <210> 930 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 930 His Asp Thr Tyr Pro Tyr 1 5 <210> 931 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 931 Gly Gly Ser Ile Lys Ser Ser Tyr Trp Thr 1 5 10 <210> 932 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 932 Tyr Met Phe Tyr Leu Gly Ser Thr Asn 1 5 <210> 933 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 933 Glu Arg Pro Val Leu Asp Ala Phe Asp Ile 1 5 10 <210> 934 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 934 Arg Ala Ser Gln Asp Ile Thr Asn Tyr Leu Ala 1 5 10 <210> 935 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 935 Ala Ala Ser Ser Leu Gln Gly 1 5 <210> 936 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 936 Leu Gln His Asp Thr Tyr Pro Tyr Thr 1 5 <210> 937 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 937 Lys Ser Ser Tyr Trp Thr 1 5 <210> 938 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 938 Trp Ile Gly Tyr Met Phe Tyr Leu Gly Ser Thr Asn 1 5 10 <210> 939 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 939 Ser Arg Glu Arg Pro Val Leu Asp Ala Phe Asp 1 5 10 <210> 940 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 940 Thr Asn Tyr Leu Ala Trp Phe 1 5 <210> 941 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 941 Arg Leu Ile Tyr Ala Ala Ser Ser Leu Gln 1 5 10 <210> 942 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 942 Leu Gln His Asp Thr Tyr Pro Tyr 1 5 <210> 943 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 943 Gly Gly Ser Ile Lys Ser Ser Tyr 1 5 <210> 944 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 944 Met Phe Tyr Leu Gly Ser Thr 1 5 <210> 945 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 945 Ser Arg Glu Arg Pro Val Leu Asp Ala Phe Asp Ile 1 5 10 <210> 946 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 946 Gln Asp Ile Thr Asn Tyr 1 5 <210> 947 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 947 Ala Ala Ser One <210> 948 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 948 Leu Gln His Asp Thr Tyr Pro Tyr Thr 1 5 <210> 949 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 949 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Lys Ser Ser 20 25 30 Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Met Phe Tyr Leu Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Ile Asp Thr Ser Arg Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ser 85 90 95 Arg Glu Arg Pro Val Leu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 950 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 950 Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Thr Asn Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Lys Arg Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ser Thr Tyr Tyr Cys Leu Gln His Asp Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100 105 <210> 951 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 951 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Lys Ser Ser 20 25 30 Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Met Phe Tyr Leu Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Ile Asp Thr Ser Arg Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ser 85 90 95 Arg Glu Arg Pro Val Leu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 952 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 952 Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Thr Asn Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Lys Arg Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ser Thr Tyr Tyr Cys Leu Gln His Asp Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 953 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 953 Asn Tyr Asp Met Asn 1 5 <210> 954 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 954 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 955 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 955 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 956 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 956 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 957 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 957 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 958 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 958 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 959 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 959 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 960 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 960 Ser Ser Ser Ser Ser Tyr 1 5 <210> 961 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 961 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 962 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 962 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 963 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 963 Gly Ala Ser One <210> 964 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 964 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 965 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 965 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 966 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 966 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 967 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 967 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 968 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 968 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 969 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 969 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 970 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 970 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 971 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 971 Ser Asn Tyr Asp Met Asn 1 5 <210> 972 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 972 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 973 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 973 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 974 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 974 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 975 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 975 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 976 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 976 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 977 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 977 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 978 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 978 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 979 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 979 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 980 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 980 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 981 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 981 Gly Ala Ser One <210> 982 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 982 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 983 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 983 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 984 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 984 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 985 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 985 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 986 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 986 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 987 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 987 Asn Tyr Asp Met Asn 1 5 <210> 988 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 988 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 989 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 989 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 990 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 990 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 991 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 991 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 992 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 992 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 993 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 993 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 994 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 994 Ser Ser Ser Ser Ser Tyr 1 5 <210> 995 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 995 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 996 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 996 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 997 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 997 Gly Ala Ser One <210> 998 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 998 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 999 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 999 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 1000 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1000 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1001 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1001 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1002 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1002 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 1003 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1003 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1004 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1004 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1005 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1005 Ser Asn Tyr Asp Met Asn 1 5 <210> 1006 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1006 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1007 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1007 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 1008 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1008 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 1009 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1009 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 1010 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1010 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1011 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1011 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 1012 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1012 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 1013 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1013 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 1014 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1014 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 1015 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1015 Gly Ala Ser One <210> 1016 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1016 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1017 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1017 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1018 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1018 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1019 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1019 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 1020 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1020 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1021 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1021 Thr Tyr Gly Met Asn 1 5 <210> 1022 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1022 Tyr Ile Ser Thr Ser Ser Tyr Thr Ile Tyr Tyr Ser Asp Ser Val Lys 1 5 10 15 Gly <210> 1023 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1023 Glu Gly Asp Trp Trp Tyr Phe Asp Leu 1 5 <210> 1024 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1024 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 1025 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1025 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 1026 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1026 Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val 1 5 10 <210> 1027 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1027 Gly Phe Thr Phe Ser Thr Tyr 1 5 <210> 1028 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1028 Ser Thr Ser Ser Tyr Thr 1 5 <210> 1029 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1029 Glu Gly Asp Trp Trp Tyr Phe Asp 1 5 <210> 1030 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1030 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 1031 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1031 Glu Val Ser One <210> 1032 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1032 Tyr Thr Ser Ser Ser Thr Leu 1 5 <210> 1033 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1033 Gly Phe Thr Phe Ser Thr Tyr Gly Met Asn 1 5 10 <210> 1034 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1034 Tyr Ile Ser Thr Ser Ser Tyr Thr Ile Tyr 1 5 10 <210> 1035 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1035 Glu Gly Asp Trp Trp Tyr Phe Asp Leu 1 5 <210> 1036 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1036 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 1037 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1037 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 1038 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1038 Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val 1 5 10 <210> 1039 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1039 Ser Thr Tyr Gly Met Asn 1 5 <210> 1040 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1040 Trp Ile Ser Tyr Ile Ser Thr Ser Ser Tyr Thr Ile Tyr 1 5 10 <210> 1041 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1041 Ala Arg Glu Gly Asp Trp Trp Tyr Phe Asp 1 5 10 <210> 1042 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1042 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 1043 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1043 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 1044 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1044 Ser Ser Tyr Thr Ser Ser Ser Thr Leu 1 5 <210> 1045 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1045 Gly Phe Thr Phe Ser Thr Tyr Gly 1 5 <210> 1046 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1046 Ile Ser Thr Ser Ser Tyr Thr Ile 1 5 <210> 1047 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1047 Ala Arg Glu Gly Asp Trp Trp Tyr Phe Asp Leu 1 5 10 <210> 1048 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1048 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 1049 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1049 Glu Val Ser One <210> 1050 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1050 Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val 1 5 10 <210> 1051 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1051 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Ser Tyr Ile Ser Thr Ser Ser Tyr Thr Ile Tyr Tyr Ser Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Asp Trp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 1052 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1052 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Tyr Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1053 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1053 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Ser Tyr Ile Ser Thr Ser Ser Tyr Thr Ile Tyr Tyr Ser Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Asp Trp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr 100 105 110 Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 1054 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1054 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Tyr Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Leu Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 1055 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1055 Asn Tyr Asp Met Asn 1 5 <210> 1056 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1056 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1057 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1057 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1058 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1058 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 1059 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1059 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1060 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1060 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1061 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1061 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 1062 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1062 Ser Ser Ser Ser Ser Tyr 1 5 <210> 1063 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1063 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 1064 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1064 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 1065 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1065 Gly Ala Ser One <210> 1066 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1066 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1067 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1067 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 1068 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1068 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1069 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1069 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1070 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1070 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 1071 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1071 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1072 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1072 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1073 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1073 Ser Asn Tyr Asp Met Asn 1 5 <210> 1074 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1074 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1075 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1075 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 1076 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1076 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 1077 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1077 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 1078 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1078 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1079 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1079 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 1080 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1080 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 1081 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1081 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 1082 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1082 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 1083 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1083 Gly Ala Ser One <210> 1084 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1084 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1085 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1085 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1086 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1086 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1087 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1087 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 1088 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1088 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1089 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1089 His Tyr Asp Met Asn 1 5 <210> 1090 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1090 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1091 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1091 Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly Leu Asp 1 5 10 15 Val <210> 1092 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1092 Arg Ala Ser Gln Gly Ile Ala Thr Tyr Leu Ala 1 5 10 <210> 1093 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1093 Ala Ala Ser Thr Leu Gln Ser 1 5 <210> 1094 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1094 Gln Lys Tyr Asn Ser Ala Pro Pro Trp Thr 1 5 10 <210> 1095 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1095 Gly Phe Thr Phe Ser His Tyr 1 5 <210> 1096 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1096 Ser Ser Ser Ser Ser Tyr 1 5 <210> 1097 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1097 Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly Leu Asp 1 5 10 15 <210> 1098 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1098 Ser Gln Gly Ile Ala Thr Tyr 1 5 <210> 1099 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1099 Ala Ala Ser One <210> 1100 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1100 Tyr Asn Ser Ala Pro Pro Trp 1 5 <210> 1101 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1101 Gly Phe Thr Phe Ser His Tyr Asp Met Asn 1 5 10 <210> 1102 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1102 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 1103 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1103 Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly Leu Asp 1 5 10 15 Val <210> 1104 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1104 Arg Ala Ser Gln Gly Ile Ala Thr Tyr Leu Ala 1 5 10 <210> 1105 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1105 Ala Ala Ser Thr Leu Gln Ser 1 5 <210> 1106 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1106 Gln Lys Tyr Asn Ser Ala Pro Pro Trp Thr 1 5 10 <210> 1107 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1107 Ser His Tyr Asp Met Asn 1 5 <210> 1108 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1108 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 1109 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1109 Ala Arg Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly 1 5 10 15 Leu Asp <210> 1110 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1110 Ala Thr Tyr Leu Ala Trp Tyr 1 5 <210> 1111 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1111 Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln 1 5 10 <210> 1112 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1112 Gln Lys Tyr Asn Ser Ala Pro Pro Trp 1 5 <210> 1113 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1113 Gly Phe Thr Phe Ser His Tyr Asp 1 5 <210> 1114 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1114 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 1115 <211> 19 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1115 Ala Arg Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly 1 5 10 15 Leu Asp Val <210> 1116 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1116 Gln Gly Ile Ala Thr Tyr 1 5 <210> 1117 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1117 Ala Ala Ser One <210> 1118 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1118 Gln Lys Tyr Asn Ser Ala Pro Pro Trp Thr 1 5 10 <210> 1119 <211> 126 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1119 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Leu 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly 100 105 110 Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1120 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1120 Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ala Thr Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Asn Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Pro 85 90 95 Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1121 <211> 456 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1121 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Leu 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Arg Gly Val Gly Asp Thr Ser Asp Tyr Tyr Ser Phe Gly 100 105 110 Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser 115 120 125 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 130 135 140 Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 145 150 155 160 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 165 170 175 His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 180 185 190 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile 195 200 205 Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val 210 215 220 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 225 230 235 240 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 245 250 255 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 260 265 270 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 275 280 285 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 290 295 300 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 305 310 315 320 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 325 330 335 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 340 345 350 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 355 360 365 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 370 375 380 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 385 390 395 400 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 405 410 415 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 420 425 430 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 435 440 445 Ser Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 1122 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1122 Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ala Thr Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Asn Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Pro 85 90 95 Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1123 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1123 Asn Tyr Gly Met Asn 1 5 <210> 1124 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1124 Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met Lys 1 5 10 15 Gly <210> 1125 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1125 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1126 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1126 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 1127 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1127 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 1128 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1128 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 1129 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1129 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 1130 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1130 Ser Ser Gly Ser Ser Tyr 1 5 <210> 1131 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1131 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 1132 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1132 Ser Gln Gly Ile Asn Ser Trp 1 5 <210> 1133 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1133 Ala Ala Ser One <210> 1134 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1134 Ala Asn Ser Phe Pro Trp 1 5 <210> 1135 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1135 Gly Phe Thr Phe Ser Asn Tyr Gly Met Asn 1 5 10 <210> 1136 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1136 Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr 1 5 10 <210> 1137 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1137 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1138 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1138 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 1139 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1139 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 1140 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1140 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 1141 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1141 Ser Asn Tyr Gly Met Asn 1 5 <210> 1142 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1142 Trp Val Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr 1 5 10 <210> 1143 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1143 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 1144 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1144 Asn Ser Trp Leu Ala Trp Tyr 1 5 <210> 1145 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1145 Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln 1 5 10 <210> 1146 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1146 Gln Gln Ala Asn Ser Phe Pro Trp 1 5 <210> 1147 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1147 Gly Phe Thr Phe Ser Asn Tyr Gly 1 5 <210> 1148 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1148 Ile Ser Ser Gly Ser Ser Tyr Lys 1 5 <210> 1149 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1149 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1150 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1150 Gln Gly Ile Asn Ser Trp 1 5 <210> 1151 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1151 Ala Ala Ser One <210> 1152 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1152 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 1153 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1153 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Leu Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Ser Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1154 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1154 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1155 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1155 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Leu Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Ser Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 1156 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1156 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 1157 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1157 Ser Tyr Thr Met Asn 1 5 <210> 1158 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1158 Ser Ile Ser Thr Ser Ser Ser Tyr Ile Asp Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1159 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1159 Asp Gly Asp Met Val Ala Pro Ile Lys Gly Ser Phe Asp Tyr 1 5 10 <210> 1160 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1160 Arg Ser Ser Gln Ser Leu Leu Asn Ser Asp Asp Gly Asn Thr Tyr Leu 1 5 10 15 Asp <210> 1161 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1161 Thr Leu Ser Tyr Arg Ala Ser 1 5 <210> 1162 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1162 Met Gln Arg Ile Glu Phe Pro Ile Thr 1 5 <210> 1163 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1163 Gly Phe Thr Phe Ser Ser Tyr 1 5 <210> 1164 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1164 Ser Thr Ser Ser Ser Tyr 1 5 <210> 1165 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1165 Asp Gly Asp Met Val Ala Pro Ile Lys Gly Ser Phe Asp 1 5 10 <210> 1166 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1166 Ser Gln Ser Leu Leu Asn Ser Asp Asp Gly Asn Thr Tyr 1 5 10 <210> 1167 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1167 Thr Leu Ser One <210> 1168 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1168 Arg Ile Glu Phe Pro Ile 1 5 <210> 1169 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1169 Gly Phe Thr Phe Ser Ser Tyr Thr Met Asn 1 5 10 <210> 1170 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1170 Ser Ile Ser Thr Ser Ser Ser Tyr Ile Asp 1 5 10 <210> 1171 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1171 Asp Gly Asp Met Val Ala Pro Ile Lys Gly Ser Phe Asp Tyr 1 5 10 <210> 1172 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1172 Arg Ser Ser Gln Ser Leu Leu Asn Ser Asp Asp Gly Asn Thr Tyr Leu 1 5 10 15 Asp <210> 1173 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1173 Thr Leu Ser Tyr Arg Ala Ser 1 5 <210> 1174 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1174 Met Gln Arg Ile Glu Phe Pro Ile Thr 1 5 <210> 1175 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1175 Ser Ser Tyr Thr Met Asn 1 5 <210> 1176 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1176 Trp Val Ser Ser Ile Ser Thr Ser Ser Ser Tyr Ile Asp 1 5 10 <210> 1177 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1177 Ala Arg Asp Gly Asp Met Val Ala Pro Ile Lys Gly Ser Phe Asp 1 5 10 15 <210> 1178 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1178 Leu Asn Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr 1 5 10 <210> 1179 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1179 Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala 1 5 10 <210> 1180 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1180 Met Gln Arg Ile Glu Phe Pro Ile 1 5 <210> 1181 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1181 Gly Phe Thr Phe Ser Ser Tyr Thr 1 5 <210> 1182 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1182 Ile Ser Thr Ser Ser Ser Tyr Ile 1 5 <210> 1183 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1183 Ala Arg Asp Gly Asp Met Val Ala Pro Ile Lys Gly Ser Phe Asp Tyr 1 5 10 15 <210> 1184 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1184 Gln Ser Leu Leu Asn Ser Asp Asp Gly Asn Thr Tyr 1 5 10 <210> 1185 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1185 Thr Leu Ser One <210> 1186 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1186 Met Gln Arg Ile Glu Phe Pro Ile Thr 1 5 <210> 1187 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1187 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Thr Ser Ser Ser Tyr Ile Asp Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Asp Met Val Ala Pro Ile Lys Gly Ser Phe Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 1188 <211> 113 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1188 Glu Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln 35 40 45 Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys 65 70 75 80 Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln 85 90 95 Arg Ile Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile 100 105 110 Lys <210> 1189 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1189 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Thr Ser Ser Ser Tyr Ile Asp Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Asp Met Val Ala Pro Ile Lys Gly Ser Phe Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 1190 <211> 220 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1190 Glu Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln 35 40 45 Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys 65 70 75 80 Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln 85 90 95 Arg Ile Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile 100 105 110 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155 160 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 165 170 175 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 180 185 190 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 195 200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 220 <210> 1191 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1191 Ser Ser Gly Met Cys Val Ser 1 5 <210> 1192 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1192 Leu Ile Asp Trp Phe Asp Asp Lys Tyr Tyr Ser Thr Ser Leu Lys Thr 1 5 10 15 <210> 1193 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1193 Ile Arg Gly Thr Gly Ala Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 <210> 1194 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1194 Ser Gly Asn Glu Leu Gly Asp Lys Tyr Ala Ser 1 5 10 <210> 1195 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1195 Gln Asp Asn Lys Arg Pro Ser 1 5 <210> 1196 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1196 Gln Ala Trp Asp Ser Ser Lys Val Val 1 5 <210> 1197 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1197 Gly Phe Ser Leu Ser Ser Ser Gly Met 1 5 <210> 1198 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1198 Asp Trp Phe Asp Asp 1 5 <210> 1199 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1199 Ile Arg Gly Thr Gly Ala Tyr Tyr Tyr Gly Leu Asp 1 5 10 <210> 1200 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1200 Asn Glu Leu Gly Asp Lys Tyr 1 5 <210> 1201 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1201 Gln Asp Asn One <210> 1202 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1202 Trp Asp Ser Ser Lys Val 1 5 <210> 1203 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1203 Gly Phe Ser Leu Ser Ser Ser Gly Met Cys Val Ser 1 5 10 <210> 1204 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1204 Leu Ile Asp Trp Phe Asp Asp Lys Tyr 1 5 <210> 1205 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1205 Ile Arg Gly Thr Gly Ala Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 <210> 1206 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1206 Ser Gly Asn Glu Leu Gly Asp Lys Tyr Ala Ser 1 5 10 <210> 1207 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1207 Gln Asp Asn Lys Arg Pro Ser 1 5 <210> 1208 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1208 Gln Ala Trp Asp Ser Ser Lys Val Val 1 5 <210> 1209 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1209 Ser Ser Ser Gly Met Cys Val Ser 1 5 <210> 1210 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1210 Trp Leu Thr Leu Ile Asp Trp Phe Asp Asp Lys Tyr 1 5 10 <210> 1211 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1211 Ala Arg Ile Arg Gly Thr Gly Ala Tyr Tyr Tyr Gly Leu Asp 1 5 10 <210> 1212 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1212 Asp Lys Tyr Ala Ser Trp Tyr 1 5 <210> 1213 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1213 Leu Val Ile Tyr Gln Asp Asn Lys Arg Pro 1 5 10 <210> 1214 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1214 Gln Ala Trp Asp Ser Ser Lys Val 1 5 <210> 1215 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1215 Gly Phe Ser Leu Ser Ser Ser Gly Met Cys 1 5 10 <210> 1216 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1216 Ile Asp Trp Phe Asp Asp Lys 1 5 <210> 1217 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1217 Ala Arg Ile Arg Gly Thr Gly Ala Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 15 <210> 1218 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1218 Glu Leu Gly Asp Lys Tyr 1 5 <210> 1219 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1219 Gln Asp Asn One <210> 1220 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1220 Gln Ala Trp Asp Ser Ser Lys Val Val 1 5 <210> 1221 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1221 Gln Val Gln Leu Gln Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ser Ser 20 25 30 Gly Met Cys Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Thr Leu Ile Asp Trp Phe Asp Asp Lys Tyr Tyr Ser Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Arg Gly Thr Gly Ala Tyr Tyr Tyr Gly Leu Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1222 <211> 106 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1222 Ser Tyr Glu Leu Met Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asn Glu Leu Gly Asp Lys Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Gln Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln Asp Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Lys Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 1223 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1223 Gln Val Gln Leu Gln Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ser Ser 20 25 30 Gly Met Cys Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Thr Leu Ile Asp Trp Phe Asp Asp Lys Tyr Tyr Ser Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Arg Gly Thr Gly Ala Tyr Tyr Tyr Gly Leu Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 1224 <211> 212 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1224 Ser Tyr Glu Leu Met Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asn Glu Leu Gly Asp Lys Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Gln Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln Asp Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Lys Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala 100 105 110 Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn 115 120 125 Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val 130 135 140 Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu 145 150 155 160 Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser 165 170 175 Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser 180 185 190 Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro 195 200 205 Thr Glu Cys Ser 210 <210> 1225 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1225 Asn Tyr Asp Met Asn 1 5 <210> 1226 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1226 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1227 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1227 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1228 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1228 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 1229 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1229 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1230 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1230 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1231 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1231 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 1232 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1232 Ser Ser Ser Ser Ser Tyr 1 5 <210> 1233 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1233 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 1234 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1234 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 1235 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1235 Gly Ala Ser One <210> 1236 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1236 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1237 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1237 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 1238 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1238 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1239 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1239 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1240 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1240 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 1241 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1241 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1242 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1242 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1243 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1243 Ser Asn Tyr Asp Met Asn 1 5 <210> 1244 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1244 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1245 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1245 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 1246 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1246 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 1247 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1247 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 1248 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1248 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1249 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1249 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 1250 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1250 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 1251 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1251 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 1252 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1252 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 1253 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1253 Gly Ala Ser One <210> 1254 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1254 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1255 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1256 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1256 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1257 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1257 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 1258 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1258 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1259 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1259 Ser Tyr Gly Met Tyr 1 5 <210> 1260 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1260 Ser Ile Ser Thr Gly Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1261 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1261 Asp Lys Gly Leu Ala Val Thr Gly Tyr Ile Met Asp Val 1 5 10 <210> 1262 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1262 Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 1263 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1263 Asp Ala Ser Asn Leu Glu Thr 1 5 <210> 1264 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1264 Gln Gln Tyr Asp Asn Leu Pro Met Tyr Thr 1 5 10 <210> 1265 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1265 Gly Phe Thr Phe Ser Ser Tyr 1 5 <210> 1266 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1266 Ser Thr Gly Ser Ser Tyr 1 5 <210> 1267 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1267 Asp Lys Gly Leu Ala Val Thr Gly Tyr Ile Met Asp 1 5 10 <210> 1268 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1268 Ser Gln Asp Ile Ser Asn Tyr 1 5 <210> 1269 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1269 Asp Ala Ser One <210> 1270 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1270 Tyr Asp Asn Leu Pro Met Tyr 1 5 <210> 1271 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1271 Gly Phe Thr Phe Ser Ser Tyr Gly Met Tyr 1 5 10 <210> 1272 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1272 Ser Ile Ser Thr Gly Ser Ser Tyr Ile Tyr 1 5 10 <210> 1273 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1273 Asp Lys Gly Leu Ala Val Thr Gly Tyr Ile Met Asp Val 1 5 10 <210> 1274 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1274 Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 1275 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1275 Asp Ala Ser Asn Leu Glu Thr 1 5 <210> 1276 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1276 Gln Gln Tyr Asp Asn Leu Pro Met Tyr Thr 1 5 10 <210> 1277 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1277 Ser Ser Tyr Gly Met Tyr 1 5 <210> 1278 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1278 Trp Val Ser Ser Ile Ser Thr Gly Ser Ser Tyr Ile Tyr 1 5 10 <210> 1279 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1279 Ala Arg Asp Lys Gly Leu Ala Val Thr Gly Tyr Ile Met Asp 1 5 10 <210> 1280 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1280 Ser Asn Tyr Leu Asn Trp Tyr 1 5 <210> 1281 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1281 Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu 1 5 10 <210> 1282 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1282 Gln Gln Tyr Asp Asn Leu Pro Met Tyr 1 5 <210> 1283 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1283 Gly Phe Thr Phe Ser Ser Tyr Gly 1 5 <210> 1284 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1284 Ile Ser Thr Gly Ser Ser Tyr Ile 1 5 <210> 1285 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1285 Ala Arg Asp Lys Gly Leu Ala Val Thr Gly Tyr Ile Met Asp Val 1 5 10 15 <210> 1286 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1286 Gln Asp Ile Ser Asn Tyr 1 5 <210> 1287 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1287 Asp Ala Ser One <210> 1288 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1288 Gln Gln Tyr Asp Asn Leu Pro Met Tyr Thr 1 5 10 <210> 1289 <211> 122 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1289 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ser Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Thr Gly Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Lys Gly Leu Ala Val Thr Gly Tyr Ile Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 1290 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1290 Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Ile Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Met 85 90 95 Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1291 <211> 452 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1291 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ser Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Thr Gly Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Lys Gly Leu Ala Val Thr Gly Tyr Ile Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Lys 450 <210> 1292 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1292 Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Ile Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Met 85 90 95 Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1293 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1293 Asn Tyr Asp Met Asn 1 5 <210> 1294 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1294 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1295 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1295 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1296 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1296 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 1297 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1297 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1298 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1298 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1299 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1299 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 1300 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1300 Ser Ser Ser Ser Ser Tyr 1 5 <210> 1301 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1301 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 1302 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1302 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 1303 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1303 Gly Ala Ser One <210> 1304 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1304 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1305 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1305 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 1306 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1306 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1307 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1307 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1308 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1308 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 1309 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1309 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1310 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1310 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1311 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1311 Ser Asn Tyr Asp Met Asn 1 5 <210> 1312 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1312 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1313 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1313 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 1314 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1314 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 1315 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1315 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 1316 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1316 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1317 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1317 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 1318 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1318 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 1319 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1319 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 1320 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1320 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 1321 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1321 Gly Ala Ser One <210> 1322 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1322 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1323 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1323 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 1324 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1324 Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1325 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1325 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 1326 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1326 Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1327 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1327 Arg Tyr Ser Met Asn 1 5 <210> 1328 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1328 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1329 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1329 Asp Gly Pro Thr Val Asn Trp Asp Tyr Tyr Phe Asp Leu 1 5 10 <210> 1330 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1330 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1331 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1331 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1332 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1332 Gly Thr Trp Asp Ser Ser Leu Ser Thr Ser Val Val 1 5 10 <210> 1333 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1333 Gly Phe Thr Phe Ser Arg Tyr 1 5 <210> 1334 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1334 Ser Ser Ser Ser Ser Tyr 1 5 <210> 1335 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1335 Asp Gly Pro Thr Val Asn Trp Asp Tyr Tyr Phe Asp 1 5 10 <210> 1336 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1336 Ser Ser Ser Asn Ile Gly Asn Asn Tyr 1 5 <210> 1337 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1337 Asp Asn Asn One <210> 1338 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1338 Trp Asp Ser Ser Leu Ser Thr Ser Val 1 5 <210> 1339 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1339 Gly Phe Thr Phe Ser Arg Tyr Ser Met Asn 1 5 10 <210> 1340 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1340 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1341 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1341 Asp Gly Pro Thr Val Asn Trp Asp Tyr Tyr Phe Asp Leu 1 5 10 <210> 1342 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1342 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1343 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1343 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1344 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1344 Gly Thr Trp Asp Ser Ser Leu Ser Thr Ser Val Val 1 5 10 <210> 1345 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1345 Ser Arg Tyr Ser Met Asn 1 5 <210> 1346 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1346 Gly Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1347 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1347 Ala Arg Asp Gly Pro Thr Val Asn Trp Asp Tyr Tyr Phe Asp 1 5 10 <210> 1348 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1348 Ile Gly Asn Asn Tyr Val Ser Trp Tyr 1 5 <210> 1349 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1349 Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro 1 5 10 <210> 1350 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1350 Gly Thr Trp Asp Ser Ser Leu Ser Thr Ser Val 1 5 10 <210> 1351 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1351 Gly Phe Thr Phe Ser Arg Tyr Ser 1 5 <210> 1352 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1352 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 1353 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1353 Ala Arg Asp Gly Pro Thr Val Asn Trp Asp Tyr Tyr Phe Asp Leu 1 5 10 15 <210> 1354 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1354 Ser Ser Asn Ile Gly Asn Asn Tyr 1 5 <210> 1355 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1355 Asp Asn Asn One <210> 1356 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1356 Gly Thr Trp Asp Ser Ser Leu Ser Thr Ser Val Val 1 5 10 <210> 1357 <211> 122 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1357 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Gly Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Pro Thr Val Asn Trp Asp Tyr Tyr Phe Asp Leu Trp 100 105 110 Gly Arg Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 1358 <211> 111 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1358 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Thr Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1359 <211> 452 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1359 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Gly Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Pro Thr Val Asn Trp Asp Tyr Tyr Phe Asp Leu Trp 100 105 110 Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Lys 450 <210> 1360 <211> 217 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1360 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Thr Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 1361 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1361 Ser Asn Ser Ala Ala Trp Asn 1 5 <210> 1362 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1362 Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Pro Ile Ser Val 1 5 10 15 Lys Ser <210> 1363 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1363 Glu Ser Gly Ser Tyr Tyr Thr Asp Gly Phe Asp Ile 1 5 10 <210> 1364 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1364 Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 1365 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1365 Ala Ala Ser Thr Leu Gln Ser 1 5 <210> 1366 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1366 Gln Glu Phe Asn Ser Tyr Pro Tyr Thr 1 5 <210> 1367 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1367 Gly Asp Ser Val Ser Ser Asn Ser Ala 1 5 <210> 1368 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1368 Tyr Tyr Arg Ser Lys Trp Tyr 1 5 <210> 1369 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1369 Glu Ser Gly Ser Tyr Tyr Thr Asp Gly Phe Asp 1 5 10 <210> 1370 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1370 Ser Gln Gly Ile Ser Ser Tyr 1 5 <210> 1371 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1371 Ala Ala Ser One <210> 1372 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1372 Phe Asn Ser Tyr Pro Tyr 1 5 <210> 1373 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1373 Gly Asp Ser Val Ser Ser Asn Ser Ala Ala Trp Asn 1 5 10 <210> 1374 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1374 Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp 1 5 10 <210> 1375 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1375 Glu Ser Gly Ser Tyr Tyr Thr Asp Gly Phe Asp Ile 1 5 10 <210> 1376 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1376 Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 1377 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1377 Ala Ala Ser Thr Leu Gln Ser 1 5 <210> 1378 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1378 Gln Glu Phe Asn Ser Tyr Pro Tyr Thr 1 5 <210> 1379 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1379 Ser Ser Asn Ser Ala Ala Trp Asn 1 5 <210> 1380 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1380 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp 1 5 10 <210> 1381 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1381 Ala Arg Glu Ser Gly Ser Tyr Tyr Thr Asp Gly Phe Asp 1 5 10 <210> 1382 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1382 Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 1383 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1383 Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln 1 5 10 <210> 1384 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1384 Gln Glu Phe Asn Ser Tyr Pro Tyr 1 5 <210> 1385 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1385 Gly Asp Ser Val Ser Ser Asn Ser Ala Ala 1 5 10 <210> 1386 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1386 Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn 1 5 <210> 1387 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1387 Ala Arg Glu Ser Gly Ser Tyr Tyr Thr Asp Gly Phe Asp Ile 1 5 10 <210> 1388 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1388 Gln Gly Ile Ser Ser Tyr 1 5 <210> 1389 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1389 Ala Ala Ser One <210> 1390 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1390 Gln Glu Phe Asn Ser Tyr Pro Tyr Thr 1 5 <210> 1391 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1391 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 35 40 45 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Pro 50 55 60 Ile Ser Val Lys Ser Arg Ile Ser Ile Asn Pro Asp Thr Ser Lys Asn 65 70 75 80 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Ala Arg Glu Ser Gly Ser Tyr Tyr Thr Asp Gly Phe Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1392 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1392 Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Phe Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1393 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1393 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 35 40 45 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Pro 50 55 60 Ile Ser Val Lys Ser Arg Ile Ser Ile Asn Pro Asp Thr Ser Lys Asn 65 70 75 80 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Ala Arg Glu Ser Gly Ser Tyr Tyr Thr Asp Gly Phe Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 1394 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1394 Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Phe Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 1395 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1395 Ser Tyr Thr Met Asn 1 5 <210> 1396 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1396 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Asp Tyr Ala Glu Ser Val Lys 1 5 10 15 Gly <210> 1397 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1397 Asp Gly Asp Ile Leu Ala Thr Ile Arg Gly Ser Phe Asp Tyr 1 5 10 <210> 1398 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1398 Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Ala Gly Asn Thr Tyr Leu 1 5 10 15 Asp <210> 1399 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1399 Thr Leu Ser Tyr Arg Ala Ser 1 5 <210> 1400 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1400 Met Gln Arg Ile Glu Phe Pro Ile Thr 1 5 <210> 1401 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1401 Gly Phe Thr Phe Ser Ser Tyr 1 5 <210> 1402 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1402 Ser Ser Ser Ser Ser Tyr 1 5 <210> 1403 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1403 Asp Gly Asp Ile Leu Ala Thr Ile Arg Gly Ser Phe Asp 1 5 10 <210> 1404 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1404 Ser Gln Ser Leu Leu Asp Ser Asp Ala Gly Asn Thr Tyr 1 5 10 <210> 1405 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1405 Thr Leu Ser One <210> 1406 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1406 Arg Ile Glu Phe Pro Ile 1 5 <210> 1407 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1407 Gly Phe Thr Phe Ser Ser Tyr Thr Met Asn 1 5 10 <210> 1408 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1408 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Asp 1 5 10 <210> 1409 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1409 Asp Gly Asp Ile Leu Ala Thr Ile Arg Gly Ser Phe Asp Tyr 1 5 10 <210> 1410 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1410 Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Ala Gly Asn Thr Tyr Leu 1 5 10 15 Asp <210> 1411 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1411 Thr Leu Ser Tyr Arg Ala Ser 1 5 <210> 1412 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1412 Met Gln Arg Ile Glu Phe Pro Ile Thr 1 5 <210> 1413 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1413 Ser Ser Tyr Thr Met Asn 1 5 <210> 1414 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1414 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Asp 1 5 10 <210> 1415 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1415 Ala Arg Asp Gly Asp Ile Leu Ala Thr Ile Arg Gly Ser Phe Asp 1 5 10 15 <210> 1416 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1416 Leu Asp Ser Asp Ala Gly Asn Thr Tyr Leu Asp Trp Tyr 1 5 10 <210> 1417 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1417 Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala 1 5 10 <210> 1418 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1418 Met Gln Arg Ile Glu Phe Pro Ile 1 5 <210> 1419 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1419 Gly Phe Thr Phe Ser Ser Tyr Thr 1 5 <210> 1420 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1420 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 1421 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1421 Ala Arg Asp Gly Asp Ile Leu Ala Thr Ile Arg Gly Ser Phe Asp Tyr 1 5 10 15 <210> 1422 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1422 Gln Ser Leu Leu Asp Ser Asp Ala Gly Asn Thr Tyr 1 5 10 <210> 1423 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1423 Thr Leu Ser One <210> 1424 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1424 Met Gln Arg Ile Glu Phe Pro Ile Thr 1 5 <210> 1425 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1425 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Asp Tyr Ala Glu Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Asp Ile Leu Ala Thr Ile Arg Gly Ser Phe Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 1426 <211> 113 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1426 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Ala Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln 35 40 45 Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys 65 70 75 80 Ile Ser Arg Val Glu Ala Glu Asp Val Ala Ile Tyr Tyr Cys Met Gln 85 90 95 Arg Ile Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110 Lys <210> 1427 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1427 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Asp Tyr Ala Glu Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Asp Ile Leu Ala Thr Ile Arg Gly Ser Phe Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 1428 <211> 220 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1428 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Ala Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln 35 40 45 Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys 65 70 75 80 Ile Ser Arg Val Glu Ala Glu Asp Val Ala Ile Tyr Tyr Cys Met Gln 85 90 95 Arg Ile Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155 160 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 165 170 175 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 180 185 190 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 195 200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 220 <210> 1429 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1429 Asn Tyr Gly Met Asn 1 5 <210> 1430 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1430 Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met Lys 1 5 10 15 Gly <210> 1431 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1431 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1432 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1432 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 1433 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1433 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 1434 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1434 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 1435 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1435 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 1436 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1436 Ser Ser Gly Ser Ser Tyr 1 5 <210> 1437 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1437 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 1438 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1438 Ser Gln Gly Ile Asn Ser Trp 1 5 <210> 1439 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1439 Ala Ala Ser One <210> 1440 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1440 Ala Asn Ser Phe Pro Trp 1 5 <210> 1441 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1441 Gly Phe Thr Phe Ser Asn Tyr Gly Met Asn 1 5 10 <210> 1442 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1442 Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr 1 5 10 <210> 1443 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1443 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1444 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1444 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 1445 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1445 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 1446 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1446 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 1447 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1447 Ser Asn Tyr Gly Met Asn 1 5 <210> 1448 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1448 Trp Val Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr 1 5 10 <210> 1449 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1449 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 1450 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1450 Asn Ser Trp Leu Ala Trp Tyr 1 5 <210> 1451 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1451 Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln 1 5 10 <210> 1452 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1452 Gln Gln Ala Asn Ser Phe Pro Trp 1 5 <210> 1453 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1453 Gly Phe Thr Phe Ser Asn Tyr Gly 1 5 <210> 1454 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1454 Ile Ser Ser Gly Ser Ser Tyr Lys 1 5 <210> 1455 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1455 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1456 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1456 Gln Gly Ile Asn Ser Trp 1 5 <210> 1457 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1457 Ala Ala Ser One <210> 1458 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1458 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 1459 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1459 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Leu Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Ser Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1460 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1460 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100 105 <210> 1461 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1461 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Leu Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Ser Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 1462 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1462 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 1463 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1463 Ala Tyr Thr Met Asn 1 5 <210> 1464 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1464 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Asp Phe Ala Glu Ser Val Lys 1 5 10 15 Gly <210> 1465 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1465 Asp Gly Asp Ile Val Ser Thr Ile Arg Gly Ser Phe Asp Tyr 1 5 10 <210> 1466 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1466 Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu 1 5 10 15 Asp <210> 1467 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1467 Thr Leu Ser Tyr Arg Ala Ser 1 5 <210> 1468 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1468 Met Gln Arg Ile Glu Phe Pro Ile Thr 1 5 <210> 1469 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1469 Gly Phe Thr Phe Gly Ala Tyr 1 5 <210> 1470 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1470 Ser Ser Ser Ser Ser Tyr 1 5 <210> 1471 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1471 Asp Gly Asp Ile Val Ser Thr Ile Arg Gly Ser Phe Asp 1 5 10 <210> 1472 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1472 Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr 1 5 10 <210> 1473 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1473 Thr Leu Ser One <210> 1474 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1474 Arg Ile Glu Phe Pro Ile 1 5 <210> 1475 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1475 Gly Phe Thr Phe Gly Ala Tyr Thr Met Asn 1 5 10 <210> 1476 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1476 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Asp 1 5 10 <210> 1477 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1477 Asp Gly Asp Ile Val Ser Thr Ile Arg Gly Ser Phe Asp Tyr 1 5 10 <210> 1478 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1478 Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu 1 5 10 15 Asp <210> 1479 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1479 Thr Leu Ser Tyr Arg Ala Ser 1 5 <210> 1480 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1480 Met Gln Arg Ile Glu Phe Pro Ile Thr 1 5 <210> 1481 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1481 Gly Ala Tyr Thr Met Asn 1 5 <210> 1482 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1482 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Asp 1 5 10 <210> 1483 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1483 Ala Arg Asp Gly Asp Ile Val Ser Thr Ile Arg Gly Ser Phe Asp 1 5 10 15 <210> 1484 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1484 Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr 1 5 10 <210> 1485 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1485 Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala 1 5 10 <210> 1486 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1486 Met Gln Arg Ile Glu Phe Pro Ile 1 5 <210> 1487 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1487 Gly Phe Thr Phe Gly Ala Tyr Thr 1 5 <210> 1488 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1488 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 1489 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1489 Ala Arg Asp Gly Asp Ile Val Ser Thr Ile Arg Gly Ser Phe Asp Tyr 1 5 10 15 <210> 1490 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1490 Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr 1 5 10 <210> 1491 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1491 Thr Leu Ser One <210> 1492 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1492 Met Gln Arg Ile Glu Phe Pro Ile Thr 1 5 <210> 1493 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1493 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Ala Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Asp Phe Ala Glu Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Ile Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Asp Ile Val Ser Thr Ile Arg Gly Ser Phe Asp Tyr 100 105 110 Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ser 115 120 <210> 1494 <211> 113 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1494 Glu Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln 35 40 45 Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys 65 70 75 80 Ile Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln 85 90 95 Arg Ile Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110 Lys <210> 1495 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1495 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Ala Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Asp Phe Ala Glu Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Ile Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Asp Ile Val Ser Thr Ile Arg Gly Ser Phe Asp Tyr 100 105 110 Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 1496 <211> 220 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1496 Glu Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln 35 40 45 Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys 65 70 75 80 Ile Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln 85 90 95 Arg Ile Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155 160 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 165 170 175 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 180 185 190 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 195 200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 220 <210> 1497 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1497 Ser Tyr Ser Met Asp 1 5 <210> 1498 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1498 Ser Ile Gly Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1499 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1499 Ser Tyr Ser Trp Asn Tyr Gly Gly Ala Phe Asp Ile 1 5 10 <210> 1500 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1500 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 1501 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1501 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1502 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1502 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1503 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1503 Gly Ile Thr Phe Ser Ser Tyr 1 5 <210> 1504 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1504 Gly Ser Ser Ser Ser Tyr 1 5 <210> 1505 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1505 Ser Tyr Ser Trp Asn Tyr Gly Gly Ala Phe Asp 1 5 10 <210> 1506 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1506 Ser Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 1507 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1507 Gly Ala Ser One <210> 1508 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1508 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1509 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1509 Gly Ile Thr Phe Ser Ser Tyr Ser Met Asp 1 5 10 <210> 1510 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1510 Ser Ile Gly Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 1511 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1511 Ser Tyr Ser Trp Asn Tyr Gly Gly Ala Phe Asp Ile 1 5 10 <210> 1512 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1512 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 1513 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1513 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1514 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1514 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1515 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1515 Ser Ser Tyr Ser Met Asp 1 5 <210> 1516 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1516 Trp Val Ser Ser Ile Gly Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 1517 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1517 Ala Thr Ser Tyr Ser Trp Asn Tyr Gly Gly Ala Phe Asp 1 5 10 <210> 1518 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1518 Ser Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 1519 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1519 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 1520 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1520 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1521 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1521 Gly Ile Thr Phe Ser Ser Tyr Ser 1 5 <210> 1522 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1522 Ile Gly Ser Ser Ser Ser Tyr Ile 1 5 <210> 1523 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1523 Ala Thr Ser Tyr Ser Trp Asn Tyr Gly Gly Ala Phe Asp Ile 1 5 10 <210> 1524 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1524 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 1525 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1525 Gly Ala Ser One <210> 1526 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1526 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1527 <211> 121 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1527 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Phe Gly Ile Thr Phe Ser Ser Tyr 20 25 30 Ser Met Asp Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Gly Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Ser Tyr Ser Trp Asn Tyr Gly Gly Ala Phe Asp Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1528 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1528 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1529 <211> 451 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1529 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Phe Gly Ile Thr Phe Ser Ser Tyr 20 25 30 Ser Met Asp Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Gly Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Ser Tyr Ser Trp Asn Tyr Gly Gly Ala Phe Asp Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys 450 <210> 1530 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1530 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1531 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1531 Ser Tyr Asn Met Asn 1 5 <210> 1532 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1532 Ser Ile Ser Thr Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1533 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1533 Asp Thr Ser Val Thr Lys Tyr Pro Asp Thr Phe Asp Ile 1 5 10 <210> 1534 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1534 Arg Ala Ser Gln Asp Ile Asn Asn Tyr Leu Ala 1 5 10 <210> 1535 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1535 Gly Ala Ser Thr Leu Gln Ser 1 5 <210> 1536 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1536 Gln Lys Tyr Asn Ser Ala Pro Phe Thr 1 5 <210> 1537 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1537 Gly Phe Thr Phe Ser Ser Tyr 1 5 <210> 1538 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1538 Ser Thr Ser Ser Ser Tyr 1 5 <210> 1539 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1539 Asp Thr Ser Val Thr Lys Tyr Pro Asp Thr Phe Asp 1 5 10 <210> 1540 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1540 Ser Gln Asp Ile Asn Asn Tyr 1 5 <210> 1541 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1541 Gly Ala Ser One <210> 1542 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1542 Tyr Asn Ser Ala Pro Phe 1 5 <210> 1543 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1543 Gly Phe Thr Phe Ser Ser Tyr Asn Met Asn 1 5 10 <210> 1544 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1544 Ser Ile Ser Thr Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1545 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1545 Asp Thr Ser Val Thr Lys Tyr Pro Asp Thr Phe Asp Ile 1 5 10 <210> 1546 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1546 Arg Ala Ser Gln Asp Ile Asn Asn Tyr Leu Ala 1 5 10 <210> 1547 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1547 Gly Ala Ser Thr Leu Gln Ser 1 5 <210> 1548 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1548 Gln Lys Tyr Asn Ser Ala Pro Phe Thr 1 5 <210> 1549 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1549 Ser Ser Tyr Asn Met Asn 1 5 <210> 1550 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1550 Trp Val Ser Ser Ile Ser Thr Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1551 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1551 Ala Arg Asp Thr Ser Val Thr Lys Tyr Pro Asp Thr Phe Asp 1 5 10 <210> 1552 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1552 Asn Asn Tyr Leu Ala Trp Phe 1 5 <210> 1553 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1553 Leu Leu Ile Tyr Gly Ala Ser Thr Leu Gln 1 5 10 <210> 1554 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1554 Gln Lys Tyr Asn Ser Ala Pro Phe 1 5 <210> 1555 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1555 Gly Phe Thr Phe Ser Ser Tyr Asn 1 5 <210> 1556 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1556 Ile Ser Thr Ser Ser Ser Tyr Ile 1 5 <210> 1557 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1557 Ala Arg Asp Thr Ser Val Thr Lys Tyr Pro Asp Thr Phe Asp Ile 1 5 10 15 <210> 1558 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1558 Gln Asp Ile Asn Asn Tyr 1 5 <210> 1559 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1559 Gly Ala Ser One <210> 1560 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1560 Gln Lys Tyr Asn Ser Ala Pro Phe Thr 1 5 <210> 1561 <211> 122 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1561 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Thr Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Gly Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Thr Ser Val Thr Lys Tyr Pro Asp Thr Phe Asp Ile Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1562 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1562 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Asn Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 <210> 1563 <211> 452 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1563 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Thr Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Gly Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Thr Ser Val Thr Lys Tyr Pro Asp Thr Phe Asp Ile Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Lys 450 <210> 1564 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1564 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Asn Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 1565 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1565 Gly Asp Tyr Met His 1 5 <210> 1566 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1566 Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1567 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1567 Glu Gly Asp Ala Phe Asp Val 1 5 <210> 1568 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1568 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 1569 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1569 Glu Val Ser Lys Arg Pro Ser 1 5 <210> 1570 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1570 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu Val 1 5 10 <210> 1571 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1571 Gly Tyr Thr Phe Thr Gly Asp 1 5 <210> 1572 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1572 Asn Pro Asn Ser Gly Tyr 1 5 <210> 1573 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1573 Glu Gly Asp Ala Phe Asp 1 5 <210> 1574 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1574 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 1575 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1575 Glu Val Ser One <210> 1576 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1576 Tyr Ala Gly Ser Asn Asn Phe Glu 1 5 <210> 1577 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1577 Gly Tyr Thr Phe Thr Gly Asp Tyr Met His 1 5 10 <210> 1578 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1578 Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn 1 5 10 <210> 1579 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1579 Glu Gly Asp Ala Phe Asp Val 1 5 <210> 1580 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1580 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 1581 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1581 Glu Val Ser Lys Arg Pro Ser 1 5 <210> 1582 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1582 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu Val 1 5 10 <210> 1583 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1583 Thr Gly Asp Tyr Met His 1 5 <210> 1584 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1584 Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn 1 5 10 <210> 1585 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1585 Ala Arg Glu Gly Asp Ala Phe Asp 1 5 <210> 1586 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1586 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 1587 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1587 Leu Met Ile Tyr Glu Val Ser Lys Arg Pro 1 5 10 <210> 1588 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1588 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu 1 5 10 <210> 1589 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1589 Gly Tyr Thr Phe Thr Gly Asp Tyr 1 5 <210> 1590 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1590 Ile Asn Pro Asn Ser Gly Tyr Thr 1 5 <210> 1591 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1591 Ala Arg Glu Gly Asp Ala Phe Asp Val 1 5 <210> 1592 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1592 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 1593 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1593 Glu Val Ser One <210> 1594 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1594 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu Val 1 5 10 <210> 1595 <211> 116 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1595 Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Thr Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Asp 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Asp Ala Phe Asp Val Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser 115 <210> 1596 <211> 111 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1596 Gln Leu Val Leu Thr Gln Ser Ser Ser Ala Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ala Gly Ser 85 90 95 Asn Asn Phe Glu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1597 <211> 446 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1597 Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Thr Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Asp 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Asp Ala Phe Asp Val Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 115 120 125 Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 130 135 140 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 145 150 155 160 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 165 170 175 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 180 185 190 Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 195 200 205 Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr 210 215 220 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 225 230 235 240 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 260 265 270 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 305 310 315 320 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 325 330 335 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 340 345 350 Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 355 360 365 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 405 410 415 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 1598 <211> 217 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1598 Gln Leu Val Leu Thr Gln Ser Ser Ser Ala Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ala Gly Ser 85 90 95 Asn Asn Phe Glu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 1599 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1599 Ser Tyr Ser Met Ile 1 5 <210> 1600 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1600 Ser Ile Ser Ser Ser Ser Asp Tyr Ile Tyr Asn Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1601 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1601 Asp Trp Glu Leu Leu Gly Phe Asp Cys 1 5 <210> 1602 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1602 Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys 1 5 10 <210> 1603 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1603 Gln His Asn Lys Arg Pro Ser 1 5 <210> 1604 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1604 Gln Ala Trp Asp Ser Thr Thr Val Val 1 5 <210> 1605 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1605 Gly Phe Thr Phe Ser Ser Tyr 1 5 <210> 1606 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1606 Ser Ser Ser Ser Asp Tyr 1 5 <210> 1607 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1607 Asp Trp Glu Leu Leu Gly Phe Asp 1 5 <210> 1608 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1608 Asp Lys Leu Gly Asp Lys Tyr 1 5 <210> 1609 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1609 Gln His Asn One <210> 1610 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1610 Trp Asp Ser Thr Thr Val 1 5 <210> 1611 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1611 Gly Phe Thr Phe Ser Ser Tyr Ser Met Ile 1 5 10 <210> 1612 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1612 Ser Ile Ser Ser Ser Ser Asp Tyr Ile Tyr 1 5 10 <210> 1613 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1613 Asp Trp Glu Leu Leu Gly Phe Asp Cys 1 5 <210> 1614 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1614 Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys 1 5 10 <210> 1615 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1615 Gln His Asn Lys Arg Pro Ser 1 5 <210> 1616 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1616 Gln Ala Trp Asp Ser Thr Thr Val Val 1 5 <210> 1617 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1617 Ser Ser Tyr Ser Met Ile 1 5 <210> 1618 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1618 Trp Val Ser Ser Ile Ser Ser Ser Ser Asp Tyr Ile Tyr 1 5 10 <210> 1619 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1619 Ala Arg Asp Trp Glu Leu Leu Gly Phe Asp 1 5 10 <210> 1620 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1620 Asp Lys Tyr Ala Cys Trp Tyr 1 5 <210> 1621 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1621 Leu Val Ile Tyr Gln His Asn Lys Arg Pro 1 5 10 <210> 1622 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1622 Gln Ala Trp Asp Ser Thr Thr Val 1 5 <210> 1623 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1623 Gly Phe Thr Phe Ser Ser Tyr Ser 1 5 <210> 1624 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1624 Ile Ser Ser Ser Ser Asp Tyr Ile 1 5 <210> 1625 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1625 Ala Arg Asp Trp Glu Leu Leu Gly Phe Asp Cys 1 5 10 <210> 1626 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1626 Lys Leu Gly Asp Lys Tyr 1 5 <210> 1627 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1627 Gln His Asn One <210> 1628 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1628 Gln Ala Trp Asp Ser Thr Thr Val Val 1 5 <210> 1629 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1629 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Arg Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Asp Tyr Ile Tyr Asn Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Glu Leu Leu Gly Phe Asp Cys Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 1630 <211> 106 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1630 Ser Tyr Glu Leu Met Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln His Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Lys Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Thr Thr Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 1631 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1631 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Arg Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Asp Tyr Ile Tyr Asn Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Glu Leu Leu Gly Phe Asp Cys Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 1632 <211> 212 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1632 Ser Tyr Glu Leu Met Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln His Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Lys Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Thr Thr Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala 100 105 110 Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn 115 120 125 Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val 130 135 140 Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu 145 150 155 160 Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser 165 170 175 Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser 180 185 190 Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro 195 200 205 Thr Glu Cys Ser 210 <210> 1633 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1633 Ile Ser Gly Val Ser Val Gly 1 5 <210> 1634 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1634 Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser Leu Gln Ser 1 5 10 15 <210> 1635 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1635 Ser Gly Gln Trp Leu Glu Gly Asp Ala Phe Asp Ile 1 5 10 <210> 1636 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1636 Arg Ser Ser Glu Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 1637 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1637 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 1638 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1638 Met Gln Ala Thr Gln Phe Pro Leu Thr 1 5 <210> 1639 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1639 Gly Phe Ser Leu Ser Ile Ser Gly Val 1 5 <210> 1640 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1640 Tyr Trp Asn Asp Asp 1 5 <210> 1641 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1641 Ser Gly Gln Trp Leu Glu Gly Asp Ala Phe Asp 1 5 10 <210> 1642 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1642 Ser Glu Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 1643 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1643 Lys Ile Ser One <210> 1644 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1644 Ala Thr Gln Phe Pro Leu 1 5 <210> 1645 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1645 Gly Phe Ser Leu Ser Ile Ser Gly Val Ser Val Gly 1 5 10 <210> 1646 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1646 Leu Ile Tyr Trp Asn Asp Asp Lys Arg 1 5 <210> 1647 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1647 Ser Gly Gln Trp Leu Glu Gly Asp Ala Phe Asp Ile 1 5 10 <210> 1648 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1648 Arg Ser Ser Glu Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 1649 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1649 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 1650 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1650 Met Gln Ala Thr Gln Phe Pro Leu Thr 1 5 <210> 1651 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1651 Ser Ile Ser Gly Val Ser Val Gly 1 5 <210> 1652 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1652 Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg 1 5 10 <210> 1653 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1653 Val His Ser Gly Gln Trp Leu Glu Gly Asp Ala Phe Asp 1 5 10 <210> 1654 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1654 Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu 1 5 10 <210> 1655 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1655 Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe 1 5 10 <210> 1656 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1656 Met Gln Ala Thr Gln Phe Pro Leu 1 5 <210> 1657 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1657 Gly Phe Ser Leu Ser Ile Ser Gly Val Ser 1 5 10 <210> 1658 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1658 Ile Tyr Trp Asn Asp Asp Lys 1 5 <210> 1659 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1659 Val His Ser Gly Gln Trp Leu Glu Gly Asp Ala Phe Asp Ile 1 5 10 <210> 1660 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1660 Glu Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 1661 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1661 Lys Ile Ser One <210> 1662 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1662 Met Gln Ala Thr Gln Phe Pro Leu Thr 1 5 <210> 1663 <211> 122 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1663 Gln Val Gln Leu Val Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ile Ser 20 25 30 Gly Val Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser 50 55 60 Leu Gln Ser Arg Val Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Val Thr Asn Met Asp Ser Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Val His Ser Gly Gln Trp Leu Glu Gly Asp Ala Phe Asp Ile Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1664 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1664 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Glu Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Ser Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Thr Gln Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 1665 <211> 452 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1665 Gln Val Gln Leu Val Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ile Ser 20 25 30 Gly Val Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser 50 55 60 Leu Gln Ser Arg Val Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Val Thr Asn Met Asp Ser Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Val His Ser Gly Gln Trp Leu Glu Gly Asp Ala Phe Asp Ile Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Lys 450 <210> 1666 <211> 219 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1666 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Glu Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Ser Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Thr Gln Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1667 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1667 Asn Tyr Asp Met Asn 1 5 <210> 1668 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1668 Ser Ile Ser Ser Ser Ser His Tyr Ile Tyr Tyr Ala Asp Ser Leu Lys 1 5 10 15 Gly <210> 1669 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1669 Asp Arg Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Ala Leu Asp Val 1 5 10 15 <210> 1670 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1670 Arg Ala Ser Gln Gly Ile Tyr Asn Tyr Leu Ala 1 5 10 <210> 1671 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1671 Ala Ala Ser Thr Leu Gln Ser 1 5 <210> 1672 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1672 Gln Lys Tyr Asn Arg Ala Pro Phe Thr 1 5 <210> 1673 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1673 Gly Phe Ser Phe Ser Asn Tyr 1 5 <210> 1674 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1674 Ser Ser Ser Ser His Tyr 1 5 <210> 1675 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1675 Asp Arg Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Ala Leu Asp 1 5 10 <210> 1676 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1676 Ser Gln Gly Ile Tyr Asn Tyr 1 5 <210> 1677 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1677 Ala Ala Ser One <210> 1678 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1678 Tyr Asn Arg Ala Pro Phe 1 5 <210> 1679 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1679 Gly Phe Ser Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 1680 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1680 Ser Ile Ser Ser Ser Ser His Tyr Ile Tyr 1 5 10 <210> 1681 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1681 Asp Arg Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Ala Leu Asp Val 1 5 10 15 <210> 1682 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1682 Arg Ala Ser Gln Gly Ile Tyr Asn Tyr Leu Ala 1 5 10 <210> 1683 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1683 Ala Ala Ser Thr Leu Gln Ser 1 5 <210> 1684 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1684 Gln Lys Tyr Asn Arg Ala Pro Phe Thr 1 5 <210> 1685 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1685 Ser Asn Tyr Asp Met Asn 1 5 <210> 1686 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1686 Trp Val Ser Ser Ile Ser Ser Ser Ser His Tyr Ile Tyr 1 5 10 <210> 1687 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1687 Ala Arg Asp Arg Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Ala Leu Asp 1 5 10 15 <210> 1688 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1688 Tyr Asn Tyr Leu Ala Trp Tyr 1 5 <210> 1689 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1689 Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln 1 5 10 <210> 1690 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1690 Gln Lys Tyr Asn Arg Ala Pro Phe 1 5 <210> 1691 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1691 Gly Phe Ser Phe Ser Asn Tyr Asp 1 5 <210> 1692 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1692 Ile Ser Ser Ser Ser His Tyr Ile 1 5 <210> 1693 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1693 Ala Arg Asp Arg Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Ala Leu Asp 1 5 10 15 Val <210> 1694 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1694 Gln Gly Ile Tyr Asn Tyr 1 5 <210> 1695 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1695 Ala Ala Ser One <210> 1696 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1696 Gln Lys Tyr Asn Arg Ala Pro Phe Thr 1 5 <210> 1697 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1697 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Arg Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser His Tyr Ile Tyr Tyr Ala Asp Ser Leu 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Ala Leu Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1698 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1698 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Tyr Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Val Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Thr Thr Tyr Tyr Cys Gln Lys Tyr Asn Arg Ala Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 <210> 1699 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1699 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Arg Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser His Tyr Ile Tyr Tyr Ala Asp Ser Leu 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Ala Leu Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 1700 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1700 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Tyr Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Val Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Thr Thr Tyr Tyr Cys Gln Lys Tyr Asn Arg Ala Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 1701 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1701 Thr Tyr Gly Met His 1 5 <210> 1702 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1702 Val Ile Trp Tyr Asn Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1703 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1703 Gly Gly Phe Gly Glu Ser Phe Asp Ser 1 5 <210> 1704 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1704 Arg Ala Ser Gln Ser Val Ile Asp Tyr Leu Ala 1 5 10 <210> 1705 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1705 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 1706 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1706 Gln Gln Arg Ser Asn Trp Pro Leu Thr 1 5 <210> 1707 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1707 Gly Phe Thr Phe Gly Thr Tyr 1 5 <210> 1708 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1708 Trp Tyr Asn Gly Ser Asn 1 5 <210> 1709 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1709 Gly Gly Phe Gly Glu Ser Phe Asp 1 5 <210> 1710 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1710 Ser Gln Ser Val Ile Asp Tyr 1 5 <210> 1711 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1711 Asp Ala Ser One <210> 1712 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1712 Arg Ser Asn Trp Pro Leu 1 5 <210> 1713 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1713 Gly Phe Thr Phe Gly Thr Tyr Gly Met His 1 5 10 <210> 1714 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1714 Val Ile Trp Tyr Asn Gly Ser Asn Lys Tyr 1 5 10 <210> 1715 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1715 Gly Gly Phe Gly Glu Ser Phe Asp Ser 1 5 <210> 1716 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1716 Arg Ala Ser Gln Ser Val Ile Asp Tyr Leu Ala 1 5 10 <210> 1717 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1717 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 1718 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1718 Gln Gln Arg Ser Asn Trp Pro Leu Thr 1 5 <210> 1719 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1719 Gly Thr Tyr Gly Met His 1 5 <210> 1720 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1720 Trp Val Ala Val Ile Trp Tyr Asn Gly Ser Asn Lys Tyr 1 5 10 <210> 1721 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1721 Ala Arg Gly Gly Phe Gly Glu Ser Phe Asp 1 5 10 <210> 1722 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1722 Ile Asp Tyr Leu Ala Trp Phe 1 5 <210> 1723 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1723 Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala 1 5 10 <210> 1724 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1724 Gln Gln Arg Ser Asn Trp Pro Leu 1 5 <210> 1725 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1725 Gly Phe Thr Phe Gly Thr Tyr Gly 1 5 <210> 1726 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1726 Ile Trp Tyr Asn Gly Ser Asn Lys 1 5 <210> 1727 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1727 Ala Arg Gly Gly Phe Gly Glu Ser Phe Asp Ser 1 5 10 <210> 1728 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1728 Gln Ser Val Ile Asp Tyr 1 5 <210> 1729 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1729 Asp Ala Ser One <210> 1730 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1730 Gln Gln Arg Ser Asn Trp Pro Leu Thr 1 5 <210> 1731 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1731 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Thr Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val 35 40 45 Ala Val Ile Trp Tyr Asn Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Phe Gly Glu Ser Phe Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 1732 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1732 Asp Ile Val Met Thr Gln Thr Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ile Asp Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1733 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1733 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Thr Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val 35 40 45 Ala Val Ile Trp Tyr Asn Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Phe Gly Glu Ser Phe Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 1734 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1734 Asp Ile Val Met Thr Gln Thr Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ile Asp Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 1735 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1735 Thr Tyr Thr Met Asn 1 5 <210> 1736 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1736 Ser Ile Ser Ser Ser Ser Phe Tyr Met Asp Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1737 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1737 Asp Gly Asp Ile Val Ala Thr Ile Arg Gly Ser Phe Asp Tyr 1 5 10 <210> 1738 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1738 Arg Ala Ser Gln Asp Ile Thr Asn Phe Leu Ala 1 5 10 <210> 1739 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1739 Thr Ala Ser Thr Leu Gln Ser 1 5 <210> 1740 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1740 Gln Lys Tyr Asn Ser Ala Pro Phe Thr 1 5 <210> 1741 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1741 Gly Phe Thr Phe Ser Thr Tyr 1 5 <210> 1742 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1742 Ser Ser Ser Ser Phe Tyr 1 5 <210> 1743 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1743 Asp Gly Asp Ile Val Ala Thr Ile Arg Gly Ser Phe Asp 1 5 10 <210> 1744 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1744 Ser Gln Asp Ile Thr Asn Phe 1 5 <210> 1745 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1745 Thr Ala Ser One <210> 1746 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1746 Tyr Asn Ser Ala Pro Phe 1 5 <210> 1747 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1747 Gly Phe Thr Phe Ser Thr Tyr Thr Met Asn 1 5 10 <210> 1748 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1748 Ser Ile Ser Ser Ser Ser Phe Tyr Met Asp 1 5 10 <210> 1749 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1749 Asp Gly Asp Ile Val Ala Thr Ile Arg Gly Ser Phe Asp Tyr 1 5 10 <210> 1750 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1750 Arg Ala Ser Gln Asp Ile Thr Asn Phe Leu Ala 1 5 10 <210> 1751 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1751 Thr Ala Ser Thr Leu Gln Ser 1 5 <210> 1752 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1752 Gln Lys Tyr Asn Ser Ala Pro Phe Thr 1 5 <210> 1753 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1753 Ser Thr Tyr Thr Met Asn 1 5 <210> 1754 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1754 Trp Val Ser Ser Ile Ser Ser Ser Ser Phe Tyr Met Asp 1 5 10 <210> 1755 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1755 Ala Arg Asp Gly Asp Ile Val Ala Thr Ile Arg Gly Ser Phe Asp 1 5 10 15 <210> 1756 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1756 Thr Asn Phe Leu Ala Trp Tyr 1 5 <210> 1757 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1757 Leu Leu Ile Tyr Thr Ala Ser Thr Leu Gln 1 5 10 <210> 1758 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1758 Gln Lys Tyr Asn Ser Ala Pro Phe 1 5 <210> 1759 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1759 Gly Phe Thr Phe Ser Thr Tyr Thr 1 5 <210> 1760 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1760 Ile Ser Ser Ser Ser Phe Tyr Met 1 5 <210> 1761 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1761 Ala Arg Asp Gly Asp Ile Val Ala Thr Ile Arg Gly Ser Phe Asp Tyr 1 5 10 15 <210> 1762 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1762 Gln Asp Ile Thr Asn Phe 1 5 <210> 1763 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1763 Thr Ala Ser One <210> 1764 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1764 Gln Lys Tyr Asn Ser Ala Pro Phe Thr 1 5 <210> 1765 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1765 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Phe Tyr Met Asp Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Ser 65 70 75 80 Leu Leu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Asp Ile Val Ala Thr Ile Arg Gly Ser Phe Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 1766 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1766 Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Thr Asn Phe 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Leu Pro Lys Leu Leu Ile 35 40 45 Tyr Thr Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Ala Ser Gly Pro Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1767 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1767 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Phe Tyr Met Asp Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Ser 65 70 75 80 Leu Leu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Asp Ile Val Ala Thr Ile Arg Gly Ser Phe Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 1768 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1768 Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Thr Asn Phe 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Leu Pro Lys Leu Leu Ile 35 40 45 Tyr Thr Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Ala Ser Gly Pro Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 1769 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1769 Arg Tyr Ala Met Asn 1 5 <210> 1770 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1770 Phe Ile Ser Gly Thr Gly Tyr Thr Val Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1771 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1771 Asp Gln Glu Pro Gly Phe Asp Tyr 1 5 <210> 1772 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1772 Arg Ser Gly Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 1773 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1773 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 1774 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1774 Met Gln Ala Thr His Phe Pro Phe Thr 1 5 <210> 1775 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1775 Gly Phe Thr Phe Ser Arg Tyr 1 5 <210> 1776 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1776 Ser Gly Thr Gly Tyr Thr 1 5 <210> 1777 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1777 Asp Gln Glu Pro Gly Phe Asp 1 5 <210> 1778 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1778 Gly Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 1779 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1779 Lys Ile Ser One <210> 1780 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1780 Ala Thr His Phe Pro Phe 1 5 <210> 1781 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1781 Gly Phe Thr Phe Ser Arg Tyr Ala Met Asn 1 5 10 <210> 1782 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1782 Phe Ile Ser Gly Thr Gly Tyr Thr Val Tyr 1 5 10 <210> 1783 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1783 Asp Gln Glu Pro Gly Phe Asp Tyr 1 5 <210> 1784 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1784 Arg Ser Gly Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 1785 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1785 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 1786 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1786 Met Gln Ala Thr His Phe Pro Phe Thr 1 5 <210> 1787 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1787 Ser Arg Tyr Ala Met Asn 1 5 <210> 1788 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1788 Trp Val Ser Phe Ile Ser Gly Thr Gly Tyr Thr Val Tyr 1 5 10 <210> 1789 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1789 Ala Arg Asp Gln Glu Pro Gly Phe Asp 1 5 <210> 1790 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1790 Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu 1 5 10 <210> 1791 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1791 Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe 1 5 10 <210> 1792 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1792 Met Gln Ala Thr His Phe Pro Phe 1 5 <210> 1793 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1793 Gly Phe Thr Phe Ser Arg Tyr Ala 1 5 <210> 1794 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1794 Ile Ser Gly Thr Gly Tyr Thr Val 1 5 <210> 1795 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1795 Ala Arg Asp Gln Glu Pro Gly Phe Asp Tyr 1 5 10 <210> 1796 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1796 Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 1797 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1797 Lys Ile Ser One <210> 1798 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1798 Met Gln Ala Thr His Phe Pro Phe Thr 1 5 <210> 1799 <211> 117 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1799 Glu Val Gln Leu Val Gln Ser Gly Gly Asp Leu Leu Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Phe Ile Ser Gly Thr Gly Tyr Thr Val Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gln Glu Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 1800 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1800 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Thr His Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 1801 <211> 447 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1801 Glu Val Gln Leu Val Gln Ser Gly Gly Asp Leu Leu Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Phe Ile Ser Gly Thr Gly Tyr Thr Val Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gln Glu Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His 210 215 220 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 1802 <211> 219 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1802 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Thr His Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1803 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1803 Ser His Asp Met Asn 1 5 <210> 1804 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1804 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1805 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1805 Asp Leu Gly Val Gly Val Arg Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1806 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1806 Arg Ala Ser Gln Asp Ile Thr Asn Tyr Leu Ala 1 5 10 <210> 1807 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1807 Ala Ala Ser Ser Leu Gln Gly 1 5 <210> 1808 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1808 Leu Gln His Asp Thr Tyr Pro Tyr Thr 1 5 <210> 1809 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1809 Gly Phe Thr Phe Ser Ser His 1 5 <210> 1810 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1810 Ser Ser Ser Ser Ser Tyr 1 5 <210> 1811 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1811 Asp Leu Gly Val Gly Val Arg Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 1812 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1812 Ser Gln Asp Ile Thr Asn Tyr 1 5 <210> 1813 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1813 Ala Ala Ser One <210> 1814 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1814 His Asp Thr Tyr Pro Tyr 1 5 <210> 1815 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1815 Gly Phe Thr Phe Ser Ser His Asp Met Asn 1 5 10 <210> 1816 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1816 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 1817 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1817 Asp Leu Gly Val Gly Val Arg Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1818 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1818 Arg Ala Ser Gln Asp Ile Thr Asn Tyr Leu Ala 1 5 10 <210> 1819 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1819 Ala Ala Ser Ser Leu Gln Gly 1 5 <210> 1820 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1820 Leu Gln His Asp Thr Tyr Pro Tyr Thr 1 5 <210> 1821 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1821 Ser Ser His Asp Met Asn 1 5 <210> 1822 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1822 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe 1 5 10 <210> 1823 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1823 Ala Arg Asp Leu Gly Val Gly Val Arg Asp Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp <210> 1824 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1824 Thr Asn Tyr Leu Ala Trp Phe 1 5 <210> 1825 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1825 Arg Leu Ile Tyr Ala Ala Ser Ser Leu Gln 1 5 10 <210> 1826 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1826 Leu Gln His Asp Thr Tyr Pro Tyr 1 5 <210> 1827 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1827 Gly Phe Thr Phe Ser Ser His Asp 1 5 <210> 1828 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1828 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 1829 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1829 Ala Arg Asp Leu Gly Val Gly Val Arg Asp Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1830 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1830 Gln Asp Ile Thr Asn Tyr 1 5 <210> 1831 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1831 Ala Ala Ser One <210> 1832 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1832 Leu Gln His Asp Thr Tyr Pro Tyr Thr 1 5 <210> 1833 <211> 125 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1833 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gly Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Leu Gly Val Gly Val Arg Asp Tyr Tyr Tyr Tyr Gly Met 100 105 110 Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 1834 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1834 Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Thr Asn Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Lys Arg Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ser Thr Tyr Tyr Cys Leu Gln His Asp Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1835 <211> 455 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1835 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gly Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Leu Gly Val Gly Val Arg Asp Tyr Tyr Tyr Tyr Gly Met 100 105 110 Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr 115 120 125 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 130 135 140 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 145 150 155 160 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 165 170 175 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 180 185 190 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 195 200 205 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu 210 215 220 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 225 230 235 240 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 245 250 255 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 260 265 270 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 275 280 285 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 290 295 300 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 305 310 315 320 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 325 330 335 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 340 345 350 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 355 360 365 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 370 375 380 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 385 390 395 400 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 405 410 415 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 420 425 430 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 435 440 445 Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 1836 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1836 Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Thr Asn Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Lys Arg Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ser Thr Tyr Tyr Cys Leu Gln His Asp Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 1837 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1837 Thr Tyr Gly Val Gly Val Gly 1 5 <210> 1838 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1838 Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Tyr Pro Ser Leu Asn Asn 1 5 10 15 <210> 1839 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1839 Asp Tyr Asp Phe Trp Ser Gly Tyr Phe Asp Tyr 1 5 10 <210> 1840 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1840 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 1841 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1841 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1842 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1842 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 1843 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1843 Gly Phe Ser Leu Thr Thr Tyr Gly Val 1 5 <210> 1844 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1844 Tyr Trp Asn Asp Asp 1 5 <210> 1845 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1845 Asp Tyr Asp Phe Trp Ser Gly Tyr Phe Asp 1 5 10 <210> 1846 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1846 Ser Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 1847 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1847 Gly Ala Ser One <210> 1848 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1848 Tyr Gly Ser Ser Pro Leu 1 5 <210> 1849 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1849 Gly Phe Ser Leu Thr Thr Tyr Gly Val Gly Val Gly 1 5 10 <210> 1850 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1850 Leu Ile Tyr Trp Asn Asp Asp Lys Arg 1 5 <210> 1851 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1851 Asp Tyr Asp Phe Trp Ser Gly Tyr Phe Asp Tyr 1 5 10 <210> 1852 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1852 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 1853 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1853 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1854 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1854 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 1855 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1855 Thr Thr Tyr Gly Val Gly Val Gly 1 5 <210> 1856 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1856 Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg 1 5 10 <210> 1857 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1857 Ala His Asp Tyr Asp Phe Trp Ser Gly Tyr Phe Asp 1 5 10 <210> 1858 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1858 Ser Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 1859 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1859 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 1860 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1860 Gln Gln Tyr Gly Ser Ser Pro Leu 1 5 <210> 1861 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1861 Gly Phe Ser Leu Thr Thr Tyr Gly Val Gly 1 5 10 <210> 1862 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1862 Ile Tyr Trp Asn Asp Asp Lys 1 5 <210> 1863 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1863 Ala His Asp Tyr Asp Phe Trp Ser Gly Tyr Phe Asp Tyr 1 5 10 <210> 1864 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1864 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 1865 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1865 Gly Ala Ser One <210> 1866 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1866 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 1867 <211> 121 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1867 Gln Val Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Thr Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Tyr 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Tyr Pro Ser 50 55 60 Leu Asn Asn Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys His Leu Val 65 70 75 80 Val Leu Thr Leu Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala His Asp Tyr Asp Phe Trp Ser Gly Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 1868 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1868 Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1869 <211> 451 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1869 Gln Val Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Thr Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Tyr 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Tyr Pro Ser 50 55 60 Leu Asn Asn Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys His Leu Val 65 70 75 80 Val Leu Thr Leu Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala His Asp Tyr Asp Phe Trp Ser Gly Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys 450 <210> 1870 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1870 Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1871 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1871 Gly Tyr Tyr Met His 1 5 <210> 1872 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1872 Arg Ile Asn Pro Asn Ser Gly Val Thr His Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1873 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1873 Gly Gly Ser Leu Val Arg Gly Val Ile Ser Gly Leu Asp Tyr 1 5 10 <210> 1874 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1874 Arg Ala Ser Gln Ser Phe Ser Gly Ser Tyr Leu Ala 1 5 10 <210> 1875 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1875 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1876 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1876 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1877 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1877 Gly Tyr Thr Phe Thr Gly Tyr 1 5 <210> 1878 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1878 Asn Pro Asn Ser Gly Val 1 5 <210> 1879 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1879 Gly Gly Ser Leu Val Arg Gly Val Ile Ser Gly Leu Asp 1 5 10 <210> 1880 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1880 Ser Gln Ser Phe Ser Gly Ser Tyr 1 5 <210> 1881 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1881 Gly Ala Ser One <210> 1882 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1882 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1883 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1883 Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His 1 5 10 <210> 1884 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1884 Arg Ile Asn Pro Asn Ser Gly Val Thr His 1 5 10 <210> 1885 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1885 Gly Gly Ser Leu Val Arg Gly Val Ile Ser Gly Leu Asp Tyr 1 5 10 <210> 1886 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1886 Arg Ala Ser Gln Ser Phe Ser Gly Ser Tyr Leu Ala 1 5 10 <210> 1887 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1887 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1888 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1888 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1889 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1889 Thr Gly Tyr Tyr Met His 1 5 <210> 1890 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1890 Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Val Thr His 1 5 10 <210> 1891 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1891 Ala Arg Gly Gly Ser Leu Val Arg Gly Val Ile Ser Gly Leu Asp 1 5 10 15 <210> 1892 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1892 Ser Gly Ser Tyr Leu Ala Trp Tyr 1 5 <210> 1893 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1893 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 1894 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1894 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1895 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1895 Gly Tyr Thr Phe Thr Gly Tyr Tyr 1 5 <210> 1896 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1896 Ile Asn Pro Asn Ser Gly Val Thr 1 5 <210> 1897 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1897 Ala Arg Gly Gly Ser Leu Val Arg Gly Val Ile Ser Gly Leu Asp Tyr 1 5 10 15 <210> 1898 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1898 Gln Ser Phe Ser Gly Ser Tyr 1 5 <210> 1899 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1899 Gly Ala Ser One <210> 1900 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1900 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1901 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1901 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asn Pro Asn Ser Gly Val Thr His Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Ser Leu Val Arg Gly Val Ile Ser Gly Leu Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 1902 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1902 Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Phe Ser Gly Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ser Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1903 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1903 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asn Pro Asn Ser Gly Val Thr His Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Ser Leu Val Arg Gly Val Ile Ser Gly Leu Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 1904 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1904 Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Phe Ser Gly Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ser Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1905 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1905 Ser Tyr Tyr Met His 1 5 <210> 1906 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1906 Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1907 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1907 Gly Ser Tyr Gly Trp Tyr Phe Asp Leu 1 5 <210> 1908 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1908 Arg Ala Ser Gln Ser Val Thr Ser Ser Tyr Leu Ala 1 5 10 <210> 1909 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1909 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1910 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1910 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1911 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1911 Gly Tyr Thr Leu Thr Ser Tyr 1 5 <210> 1912 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1912 Asn Pro Ser Gly Gly Ser 1 5 <210> 1913 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1913 Gly Ser Tyr Gly Trp Tyr Phe Asp 1 5 <210> 1914 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1914 Ser Gln Ser Val Thr Ser Ser Tyr 1 5 <210> 1915 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1915 Gly Ala Ser One <210> 1916 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1916 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1917 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1917 Gly Tyr Thr Leu Thr Ser Tyr Tyr Met His 1 5 10 <210> 1918 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1918 Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser 1 5 10 <210> 1919 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1919 Gly Ser Tyr Gly Trp Tyr Phe Asp Leu 1 5 <210> 1920 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1920 Arg Ala Ser Gln Ser Val Thr Ser Ser Tyr Leu Ala 1 5 10 <210> 1921 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1921 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1922 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1922 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1923 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1923 Thr Ser Tyr Tyr Met His 1 5 <210> 1924 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1924 Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser 1 5 10 <210> 1925 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1925 Ala Arg Gly Ser Tyr Gly Trp Tyr Phe Asp 1 5 10 <210> 1926 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1926 Thr Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 1927 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1927 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 1928 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1928 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1929 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1929 Gly Tyr Thr Leu Thr Ser Tyr Tyr 1 5 <210> 1930 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1930 Ile Asn Pro Ser Gly Gly Ser Thr 1 5 <210> 1931 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1931 Ala Arg Gly Ser Tyr Gly Trp Tyr Phe Asp Leu 1 5 10 <210> 1932 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1932 Gln Ser Val Thr Ser Ser Tyr 1 5 <210> 1933 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1933 Gly Ala Ser One <210> 1934 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1934 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1935 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1935 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ser Tyr Gly Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 1936 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1936 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Thr Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Ile Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Val Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1937 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1937 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ser Tyr Gly Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 1938 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1938 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Thr Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Ile Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Val Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 1939 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1939 Asn Tyr Asp Met Asn 1 5 <210> 1940 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1940 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1941 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1941 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1942 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1942 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 1943 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1943 Ala Ala Ser Thr Leu Gln Ser 1 5 <210> 1944 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1944 Gln Gln Tyr Asn Asn Trp Pro Arg Thr 1 5 <210> 1945 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1945 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 1946 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1946 Ser Ser Ser Ser Ser Tyr 1 5 <210> 1947 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1947 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 1948 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1948 Ser Gln Gly Ile Asn Ser Trp 1 5 <210> 1949 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1949 Ala Ala Ser One <210> 1950 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1950 Tyr Asn Asn Trp Pro Arg 1 5 <210> 1951 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1951 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 1952 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1952 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1953 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1953 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 1954 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1954 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 1955 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1955 Ala Ala Ser Thr Leu Gln Ser 1 5 <210> 1956 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1956 Gln Gln Tyr Asn Asn Trp Pro Arg Thr 1 5 <210> 1957 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1957 Ser Asn Tyr Asp Met Asn 1 5 <210> 1958 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1958 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 1959 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1959 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 1960 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1960 Asn Ser Trp Leu Ala Trp Tyr 1 5 <210> 1961 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1961 Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln 1 5 10 <210> 1962 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1962 Gln Gln Tyr Asn Asn Trp Pro Arg 1 5 <210> 1963 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1963 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 1964 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1964 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 1965 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1965 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 1966 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1966 Gln Gly Ile Asn Ser Trp 1 5 <210> 1967 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1967 Ala Ala Ser One <210> 1968 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1968 Gln Gln Tyr Asn Asn Trp Pro Arg Thr 1 5 <210> 1969 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1969 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 1970 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1970 Glu Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Asp Pro Tyr Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Gly Gly 50 55 60 Arg Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Arg 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100 105 <210> 1971 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1971 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 1972 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 1972 Glu Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Asp Pro Tyr Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Gly Gly 50 55 60 Arg Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Arg 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 1973 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1973 Ser Tyr Val Ile Ser 1 5 <210> 1974 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1974 Gly Ile Leu Pro Ile Leu Ser Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1975 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1975 Ala His Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1976 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1976 Arg Ala Ser Gln Ser Val Ser Asn Asn Tyr Leu Ala 1 5 10 <210> 1977 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1977 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1978 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1978 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1979 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1979 Gly Gly Thr Phe Ser Ser Tyr 1 5 <210> 1980 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1980 Leu Pro Ile Leu Ser Thr 1 5 <210> 1981 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1981 Ala His Asp Tyr Tyr Tyr Gly Met Asp 1 5 <210> 1982 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1982 Ser Gln Ser Val Ser Asn Asn Tyr 1 5 <210> 1983 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1983 Gly Ala Ser One <210> 1984 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1984 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1985 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1985 Gly Gly Thr Phe Ser Ser Tyr Val Ile Ser 1 5 10 <210> 1986 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1986 Gly Ile Leu Pro Ile Leu Ser Thr Ala Asn 1 5 10 <210> 1987 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1987 Ala His Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1988 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1988 Arg Ala Ser Gln Ser Val Ser Asn Asn Tyr Leu Ala 1 5 10 <210> 1989 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1989 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 1990 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1990 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1991 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1991 Ser Ser Tyr Val Ile Ser 1 5 <210> 1992 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1992 Trp Met Gly Gly Ile Leu Pro Ile Leu Ser Thr Ala Asn 1 5 10 <210> 1993 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1993 Ala Arg Ala His Asp Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 1994 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1994 Ser Asn Asn Tyr Leu Ala Trp Tyr 1 5 <210> 1995 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1995 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 1996 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1996 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 1997 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1997 Gly Gly Thr Phe Ser Ser Tyr Val 1 5 <210> 1998 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1998 Ile Leu Pro Ile Leu Ser Thr Ala 1 5 <210> 1999 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1999 Ala Arg Ala His Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 2000 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2000 Gln Ser Val Ser Asn Asn Tyr 1 5 <210> 2001 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2001 Gly Ala Ser One <210> 2002 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2002 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 2003 <211> 119 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2003 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Val Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Leu Pro Ile Leu Ser Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala His Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly 100 105 110 Thr Thr Val Thr Val Ser Ser 115 <210> 2004 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2004 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100 105 <210> 2005 <211> 449 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2005 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Val Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Leu Pro Ile Leu Ser Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala His Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly 100 105 110 Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 Lys <210> 2006 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2006 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 2007 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2007 Gly Tyr Tyr Trp Asn 1 5 <210> 2008 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2008 Arg Ile Phe Thr Thr Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2009 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2009 Glu Lys Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp Phe 1 5 10 <210> 2010 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2010 Thr Gly Ser Ser Ser Asn Ile Gly Ala Asp Tyr Asp Val Lys 1 5 10 <210> 2011 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2011 Gly Asn Thr Asp Arg Pro Ser 1 5 <210> 2012 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2012 Gln Ser Tyr Asp Ser Arg Leu Thr Gly Tyr Val Val 1 5 10 <210> 2013 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2013 Gly Asp Ser Ile Arg Gly Tyr 1 5 <210> 2014 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2014 Phe Thr Thr Gly Asn 1 5 <210> 2015 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2015 Glu Lys Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp 1 5 10 <210> 2016 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2016 Ser Ser Ser Asn Ile Gly Ala Asp Tyr Asp 1 5 10 <210> 2017 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2017 Gly Asn Thr One <210> 2018 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2018 Tyr Asp Ser Arg Leu Thr Gly Tyr Val 1 5 <210> 2019 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2019 Gly Asp Ser Ile Arg Gly Tyr Tyr Trp Asn 1 5 10 <210> 2020 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2020 Arg Ile Phe Thr Thr Gly Asn Thr Asn 1 5 <210> 2021 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2021 Glu Lys Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp Phe 1 5 10 <210> 2022 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2022 Thr Gly Ser Ser Ser Asn Ile Gly Ala Asp Tyr Asp Val Lys 1 5 10 <210> 2023 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2023 Gly Asn Thr Asp Arg Pro Ser 1 5 <210> 2024 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2024 Gln Ser Tyr Asp Ser Arg Leu Thr Gly Tyr Val Val 1 5 10 <210> 2025 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2025 Arg Gly Tyr Tyr Trp Asn 1 5 <210> 2026 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2026 Trp Ile Gly Arg Ile Phe Thr Thr Gly Asn Thr Asn 1 5 10 <210> 2027 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2027 Ala Arg Glu Lys Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp 1 5 10 15 <210> 2028 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2028 Ile Gly Ala Asp Tyr Asp Val Lys Trp Tyr 1 5 10 <210> 2029 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2029 Leu Leu Ile Tyr Gly Asn Thr Asp Arg Pro 1 5 10 <210> 2030 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2030 Gln Ser Tyr Asp Ser Arg Leu Thr Gly Tyr Val 1 5 10 <210> 2031 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2031 Gly Asp Ser Ile Arg Gly Tyr Tyr 1 5 <210> 2032 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2032 Ile Phe Thr Thr Gly Asn Thr 1 5 <210> 2033 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2033 Ala Arg Glu Lys Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp Phe 1 5 10 15 <210> 2034 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2034 Ser Ser Asn Ile Gly Ala Asp Tyr Asp 1 5 <210> 2035 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2035 Gly Asn Thr One <210> 2036 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2036 Gln Ser Tyr Asp Ser Arg Leu Thr Gly Tyr Val Val 1 5 10 <210> 2037 <211> 122 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2037 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Arg Gly Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Phe Thr Thr Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Leu Thr Met Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Glu Lys Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp Phe Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2038 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2038 Gln Ser Val Leu Thr Gln Ala Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Asp 20 25 30 Tyr Asp Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Thr Asp Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Arg 85 90 95 Leu Thr Gly Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2039 <211> 452 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2039 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Arg Gly Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Phe Thr Thr Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Leu Thr Met Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Glu Lys Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp Phe Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Lys 450 <210> 2040 <211> 218 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2040 Gln Ser Val Leu Thr Gln Ala Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Asp 20 25 30 Tyr Asp Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Thr Asp Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Arg 85 90 95 Leu Thr Gly Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 115 120 125 Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 130 135 140 Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro 145 150 155 160 Val Lys Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn 165 170 175 Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys 180 185 190 Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val 195 200 205 Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2041 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2041 Thr Ser Gly Val Gly Val Gly 1 5 <210> 2042 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2042 Leu Ile Leu Trp Asn Asp His Thr Ile Tyr Ser Pro Ser Leu Lys Ser 1 5 10 15 <210> 2043 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2043 Asp Lys Trp Glu Leu Arg Asp Ala Phe Asp Ile 1 5 10 <210> 2044 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2044 Arg Ala Ser Gln Gly Ile Ser Arg Tyr Leu Ala 1 5 10 <210> 2045 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2045 Val Ala Ser Thr Leu Gln Ser 1 5 <210> 2046 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2046 Gln Gln Leu Ile Ser Tyr Pro Tyr Thr 1 5 <210> 2047 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2047 Gly Phe Ser Leu Thr Thr Ser Gly Val 1 5 <210> 2048 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2048 Leu Trp Asn Asp His 1 5 <210> 2049 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2049 Asp Lys Trp Glu Leu Arg Asp Ala Phe Asp 1 5 10 <210> 2050 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2050 Ser Gln Gly Ile Ser Arg Tyr 1 5 <210> 2051 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2051 Val Ala Ser One <210> 2052 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2052 Leu Ile Ser Tyr Pro Tyr 1 5 <210> 2053 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2053 Gly Phe Ser Leu Thr Thr Ser Gly Val Gly Val Gly 1 5 10 <210> 2054 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2054 Leu Ile Leu Trp Asn Asp His Thr Ile 1 5 <210> 2055 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2055 Asp Lys Trp Glu Leu Arg Asp Ala Phe Asp Ile 1 5 10 <210> 2056 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2056 Arg Ala Ser Gln Gly Ile Ser Arg Tyr Leu Ala 1 5 10 <210> 2057 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2057 Val Ala Ser Thr Leu Gln Ser 1 5 <210> 2058 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2058 Gln Gln Leu Ile Ser Tyr Pro Tyr Thr 1 5 <210> 2059 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2059 Thr Thr Ser Gly Val Gly Val Gly 1 5 <210> 2060 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2060 Trp Leu Ala Leu Ile Leu Trp Asn Asp His Thr Ile 1 5 10 <210> 2061 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2061 Ala Arg Asp Lys Trp Glu Leu Arg Asp Ala Phe Asp 1 5 10 <210> 2062 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2062 Ser Arg Tyr Leu Ala Trp Tyr 1 5 <210> 2063 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2063 Leu Leu Ile Tyr Val Ala Ser Thr Leu Gln 1 5 10 <210> 2064 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2064 Gln Gln Leu Ile Ser Tyr Pro Tyr 1 5 <210> 2065 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2065 Gly Phe Ser Leu Thr Thr Ser Gly Val Gly 1 5 10 <210> 2066 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2066 Ile Leu Trp Asn Asp His Thr 1 5 <210> 2067 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2067 Ala Arg Asp Lys Trp Glu Leu Arg Asp Ala Phe Asp Ile 1 5 10 <210> 2068 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2068 Gln Gly Ile Ser Arg Tyr 1 5 <210> 2069 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2069 Val Ala Ser One <210> 2070 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2070 Gln Gln Leu Ile Ser Tyr Pro Tyr Thr 1 5 <210> 2071 <211> 121 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2071 Gln Val Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Leu Trp Asn Asp His Thr Ile Tyr Ser Pro Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Ala Tyr Phe 85 90 95 Cys Ala Arg Asp Lys Trp Glu Leu Arg Asp Ala Phe Asp Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2072 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2072 Glu Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Phe Thr Cys Arg Ala Ser Gln Gly Ile Ser Arg Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Asn Leu Leu Ile 35 40 45 Tyr Val Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Leu Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Ile Ser Tyr Pro Tyr 85 90 95 Thr Phe Ser Gln Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 2073 <211> 451 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2073 Gln Val Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Leu Trp Asn Asp His Thr Ile Tyr Ser Pro Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Ala Tyr Phe 85 90 95 Cys Ala Arg Asp Lys Trp Glu Leu Arg Asp Ala Phe Asp Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys 450 <210> 2074 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2074 Glu Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Phe Thr Cys Arg Ala Ser Gln Gly Ile Ser Arg Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Asn Leu Leu Ile 35 40 45 Tyr Val Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Leu Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Ile Ser Tyr Pro Tyr 85 90 95 Thr Phe Ser Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 2075 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2075 Thr Tyr Ser Val Asn 1 5 <210> 2076 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2076 Ser Ile Ser Ser Asp Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Met Lys 1 5 10 15 Gly <210> 2077 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2077 Asp Ser Val Thr Gly Pro Phe Asp Tyr 1 5 <210> 2078 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2078 Gln Ala Ser Gln Asp Ile Ser His Tyr Leu Asn 1 5 10 <210> 2079 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2079 Asp Ser Tyr Ile Leu Glu Thr 1 5 <210> 2080 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2080 Gln Gln Tyr Asp Asn Leu Pro Tyr Thr 1 5 <210> 2081 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2081 Gly Phe Thr Phe Ser Thr Tyr 1 5 <210> 2082 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2082 Ser Ser Asp Ser Ser Tyr 1 5 <210> 2083 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2083 Asp Ser Val Thr Gly Pro Phe Asp 1 5 <210> 2084 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2084 Ser Gln Asp Ile Ser His Tyr 1 5 <210> 2085 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2085 Asp Ser Tyr One <210> 2086 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2086 Tyr Asp Asn Leu Pro Tyr 1 5 <210> 2087 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2087 Gly Phe Thr Phe Ser Thr Tyr Ser Val Asn 1 5 10 <210> 2088 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2088 Ser Ile Ser Ser Asp Ser Ser Tyr Ile Phe 1 5 10 <210> 2089 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2089 Asp Ser Val Thr Gly Pro Phe Asp Tyr 1 5 <210> 2090 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2090 Gln Ala Ser Gln Asp Ile Ser His Tyr Leu Asn 1 5 10 <210> 2091 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2091 Asp Ser Tyr Ile Leu Glu Thr 1 5 <210> 2092 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2092 Gln Gln Tyr Asp Asn Leu Pro Tyr Thr 1 5 <210> 2093 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2093 Ser Thr Tyr Ser Val Asn 1 5 <210> 2094 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2094 Trp Val Ser Ser Ile Ser Ser Asp Ser Ser Tyr Ile Phe 1 5 10 <210> 2095 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2095 Ala Arg Asp Ser Val Thr Gly Pro Phe Asp 1 5 10 <210> 2096 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2096 Ser His Tyr Leu Asn Trp Tyr 1 5 <210> 2097 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2097 Leu Leu Ile Tyr Asp Ser Tyr Ile Leu Glu 1 5 10 <210> 2098 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2098 Gln Gln Tyr Asp Asn Leu Pro Tyr 1 5 <210> 2099 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2099 Gly Phe Thr Phe Ser Thr Tyr Ser 1 5 <210> 2100 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2100 Ile Ser Ser Asp Ser Ser Tyr Ile 1 5 <210> 2101 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2101 Ala Arg Asp Ser Val Thr Gly Pro Phe Asp Tyr 1 5 10 <210> 2102 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2102 Gln Asp Ile Ser His Tyr 1 5 <210> 2103 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2103 Asp Ser Tyr One <210> 2104 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2104 Gln Gln Tyr Asp Asn Leu Pro Tyr Thr 1 5 <210> 2105 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2105 Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ser Val Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Asp Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Ser Val Thr Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 2106 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2106 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser His Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ser Tyr Ile Leu Glu Thr Gly Val Thr Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Asn Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Ile Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 2107 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2107 Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ser Val Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Asp Ser Ser Tyr Ile Phe Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Ser Val Thr Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 2108 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2108 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser His Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ser Tyr Ile Leu Glu Thr Gly Val Thr Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Asn Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Ile Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 2109 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2109 Asn Tyr Phe Trp Asn 1 5 <210> 2110 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2110 Tyr Ile Phe Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2111 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2111 Val Gly Arg Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2112 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2112 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 2113 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2113 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2114 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2114 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Gly Val 1 5 10 <210> 2115 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2115 Gly Gly Ser Ile Thr Asn Tyr 1 5 <210> 2116 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2116 Phe Tyr Ser Gly Ser 1 5 <210> 2117 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2117 Val Gly Arg Trp Glu Leu Arg Thr Ala Phe Asp 1 5 10 <210> 2118 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2118 Ser Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 2119 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2119 Ser Asn Asn One <210> 2120 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2120 Trp Asp Asp Ser Leu Asn Gly Pro Gly 1 5 <210> 2121 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2121 Gly Gly Ser Ile Thr Asn Tyr Phe Trp Asn 1 5 10 <210> 2122 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2122 Tyr Ile Phe Tyr Ser Gly Ser Thr Ser 1 5 <210> 2123 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2123 Val Gly Arg Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2124 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2124 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 2125 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2125 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2126 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2126 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Gly Val 1 5 10 <210> 2127 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2127 Thr Asn Tyr Phe Trp Asn 1 5 <210> 2128 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2128 Trp Ile Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Ser 1 5 10 <210> 2129 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2129 Ala Arg Val Gly Arg Trp Glu Leu Arg Thr Ala Phe Asp 1 5 10 <210> 2130 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2130 Ile Gly Ser Asn Thr Val Asn Trp Tyr 1 5 <210> 2131 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2131 Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro 1 5 10 <210> 2132 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2132 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Gly 1 5 10 <210> 2133 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2133 Gly Gly Ser Ile Thr Asn Tyr Phe 1 5 <210> 2134 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2134 Ile Phe Tyr Ser Gly Ser Thr 1 5 <210> 2135 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2135 Ala Arg Val Gly Arg Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2136 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2136 Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 2137 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2137 Ser Asn Asn One <210> 2138 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2138 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Gly Val 1 5 10 <210> 2139 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2139 Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Thr Asn Tyr 20 25 30 Phe Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Arg Phe Ser Leu 65 70 75 80 Lys Leu Ile Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Gly Arg Trp Glu Leu Arg Thr Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2140 <211> 111 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2140 Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2141 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2141 Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Thr Asn Tyr 20 25 30 Phe Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Arg Phe Ser Leu 65 70 75 80 Lys Leu Ile Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Gly Arg Trp Glu Leu Arg Thr Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2142 <211> 217 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2142 Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2143 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2143 Thr Tyr Arg Met Asn 1 5 <210> 2144 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2144 Ser Ile Ser Ser Ser Ser Ile Tyr Ile His Ser Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 2145 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2145 Glu Arg Val Tyr Thr Val Ser Phe Asp Tyr 1 5 10 <210> 2146 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2146 Gln Ala Ser Gln Asp Ile Ser His Tyr Leu Asn 1 5 10 <210> 2147 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2147 Asp Ser Tyr Ile Leu Glu Thr 1 5 <210> 2148 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2148 Gln Gln Tyr Asp Asn Leu Pro Tyr Thr 1 5 <210> 2149 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2149 Gly Phe Thr Phe Thr Thr Tyr 1 5 <210> 2150 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2150 Ser Ser Ser Ser Ile Tyr 1 5 <210> 2151 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2151 Glu Arg Val Tyr Thr Val Ser Phe Asp 1 5 <210> 2152 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2152 Ser Gln Asp Ile Ser His Tyr 1 5 <210> 2153 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2153 Asp Ser Tyr One <210> 2154 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2154 Tyr Asp Asn Leu Pro Tyr 1 5 <210> 2155 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2155 Gly Phe Thr Phe Thr Thr Tyr Arg Met Asn 1 5 10 <210> 2156 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2156 Ser Ile Ser Ser Ser Ser Ile Tyr Ile His 1 5 10 <210> 2157 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2157 Glu Arg Val Tyr Thr Val Ser Phe Asp Tyr 1 5 10 <210> 2158 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2158 Gln Ala Ser Gln Asp Ile Ser His Tyr Leu Asn 1 5 10 <210> 2159 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2159 Asp Ser Tyr Ile Leu Glu Thr 1 5 <210> 2160 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2160 Gln Gln Tyr Asp Asn Leu Pro Tyr Thr 1 5 <210> 2161 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2161 Thr Thr Tyr Arg Met Asn 1 5 <210> 2162 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2162 Trp Val Ser Ser Ile Ser Ser Ser Ser Ile Tyr Ile His 1 5 10 <210> 2163 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2163 Ala Arg Glu Arg Val Tyr Thr Val Ser Phe Asp 1 5 10 <210> 2164 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2164 Ser His Tyr Leu Asn Trp Tyr 1 5 <210> 2165 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2165 Leu Leu Ile Tyr Asp Ser Tyr Ile Leu Glu 1 5 10 <210> 2166 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2166 Gln Gln Tyr Asp Asn Leu Pro Tyr 1 5 <210> 2167 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2167 Gly Phe Thr Phe Thr Thr Tyr Arg 1 5 <210> 2168 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2168 Ile Ser Ser Ser Ser Ile Tyr Ile 1 5 <210> 2169 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2169 Ala Arg Glu Arg Val Tyr Thr Val Ser Phe Asp Tyr 1 5 10 <210> 2170 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2170 Gln Asp Ile Ser His Tyr 1 5 <210> 2171 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2171 Asp Ser Tyr One <210> 2172 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2172 Gln Gln Tyr Asp Asn Leu Pro Tyr Thr 1 5 <210> 2173 <211> 119 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2173 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Thr Tyr 20 25 30 Arg Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ile Tyr Ile His Ser Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Glu Arg Val Tyr Thr Val Ser Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 2174 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2174 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser His Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ser Tyr Ile Leu Glu Thr Gly Val Thr Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Asn Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Ile Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 2175 <211> 449 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2175 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Thr Tyr 20 25 30 Arg Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ile Tyr Ile His Ser Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Glu Arg Val Tyr Thr Val Ser Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 Lys <210> 2176 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2176 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser His Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ser Tyr Ile Leu Glu Thr Gly Val Thr Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Asn Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Ile Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 2177 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2177 Thr His Gly Val Gly Val Gly 1 5 <210> 2178 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2178 Leu Ile Tyr Trp Asn Ala Asp Lys His Tyr Ser Pro Ser Leu Lys Ser 1 5 10 15 <210> 2179 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2179 Glu Gly Asp Trp Gly His Tyr Phe Asp Phe 1 5 10 <210> 2180 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2180 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Asp Val Ser 1 5 10 <210> 2181 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2181 Asp Asn Asn Arg Arg Pro Ser 1 5 <210> 2182 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2182 Glu Thr Trp Asp Ser Ser Leu Ser Ala Ile Trp Val 1 5 10 <210> 2183 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2183 Gly Phe Ser Leu Thr Thr His Gly Val 1 5 <210> 2184 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2184 Tyr Trp Asn Ala Asp 1 5 <210> 2185 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2185 Glu Gly Asp Trp Gly His Tyr Phe Asp 1 5 <210> 2186 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2186 Ser Ser Ser Asn Ile Gly Asn Asn Asp 1 5 <210> 2187 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2187 Asp Asn Asn One <210> 2188 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2188 Trp Asp Ser Ser Leu Ser Ala Ile Trp 1 5 <210> 2189 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2189 Gly Phe Ser Leu Thr Thr His Gly Val Gly Val Gly 1 5 10 <210> 2190 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2190 Leu Ile Tyr Trp Asn Ala Asp Lys His 1 5 <210> 2191 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2191 Glu Gly Asp Trp Gly His Tyr Phe Asp Phe 1 5 10 <210> 2192 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2192 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Asp Val Ser 1 5 10 <210> 2193 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2193 Asp Asn Asn Arg Arg Pro Ser 1 5 <210> 2194 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2194 Glu Thr Trp Asp Ser Ser Leu Ser Ala Ile Trp Val 1 5 10 <210> 2195 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2195 Thr Thr His Gly Val Gly Val Gly 1 5 <210> 2196 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2196 Trp Leu Ala Leu Ile Tyr Trp Asn Ala Asp Lys His 1 5 10 <210> 2197 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2197 Ala His Glu Gly Asp Trp Gly His Tyr Phe Asp 1 5 10 <210> 2198 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2198 Ile Gly Asn Asn Asp Val Ser Trp Tyr 1 5 <210> 2199 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2199 Leu Leu Ile Tyr Asp Asn Asn Arg Arg Pro 1 5 10 <210> 2200 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2200 Glu Thr Trp Asp Ser Ser Leu Ser Ala Ile Trp 1 5 10 <210> 2201 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2201 Gly Phe Ser Leu Thr Thr His Gly Val Gly 1 5 10 <210> 2202 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2202 Ile Tyr Trp Asn Ala Asp Lys 1 5 <210> 2203 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2203 Ala His Glu Gly Asp Trp Gly His Tyr Phe Asp Phe 1 5 10 <210> 2204 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2204 Ser Ser Asn Ile Gly Asn Asn Asp 1 5 <210> 2205 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2205 Asp Asn Asn One <210> 2206 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2206 Glu Thr Trp Asp Ser Ser Leu Ser Ala Ile Trp Val 1 5 10 <210> 2207 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2207 Gln Val Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr His 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Arg Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Tyr Trp Asn Ala Asp Lys His Tyr Ser Pro Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr His Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala His Glu Gly Asp Trp Gly His Tyr Phe Asp Phe Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2208 <211> 111 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2208 Gln Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Asp Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Arg Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Glu Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Ile Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2209 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2209 Gln Val Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr His 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Arg Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Tyr Trp Asn Ala Asp Lys His Tyr Ser Pro Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr His Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala His Glu Gly Asp Trp Gly His Tyr Phe Asp Phe Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2210 <211> 217 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2210 Gln Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Asp Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Arg Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Glu Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Ile Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2211 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2211 Ser Tyr Phe Trp Ser 1 5 <210> 2212 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2212 Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2213 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2213 Val Gly Arg Trp Glu Leu Arg Gly Ala Phe Asp Ile 1 5 10 <210> 2214 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2214 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 2215 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2215 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2216 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2216 Ala Ala Trp Asp Asp Ser Leu Asn Ser Pro Gly Val 1 5 10 <210> 2217 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2217 Gly Gly Ser Ile Ser Ser Tyr 1 5 <210> 2218 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2218 Phe Tyr Ser Gly Ser 1 5 <210> 2219 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2219 Val Gly Arg Trp Glu Leu Arg Gly Ala Phe Asp 1 5 10 <210> 2220 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2220 Ser Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 2221 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2221 Ser Asn Asn One <210> 2222 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2222 Trp Asp Asp Ser Leu Asn Ser Pro Gly 1 5 <210> 2223 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2223 Gly Gly Ser Ile Ser Ser Tyr Phe Trp Ser 1 5 10 <210> 2224 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2224 Tyr Ile Phe Tyr Ser Gly Ser Thr Asn 1 5 <210> 2225 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2225 Val Gly Arg Trp Glu Leu Arg Gly Ala Phe Asp Ile 1 5 10 <210> 2226 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2226 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 2227 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2227 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2228 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2228 Ala Ala Trp Asp Asp Ser Leu Asn Ser Pro Gly Val 1 5 10 <210> 2229 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2229 Ser Ser Tyr Phe Trp Ser 1 5 <210> 2230 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2230 Trp Ile Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn 1 5 10 <210> 2231 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2231 Ala Arg Val Gly Arg Trp Glu Leu Arg Gly Ala Phe Asp 1 5 10 <210> 2232 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2232 Ile Gly Ser Asn Thr Val Asn Trp Tyr 1 5 <210> 2233 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2233 Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro 1 5 10 <210> 2234 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2234 Ala Ala Trp Asp Asp Ser Leu Asn Ser Pro Gly 1 5 10 <210> 2235 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2235 Gly Gly Ser Ile Ser Ser Tyr Phe 1 5 <210> 2236 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2236 Ile Phe Tyr Ser Gly Ser Thr 1 5 <210> 2237 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2237 Ala Arg Val Gly Arg Trp Glu Leu Arg Gly Ala Phe Asp Ile 1 5 10 <210> 2238 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2238 Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 2239 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2239 Ser Asn Asn One <210> 2240 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2240 Ala Ala Trp Asp Asp Ser Leu Asn Ser Pro Gly Val 1 5 10 <210> 2241 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2241 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Phe Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Leu Val Asp Thr Ser Lys Asn His Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Gly Arg Trp Glu Leu Arg Gly Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2242 <211> 111 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2242 Gln Pro Val Leu Thr Gln Ser Ser Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Ser Pro Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2243 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2243 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Phe Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Leu Val Asp Thr Ser Lys Asn His Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Gly Arg Trp Glu Leu Arg Gly Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2244 <211> 217 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2244 Gln Pro Val Leu Thr Gln Ser Ser Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Ser Pro Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2245 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2245 Ser Tyr Tyr Trp Asn 1 5 <210> 2246 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2246 Arg Ile Tyr Thr Ile Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2247 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2247 Glu Gly Tyr Tyr Asp Ser Ser Gly Ser Phe Phe Pro Gly Ala Phe Gly 1 5 10 15 Ile <210> 2248 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2248 Thr Gly Thr Ser Asn Asp Val Gly Ser Tyr Asn Leu Val Ser 1 5 10 <210> 2249 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2249 Ala Gly Ser Lys Arg Pro Ser 1 5 <210> 2250 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2250 Cys Ser Phe Ala Gly Ala Thr Asn Val Val 1 5 10 <210> 2251 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2251 Ser Gly Ser Ile Ser Ser Tyr 1 5 <210> 2252 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2252 Tyr Thr Ile Gly Asn 1 5 <210> 2253 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2253 Glu Gly Tyr Tyr Asp Ser Ser Gly Ser Phe Phe Pro Gly Ala Phe Gly 1 5 10 15 <210> 2254 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2254 Thr Ser Asn Asp Val Gly Ser Tyr Asn Leu 1 5 10 <210> 2255 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2255 Ala Gly Ser One <210> 2256 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2256 Phe Ala Gly Ala Thr Asn Val 1 5 <210> 2257 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2257 Ser Gly Ser Ile Ser Ser Tyr Tyr Trp Asn 1 5 10 <210> 2258 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2258 Arg Ile Tyr Thr Ile Gly Asn Thr Asn 1 5 <210> 2259 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2259 Glu Gly Tyr Tyr Asp Ser Ser Gly Ser Phe Phe Pro Gly Ala Phe Gly 1 5 10 15 Ile <210> 2260 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2260 Thr Gly Thr Ser Asn Asp Val Gly Ser Tyr Asn Leu Val Ser 1 5 10 <210> 2261 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2261 Ala Gly Ser Lys Arg Pro Ser 1 5 <210> 2262 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2262 Cys Ser Phe Ala Gly Ala Thr Asn Val Val 1 5 10 <210> 2263 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2263 Ser Ser Tyr Tyr Trp Asn 1 5 <210> 2264 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2264 Trp Val Gly Arg Ile Tyr Thr Ile Gly Asn Thr Asn 1 5 10 <210> 2265 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2265 Ala Arg Glu Gly Tyr Tyr Asp Ser Ser Gly Ser Phe Phe Pro Gly Ala 1 5 10 15 Phe Gly <210> 2266 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2266 Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr 1 5 10 <210> 2267 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2267 Leu Met Ile Tyr Ala Gly Ser Lys Arg Pro 1 5 10 <210> 2268 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2268 Cys Ser Phe Ala Gly Ala Thr Asn Val 1 5 <210> 2269 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2269 Ser Gly Ser Ile Ser Ser Tyr Tyr 1 5 <210> 2270 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2270 Ile Tyr Thr Ile Gly Asn Thr 1 5 <210> 2271 <211> 19 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2271 Ala Arg Glu Gly Tyr Tyr Asp Ser Ser Gly Ser Phe Phe Pro Gly Ala 1 5 10 15 Phe Gly Ile <210> 2272 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2272 Ser Asn Asp Val Gly Ser Tyr Asn Leu 1 5 <210> 2273 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2273 Ala Gly Ser One <210> 2274 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2274 Cys Ser Phe Ala Gly Ala Thr Asn Val Val 1 5 10 <210> 2275 <211> 125 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2275 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Ser Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Tyr Thr Ile Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Asn Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 85 90 95 Arg Glu Gly Tyr Tyr Asp Ser Ser Gly Ser Phe Phe Pro Gly Ala Phe 100 105 110 Gly Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 2276 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2276 Ser Ser Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Asn Asp Val Gly Ser Tyr 20 25 30 Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Ala Gly Ser Lys Arg Pro Ser Gly Ile Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Phe Ala Gly Ala 85 90 95 Thr Asn Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2277 <211> 455 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2277 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Ser Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Tyr Thr Ile Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Asn Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 85 90 95 Arg Glu Gly Tyr Tyr Asp Ser Ser Gly Ser Phe Phe Pro Gly Ala Phe 100 105 110 Gly Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr 115 120 125 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 130 135 140 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 145 150 155 160 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 165 170 175 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 180 185 190 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 195 200 205 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu 210 215 220 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 225 230 235 240 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 245 250 255 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 260 265 270 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 275 280 285 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 290 295 300 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 305 310 315 320 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 325 330 335 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 340 345 350 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 355 360 365 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 370 375 380 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 385 390 395 400 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 405 410 415 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 420 425 430 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 435 440 445 Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 2278 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2278 Ser Ser Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Asn Asp Val Gly Ser Tyr 20 25 30 Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Ala Gly Ser Lys Arg Pro Ser Gly Ile Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Phe Ala Gly Ala 85 90 95 Thr Asn Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2279 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2279 Gly Tyr Tyr Trp Asn 1 5 <210> 2280 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2280 Arg Ile Phe Thr Thr Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2281 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2281 Glu Arg Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp Tyr 1 5 10 <210> 2282 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2282 Thr Gly Ser Ser Ser Asn Ile Gly Ala Asp Tyr Asp Ile Lys 1 5 10 <210> 2283 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2283 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 2284 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2284 Gln Ser Tyr Asp Ser Ser Met Ser Gly Tyr Val Val 1 5 10 <210> 2285 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2285 Gly Asp Ser Ile Ser Gly Tyr 1 5 <210> 2286 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2286 Phe Thr Thr Gly Asn 1 5 <210> 2287 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2287 Glu Arg Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp 1 5 10 <210> 2288 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2288 Ser Ser Ser Asn Ile Gly Ala Asp Tyr Asp 1 5 10 <210> 2289 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2289 Gly Asn Ser One <210> 2290 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2290 Tyr Asp Ser Ser Met Ser Gly Tyr Val 1 5 <210> 2291 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2291 Gly Asp Ser Ile Ser Gly Tyr Tyr Trp Asn 1 5 10 <210> 2292 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2292 Arg Ile Phe Thr Thr Gly Asn Thr Asn 1 5 <210> 2293 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2293 Glu Arg Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp Tyr 1 5 10 <210> 2294 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2294 Thr Gly Ser Ser Ser Asn Ile Gly Ala Asp Tyr Asp Ile Lys 1 5 10 <210> 2295 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2295 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 2296 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2296 Gln Ser Tyr Asp Ser Ser Met Ser Gly Tyr Val Val 1 5 10 <210> 2297 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2297 Ser Gly Tyr Tyr Trp Asn 1 5 <210> 2298 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2298 Trp Ile Gly Arg Ile Phe Thr Thr Gly Asn Thr Asn 1 5 10 <210> 2299 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2299 Ala Arg Glu Arg Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp 1 5 10 15 <210> 2300 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2300 Ile Gly Ala Asp Tyr Asp Ile Lys Trp Tyr 1 5 10 <210> 2301 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2301 Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro 1 5 10 <210> 2302 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2302 Gln Ser Tyr Asp Ser Ser Met Ser Gly Tyr Val 1 5 10 <210> 2303 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2303 Gly Asp Ser Ile Ser Gly Tyr Tyr 1 5 <210> 2304 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2304 Ile Phe Thr Thr Gly Asn Thr 1 5 <210> 2305 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2305 Ala Arg Glu Arg Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp Tyr 1 5 10 15 <210> 2306 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2306 Ser Ser Asn Ile Gly Ala Asp Tyr Asp 1 5 <210> 2307 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2307 Gly Asn Ser One <210> 2308 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2308 Gln Ser Tyr Asp Ser Ser Met Ser Gly Tyr Val Val 1 5 10 <210> 2309 <211> 122 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2309 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Tyr 20 25 30 Tyr Trp Asn Tyr Ile Arg Gln Pro Ala Gly Lys Gly Leu Asp Trp Ile 35 40 45 Gly Arg Ile Phe Thr Thr Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Glu Arg Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2310 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2310 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Asp 20 25 30 Tyr Asp Ile Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Val Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Met Ser Gly Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2311 <211> 452 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2311 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Tyr 20 25 30 Tyr Trp Asn Tyr Ile Arg Gln Pro Ala Gly Lys Gly Leu Asp Trp Ile 35 40 45 Gly Arg Ile Phe Thr Thr Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Glu Arg Trp Asp Ser Ser Ser Ser Ala Leu Tyr Phe Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Lys 450 <210> 2312 <211> 218 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2312 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Asp 20 25 30 Tyr Asp Ile Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Val Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Met Ser Gly Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 115 120 125 Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 130 135 140 Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro 145 150 155 160 Val Lys Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn 165 170 175 Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys 180 185 190 Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val 195 200 205 Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2313 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2313 Gly Tyr Phe Trp Asn 1 5 <210> 2314 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2314 Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2315 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2315 Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2316 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2316 Ser Gly Ser Thr Ser Asn Ile Gly Ser Asp Thr Val Asn 1 5 10 <210> 2317 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2317 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2318 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2318 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2319 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2319 Asn Gly Ser Ile Ser Gly Tyr 1 5 <210> 2320 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2320 Phe Tyr Ser Gly Ser 1 5 <210> 2321 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2321 Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp 1 5 10 <210> 2322 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2322 Ser Thr Ser Asn Ile Gly Ser Asp Thr 1 5 <210> 2323 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2323 Ser Asn Asn One <210> 2324 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2324 Trp Asp Asp Ser Leu Asn Gly Pro 1 5 <210> 2325 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2325 Asn Gly Ser Ile Ser Gly Tyr Phe Trp Asn 1 5 10 <210> 2326 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2326 Tyr Ile Phe Tyr Ser Gly Ser Thr Asn 1 5 <210> 2327 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2327 Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2328 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2328 Ser Gly Ser Thr Ser Asn Ile Gly Ser Asp Thr Val Asn 1 5 10 <210> 2329 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2329 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2330 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2330 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2331 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2331 Ser Gly Tyr Phe Trp Asn 1 5 <210> 2332 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2332 Trp Ile Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn 1 5 10 <210> 2333 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2333 Ala Lys Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp 1 5 10 <210> 2334 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2334 Ile Gly Ser Asp Thr Val Asn Trp Tyr 1 5 <210> 2335 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2335 Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro 1 5 10 <210> 2336 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2336 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro 1 5 10 <210> 2337 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2337 Asn Gly Ser Ile Ser Gly Tyr Phe 1 5 <210> 2338 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2338 Ile Phe Tyr Ser Gly Ser Thr 1 5 <210> 2339 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2339 Ala Lys Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2340 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2340 Thr Ser Asn Ile Gly Ser Asp Thr 1 5 <210> 2341 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2341 Ser Asn Asn One <210> 2342 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2342 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2343 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2343 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Met Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Asn Gly Ser Ile Ser Gly Tyr 20 25 30 Phe Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Leu Val Ser Leu 65 70 75 80 Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 85 90 95 Lys Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2344 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2344 Gln Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Ser Asp 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Thr Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2345 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2345 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Met Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Asn Gly Ser Ile Ser Gly Tyr 20 25 30 Phe Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Leu Val Ser Leu 65 70 75 80 Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 85 90 95 Lys Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2346 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2346 Gln Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Ser Asp 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Thr Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2347 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2347 Gly Tyr Phe Trp Asn 1 5 <210> 2348 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2348 Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2349 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2349 Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2350 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2350 Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys 1 5 10 <210> 2351 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2351 Gln Asp Ser Lys Arg Pro Ser 1 5 <210> 2352 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2352 Gln Ala Trp Asp Ser Ser Thr Val Val 1 5 <210> 2353 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2353 Asn Gly Ser Ile Ser Gly Tyr 1 5 <210> 2354 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2354 Phe Tyr Ser Gly Ser 1 5 <210> 2355 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2355 Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp 1 5 10 <210> 2356 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2356 Asp Lys Leu Gly Asp Lys Tyr 1 5 <210> 2357 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2357 Gln Asp Ser One <210> 2358 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2358 Trp Asp Ser Ser Thr Val 1 5 <210> 2359 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2359 Asn Gly Ser Ile Ser Gly Tyr Phe Trp Asn 1 5 10 <210> 2360 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2360 Tyr Ile Phe Tyr Ser Gly Ser Thr Asn 1 5 <210> 2361 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2361 Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2362 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2362 Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys 1 5 10 <210> 2363 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2363 Gln Asp Ser Lys Arg Pro Ser 1 5 <210> 2364 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2364 Gln Ala Trp Asp Ser Ser Thr Val Val 1 5 <210> 2365 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2365 Ser Gly Tyr Phe Trp Asn 1 5 <210> 2366 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2366 Trp Ile Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn 1 5 10 <210> 2367 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2367 Ala Lys Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp 1 5 10 <210> 2368 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2368 Asp Lys Tyr Ala Cys Trp Tyr 1 5 <210> 2369 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2369 Leu Val Ile Tyr Gln Asp Ser Lys Arg Pro 1 5 10 <210> 2370 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2370 Gln Ala Trp Asp Ser Ser Thr Val 1 5 <210> 2371 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2371 Asn Gly Ser Ile Ser Gly Tyr Phe 1 5 <210> 2372 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2372 Ile Phe Tyr Ser Gly Ser Thr 1 5 <210> 2373 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2373 Ala Lys Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2374 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2374 Lys Leu Gly Asp Lys Tyr 1 5 <210> 2375 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2375 Gln Asp Ser One <210> 2376 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2376 Gln Ala Trp Asp Ser Ser Thr Val Val 1 5 <210> 2377 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2377 Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Met Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Asn Gly Ser Ile Ser Gly Tyr 20 25 30 Phe Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Leu Val Ser Leu 65 70 75 80 Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 85 90 95 Lys Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2378 <211> 106 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2378 Ser Ser Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 2379 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2379 Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Met Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Asn Gly Ser Ile Ser Gly Tyr 20 25 30 Phe Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Leu Val Ser Leu 65 70 75 80 Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 85 90 95 Lys Leu Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2380 <211> 212 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2380 Ser Ser Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala 100 105 110 Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn 115 120 125 Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val 130 135 140 Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu 145 150 155 160 Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser 165 170 175 Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser 180 185 190 Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro 195 200 205 Thr Glu Cys Ser 210 <210> 2381 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2381 Ser Ser Tyr Trp Ser 1 5 <210> 2382 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2382 Arg Phe Tyr Ser Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2383 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2383 Tyr Ser Gly Ser Tyr Trp Tyr Phe Asp Leu 1 5 10 <210> 2384 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2384 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 2385 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2385 Asp Thr Ser Asn Arg Ala Thr 1 5 <210> 2386 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2386 Gln Gln Arg Ser Asp Trp Leu Leu Thr 1 5 <210> 2387 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2387 Gly Asp Ser Ile Ser Ser Ser 1 5 <210> 2388 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2388 Tyr Ser Ser Gly Ser 1 5 <210> 2389 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2389 Tyr Ser Gly Ser Tyr Trp Tyr Phe Asp 1 5 <210> 2390 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2390 Ser Gln Ser Val Ser Ser Tyr 1 5 <210> 2391 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2391 Asp Thr Ser One <210> 2392 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2392 Arg Ser Asp Trp Leu Leu 1 5 <210> 2393 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2393 Gly Asp Ser Ile Ser Ser Ser Tyr Trp Ser 1 5 10 <210> 2394 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2394 Arg Phe Tyr Ser Ser Gly Ser Thr Ser 1 5 <210> 2395 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2395 Tyr Ser Gly Ser Tyr Trp Tyr Phe Asp Leu 1 5 10 <210> 2396 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2396 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 2397 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2397 Asp Thr Ser Asn Arg Ala Thr 1 5 <210> 2398 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2398 Gln Gln Arg Ser Asp Trp Leu Leu Thr 1 5 <210> 2399 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2399 Ser Ser Ser Tyr Trp Ser 1 5 <210> 2400 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2400 Cys Ile Gly Arg Phe Tyr Ser Ser Gly Ser Thr Ser 1 5 10 <210> 2401 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2401 Ala Arg Tyr Ser Gly Ser Tyr Trp Tyr Phe Asp 1 5 10 <210> 2402 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2402 Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 2403 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2403 Leu Leu Ile Tyr Asp Thr Ser Asn Arg Ala 1 5 10 <210> 2404 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2404 Gln Gln Arg Ser Asp Trp Leu Leu 1 5 <210> 2405 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2405 Gly Asp Ser Ile Ser Ser Ser Tyr 1 5 <210> 2406 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2406 Phe Tyr Ser Ser Gly Ser Thr 1 5 <210> 2407 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2407 Ala Arg Tyr Ser Gly Ser Tyr Trp Tyr Phe Asp Leu 1 5 10 <210> 2408 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2408 Gln Ser Val Ser Ser Tyr 1 5 <210> 2409 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2409 Asp Thr Ser One <210> 2410 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2410 Gln Gln Arg Ser Asp Trp Leu Leu Thr 1 5 <210> 2411 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2411 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Cys Ile 35 40 45 Gly Arg Phe Tyr Ser Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ala Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Tyr Ser Gly Ser Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 2412 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2412 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Thr Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Ala Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asp Trp Leu Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 2413 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2413 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Cys Ile 35 40 45 Gly Arg Phe Tyr Ser Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ala Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Tyr Ser Gly Ser Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr 100 105 110 Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 2414 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2414 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Thr Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Ala Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Cys Gln Gln Arg Ser Asp Trp Leu Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 2415 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2415 Tyr Tyr Phe Trp Asn 1 5 <210> 2416 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2416 Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2417 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2417 Glu Gly Lys Trp Glu Leu Arg Thr Thr Phe Asp Ile 1 5 10 <210> 2418 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2418 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 2419 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2419 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2420 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2420 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2421 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2421 Gly Gly Ser Ile Ser Tyr Tyr 1 5 <210> 2422 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2422 Tyr Tyr Ser Gly Ser 1 5 <210> 2423 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2423 Glu Gly Lys Trp Glu Leu Arg Thr Thr Phe Asp 1 5 10 <210> 2424 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2424 Ser Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 2425 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2425 Ser Asn Asn One <210> 2426 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2426 Trp Asp Asp Ser Leu Asn Gly Pro 1 5 <210> 2427 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2427 Gly Gly Ser Ile Ser Tyr Tyr Phe Trp Asn 1 5 10 <210> 2428 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2428 Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn 1 5 <210> 2429 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2429 Glu Gly Lys Trp Glu Leu Arg Thr Thr Phe Asp Ile 1 5 10 <210> 2430 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2430 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 2431 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2431 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2432 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2432 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2433 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2433 Ser Tyr Tyr Phe Trp Asn 1 5 <210> 2434 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2434 Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn 1 5 10 <210> 2435 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2435 Ala Arg Glu Gly Lys Trp Glu Leu Arg Thr Thr Phe Asp 1 5 10 <210> 2436 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2436 Ile Gly Ser Asn Thr Val Asn Trp Tyr 1 5 <210> 2437 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2437 Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro 1 5 10 <210> 2438 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2438 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro 1 5 10 <210> 2439 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2439 Gly Gly Ser Ile Ser Tyr Tyr Phe 1 5 <210> 2440 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2440 Ile Tyr Tyr Ser Gly Ser Thr 1 5 <210> 2441 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2441 Ala Arg Glu Gly Lys Trp Glu Leu Arg Thr Thr Phe Asp Ile 1 5 10 <210> 2442 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2442 Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 2443 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2443 Ser Asn Asn One <210> 2444 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2444 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2445 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2445 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Tyr Tyr 20 25 30 Phe Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Glu Gly Lys Trp Glu Leu Arg Thr Thr Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2446 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2446 Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2447 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2447 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Tyr Tyr 20 25 30 Phe Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Glu Gly Lys Trp Glu Leu Arg Thr Thr Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2448 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2448 Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2449 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2449 Ser Tyr Tyr Trp Ser 1 5 <210> 2450 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2450 Arg Phe Tyr Thr Gly Gly Arg Asn Asn Tyr Asn Pro Ser Phe Lys Ser 1 5 10 15 <210> 2451 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2451 Asp Met Glu Tyr Tyr Tyr Asp Arg Ser Gly Tyr Ser Tyr Trp Tyr Phe 1 5 10 15 Asp Leu <210> 2452 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2452 Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His 1 5 10 <210> 2453 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2453 Asp Asp Ser Asp Arg Pro Ser 1 5 <210> 2454 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2454 Gln Val Trp Asp Ser Ser Ser Asp His Val Val 1 5 10 <210> 2455 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2455 Gly Gly Ser Ile Ser Ser Tyr 1 5 <210> 2456 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2456 Tyr Thr Gly Gly Arg 1 5 <210> 2457 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2457 Asp Met Glu Tyr Tyr Tyr Asp Arg Ser Gly Tyr Ser Tyr Trp Tyr Phe 1 5 10 15 Asp <210> 2458 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2458 Asn Asn Ile Gly Ser Lys Ser 1 5 <210> 2459 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2459 Asp Asp Ser One <210> 2460 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2460 Trp Asp Ser Ser Ser Asp His Val 1 5 <210> 2461 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2461 Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser 1 5 10 <210> 2462 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2462 Arg Phe Tyr Thr Gly Gly Arg Asn Asn 1 5 <210> 2463 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2463 Asp Met Glu Tyr Tyr Tyr Asp Arg Ser Gly Tyr Ser Tyr Trp Tyr Phe 1 5 10 15 Asp Leu <210> 2464 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2464 Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His 1 5 10 <210> 2465 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2465 Asp Asp Ser Asp Arg Pro Ser 1 5 <210> 2466 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2466 Gln Val Trp Asp Ser Ser Ser Asp His Val Val 1 5 10 <210> 2467 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2467 Ser Ser Tyr Tyr Trp Ser 1 5 <210> 2468 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2468 Trp Ile Gly Arg Phe Tyr Thr Gly Gly Arg Asn Asn 1 5 10 <210> 2469 <211> 19 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2469 Ala Arg Asp Met Glu Tyr Tyr Tyr Asp Arg Ser Gly Tyr Ser Tyr Trp 1 5 10 15 Tyr Phe Asp <210> 2470 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2470 Ser Lys Ser Val His Trp Tyr 1 5 <210> 2471 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2471 Leu Val Val Tyr Asp Asp Ser Asp Arg Pro 1 5 10 <210> 2472 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2472 Gln Val Trp Asp Ser Ser Ser Asp His Val 1 5 10 <210> 2473 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2473 Gly Gly Ser Ile Ser Ser Tyr Tyr 1 5 <210> 2474 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2474 Phe Tyr Thr Gly Gly Arg Asn 1 5 <210> 2475 <211> 20 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2475 Ala Arg Asp Met Glu Tyr Tyr Tyr Asp Arg Ser Gly Tyr Ser Tyr Trp 1 5 10 15 Tyr Phe Asp Leu 20 <210> 2476 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2476 Asn Ile Gly Ser Lys Ser 1 5 <210> 2477 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2477 Asp Asp Ser One <210> 2478 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2478 Gln Val Trp Asp Ser Ser Ser Asp His Val Val 1 5 10 <210> 2479 <211> 126 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2479 Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Phe Tyr Thr Gly Gly Arg Asn Asn Tyr Asn Pro Ser Phe Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Gln Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Met Glu Tyr Tyr Tyr Asp Arg Ser Gly Tyr Ser Tyr Trp Tyr 100 105 110 Phe Asp Leu Trp Gly Arg Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2480 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2480 Ser Tyr Glu Leu Met Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln 1 5 10 15 Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr 35 40 45 Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His 85 90 95 Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 2481 <211> 456 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2481 Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Phe Tyr Thr Gly Gly Arg Asn Asn Tyr Asn Pro Ser Phe Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Gln Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Met Glu Tyr Tyr Tyr Asp Arg Ser Gly Tyr Ser Tyr Trp Tyr 100 105 110 Phe Asp Leu Trp Gly Arg Gly Thr Thr Val Thr Val Ser Ser Ala Ser 115 120 125 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 130 135 140 Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 145 150 155 160 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 165 170 175 His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 180 185 190 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile 195 200 205 Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val 210 215 220 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 225 230 235 240 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 245 250 255 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 260 265 270 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 275 280 285 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 290 295 300 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 305 310 315 320 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 325 330 335 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 340 345 350 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 355 360 365 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 370 375 380 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 385 390 395 400 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 405 410 415 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 420 425 430 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 435 440 445 Ser Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 2482 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2482 Ser Tyr Glu Leu Met Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln 1 5 10 15 Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr 35 40 45 Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His 85 90 95 Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys 100 105 110 Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 115 120 125 Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 130 135 140 Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 145 150 155 160 Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 165 170 175 Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 180 185 190 Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 195 200 205 Ala Pro Thr Glu Cys Ser 210 <210> 2483 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2483 Ser Tyr Tyr Trp Asn 1 5 <210> 2484 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2484 Arg Ile Tyr Thr Ile Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2485 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2485 Glu Gly Tyr Tyr Glu Ser Asp Gly Ser Phe Phe Pro Gly Ala Phe Asn 1 5 10 15 Ile <210> 2486 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2486 Thr Gly Thr Ser Asn Asp Val Gly Ser Tyr Asn Leu Val Ser 1 5 10 <210> 2487 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2487 Ala Gly Ser Lys Arg Pro Ser 1 5 <210> 2488 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2488 Cys Ser Tyr Ala Gly Thr Thr Asn Val Val 1 5 10 <210> 2489 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2489 Gly Gly Ser Ile Thr Ser Tyr 1 5 <210> 2490 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2490 Tyr Thr Ile Gly Asn 1 5 <210> 2491 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2491 Glu Gly Tyr Tyr Glu Ser Asp Gly Ser Phe Phe Pro Gly Ala Phe Asn 1 5 10 15 <210> 2492 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2492 Thr Ser Asn Asp Val Gly Ser Tyr Asn Leu 1 5 10 <210> 2493 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2493 Ala Gly Ser One <210> 2494 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2494 Tyr Ala Gly Thr Thr Asn Val 1 5 <210> 2495 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2495 Gly Gly Ser Ile Thr Ser Tyr Tyr Trp Asn 1 5 10 <210> 2496 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2496 Arg Ile Tyr Thr Ile Gly Asn Thr Asn 1 5 <210> 2497 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2497 Glu Gly Tyr Tyr Glu Ser Asp Gly Ser Phe Phe Pro Gly Ala Phe Asn 1 5 10 15 Ile <210> 2498 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2498 Thr Gly Thr Ser Asn Asp Val Gly Ser Tyr Asn Leu Val Ser 1 5 10 <210> 2499 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2499 Ala Gly Ser Lys Arg Pro Ser 1 5 <210> 2500 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2500 Cys Ser Tyr Ala Gly Thr Thr Asn Val Val 1 5 10 <210> 2501 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2501 Thr Ser Tyr Tyr Trp Asn 1 5 <210> 2502 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2502 Trp Ile Gly Arg Ile Tyr Thr Ile Gly Asn Thr Asn 1 5 10 <210> 2503 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2503 Ala Arg Glu Gly Tyr Tyr Glu Ser Asp Gly Ser Phe Phe Pro Gly Ala 1 5 10 15 Phe Asn <210> 2504 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2504 Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr 1 5 10 <210> 2505 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2505 Leu Met Ile Tyr Ala Gly Ser Lys Arg Pro 1 5 10 <210> 2506 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2506 Cys Ser Tyr Ala Gly Thr Thr Asn Val 1 5 <210> 2507 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2507 Gly Gly Ser Ile Thr Ser Tyr Tyr 1 5 <210> 2508 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2508 Ile Tyr Thr Ile Gly Asn Thr 1 5 <210> 2509 <211> 19 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2509 Ala Arg Glu Gly Tyr Tyr Glu Ser Asp Gly Ser Phe Phe Pro Gly Ala 1 5 10 15 Phe Asn Ile <210> 2510 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2510 Ser Asn Asp Val Gly Ser Tyr Asn Leu 1 5 <210> 2511 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2511 Ala Gly Ser One <210> 2512 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2512 Cys Ser Tyr Ala Gly Thr Thr Asn Val Val 1 5 10 <210> 2513 <211> 125 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2513 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Thr Ile Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Ile Asp Thr Ser Lys His Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Gly Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Glu Gly Tyr Tyr Glu Ser Asp Gly Ser Phe Phe Pro Gly Ala Phe 100 105 110 Asn Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 2514 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2514 Ser Ser Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Asn Asp Val Gly Ser Tyr 20 25 30 Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Ala Gly Ser Lys Arg Pro Ser Gly Ile Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Thr 85 90 95 Thr Asn Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2515 <211> 455 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2515 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Thr Ile Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Ile Asp Thr Ser Lys His Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Gly Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Glu Gly Tyr Tyr Glu Ser Asp Gly Ser Phe Phe Pro Gly Ala Phe 100 105 110 Asn Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr 115 120 125 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 130 135 140 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 145 150 155 160 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 165 170 175 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 180 185 190 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 195 200 205 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu 210 215 220 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 225 230 235 240 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 245 250 255 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 260 265 270 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 275 280 285 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 290 295 300 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 305 310 315 320 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 325 330 335 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 340 345 350 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 355 360 365 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 370 375 380 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 385 390 395 400 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 405 410 415 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 420 425 430 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 435 440 445 Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 2516 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2516 Ser Ser Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Asn Asp Val Gly Ser Tyr 20 25 30 Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Ala Gly Ser Lys Arg Pro Ser Gly Ile Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Thr 85 90 95 Thr Asn Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2517 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2517 Gly Asp Tyr Met His 1 5 <210> 2518 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2518 Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn Asn Ala Glu Lys Phe Gln 1 5 10 15 Gly <210> 2519 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2519 Glu Leu Asp Ala Leu Asp Val 1 5 <210> 2520 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2520 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 2521 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2521 Glu Val Ser Lys Arg Pro Ser 1 5 <210> 2522 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2522 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu Val 1 5 10 <210> 2523 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2523 Gly Tyr Thr Phe Thr Gly Asp 1 5 <210> 2524 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2524 Asn Pro Asn Ser Gly Tyr 1 5 <210> 2525 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2525 Glu Leu Asp Ala Leu Asp 1 5 <210> 2526 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2526 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 2527 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2527 Glu Val Ser One <210> 2528 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2528 Tyr Ala Gly Ser Asn Asn Phe Glu 1 5 <210> 2529 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2529 Gly Tyr Thr Phe Thr Gly Asp Tyr Met His 1 5 10 <210> 2530 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2530 Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn 1 5 10 <210> 2531 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2531 Glu Leu Asp Ala Leu Asp Val 1 5 <210> 2532 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2532 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 2533 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2533 Glu Val Ser Lys Arg Pro Ser 1 5 <210> 2534 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2534 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu Val 1 5 10 <210> 2535 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2535 Thr Gly Asp Tyr Met His 1 5 <210> 2536 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2536 Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn 1 5 10 <210> 2537 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2537 Thr Arg Glu Leu Asp Ala Leu Asp 1 5 <210> 2538 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2538 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 2539 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2539 Leu Met Ile Tyr Glu Val Ser Lys Arg Pro 1 5 10 <210> 2540 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2540 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu 1 5 10 <210> 2541 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2541 Gly Tyr Thr Phe Thr Gly Asp Tyr 1 5 <210> 2542 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2542 Ile Asn Pro Asn Ser Gly Tyr Thr 1 5 <210> 2543 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2543 Thr Arg Glu Leu Asp Ala Leu Asp Val 1 5 <210> 2544 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2544 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 2545 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2545 Glu Val Ser One <210> 2546 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2546 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu Val 1 5 10 <210> 2547 <211> 116 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2547 Glu Val Gln Leu Leu Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Asp 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn Asn Ala Glu Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Ser Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Glu Leu Asp Ala Leu Asp Val Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser 115 <210> 2548 <211> 111 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2548 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ala Gly Ser 85 90 95 Asn Asn Phe Glu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2549 <211> 446 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2549 Glu Val Gln Leu Leu Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Asp 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn Asn Ala Glu Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Ser Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Glu Leu Asp Ala Leu Asp Val Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 115 120 125 Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 130 135 140 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 145 150 155 160 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 165 170 175 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 180 185 190 Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 195 200 205 Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr 210 215 220 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 225 230 235 240 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 260 265 270 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 305 310 315 320 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 325 330 335 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 340 345 350 Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 355 360 365 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 405 410 415 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 2550 <211> 217 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2550 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ala Gly Ser 85 90 95 Asn Asn Phe Glu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2551 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2551 Asn His Phe Trp Ser 1 5 <210> 2552 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2552 Phe Val Phe Tyr Asn Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2553 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2553 Val Gly Arg Trp Val Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2554 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2554 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 2555 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2555 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2556 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2556 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Gly Val 1 5 10 <210> 2557 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2557 Gly Asp Ser Ile Asn Asn His 1 5 <210> 2558 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2558 Phe Tyr Asn Gly Asn 1 5 <210> 2559 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2559 Val Gly Arg Trp Val Leu Arg Thr Ala Phe Asp 1 5 10 <210> 2560 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2560 Ser Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 2561 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2561 Ser Asn Asn One <210> 2562 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2562 Trp Asp Asp Ser Leu Asn Gly Pro Gly 1 5 <210> 2563 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2563 Gly Asp Ser Ile Asn Asn His Phe Trp Ser 1 5 10 <210> 2564 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2564 Phe Val Phe Tyr Asn Gly Asn Thr Asn 1 5 <210> 2565 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2565 Val Gly Arg Trp Val Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2566 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2566 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 2567 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2567 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2568 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2568 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Gly Val 1 5 10 <210> 2569 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2569 Asn Asn His Phe Trp Ser 1 5 <210> 2570 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2570 Trp Ile Gly Phe Val Phe Tyr Asn Gly Asn Thr Asn 1 5 10 <210> 2571 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2571 Ala Arg Val Gly Arg Trp Val Leu Arg Thr Ala Phe Asp 1 5 10 <210> 2572 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2572 Ile Gly Ser Asn Thr Val Asn Trp Tyr 1 5 <210> 2573 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2573 Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro 1 5 10 <210> 2574 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2574 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Gly 1 5 10 <210> 2575 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2575 Gly Asp Ser Ile Asn Asn His Phe 1 5 <210> 2576 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2576 Val Phe Tyr Asn Gly Asn Thr 1 5 <210> 2577 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2577 Ala Arg Val Gly Arg Trp Val Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2578 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2578 Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 2579 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2579 Ser Asn Asn One <210> 2580 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2580 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Gly Val 1 5 10 <210> 2581 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2581 Gln Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Asn Asn His 20 25 30 Phe Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Phe Val Phe Tyr Asn Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Ser Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Gly Arg Trp Val Leu Arg Thr Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2582 <211> 111 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2582 Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Ala Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2583 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2583 Gln Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Asn Asn His 20 25 30 Phe Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Phe Val Phe Tyr Asn Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Ser Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Gly Arg Trp Val Leu Arg Thr Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2584 <211> 217 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2584 Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Ala Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2585 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2585 Asn Tyr Phe Trp Ser 1 5 <210> 2586 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2586 Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2587 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2587 Glu Gly Lys Trp Glu Leu Arg Ser Ala Phe Asp Ile 1 5 10 <210> 2588 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2588 Ser Gly Ser Ser Ser Asn Ile Glu Ser Asn Thr Val Asn 1 5 10 <210> 2589 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2589 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2590 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2590 Thr Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2591 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2591 Gly Gly Ser Ile Asn Asn Tyr 1 5 <210> 2592 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2592 Tyr Tyr Ser Gly Ser 1 5 <210> 2593 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2593 Glu Gly Lys Trp Glu Leu Arg Ser Ala Phe Asp 1 5 10 <210> 2594 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2594 Ser Ser Ser Asn Ile Glu Ser Asn Thr 1 5 <210> 2595 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2595 Ser Asn Asn One <210> 2596 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2596 Trp Asp Asp Ser Leu Asn Gly Pro 1 5 <210> 2597 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2597 Gly Gly Ser Ile Asn Asn Tyr Phe Trp Ser 1 5 10 <210> 2598 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2598 Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn 1 5 <210> 2599 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2599 Glu Gly Lys Trp Glu Leu Arg Ser Ala Phe Asp Ile 1 5 10 <210> 2600 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2600 Ser Gly Ser Ser Ser Asn Ile Glu Ser Asn Thr Val Asn 1 5 10 <210> 2601 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2601 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2602 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2602 Thr Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2603 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2603 Asn Asn Tyr Phe Trp Ser 1 5 <210> 2604 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2604 Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn 1 5 10 <210> 2605 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2605 Ala Arg Glu Gly Lys Trp Glu Leu Arg Ser Ala Phe Asp 1 5 10 <210> 2606 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2606 Ile Glu Ser Asn Thr Val Asn Trp Tyr 1 5 <210> 2607 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2607 Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro 1 5 10 <210> 2608 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2608 Thr Ala Trp Asp Asp Ser Leu Asn Gly Pro 1 5 10 <210> 2609 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2609 Gly Gly Ser Ile Asn Asn Tyr Phe 1 5 <210> 2610 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2610 Ile Tyr Tyr Ser Gly Ser Thr 1 5 <210> 2611 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2611 Ala Arg Glu Gly Lys Trp Glu Leu Arg Ser Ala Phe Asp Ile 1 5 10 <210> 2612 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2612 Ser Ser Asn Ile Glu Ser Asn Thr 1 5 <210> 2613 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2613 Ser Asn Asn One <210> 2614 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2614 Thr Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2615 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2615 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asn Asn Tyr 20 25 30 Phe Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Val Thr Ser Met Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Glu Gly Lys Trp Glu Leu Arg Ser Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2616 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2616 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Glu Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Arg Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Thr Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2617 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2617 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asn Asn Tyr 20 25 30 Phe Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Val Thr Ser Met Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Glu Gly Lys Trp Glu Leu Arg Ser Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2618 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2618 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Glu Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Arg Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Thr Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2619 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2619 Ser Glu Tyr Ile His 1 5 <210> 2620 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2620 Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Arg Phe Gln 1 5 10 15 Gly <210> 2621 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2621 Glu Arg Gly Tyr Ser Tyr Gly Ser Phe Asp Tyr 1 5 10 <210> 2622 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2622 Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 2623 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2623 Ala Ala Ser Thr Leu Gln Ser 1 5 <210> 2624 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2624 Gln Gln Phe Asn Ser Tyr Ser Leu Thr 1 5 <210> 2625 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2625 Gly Tyr Thr Phe Thr Ser Glu 1 5 <210> 2626 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2626 Asn Pro Ser Gly Gly Ser 1 5 <210> 2627 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2627 Glu Arg Gly Tyr Ser Tyr Gly Ser Phe Asp 1 5 10 <210> 2628 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2628 Ser Gln Gly Ile Ser Ser Tyr 1 5 <210> 2629 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2629 Ala Ala Ser One <210> 2630 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2630 Phe Asn Ser Tyr Ser Leu 1 5 <210> 2631 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2631 Gly Tyr Thr Phe Thr Ser Glu Tyr Ile His 1 5 10 <210> 2632 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2632 Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser 1 5 10 <210> 2633 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2633 Glu Arg Gly Tyr Ser Tyr Gly Ser Phe Asp Tyr 1 5 10 <210> 2634 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2634 Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 2635 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2635 Ala Ala Ser Thr Leu Gln Ser 1 5 <210> 2636 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2636 Gln Gln Phe Asn Ser Tyr Ser Leu Thr 1 5 <210> 2637 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2637 Thr Ser Glu Tyr Ile His 1 5 <210> 2638 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2638 Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser 1 5 10 <210> 2639 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2639 Ala Arg Glu Arg Gly Tyr Ser Tyr Gly Ser Phe Asp 1 5 10 <210> 2640 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2640 Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 2641 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2641 Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln 1 5 10 <210> 2642 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2642 Gln Gln Phe Asn Ser Tyr Ser Leu 1 5 <210> 2643 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2643 Gly Tyr Thr Phe Thr Ser Glu Tyr 1 5 <210> 2644 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2644 Ile Asn Pro Ser Gly Gly Ser Thr 1 5 <210> 2645 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2645 Ala Arg Glu Arg Gly Tyr Ser Tyr Gly Ser Phe Asp Tyr 1 5 10 <210> 2646 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2646 Gln Gly Ile Ser Ser Tyr 1 5 <210> 2647 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2647 Ala Ala Ser One <210> 2648 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2648 Gln Gln Phe Asn Ser Tyr Ser Leu Thr 1 5 <210> 2649 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2649 Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Glu 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Arg Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Val Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Arg Gly Tyr Ser Tyr Gly Ser Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2650 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2650 Glu Ile Val Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Ala Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Ser Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 2651 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2651 Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Glu 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Arg Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Val Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Arg Gly Tyr Ser Tyr Gly Ser Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2652 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2652 Glu Ile Val Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Ala Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Ser Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 2653 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2653 Gly Tyr Tyr Trp Ser 1 5 <210> 2654 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2654 Tyr Ile Phe Tyr Ser Gly Ser Ile Asn Tyr Asn Pro Ser Leu Lys Asn 1 5 10 15 <210> 2655 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2655 Val Gly Lys Trp Glu Leu Arg Ser Ser Phe Asp Ile 1 5 10 <210> 2656 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2656 Ser Gly Ser Thr Ser Asn Ile Gly Asn Asn Asp Val Ser 1 5 10 <210> 2657 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2657 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 2658 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2658 Gly Thr Trp Asp Ser Ser Leu Ser Val Trp Val 1 5 10 <210> 2659 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2659 Gly Gly Ser Ile Ser Gly Tyr 1 5 <210> 2660 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2660 Phe Tyr Ser Gly Ser 1 5 <210> 2661 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2661 Val Gly Lys Trp Glu Leu Arg Ser Ser Phe Asp 1 5 10 <210> 2662 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2662 Ser Thr Ser Asn Ile Gly Asn Asn Asp 1 5 <210> 2663 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2663 Asp Asn Asn One <210> 2664 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2664 Trp Asp Ser Ser Leu Ser Val Trp 1 5 <210> 2665 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2665 Gly Gly Ser Ile Ser Gly Tyr Tyr Trp Ser 1 5 10 <210> 2666 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2666 Tyr Ile Phe Tyr Ser Gly Ser Ile Asn 1 5 <210> 2667 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2667 Val Gly Lys Trp Glu Leu Arg Ser Ser Phe Asp Ile 1 5 10 <210> 2668 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2668 Ser Gly Ser Thr Ser Asn Ile Gly Asn Asn Asp Val Ser 1 5 10 <210> 2669 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2669 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 2670 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2670 Gly Thr Trp Asp Ser Ser Leu Ser Val Trp Val 1 5 10 <210> 2671 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2671 Ser Gly Tyr Tyr Trp Ser 1 5 <210> 2672 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2672 Leu Ile Gly Tyr Ile Phe Tyr Ser Gly Ser Ile Asn 1 5 10 <210> 2673 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2673 Ala Arg Val Gly Lys Trp Glu Leu Arg Ser Ser Phe Asp 1 5 10 <210> 2674 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2674 Ile Gly Asn Asn Asp Val Ser Trp Tyr 1 5 <210> 2675 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2675 Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro 1 5 10 <210> 2676 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2676 Gly Thr Trp Asp Ser Ser Leu Ser Val Trp 1 5 10 <210> 2677 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2677 Gly Gly Ser Ile Ser Gly Tyr Tyr 1 5 <210> 2678 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2678 Ile Phe Tyr Ser Gly Ser Ile 1 5 <210> 2679 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2679 Ala Arg Val Gly Lys Trp Glu Leu Arg Ser Ser Phe Asp Ile 1 5 10 <210> 2680 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2680 Thr Ser Asn Ile Gly Asn Asn Asp 1 5 <210> 2681 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2681 Asp Asn Asn One <210> 2682 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2682 Gly Thr Trp Asp Ser Ser Leu Ser Val Trp Val 1 5 10 <210> 2683 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2683 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Gly Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Leu Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Ile Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Asn Arg Val Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Gly Lys Trp Glu Leu Arg Ser Ser Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2684 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2684 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Asn Asn 20 25 30 Asp Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Val Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2685 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2685 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Gly Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Leu Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Ile Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Asn Arg Val Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Gly Lys Trp Glu Leu Arg Ser Ser Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2686 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2686 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Asn Asn 20 25 30 Asp Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Val Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2687 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2687 Asn Gly Gly Phe Tyr Trp Ser 1 5 <210> 2688 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2688 Tyr Ile Asn Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Glu Ser 1 5 10 15 <210> 2689 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2689 Asp Arg Asn Tyr Glu Trp Asn Phe Asp Leu 1 5 10 <210> 2690 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2690 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 2691 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2691 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 2692 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2692 Gln Gln Arg Ser Asn Trp Pro Leu Thr 1 5 <210> 2693 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2693 Gly Gly Ser Ile Ser Asn Gly Gly Phe 1 5 <210> 2694 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2694 Asn Tyr Ser Gly Ser 1 5 <210> 2695 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2695 Asp Arg Asn Tyr Glu Trp Asn Phe Asp 1 5 <210> 2696 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2696 Ser Gln Ser Val Ser Ser Tyr 1 5 <210> 2697 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2697 Asp Ala Ser One <210> 2698 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2698 Arg Ser Asn Trp Pro Leu 1 5 <210> 2699 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2699 Gly Gly Ser Ile Ser Asn Gly Gly Phe Tyr Trp Ser 1 5 10 <210> 2700 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2700 Tyr Ile Asn Tyr Ser Gly Ser Thr Tyr 1 5 <210> 2701 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2701 Asp Arg Asn Tyr Glu Trp Asn Phe Asp Leu 1 5 10 <210> 2702 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2702 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 2703 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2703 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 2704 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2704 Gln Gln Arg Ser Asn Trp Pro Leu Thr 1 5 <210> 2705 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2705 Ser Asn Gly Gly Phe Tyr Trp Ser 1 5 <210> 2706 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2706 Trp Leu Gly Tyr Ile Asn Tyr Ser Gly Ser Thr Tyr 1 5 10 <210> 2707 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2707 Ala Arg Asp Arg Asn Tyr Glu Trp Asn Phe Asp 1 5 10 <210> 2708 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2708 Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 2709 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2709 Leu Leu Val Tyr Asp Ala Ser Asn Arg Ala 1 5 10 <210> 2710 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2710 Gln Gln Arg Ser Asn Trp Pro Leu 1 5 <210> 2711 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2711 Gly Gly Ser Ile Ser Asn Gly Gly Phe Tyr 1 5 10 <210> 2712 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2712 Ile Asn Tyr Ser Gly Ser Thr 1 5 <210> 2713 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2713 Ala Arg Asp Arg Asn Tyr Glu Trp Asn Phe Asp Leu 1 5 10 <210> 2714 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2714 Gln Ser Val Ser Ser Tyr 1 5 <210> 2715 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2715 Asp Ala Ser One <210> 2716 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2716 Gln Gln Arg Ser Asn Trp Pro Leu Thr 1 5 <210> 2717 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2717 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Gly 20 25 30 Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu 35 40 45 Trp Leu Gly Tyr Ile Asn Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Glu Ser Arg Gly Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Asp Arg Asn Tyr Glu Trp Asn Phe Asp Leu Trp Gly Arg 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2718 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2718 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Gly Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Ala Phe Thr Leu Thr Ile Thr Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Val Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 2719 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2719 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Gly 20 25 30 Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu 35 40 45 Trp Leu Gly Tyr Ile Asn Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Glu Ser Arg Gly Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Asp Arg Asn Tyr Glu Trp Asn Phe Asp Leu Trp Gly Arg 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2720 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2720 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Gly Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Ala Phe Thr Leu Thr Ile Thr Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Val Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 2721 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2721 Asn Ile Arg Met Ser Val Ser 1 5 <210> 2722 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2722 His Ile Phe Ser Asn Asp Glu Lys Ser Tyr Asn Ser Ser Leu Lys Ser 1 5 10 15 <210> 2723 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2723 Met Arg Leu Pro Tyr Gly Met Asp Val 1 5 <210> 2724 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2724 Ser Gly Ser Thr Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 2725 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2725 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2726 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2726 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2727 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2727 Gly Phe Ser Leu Thr Asn Ile Arg Met 1 5 <210> 2728 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2728 Phe Ser Asn Asp Glu 1 5 <210> 2729 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2729 Met Arg Leu Pro Tyr Gly Met Asp 1 5 <210> 2730 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2730 Ser Thr Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 2731 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2731 Ser Asn Asn One <210> 2732 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2732 Trp Asp Asp Ser Leu Asn Gly Pro 1 5 <210> 2733 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2733 Gly Phe Ser Leu Thr Asn Ile Arg Met Ser Val Ser 1 5 10 <210> 2734 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2734 His Ile Phe Ser Asn Asp Glu Lys Ser 1 5 <210> 2735 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2735 Met Arg Leu Pro Tyr Gly Met Asp Val 1 5 <210> 2736 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2736 Ser Gly Ser Thr Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 2737 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2737 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 2738 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2738 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2739 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2739 Thr Asn Ile Arg Met Ser Val Ser 1 5 <210> 2740 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2740 Trp Leu Ala His Ile Phe Ser Asn Asp Glu Lys Ser 1 5 10 <210> 2741 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2741 Ala Arg Met Arg Leu Pro Tyr Gly Met Asp 1 5 10 <210> 2742 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2742 Ile Gly Ser Asn Thr Val Asn Trp Tyr 1 5 <210> 2743 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2743 Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro 1 5 10 <210> 2744 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2744 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro 1 5 10 <210> 2745 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2745 Gly Phe Ser Leu Thr Asn Ile Arg Met Ser 1 5 10 <210> 2746 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2746 Ile Phe Ser Asn Asp Glu Lys 1 5 <210> 2747 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2747 Ala Arg Met Arg Leu Pro Tyr Gly Met Asp Val 1 5 10 <210> 2748 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2748 Thr Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 2749 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2749 Ser Asn Asn One <210> 2750 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2750 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 2751 <211> 119 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2751 Gln Val Thr Leu Arg Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Ile 20 25 30 Arg Met Ser Val Ser Trp Ile Arg Gln Pro Pro Gly Glu Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Asn Asp Glu Lys Ser Tyr Asn Ser Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Leu Thr Asn Val Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Met Arg Leu Pro Tyr Gly Met Asp Val Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser Ser 115 <210> 2752 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2752 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Phe Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2753 <211> 449 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2753 Gln Val Thr Leu Arg Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Ile 20 25 30 Arg Met Ser Val Ser Trp Ile Arg Gln Pro Pro Gly Glu Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Asn Asp Glu Lys Ser Tyr Asn Ser Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Leu Thr Asn Val Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Met Arg Leu Pro Tyr Gly Met Asp Val Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 Lys <210> 2754 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2754 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Phe Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2755 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2755 Asn Tyr Phe Trp Ser 1 5 <210> 2756 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2756 Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2757 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2757 Val Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2758 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2758 Thr Gly Thr Ser Ser Asp Val Ala Asp Tyr Asn Tyr Val Ser 1 5 10 <210> 2759 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2759 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 2760 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2760 Cys Ser Tyr Thr Ser Ser Phe Thr Val Val 1 5 10 <210> 2761 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2761 Gly Gly Ser Ile Asn Asn Tyr 1 5 <210> 2762 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2762 Phe Tyr Ser Gly Ser 1 5 <210> 2763 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2763 Val Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp 1 5 10 <210> 2764 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2764 Thr Ser Ser Asp Val Ala Asp Tyr Asn Tyr 1 5 10 <210> 2765 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2765 Glu Val Ser One <210> 2766 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2766 Tyr Thr Ser Ser Phe Thr Val 1 5 <210> 2767 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2767 Gly Gly Ser Ile Asn Asn Tyr Phe Trp Ser 1 5 10 <210> 2768 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2768 Tyr Ile Phe Tyr Ser Gly Ser Thr Asn 1 5 <210> 2769 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2769 Val Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2770 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2770 Thr Gly Thr Ser Ser Asp Val Ala Asp Tyr Asn Tyr Val Ser 1 5 10 <210> 2771 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2771 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 2772 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2772 Cys Ser Tyr Thr Ser Ser Phe Thr Val Val 1 5 10 <210> 2773 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2773 Asn Asn Tyr Phe Trp Ser 1 5 <210> 2774 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2774 Trp Ile Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn 1 5 10 <210> 2775 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2775 Ala Arg Val Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp 1 5 10 <210> 2776 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2776 Val Ala Asp Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 2777 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2777 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 2778 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2778 Cys Ser Tyr Thr Ser Ser Phe Thr Val 1 5 <210> 2779 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2779 Gly Gly Ser Ile Asn Asn Tyr Phe 1 5 <210> 2780 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2780 Ile Phe Tyr Ser Gly Ser Thr 1 5 <210> 2781 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2781 Ala Arg Val Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile 1 5 10 <210> 2782 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2782 Ser Ser Asp Val Ala Asp Tyr Asn Tyr 1 5 <210> 2783 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2783 Glu Val Ser One <210> 2784 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2784 Cys Ser Tyr Thr Ser Ser Phe Thr Val Val 1 5 10 <210> 2785 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2785 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asn Asn Tyr 20 25 30 Phe Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Val Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2786 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2786 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Ala Asp Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Thr Ser Ser 85 90 95 Phe Thr Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2787 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2787 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asn Asn Tyr 20 25 30 Phe Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Val Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Val Gly Lys Trp Glu Leu Arg Thr Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2788 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2788 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Ala Asp Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Thr Ser Ser 85 90 95 Phe Thr Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2789 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2789 Arg Tyr Asp Met His 1 5 <210> 2790 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2790 Ala Ile Gly Ser Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys Gly 1 5 10 15 <210> 2791 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2791 Gly Lys Trp Glu Leu Arg Asp Ala Phe Asp Ile 1 5 10 <210> 2792 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2792 Arg Ala Ser Gln Gly Ile His Ser Tyr Leu Ala 1 5 10 <210> 2793 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2793 Val Ala Ser Thr Leu Gln Ser 1 5 <210> 2794 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2794 Gln Gln Leu Asn Ser Tyr Pro Tyr Thr 1 5 <210> 2795 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2795 Gly Phe Thr Phe Ser Arg Tyr 1 5 <210> 2796 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2796 Gly Ser Ala Gly Asp 1 5 <210> 2797 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2797 Gly Lys Trp Glu Leu Arg Asp Ala Phe Asp 1 5 10 <210> 2798 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2798 Ser Gln Gly Ile His Ser Tyr 1 5 <210> 2799 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2799 Val Ala Ser One <210> 2800 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2800 Leu Asn Ser Tyr Pro Tyr 1 5 <210> 2801 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2801 Gly Phe Thr Phe Ser Arg Tyr Asp Met His 1 5 10 <210> 2802 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2802 Ala Ile Gly Ser Ala Gly Asp Thr Tyr 1 5 <210> 2803 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2803 Gly Lys Trp Glu Leu Arg Asp Ala Phe Asp Ile 1 5 10 <210> 2804 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2804 Arg Ala Ser Gln Gly Ile His Ser Tyr Leu Ala 1 5 10 <210> 2805 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2805 Val Ala Ser Thr Leu Gln Ser 1 5 <210> 2806 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2806 Gln Gln Leu Asn Ser Tyr Pro Tyr Thr 1 5 <210> 2807 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2807 Ser Arg Tyr Asp Met His 1 5 <210> 2808 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2808 Trp Val Ser Ala Ile Gly Ser Ala Gly Asp Thr Tyr 1 5 10 <210> 2809 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2809 Ala Arg Gly Lys Trp Glu Leu Arg Asp Ala Phe Asp 1 5 10 <210> 2810 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2810 His Ser Tyr Leu Ala Trp Tyr 1 5 <210> 2811 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2811 Leu Leu Ile Tyr Val Ala Ser Thr Leu Gln 1 5 10 <210> 2812 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2812 Gln Gln Leu Asn Ser Tyr Pro Tyr 1 5 <210> 2813 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2813 Gly Phe Thr Phe Ser Arg Tyr Asp 1 5 <210> 2814 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2814 Ile Gly Ser Ala Gly Asp Thr 1 5 <210> 2815 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2815 Ala Arg Gly Lys Trp Glu Leu Arg Asp Ala Phe Asp Ile 1 5 10 <210> 2816 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2816 Gln Gly Ile His Ser Tyr 1 5 <210> 2817 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2817 Val Ala Ser One <210> 2818 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2818 Gln Gln Leu Asn Ser Tyr Pro Tyr Thr 1 5 <210> 2819 <211> 119 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2819 Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 20 25 30 Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Gly Ser Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Lys Trp Glu Leu Arg Asp Ala Phe Asp Ile Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser Ser 115 <210> 2820 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2820 Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile His Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Val Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 2821 <211> 449 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2821 Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 20 25 30 Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Gly Ser Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Lys Trp Glu Leu Arg Asp Ala Phe Asp Ile Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 Lys <210> 2822 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2822 Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile His Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Val Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 2823 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2823 Gly Tyr Phe Trp Asn 1 5 <210> 2824 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2824 Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2825 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2825 Glu Gly Lys Trp Glu Leu Arg Ser Thr Phe Asp Ile 1 5 10 <210> 2826 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2826 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Thr 1 5 10 <210> 2827 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2827 Gly Glu Asn Asn Arg Pro Ser 1 5 <210> 2828 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2828 Asn Ser Arg Asp Thr Gly Asp His His Leu Val 1 5 10 <210> 2829 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2829 Gly Gly Ser Ile Ser Gly Tyr 1 5 <210> 2830 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2830 Phe Tyr Ser Gly Ser 1 5 <210> 2831 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2831 Glu Gly Lys Trp Glu Leu Arg Ser Thr Phe Asp 1 5 10 <210> 2832 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2832 Asp Ser Leu Arg Ser Tyr Tyr 1 5 <210> 2833 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2833 Gly Glu Asn One <210> 2834 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2834 Arg Asp Thr Gly Asp His His Leu 1 5 <210> 2835 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2835 Gly Gly Ser Ile Ser Gly Tyr Phe Trp Asn 1 5 10 <210> 2836 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2836 Tyr Ile Phe Tyr Ser Gly Ser Thr Asn 1 5 <210> 2837 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2837 Glu Gly Lys Trp Glu Leu Arg Ser Thr Phe Asp Ile 1 5 10 <210> 2838 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2838 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Thr 1 5 10 <210> 2839 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2839 Gly Glu Asn Asn Arg Pro Ser 1 5 <210> 2840 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2840 Asn Ser Arg Asp Thr Gly Asp His His Leu Val 1 5 10 <210> 2841 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2841 Ser Gly Tyr Phe Trp Asn 1 5 <210> 2842 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2842 Trp Ile Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn 1 5 10 <210> 2843 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2843 Ala Arg Glu Gly Lys Trp Glu Leu Arg Ser Thr Phe Asp 1 5 10 <210> 2844 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2844 Ser Tyr Tyr Ala Thr Trp Tyr 1 5 <210> 2845 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2845 Leu Val Ile Tyr Gly Glu Asn Asn Arg Pro 1 5 10 <210> 2846 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2846 Asn Ser Arg Asp Thr Gly Asp His His Leu 1 5 10 <210> 2847 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2847 Gly Gly Ser Ile Ser Gly Tyr Phe 1 5 <210> 2848 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2848 Ile Phe Tyr Ser Gly Ser Thr 1 5 <210> 2849 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2849 Ala Arg Glu Gly Lys Trp Glu Leu Arg Ser Thr Phe Asp Ile 1 5 10 <210> 2850 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2850 Ser Leu Arg Ser Tyr Tyr 1 5 <210> 2851 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2851 Gly Glu Asn One <210> 2852 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2852 Asn Ser Arg Asp Thr Gly Asp His His Leu Val 1 5 10 <210> 2853 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2853 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Asn Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Gly Tyr 20 25 30 Phe Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Ala 85 90 95 Arg Glu Gly Lys Trp Glu Leu Arg Ser Thr Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2854 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2854 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ile Leu Val Ile Tyr 35 40 45 Gly Glu Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Arg Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Thr Gly Asp His His 85 90 95 Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 2855 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2855 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Asn Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Gly Tyr 20 25 30 Phe Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Ala 85 90 95 Arg Glu Gly Lys Trp Glu Leu Arg Ser Thr Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 2856 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2856 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ile Leu Val Ile Tyr 35 40 45 Gly Glu Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Arg Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Thr Gly Asp His His 85 90 95 Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys 100 105 110 Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 115 120 125 Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 130 135 140 Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 145 150 155 160 Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 165 170 175 Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 180 185 190 Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 195 200 205 Ala Pro Thr Glu Cys Ser 210 <210> 2857 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2857 Ile Tyr Ala Ile Asn 1 5 <210> 2858 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2858 Gly Ile Ile Pro Phe Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 2859 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2859 Gly Gly Asp Ser Gly Tyr Asp Trp Gly Phe Asp Tyr 1 5 10 <210> 2860 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2860 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 2861 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2861 Gln Ile Ser Asn Arg Phe Ser 1 5 <210> 2862 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2862 Met Gln Ala Thr Gln Phe Pro Leu Thr 1 5 <210> 2863 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2863 Gly Gly Thr Phe Asn Ile Tyr 1 5 <210> 2864 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2864 Ile Pro Phe Phe Gly Thr 1 5 <210> 2865 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2865 Gly Gly Asp Ser Gly Tyr Asp Trp Gly Phe Asp 1 5 10 <210> 2866 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2866 Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 2867 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2867 Gln Ile Ser One <210> 2868 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2868 Ala Thr Gln Phe Pro Leu 1 5 <210> 2869 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2869 Gly Gly Thr Phe Asn Ile Tyr Ala Ile Asn 1 5 10 <210> 2870 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2870 Gly Ile Ile Pro Phe Phe Gly Thr Ala Asn 1 5 10 <210> 2871 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2871 Gly Gly Asp Ser Gly Tyr Asp Trp Gly Phe Asp Tyr 1 5 10 <210> 2872 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2872 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 2873 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2873 Gln Ile Ser Asn Arg Phe Ser 1 5 <210> 2874 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2874 Met Gln Ala Thr Gln Phe Pro Leu Thr 1 5 <210> 2875 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2875 Asn Ile Tyr Ala Ile Asn 1 5 <210> 2876 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2876 Trp Met Gly Gly Ile Ile Pro Phe Phe Gly Thr Ala Asn 1 5 10 <210> 2877 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2877 Ala Arg Gly Gly Asp Ser Gly Tyr Asp Trp Gly Phe Asp 1 5 10 <210> 2878 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2878 Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu 1 5 10 <210> 2879 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2879 Leu Leu Ile Tyr Gln Ile Ser Asn Arg Phe 1 5 10 <210> 2880 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2880 Met Gln Ala Thr Gln Phe Pro Leu 1 5 <210> 2881 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2881 Gly Gly Thr Phe Asn Ile Tyr Ala 1 5 <210> 2882 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2882 Ile Ile Pro Phe Phe Gly Thr Ala 1 5 <210> 2883 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2883 Ala Arg Gly Gly Asp Ser Gly Tyr Asp Trp Gly Phe Asp Tyr 1 5 10 <210> 2884 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2884 Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 2885 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2885 Gln Ile Ser One <210> 2886 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2886 Met Gln Ala Thr Gln Phe Pro Leu Thr 1 5 <210> 2887 <211> 121 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2887 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ile Tyr 20 25 30 Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Phe Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Phe Tyr Cys 85 90 95 Ala Arg Gly Gly Asp Ser Gly Tyr Asp Trp Gly Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2888 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2888 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Gln Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Asn Ile 65 70 75 80 Ser Arg Val Glu Ala Asp Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Thr Gln Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 2889 <211> 451 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2889 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ile Tyr 20 25 30 Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Phe Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Phe Tyr Cys 85 90 95 Ala Arg Gly Gly Asp Ser Gly Tyr Asp Trp Gly Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys 450 <210> 2890 <211> 219 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2890 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Gln Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Asn Ile 65 70 75 80 Ser Arg Val Glu Ala Asp Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Thr Gln Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 2891 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2891 Thr Tyr Tyr Trp Ser 1 5 <210> 2892 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2892 Arg Ile Tyr Thr Ser Asp Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2893 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2893 Tyr Asn Trp Asn Tyr Trp Tyr Phe Asp Leu 1 5 10 <210> 2894 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2894 Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 2895 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2895 Thr Ala Ser Thr Leu Gln Ser 1 5 <210> 2896 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2896 Gln His Leu Asn Ser Tyr Pro Tyr Thr 1 5 <210> 2897 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2897 Gly Gly Ser Ile Asn Thr Tyr 1 5 <210> 2898 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2898 Tyr Thr Ser Asp Asn 1 5 <210> 2899 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2899 Tyr Asn Trp Asn Tyr Trp Tyr Phe Asp 1 5 <210> 2900 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2900 Ser Gln Gly Ile Ser Ser Tyr 1 5 <210> 2901 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2901 Thr Ala Ser One <210> 2902 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2902 Leu Asn Ser Tyr Pro Tyr 1 5 <210> 2903 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2903 Gly Gly Ser Ile Asn Thr Tyr Tyr Trp Ser 1 5 10 <210> 2904 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2904 Arg Ile Tyr Thr Ser Asp Asn Thr Asn 1 5 <210> 2905 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2905 Tyr Asn Trp Asn Tyr Trp Tyr Phe Asp Leu 1 5 10 <210> 2906 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2906 Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 2907 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2907 Thr Ala Ser Thr Leu Gln Ser 1 5 <210> 2908 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2908 Gln His Leu Asn Ser Tyr Pro Tyr Thr 1 5 <210> 2909 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2909 Asn Thr Tyr Tyr Trp Ser 1 5 <210> 2910 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2910 Leu Ile Gly Arg Ile Tyr Thr Ser Asp Asn Thr Asn 1 5 10 <210> 2911 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2911 Ala Arg Tyr Asn Trp Asn Tyr Trp Tyr Phe Asp 1 5 10 <210> 2912 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2912 Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 2913 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2913 Leu Leu Ile Tyr Thr Ala Ser Thr Leu Gln 1 5 10 <210> 2914 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2914 Gln His Leu Asn Ser Tyr Pro Tyr 1 5 <210> 2915 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2915 Gly Gly Ser Ile Asn Thr Tyr Tyr 1 5 <210> 2916 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2916 Ile Tyr Thr Ser Asp Asn Thr 1 5 <210> 2917 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2917 Ala Arg Tyr Asn Trp Asn Tyr Trp Tyr Phe Asp Leu 1 5 10 <210> 2918 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2918 Gln Gly Ile Ser Ser Tyr 1 5 <210> 2919 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2919 Thr Ala Ser One <210> 2920 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2920 Gln His Leu Asn Ser Tyr Pro Tyr Thr 1 5 <210> 2921 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2921 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Asn Thr Tyr 20 25 30 Tyr Trp Ser Trp Phe Arg Gln Pro Ala Gly Lys Gly Leu Glu Leu Ile 35 40 45 Gly Arg Ile Tyr Thr Ser Asp Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Tyr Asn Trp Asn Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 2922 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2922 Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Arg 1 5 10 15 Asp Arg Val Asn Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Thr Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 2923 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2923 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Asn Thr Tyr 20 25 30 Tyr Trp Ser Trp Phe Arg Gln Pro Ala Gly Lys Gly Leu Glu Leu Ile 35 40 45 Gly Arg Ile Tyr Thr Ser Asp Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Tyr Asn Trp Asn Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 2924 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2924 Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Arg 1 5 10 15 Asp Arg Val Asn Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Thr Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 2925 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2925 His Tyr Tyr Trp Asn 1 5 <210> 2926 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2926 Arg Ile Tyr Thr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 2927 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2927 Ser Gly Gly Asn Phe Tyr Trp Tyr Phe Asp Leu 1 5 10 <210> 2928 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2928 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 2929 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2929 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 2930 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2930 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 2931 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2931 Gly Asp Ser Ile Gly His Tyr 1 5 <210> 2932 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2932 Tyr Thr Ser Gly Ser 1 5 <210> 2933 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2933 Ser Gly Gly Asn Phe Tyr Trp Tyr Phe Asp 1 5 10 <210> 2934 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2934 Ser Ser Ser Asn Ile Gly Asn Asn Tyr 1 5 <210> 2935 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2935 Asp Asn Asn One <210> 2936 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2936 Trp Asp Ser Ser Leu Ser Ala Gly 1 5 <210> 2937 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2937 Gly Asp Ser Ile Gly His Tyr Tyr Trp Asn 1 5 10 <210> 2938 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2938 Arg Ile Tyr Thr Ser Gly Ser Thr Asn 1 5 <210> 2939 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2939 Ser Gly Gly Asn Phe Tyr Trp Tyr Phe Asp Leu 1 5 10 <210> 2940 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2940 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 2941 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2941 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 2942 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2942 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 2943 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2943 Gly His Tyr Tyr Trp Asn 1 5 <210> 2944 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2944 Trp Ile Gly Arg Ile Tyr Thr Ser Gly Ser Thr Asn 1 5 10 <210> 2945 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2945 Ala Arg Ser Gly Gly Asn Phe Tyr Trp Tyr Phe Asp 1 5 10 <210> 2946 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2946 Ile Gly Asn Asn Tyr Val Ser Trp Tyr 1 5 <210> 2947 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2947 Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro 1 5 10 <210> 2948 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2948 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly 1 5 10 <210> 2949 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2949 Gly Asp Ser Ile Gly His Tyr Tyr 1 5 <210> 2950 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2950 Ile Tyr Thr Ser Gly Ser Thr 1 5 <210> 2951 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2951 Ala Arg Ser Gly Gly Asn Phe Tyr Trp Tyr Phe Asp Leu 1 5 10 <210> 2952 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2952 Ser Ser Asn Ile Gly Asn Asn Tyr 1 5 <210> 2953 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2953 Asp Asn Asn One <210> 2954 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2954 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 2955 <211> 119 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2955 Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Gly His Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Thr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ser Gly Gly Asn Phe Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 2956 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2956 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Ile Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2957 <211> 449 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2957 Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Gly His Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Thr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ser Gly Gly Asn Phe Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 Lys <210> 2958 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2958 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Ile Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2959 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2959 Asn Tyr Tyr Trp Ser 1 5 <210> 2960 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2960 Arg Ile Tyr Pro Ser Gly Ile Thr Ser Tyr Asp Pro Ser Leu Lys Ser 1 5 10 15 <210> 2961 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2961 Ile Met Gly Thr Lys Gly Ala Phe Asp Ile 1 5 10 <210> 2962 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2962 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 2963 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2963 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 2964 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2964 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 2965 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2965 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 2966 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2966 Tyr Pro Ser Gly Ile 1 5 <210> 2967 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2967 Ile Met Gly Thr Lys Gly Ala Phe Asp 1 5 <210> 2968 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2968 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 2969 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2969 Glu Val Ser One <210> 2970 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2970 Tyr Thr Ser Thr Ser Val 1 5 <210> 2971 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2971 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 2972 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2972 Arg Ile Tyr Pro Ser Gly Ile Thr Ser 1 5 <210> 2973 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2973 Ile Met Gly Thr Lys Gly Ala Phe Asp Ile 1 5 10 <210> 2974 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2974 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 2975 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2975 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 2976 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2976 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 2977 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2977 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 2978 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2978 Trp Ile Gly Arg Ile Tyr Pro Ser Gly Ile Thr Ser 1 5 10 <210> 2979 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2979 Ala Gly Ile Met Gly Thr Lys Gly Ala Phe Asp 1 5 10 <210> 2980 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2980 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 2981 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2981 Leu Leu Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 2982 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2982 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 2983 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2983 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 2984 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2984 Ile Tyr Pro Ser Gly Ile Thr 1 5 <210> 2985 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2985 Ala Gly Ile Met Gly Thr Lys Gly Ala Phe Asp Ile 1 5 10 <210> 2986 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2986 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 2987 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2987 Glu Val Ser One <210> 2988 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2988 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 2989 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2989 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Ser Gly Ile Thr Ser Tyr Asp Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Met Gly Thr Lys Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 2990 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2990 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Ser Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 2991 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2991 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Ser Gly Ile Thr Ser Tyr Asp Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Met Gly Thr Lys Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 2992 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 2992 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Ser Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 2993 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2993 Ser Tyr Ala Ile Ser 1 5 <210> 2994 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2994 Gly Ile Ile Pro Ile Phe Gly Thr Ala Thr Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 2995 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2995 Gly Val Gly Trp Gly Thr Asp Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 <210> 2996 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2996 Arg Ser Ser Gln Gly Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 2997 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2997 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 2998 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2998 Met Gln Ala Thr His His Pro Leu Thr 1 5 <210> 2999 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 2999 Gly Gly Thr Phe Ser Ser Tyr 1 5 <210> 3000 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3000 Ile Pro Ile Phe Gly Thr 1 5 <210> 3001 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3001 Gly Val Gly Trp Gly Thr Asp Tyr Tyr Tyr Gly Leu Asp 1 5 10 <210> 3002 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3002 Ser Gln Gly Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 3003 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3003 Lys Ile Ser One <210> 3004 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3004 Ala Thr His His Pro Leu 1 5 <210> 3005 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3005 Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser 1 5 10 <210> 3006 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3006 Gly Ile Ile Pro Ile Phe Gly Thr Ala Thr 1 5 10 <210> 3007 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3007 Gly Val Gly Trp Gly Thr Asp Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 <210> 3008 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3008 Arg Ser Ser Gln Gly Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 3009 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3009 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 3010 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3010 Met Gln Ala Thr His His Pro Leu Thr 1 5 <210> 3011 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3011 Ser Ser Tyr Ala Ile Ser 1 5 <210> 3012 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3012 Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Thr 1 5 10 <210> 3013 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3013 Ala Arg Gly Val Gly Trp Gly Thr Asp Tyr Tyr Tyr Gly Leu Asp 1 5 10 15 <210> 3014 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3014 Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu 1 5 10 <210> 3015 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3015 Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe 1 5 10 <210> 3016 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3016 Met Gln Ala Thr His His Pro Leu 1 5 <210> 3017 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3017 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 3018 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3018 Ile Ile Pro Ile Phe Gly Thr Ala 1 5 <210> 3019 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3019 Ala Arg Gly Val Gly Trp Gly Thr Asp Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 15 <210> 3020 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3020 Gln Gly Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 3021 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3021 Lys Ile Ser One <210> 3022 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3022 Met Gln Ala Thr His His Pro Leu Thr 1 5 <210> 3023 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3023 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Thr Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Thr Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Phe Tyr Cys 85 90 95 Ala Arg Gly Val Gly Trp Gly Thr Asp Tyr Tyr Tyr Gly Leu Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 3024 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3024 Glu Thr Thr Leu Thr Gln Ser Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Gly Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Thr His His Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 3025 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3025 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Thr Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Thr Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Phe Tyr Cys 85 90 95 Ala Arg Gly Val Gly Trp Gly Thr Asp Tyr Tyr Tyr Gly Leu Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 3026 <211> 219 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3026 Glu Thr Thr Leu Thr Gln Ser Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Gly Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Thr His His Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 3027 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3027 Asn Tyr Tyr Trp Ser 1 5 <210> 3028 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3028 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3029 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3029 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3030 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3030 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3031 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3031 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3032 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3032 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3033 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3033 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3034 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3034 Tyr Ser Ser Gly Ile 1 5 <210> 3035 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3035 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3036 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3036 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3037 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3037 Glu Val Ser One <210> 3038 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3038 Tyr Thr Ser Thr Ser Val 1 5 <210> 3039 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3039 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3040 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3040 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3041 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3041 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3042 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3042 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3043 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3043 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3044 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3044 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3045 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3045 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3046 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3046 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3047 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3047 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3048 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3048 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3049 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3049 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3050 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3050 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3051 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3051 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3052 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3052 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3053 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3053 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3054 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3054 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3055 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3055 Glu Val Ser One <210> 3056 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3056 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3057 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3057 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3058 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3058 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3059 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3059 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3060 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3060 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3061 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3061 Asn Tyr Tyr Trp Ser 1 5 <210> 3062 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3062 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3063 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3063 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3064 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3064 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3065 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3065 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3066 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3066 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3067 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3067 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3068 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3068 Tyr Ser Ser Gly Ile 1 5 <210> 3069 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3069 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3070 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3070 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3071 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3071 Glu Val Ser One <210> 3072 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3072 Tyr Thr Ser Thr Ser Val 1 5 <210> 3073 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3073 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3074 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3074 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3075 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3075 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3076 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3076 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3077 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3077 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3078 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3078 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3079 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3079 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3080 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3080 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3081 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3081 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3082 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3082 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3083 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3083 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3084 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3084 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3085 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3085 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3086 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3086 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3087 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3087 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3088 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3088 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3089 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3089 Glu Val Ser One <210> 3090 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3090 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3091 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3091 Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3092 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3092 Gln Pro Val Leu Thr Gln Ser Ser Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 <210> 3093 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3093 Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3094 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3094 Gln Pro Val Leu Thr Gln Ser Ser Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3095 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3095 Gly Tyr Tyr Leu His 1 5 <210> 3096 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3096 Trp Ile Asn Pro Ser Ser Gly Asp Thr Asp Tyr Ala Gln Thr Phe Gln 1 5 10 15 Gly <210> 3097 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3097 Glu Leu Gly Ile Gly Val Phe Asp Tyr 1 5 <210> 3098 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3098 Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu 1 5 10 15 Gly <210> 3099 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3099 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 3100 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3100 Gln Gln Tyr Tyr Ser Ile Pro Tyr Thr 1 5 <210> 3101 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3101 Gly Tyr Thr Phe Thr Gly Tyr 1 5 <210> 3102 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3102 Asn Pro Ser Ser Gly Asp 1 5 <210> 3103 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3103 Glu Leu Gly Ile Gly Val Phe Asp 1 5 <210> 3104 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3104 Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr 1 5 10 <210> 3105 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3105 Trp Ala Ser One <210> 3106 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3106 Tyr Tyr Ser Ile Pro Tyr 1 5 <210> 3107 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3107 Gly Tyr Thr Phe Thr Gly Tyr Tyr Leu His 1 5 10 <210> 3108 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3108 Trp Ile Asn Pro Ser Ser Gly Asp Thr Asp 1 5 10 <210> 3109 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3109 Glu Leu Gly Ile Gly Val Phe Asp Tyr 1 5 <210> 3110 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3110 Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu 1 5 10 15 Gly <210> 3111 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3111 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 3112 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3112 Gln Gln Tyr Tyr Ser Ile Pro Tyr Thr 1 5 <210> 3113 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3113 Thr Gly Tyr Tyr Leu His 1 5 <210> 3114 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3114 Trp Val Gly Trp Ile Asn Pro Ser Ser Gly Asp Thr Asp 1 5 10 <210> 3115 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3115 Ala Asn Glu Leu Gly Ile Gly Val Phe Asp 1 5 10 <210> 3116 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3116 Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Gly Trp Tyr 1 5 10 <210> 3117 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3117 Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu 1 5 10 <210> 3118 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3118 Gln Gln Tyr Tyr Ser Ile Pro Tyr 1 5 <210> 3119 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3119 Gly Tyr Thr Phe Thr Gly Tyr Tyr 1 5 <210> 3120 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3120 Ile Asn Pro Ser Ser Gly Asp Thr 1 5 <210> 3121 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3121 Ala Asn Glu Leu Gly Ile Gly Val Phe Asp Tyr 1 5 10 <210> 3122 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3122 Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr 1 5 10 <210> 3123 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3123 Trp Ala Ser One <210> 3124 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3124 Gln Gln Tyr Tyr Ser Ile Pro Tyr Thr 1 5 <210> 3125 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3125 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Pro Ser Ser Gly Asp Thr Asp Tyr Ala Gln Thr Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Glu Leu Gly Ile Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 3126 <211> 113 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3126 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys Gln Gln 85 90 95 Tyr Tyr Ser Ile Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile 100 105 110 Lys <210> 3127 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3127 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Pro Ser Ser Gly Asp Thr Asp Tyr Ala Gln Thr Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Glu Leu Gly Ile Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3128 <211> 220 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3128 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys Gln Gln 85 90 95 Tyr Tyr Ser Ile Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile 100 105 110 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155 160 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 165 170 175 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 180 185 190 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 195 200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 220 <210> 3129 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3129 Thr Tyr Gly Val Gly Val Gly 1 5 <210> 3130 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3130 Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3131 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3131 Glu Ser Asp Trp Ser Tyr Tyr Phe Asp Tyr 1 5 10 <210> 3132 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3132 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 3133 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3133 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 3134 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3134 Gln Gln Arg Ser Ser Trp Pro Trp Thr 1 5 <210> 3135 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3135 Gly Phe Ser Leu Ser Thr Tyr Gly Val 1 5 <210> 3136 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3136 Tyr Trp Asn Asp Asp 1 5 <210> 3137 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3137 Glu Ser Asp Trp Ser Tyr Tyr Phe Asp 1 5 <210> 3138 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3138 Ser Gln Ser Val Ser Ser Tyr 1 5 <210> 3139 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3139 Asp Ala Ser One <210> 3140 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3140 Arg Ser Ser Trp Pro Trp 1 5 <210> 3141 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3141 Gly Phe Ser Leu Ser Thr Tyr Gly Val Gly Val Gly 1 5 10 <210> 3142 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3142 Leu Ile Tyr Trp Asn Asp Asp Lys Arg 1 5 <210> 3143 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3143 Glu Ser Asp Trp Ser Tyr Tyr Phe Asp Tyr 1 5 10 <210> 3144 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3144 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 3145 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3145 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 3146 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3146 Gln Gln Arg Ser Ser Trp Pro Trp Thr 1 5 <210> 3147 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3147 Ser Thr Tyr Gly Val Gly Val Gly 1 5 <210> 3148 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3148 Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg 1 5 10 <210> 3149 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3149 Ser His Glu Ser Asp Trp Ser Tyr Tyr Phe Asp 1 5 10 <210> 3150 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3150 Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 3151 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3151 Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala 1 5 10 <210> 3152 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3152 Gln Gln Arg Ser Ser Trp Pro Trp 1 5 <210> 3153 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3153 Gly Phe Ser Leu Ser Thr Tyr Gly Val Gly 1 5 10 <210> 3154 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3154 Ile Tyr Trp Asn Asp Asp Lys 1 5 <210> 3155 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3155 Ser His Glu Ser Asp Trp Ser Tyr Tyr Phe Asp Tyr 1 5 10 <210> 3156 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3156 Gln Ser Val Ser Ser Tyr 1 5 <210> 3157 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3157 Asp Ala Ser One <210> 3158 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3158 Gln Gln Arg Ser Ser Trp Pro Trp Thr 1 5 <210> 3159 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3159 Gln Val Thr Leu Arg Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Tyr 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Gly Thr Ala Thr Tyr Tyr 85 90 95 Cys Ser His Glu Ser Asp Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 3160 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3160 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Val Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Ser Trp Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100 105 <210> 3161 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3161 Gln Val Thr Leu Arg Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Tyr 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Gly Thr Ala Thr Tyr Tyr 85 90 95 Cys Ser His Glu Ser Asp Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 3162 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3162 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Val Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Ser Trp Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 3163 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3163 Ser Tyr Val Ile Ser 1 5 <210> 3164 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3164 Gly Ile Leu Pro Ile Leu Ser Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 3165 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3165 Ala His Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 3166 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3166 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 3167 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3167 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 3168 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3168 Met Gln Ala Thr His His Pro Leu Thr 1 5 <210> 3169 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3169 Gly Gly Thr Phe Ser Ser Tyr 1 5 <210> 3170 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3170 Leu Pro Ile Leu Ser Thr 1 5 <210> 3171 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3171 Ala His Asp Tyr Tyr Tyr Gly Met Asp 1 5 <210> 3172 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3172 Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 3173 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3173 Lys Ile Ser One <210> 3174 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3174 Ala Thr His His Pro Leu 1 5 <210> 3175 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3175 Gly Gly Thr Phe Ser Ser Tyr Val Ile Ser 1 5 10 <210> 3176 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3176 Gly Ile Leu Pro Ile Leu Ser Thr Ala Asn 1 5 10 <210> 3177 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3177 Ala His Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 3178 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3178 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 3179 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3179 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 3180 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3180 Met Gln Ala Thr His His Pro Leu Thr 1 5 <210> 3181 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3181 Ser Ser Tyr Val Ile Ser 1 5 <210> 3182 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3182 Trp Met Gly Gly Ile Leu Pro Ile Leu Ser Thr Ala Asn 1 5 10 <210> 3183 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3183 Ala Arg Ala His Asp Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 3184 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3184 Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu 1 5 10 <210> 3185 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3185 Leu Leu Val Tyr Lys Ile Ser Asn Arg Phe 1 5 10 <210> 3186 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3186 Met Gln Ala Thr His His Pro Leu 1 5 <210> 3187 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3187 Gly Gly Thr Phe Ser Ser Tyr Val 1 5 <210> 3188 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3188 Ile Leu Pro Ile Leu Ser Thr Ala 1 5 <210> 3189 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3189 Ala Arg Ala His Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 3190 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3190 Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 3191 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3191 Lys Ile Ser One <210> 3192 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3192 Met Gln Ala Thr His His Pro Leu Thr 1 5 <210> 3193 <211> 119 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3193 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Val Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Leu Pro Ile Leu Ser Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala His Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser Ser 115 <210> 3194 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3194 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Val Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala 85 90 95 Thr His His Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 3195 <211> 449 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3195 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Val Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Leu Pro Ile Leu Ser Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala His Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 Lys <210> 3196 <211> 219 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3196 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Val Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala 85 90 95 Thr His His Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 3197 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3197 Asn Tyr Tyr Trp Ser 1 5 <210> 3198 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3198 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3199 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3199 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3200 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3200 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3201 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3201 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3202 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3202 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3203 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3203 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3204 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3204 Tyr Ser Ser Gly Ile 1 5 <210> 3205 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3205 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3206 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3206 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3207 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3207 Glu Val Ser One <210> 3208 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3208 Tyr Thr Ser Thr Ser Val 1 5 <210> 3209 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3209 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3210 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3210 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3211 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3211 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3212 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3212 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3213 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3213 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3214 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3214 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3215 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3215 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3216 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3216 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3217 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3217 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3218 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3218 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3219 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3219 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3220 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3220 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3221 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3221 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3222 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3222 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3223 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3223 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3224 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3224 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3225 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3225 Glu Val Ser One <210> 3226 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3226 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3227 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3227 Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3228 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3228 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3229 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3229 Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3230 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3230 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3231 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3231 Ser Tyr Asp Met Asn 1 5 <210> 3232 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3232 Tyr Ile Ser Ser Ser Ser Thr Ala Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 3233 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3233 Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln His 1 5 10 <210> 3234 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3234 Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala 1 5 10 <210> 3235 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3235 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 3236 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3236 Gln Gln Arg Ser Asn Trp Thr 1 5 <210> 3237 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3237 Gly Phe Thr Phe Ser Ser Tyr 1 5 <210> 3238 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3238 Ser Ser Ser Ser Thr Ala 1 5 <210> 3239 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3239 Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln 1 5 10 <210> 3240 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3240 Ser Gln Ser Val Ser Asn Tyr 1 5 <210> 3241 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3241 Asp Ala Ser One <210> 3242 <211> 4 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3242 Arg Ser Asn Trp One <210> 3243 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3243 Gly Phe Thr Phe Ser Ser Tyr Asp Met Asn 1 5 10 <210> 3244 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3244 Tyr Ile Ser Ser Ser Ser Thr Ala Lys Tyr 1 5 10 <210> 3245 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3245 Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln His 1 5 10 <210> 3246 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3246 Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala 1 5 10 <210> 3247 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3247 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 3248 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3248 Gln Gln Arg Ser Asn Trp Thr 1 5 <210> 3249 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3249 Ser Ser Tyr Asp Met Asn 1 5 <210> 3250 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3250 Trp Val Ser Tyr Ile Ser Ser Ser Ser Thr Ala Lys Tyr 1 5 10 <210> 3251 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3251 Ala Arg Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln 1 5 10 <210> 3252 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3252 Ser Asn Tyr Leu Ala Trp Tyr 1 5 <210> 3253 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3253 Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala 1 5 10 <210> 3254 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3254 Gln Gln Arg Ser Asn Trp 1 5 <210> 3255 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3255 Gly Phe Thr Phe Ser Ser Tyr Asp 1 5 <210> 3256 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3256 Ile Ser Ser Ser Ser Thr Ala Lys 1 5 <210> 3257 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3257 Ala Arg Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln His 1 5 10 <210> 3258 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3258 Gln Ser Val Ser Asn Tyr 1 5 <210> 3259 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3259 Asp Ala Ser One <210> 3260 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3260 Gln Gln Arg Ser Asn Trp Thr 1 5 <210> 3261 <211> 121 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3261 Gln Val Gln Leu Val Gln Ser Gly Gly Thr Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Ser Ser Thr Ala Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Trp Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln His Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 3262 <211> 105 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3262 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Cys Cys Gln Gln Arg Ser Asn Trp Thr Phe 85 90 95 Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 3263 <211> 451 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3263 Gln Val Gln Leu Val Gln Ser Gly Gly Thr Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Ser Ser Thr Ala Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Trp Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln His Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys 450 <210> 3264 <211> 212 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3264 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Cys Cys Gln Gln Arg Ser Asn Trp Thr Phe 85 90 95 Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser 100 105 110 Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala 115 120 125 Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val 130 135 140 Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser 145 150 155 160 Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr 165 170 175 Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys 180 185 190 Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn 195 200 205 Arg Gly Glu Cys 210 <210> 3265 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3265 Asn His Gly Met Ser 1 5 <210> 3266 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3266 Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr Tyr Pro Asp Asn Val Lys 1 5 10 15 Gly <210> 3267 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3267 Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr 1 5 10 <210> 3268 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3268 Ser Gly Asn Ser Ser Asn Ile Gly His Asn Tyr Val Ser 1 5 10 <210> 3269 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3269 Asp Asn Asn Gln Arg Pro Ser 1 5 <210> 3270 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3270 Gly Ile Trp Asp Ser Ser Leu Ser Ile Val Val 1 5 10 <210> 3271 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3271 Gly Phe Thr Phe Ser Asn His 1 5 <210> 3272 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3272 Thr Arg Gly Gly Asp Thr 1 5 <210> 3273 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3273 Gly Pro Leu Thr Val Gly Tyr Ala Met Asp 1 5 10 <210> 3274 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3274 Asn Ser Ser Asn Ile Gly His Asn Tyr 1 5 <210> 3275 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3275 Asp Asn Asn One <210> 3276 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3276 Trp Asp Ser Ser Leu Ser Ile Val 1 5 <210> 3277 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3277 Gly Phe Thr Phe Ser Asn His Gly Met Ser 1 5 10 <210> 3278 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3278 Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr 1 5 10 <210> 3279 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3279 Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr 1 5 10 <210> 3280 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3280 Ser Gly Asn Ser Ser Asn Ile Gly His Asn Tyr Val Ser 1 5 10 <210> 3281 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3281 Asp Asn Asn Gln Arg Pro Ser 1 5 <210> 3282 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3282 Gly Ile Trp Asp Ser Ser Leu Ser Ile Val Val 1 5 10 <210> 3283 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3283 Ser Asn His Gly Met Ser 1 5 <210> 3284 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3284 Trp Val Ala Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr 1 5 10 <210> 3285 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3285 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp 1 5 10 <210> 3286 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3286 Ile Gly His Asn Tyr Val Ser Trp Tyr 1 5 <210> 3287 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3287 Leu Leu Ile Tyr Asp Asn Asn Gln Arg Pro 1 5 10 <210> 3288 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3288 Gly Ile Trp Asp Ser Ser Leu Ser Ile Val 1 5 10 <210> 3289 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3289 Gly Phe Thr Phe Ser Asn His Gly 1 5 <210> 3290 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3290 Ile Thr Arg Gly Gly Asp Thr Thr 1 5 <210> 3291 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3291 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr 1 5 10 <210> 3292 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3292 Ser Ser Asn Ile Gly His Asn Tyr 1 5 <210> 3293 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3293 Asp Asn Asn One <210> 3294 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3294 Gly Ile Trp Asp Ser Ser Leu Ser Ile Val Val 1 5 10 <210> 3295 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3295 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn His 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Ser Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr Tyr Pro Asp Asn Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 3296 <211> 110 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3296 Gln Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Asn Ser Ser Asn Ile Gly His Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Gln Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Asp Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Ile Trp Asp Ser Ser Leu 85 90 95 Ser Ile Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 3297 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3297 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn His 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Ser Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr Tyr Pro Asp Asn Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 3298 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3298 Gln Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Asn Ser Ser Asn Ile Gly His Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Gln Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Asp Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Ile Trp Asp Ser Ser Leu 85 90 95 Ser Ile Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3299 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3299 Asn Tyr Tyr Trp Ser 1 5 <210> 3300 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3300 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3301 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3301 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3302 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3302 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3303 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3303 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3304 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3304 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3305 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3305 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3306 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3306 Tyr Ser Ser Gly Ile 1 5 <210> 3307 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3307 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3308 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3308 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3309 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3309 Glu Val Ser One <210> 3310 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3310 Tyr Thr Ser Thr Ser Val 1 5 <210> 3311 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3311 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3312 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3312 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3313 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3313 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3314 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3314 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3315 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3315 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3316 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3316 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3317 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3317 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3318 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3318 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3319 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3319 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3320 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3320 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3321 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3321 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3322 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3322 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3323 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3323 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3324 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3324 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3325 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3325 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3326 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3326 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3327 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3327 Glu Val Ser One <210> 3328 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3328 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3329 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3329 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3330 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3330 Gln Ala Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3331 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3331 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3332 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3332 Gln Ala Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3333 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3333 Asn Tyr Tyr Trp Ser 1 5 <210> 3334 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3334 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3335 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3335 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3336 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3336 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3337 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3337 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3338 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3338 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3339 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3339 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3340 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3340 Tyr Ser Ser Gly Ile 1 5 <210> 3341 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3341 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3342 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3342 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3343 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3343 Glu Val Ser One <210> 3344 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3344 Tyr Thr Ser Thr Ser Val 1 5 <210> 3345 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3345 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3346 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3346 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3347 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3347 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3348 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3348 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3349 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3349 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3350 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3350 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3351 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3351 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3352 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3352 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3353 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3353 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3354 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3354 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3355 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3355 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3356 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3356 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3357 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3357 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3358 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3358 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3359 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3359 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3360 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3360 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3361 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3361 Glu Val Ser One <210> 3362 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3362 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3363 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3363 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3364 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3364 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3365 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3365 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3366 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3366 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3367 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3367 Thr Tyr Ala Ile Ser 1 5 <210> 3368 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3368 Gly Ile Ile Pro Ile Phe Gly Thr Ala Thr Tyr Ala Gln Arg Phe Gln 1 5 10 15 Asp <210> 3369 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3369 Gly Val Gly Trp Gly Ser Asp Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 <210> 3370 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3370 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 3371 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3371 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 3372 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3372 Ile Gln Ala Thr His His Pro Leu Thr 1 5 <210> 3373 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3373 Gly Gly Thr Phe Ser Thr Tyr 1 5 <210> 3374 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3374 Ile Pro Ile Phe Gly Thr 1 5 <210> 3375 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3375 Gly Val Gly Trp Gly Ser Asp Tyr Tyr Tyr Gly Leu Asp 1 5 10 <210> 3376 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3376 Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 3377 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3377 Lys Ile Ser One <210> 3378 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3378 Ala Thr His His Pro Leu 1 5 <210> 3379 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3379 Gly Gly Thr Phe Ser Thr Tyr Ala Ile Ser 1 5 10 <210> 3380 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3380 Gly Ile Ile Pro Ile Phe Gly Thr Ala Thr 1 5 10 <210> 3381 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3381 Gly Val Gly Trp Gly Ser Asp Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 <210> 3382 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3382 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 3383 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3383 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 3384 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3384 Ile Gln Ala Thr His His Pro Leu Thr 1 5 <210> 3385 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3385 Ser Thr Tyr Ala Ile Ser 1 5 <210> 3386 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3386 Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Thr 1 5 10 <210> 3387 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3387 Ala Arg Gly Val Gly Trp Gly Ser Asp Tyr Tyr Tyr Gly Leu Asp 1 5 10 15 <210> 3388 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3388 Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu 1 5 10 <210> 3389 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3389 Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe 1 5 10 <210> 3390 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3390 Ile Gln Ala Thr His His Pro Leu 1 5 <210> 3391 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3391 Gly Gly Thr Phe Ser Thr Tyr Ala 1 5 <210> 3392 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3392 Ile Ile Pro Ile Phe Gly Thr Ala 1 5 <210> 3393 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3393 Ala Arg Gly Val Gly Trp Gly Ser Asp Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 15 <210> 3394 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3394 Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 3395 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3395 Lys Ile Ser One <210> 3396 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3396 Ile Gln Ala Thr His His Pro Leu Thr 1 5 <210> 3397 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3397 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Thr Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Thr Tyr Ala Gln Arg Phe 50 55 60 Gln Asp Arg Val Met Ile Thr Ala Asp Lys Ser Thr Thr Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Phe Tyr Cys 85 90 95 Ala Arg Gly Val Gly Trp Gly Ser Asp Tyr Tyr Tyr Gly Leu Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 3398 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3398 Glu Ile Val Met Thr Gln Ser Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Arg Ile 65 70 75 80 Thr Arg Val Glu Pro Glu Asp Val Gly Val Tyr Tyr Cys Ile Gln Ala 85 90 95 Thr His His Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys 100 105 110 <210> 3399 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3399 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Thr Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Thr Tyr Ala Gln Arg Phe 50 55 60 Gln Asp Arg Val Met Ile Thr Ala Asp Lys Ser Thr Thr Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Phe Tyr Cys 85 90 95 Ala Arg Gly Val Gly Trp Gly Ser Asp Tyr Tyr Tyr Gly Leu Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 3400 <211> 219 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3400 Glu Ile Val Met Thr Gln Ser Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Arg Ile 65 70 75 80 Thr Arg Val Glu Pro Glu Asp Val Gly Val Tyr Tyr Cys Ile Gln Ala 85 90 95 Thr His His Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 3401 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3401 Asn Tyr Tyr Trp Ser 1 5 <210> 3402 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3402 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3403 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3403 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3404 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3404 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3405 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3405 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3406 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3406 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3407 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3407 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3408 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3408 Tyr Ser Ser Gly Ile 1 5 <210> 3409 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3409 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3410 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3410 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3411 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3411 Glu Val Ser One <210> 3412 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3412 Tyr Thr Ser Thr Ser Val 1 5 <210> 3413 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3413 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3414 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3414 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3415 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3415 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3416 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3416 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3417 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3417 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3418 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3418 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3419 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3419 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3420 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3420 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3421 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3421 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3422 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3422 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3423 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3423 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3424 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3424 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3425 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3425 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3426 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3426 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3427 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3427 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3428 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3428 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3429 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3429 Glu Val Ser One <210> 3430 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3430 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3431 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3431 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3432 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3432 Gln Ala Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 <210> 3433 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3433 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3434 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3434 Gln Ala Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3435 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3435 Ser Phe Tyr Trp Ser 1 5 <210> 3436 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3436 Arg Ile Tyr Thr Ser Gly Gly Thr Ile Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3437 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3437 Trp Leu Arg Ala Phe Asp Tyr 1 5 <210> 3438 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3438 Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys 1 5 10 <210> 3439 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3439 Gln Asp Ser Lys Arg Pro Ser 1 5 <210> 3440 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3440 Gln Ala Trp Asp Ser Ser Thr Val Val 1 5 <210> 3441 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3441 Tyr Gly Ser Phe Ser Ser Phe 1 5 <210> 3442 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3442 Tyr Thr Ser Gly Gly 1 5 <210> 3443 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3443 Trp Leu Arg Ala Phe Asp 1 5 <210> 3444 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3444 Asp Lys Leu Gly Asp Lys Tyr 1 5 <210> 3445 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3445 Gln Asp Ser One <210> 3446 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3446 Trp Asp Ser Ser Thr Val 1 5 <210> 3447 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3447 Tyr Gly Ser Phe Ser Ser Phe Tyr Trp Ser 1 5 10 <210> 3448 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3448 Arg Ile Tyr Thr Ser Gly Gly Thr Ile 1 5 <210> 3449 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3449 Trp Leu Arg Ala Phe Asp Tyr 1 5 <210> 3450 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3450 Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys 1 5 10 <210> 3451 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3451 Gln Asp Ser Lys Arg Pro Ser 1 5 <210> 3452 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3452 Gln Ala Trp Asp Ser Ser Thr Val Val 1 5 <210> 3453 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3453 Ser Ser Phe Tyr Trp Ser 1 5 <210> 3454 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3454 Trp Ile Gly Arg Ile Tyr Thr Ser Gly Gly Thr Ile 1 5 10 <210> 3455 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3455 Ala Arg Trp Leu Arg Ala Phe Asp 1 5 <210> 3456 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3456 Asp Lys Tyr Ala Cys Trp Tyr 1 5 <210> 3457 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3457 Leu Val Ile Tyr Gln Asp Ser Lys Arg Pro 1 5 10 <210> 3458 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3458 Gln Ala Trp Asp Ser Ser Thr Val 1 5 <210> 3459 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3459 Tyr Gly Ser Phe Ser Ser Phe Tyr 1 5 <210> 3460 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3460 Ile Tyr Thr Ser Gly Gly Thr 1 5 <210> 3461 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3461 Ala Arg Trp Leu Arg Ala Phe Asp Tyr 1 5 <210> 3462 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3462 Lys Leu Gly Asp Lys Tyr 1 5 <210> 3463 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3463 Gln Asp Ser One <210> 3464 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3464 Gln Ala Trp Asp Ser Ser Thr Val Val 1 5 <210> 3465 <211> 115 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3465 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Tyr Gly Ser Phe Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Thr Ser Gly Gly Thr Ile Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Trp Leu Arg Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 3466 <211> 106 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3466 Ser Ser Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3467 <211> 445 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3467 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Tyr Gly Ser Phe Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Thr Ser Gly Gly Thr Ile Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Trp Leu Arg Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 115 120 125 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 165 170 175 Leu Tyr Ser Leu Ser Ser Val Val Val Thr Val Pro Ser Ser Ser Leu Gly 180 185 190 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 195 200 205 Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 225 230 235 240 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 260 265 270 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 325 330 335 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 340 345 350 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 355 360 365 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 370 375 380 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 405 410 415 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 420 425 430 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3468 <211> 212 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3468 Ser Ser Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 35 40 45 Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala 100 105 110 Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn 115 120 125 Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val 130 135 140 Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu 145 150 155 160 Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser 165 170 175 Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser 180 185 190 Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro 195 200 205 Thr Glu Cys Ser 210 <210> 3469 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3469 Asn Tyr Tyr Trp Ser 1 5 <210> 3470 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3470 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3471 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3471 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3472 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3472 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3473 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3473 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3474 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3474 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3475 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3475 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3476 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3476 Tyr Ser Ser Gly Ile 1 5 <210> 3477 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3477 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3478 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3478 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3479 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3479 Glu Val Ser One <210> 3480 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3480 Tyr Thr Ser Thr Ser Val 1 5 <210> 3481 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3481 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3482 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3482 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3483 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3483 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3484 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3484 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3485 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3485 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3486 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3486 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3487 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3487 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3488 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3488 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3489 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3489 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3490 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3490 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3491 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3491 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3492 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3492 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3493 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3493 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3494 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3494 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3495 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3495 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3496 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3496 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3497 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3497 Glu Val Ser One <210> 3498 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3498 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3499 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3499 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3500 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3500 Gln Pro Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3501 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3501 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3502 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3502 Gln Pro Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3503 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3503 Asn His Gly Met Ser 1 5 <210> 3504 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3504 Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr Tyr Pro Asp Asn Val Lys 1 5 10 15 Gly <210> 3505 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3505 Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr 1 5 10 <210> 3506 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3506 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Thr 1 5 10 <210> 3507 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3507 Gly Glu Asn Asn Arg Pro Ser 1 5 <210> 3508 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3508 Asn Ser Arg Asp Thr Gly Asp His His Leu Val 1 5 10 <210> 3509 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3509 Gly Phe Thr Phe Ser Asn His 1 5 <210> 3510 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3510 Thr Arg Gly Gly Asp Thr 1 5 <210> 3511 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3511 Gly Pro Leu Thr Val Gly Tyr Ala Met Asp 1 5 10 <210> 3512 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3512 Asp Ser Leu Arg Ser Tyr Tyr 1 5 <210> 3513 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3513 Gly Glu Asn One <210> 3514 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3514 Arg Asp Thr Gly Asp His His Leu 1 5 <210> 3515 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3515 Gly Phe Thr Phe Ser Asn His Gly Met Ser 1 5 10 <210> 3516 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3516 Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr 1 5 10 <210> 3517 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3517 Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr 1 5 10 <210> 3518 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3518 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Thr 1 5 10 <210> 3519 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3519 Gly Glu Asn Asn Arg Pro Ser 1 5 <210> 3520 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3520 Asn Ser Arg Asp Thr Gly Asp His His Leu Val 1 5 10 <210> 3521 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3521 Ser Asn His Gly Met Ser 1 5 <210> 3522 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3522 Trp Val Ala Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr 1 5 10 <210> 3523 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3523 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp 1 5 10 <210> 3524 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3524 Ser Tyr Tyr Ala Thr Trp Tyr 1 5 <210> 3525 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3525 Leu Val Ile Tyr Gly Glu Asn Asn Arg Pro 1 5 10 <210> 3526 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3526 Asn Ser Arg Asp Thr Gly Asp His His Leu 1 5 10 <210> 3527 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3527 Gly Phe Thr Phe Ser Asn His Gly 1 5 <210> 3528 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3528 Ile Thr Arg Gly Gly Asp Thr Thr 1 5 <210> 3529 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3529 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr 1 5 10 <210> 3530 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3530 Ser Leu Arg Ser Tyr Tyr 1 5 <210> 3531 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3531 Gly Glu Asn One <210> 3532 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3532 Asn Ser Arg Asp Thr Gly Asp His His Leu Val 1 5 10 <210> 3533 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3533 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn His 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Ser Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr Tyr Pro Asp Asn Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 3534 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3534 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ile Leu Val Ile Tyr 35 40 45 Gly Glu Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Arg Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Thr Gly Asp His His 85 90 95 Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3535 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3535 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn His 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Ser Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr Tyr Pro Asp Asn Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 3536 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3536 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ile Leu Val Ile Tyr 35 40 45 Gly Glu Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Arg Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Thr Gly Asp His His 85 90 95 Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys 100 105 110 Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 115 120 125 Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 130 135 140 Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 145 150 155 160 Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 165 170 175 Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 180 185 190 Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 195 200 205 Ala Pro Thr Glu Cys Ser 210 <210> 3537 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3537 Asn Tyr Tyr Trp Ser 1 5 <210> 3538 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3538 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3539 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3539 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3540 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3540 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3541 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3541 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3542 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3542 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3543 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3543 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3544 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3544 Tyr Ser Ser Gly Ile 1 5 <210> 3545 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3545 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3546 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3546 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3547 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3547 Glu Val Ser One <210> 3548 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3548 Tyr Thr Ser Thr Ser Val 1 5 <210> 3549 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3549 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3550 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3550 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3551 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3551 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3552 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3552 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3553 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3553 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3554 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3554 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3555 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3555 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3556 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3556 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3557 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3557 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3558 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3558 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3559 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3559 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3560 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3560 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3561 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3561 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3562 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3562 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3563 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3563 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3564 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3564 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3565 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3565 Glu Val Ser One <210> 3566 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3566 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3567 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3567 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3568 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3568 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 <210> 3569 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3569 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3570 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3570 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3571 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3571 Asn Tyr Tyr Trp Ser 1 5 <210> 3572 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3572 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3573 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3573 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3574 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3574 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3575 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3575 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3576 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3576 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3577 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3577 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3578 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3578 Tyr Ser Ser Gly Ile 1 5 <210> 3579 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3579 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3580 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3580 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3581 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3581 Glu Val Ser One <210> 3582 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3582 Tyr Thr Ser Thr Ser Val 1 5 <210> 3583 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3583 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3584 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3584 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3585 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3585 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3586 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3586 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3587 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3587 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3588 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3588 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3589 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3589 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3590 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3590 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3591 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3591 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3592 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3592 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3593 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3593 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3594 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3594 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3595 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3595 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3596 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3596 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3597 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3597 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3598 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3598 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3599 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3599 Glu Val Ser One <210> 3600 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3600 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3601 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3601 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3602 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3602 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3603 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3603 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3604 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3604 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3605 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3605 Asn Tyr Tyr Trp Ser 1 5 <210> 3606 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3606 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3607 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3607 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3608 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3608 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3609 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3609 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3610 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3610 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3611 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3611 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3612 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3612 Tyr Ser Ser Gly Ile 1 5 <210> 3613 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3613 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3614 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3614 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3615 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3615 Glu Val Ser One <210> 3616 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3616 Tyr Thr Ser Thr Ser Val 1 5 <210> 3617 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3617 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3618 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3618 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3619 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3619 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3620 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3620 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3621 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3621 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3622 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3622 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3623 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3623 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3624 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3624 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3625 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3625 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3626 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3626 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3627 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3627 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3628 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3628 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3629 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3629 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3630 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3630 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3631 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3631 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3632 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3632 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3633 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3633 Glu Val Ser One <210> 3634 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3634 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3635 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3635 Gln Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3636 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3636 Ser Tyr Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3637 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3637 Gln Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3638 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3638 Ser Tyr Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3639 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3639 Asn Tyr Tyr Trp Ser 1 5 <210> 3640 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3640 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3641 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3641 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3642 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3642 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3643 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3643 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3644 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3644 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3645 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3645 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3646 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3646 Tyr Ser Ser Gly Ile 1 5 <210> 3647 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3647 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3648 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3648 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3649 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3649 Glu Val Ser One <210> 3650 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3650 Tyr Thr Ser Thr Ser Val 1 5 <210> 3651 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3651 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3652 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3652 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3653 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3653 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3654 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3654 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3655 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3655 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3656 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3656 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3657 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3657 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3658 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3658 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3659 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3659 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3660 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3660 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3661 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3661 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3662 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3662 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3663 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3663 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3664 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3664 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3665 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3665 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3666 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3666 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3667 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3667 Glu Val Ser One <210> 3668 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3668 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3669 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3669 Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3670 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3670 Ser Tyr Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3671 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3671 Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3672 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3672 Ser Tyr Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3673 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3673 Asn Tyr Tyr Trp Ser 1 5 <210> 3674 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3674 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3675 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3675 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3676 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3676 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3677 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3677 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3678 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3678 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3679 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3679 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3680 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3680 Tyr Ser Ser Gly Ile 1 5 <210> 3681 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3681 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3682 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3682 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3683 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3683 Glu Val Ser One <210> 3684 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3684 Tyr Thr Ser Thr Ser Val 1 5 <210> 3685 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3685 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3686 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3686 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3687 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3687 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3688 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3688 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3689 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3689 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3690 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3690 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3691 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3691 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3692 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3692 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3693 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3693 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3694 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3694 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3695 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3695 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3696 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3696 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3697 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3697 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3698 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3698 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3699 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3699 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3700 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3700 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3701 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3701 Glu Val Ser One <210> 3702 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3702 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3703 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3703 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3704 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3704 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3705 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3705 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3706 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3706 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3707 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3707 Asn Tyr Tyr Trp Ser 1 5 <210> 3708 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3708 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3709 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3709 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3710 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3710 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3711 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3711 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3712 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3712 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3713 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3713 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3714 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3714 Tyr Ser Ser Gly Ile 1 5 <210> 3715 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3715 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3716 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3716 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3717 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3717 Glu Val Ser One <210> 3718 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3718 Tyr Thr Ser Thr Ser Val 1 5 <210> 3719 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3719 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3720 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3720 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3721 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3721 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3722 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3722 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3723 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3723 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3724 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3724 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3725 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3725 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3726 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3726 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3727 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3727 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3728 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3728 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3729 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3729 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3730 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3730 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3731 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3731 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3732 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3732 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3733 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3733 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3734 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3734 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3735 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3735 Glu Val Ser One <210> 3736 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3736 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3737 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3737 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3738 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3738 Ser Tyr Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3739 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3739 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3740 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3740 Ser Tyr Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3741 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3741 Asn Tyr Tyr Trp Ser 1 5 <210> 3742 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3742 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3743 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3743 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3744 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3744 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3745 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3745 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3746 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3746 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3747 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3747 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3748 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3748 Tyr Ser Ser Gly Ile 1 5 <210> 3749 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3749 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3750 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3750 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3751 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3751 Glu Val Ser One <210> 3752 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3752 Tyr Thr Ser Thr Ser Val 1 5 <210> 3753 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3753 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3754 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3754 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3755 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3755 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3756 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3756 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3757 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3757 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3758 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3758 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3759 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3759 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3760 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3760 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3761 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3761 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3762 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3762 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3763 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3763 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3764 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3764 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3765 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3765 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3766 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3766 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3767 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3767 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3768 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3768 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3769 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3769 Glu Val Ser One <210> 3770 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3770 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3771 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3771 Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 3772 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3772 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3773 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3773 Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3774 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3774 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3775 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3775 Asn Tyr Tyr Trp Ser 1 5 <210> 3776 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3776 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3777 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3777 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3778 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3778 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3779 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3779 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3780 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3780 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3781 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3781 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3782 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3782 Tyr Ser Ser Gly Ile 1 5 <210> 3783 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3783 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3784 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3784 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3785 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3785 Glu Val Ser One <210> 3786 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3786 Tyr Thr Ser Thr Ser Val 1 5 <210> 3787 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3787 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3788 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3788 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3789 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3789 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3790 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3790 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3791 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3791 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3792 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3792 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3793 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3793 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3794 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3794 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3795 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3795 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3796 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3796 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3797 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3797 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3798 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3798 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3799 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3799 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3800 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3800 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3801 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3801 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3802 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3802 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3803 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3803 Glu Val Ser One <210> 3804 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3804 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3805 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3805 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3806 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3806 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3807 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3807 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3808 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3808 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3809 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3809 Asn Tyr Tyr Trp Ser 1 5 <210> 3810 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3810 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3811 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3811 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3812 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3812 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3813 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3813 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3814 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3814 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3815 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3815 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3816 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3816 Tyr Ser Ser Gly Ile 1 5 <210> 3817 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3817 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3818 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3818 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3819 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3819 Glu Val Ser One <210> 3820 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3820 Tyr Thr Ser Thr Ser Val 1 5 <210> 3821 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3821 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3822 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3822 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3823 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3823 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3824 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3824 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3825 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3825 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3826 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3826 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3827 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3827 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3828 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3828 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3829 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3829 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3830 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3830 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3831 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3831 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3832 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3832 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3833 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3833 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3834 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3834 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3835 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3835 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3836 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3836 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3837 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3837 Glu Val Ser One <210> 3838 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3838 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3839 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3839 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3840 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3840 Gln Ala Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3841 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3841 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3842 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3842 Gln Ala Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3843 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3843 Asn Tyr Tyr Trp Ser 1 5 <210> 3844 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3844 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3845 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3845 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3846 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3846 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3847 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3847 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3848 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3848 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3849 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3849 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3850 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3850 Tyr Ser Ser Gly Ile 1 5 <210> 3851 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3851 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3852 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3852 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3853 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3853 Glu Val Ser One <210> 3854 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3854 Tyr Thr Ser Thr Ser Val 1 5 <210> 3855 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3855 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3856 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3856 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3857 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3857 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3858 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3858 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3859 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3859 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3860 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3860 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3861 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3861 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3862 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3862 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3863 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3863 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3864 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3864 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3865 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3865 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3866 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3866 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3867 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3867 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3868 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3868 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3869 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3869 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3870 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3870 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3871 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3871 Glu Val Ser One <210> 3872 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3872 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3873 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3873 Gln Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3874 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3874 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 <210> 3875 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3875 Gln Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3876 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3876 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3877 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3877 Asn Tyr Tyr Trp Ser 1 5 <210> 3878 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3878 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3879 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3879 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3880 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3880 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3881 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3881 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3882 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3882 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3883 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3883 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3884 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3884 Tyr Ser Ser Gly Ile 1 5 <210> 3885 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3885 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3886 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3886 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3887 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3887 Glu Val Ser One <210> 3888 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3888 Tyr Thr Ser Thr Ser Val 1 5 <210> 3889 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3889 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3890 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3890 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3891 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3891 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3892 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3892 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3893 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3893 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3894 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3894 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3895 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3895 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3896 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3896 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3897 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3897 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3898 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3898 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3899 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3899 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3900 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3900 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3901 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3901 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3902 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3902 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3903 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3903 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3904 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3904 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3905 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3905 Glu Val Ser One <210> 3906 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3906 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3907 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3907 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3908 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3908 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3909 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3909 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3910 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3910 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3911 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3911 Asn Tyr Tyr Trp Ser 1 5 <210> 3912 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3912 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3913 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3913 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3914 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3914 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3915 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3915 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3916 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3916 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3917 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3917 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3918 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3918 Tyr Ser Ser Gly Ile 1 5 <210> 3919 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3919 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3920 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3920 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3921 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3921 Glu Val Ser One <210> 3922 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3922 Tyr Thr Ser Thr Ser Val 1 5 <210> 3923 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3923 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3924 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3924 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3925 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3925 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3926 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3926 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3927 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3927 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3928 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3928 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3929 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3929 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3930 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3930 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3931 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3931 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3932 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3932 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3933 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3933 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3934 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3934 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3935 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3935 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3936 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3936 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3937 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3937 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3938 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3938 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3939 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3939 Glu Val Ser One <210> 3940 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3940 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3941 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3941 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3942 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3942 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3943 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3943 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3944 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3944 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3945 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3945 Asn Tyr Tyr Trp Ser 1 5 <210> 3946 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3946 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 3947 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3947 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3948 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3948 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3949 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3949 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3950 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3950 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3951 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3951 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 3952 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3952 Tyr Ser Ser Gly Ile 1 5 <210> 3953 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3953 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 3954 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3954 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3955 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3955 Glu Val Ser One <210> 3956 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3956 Tyr Thr Ser Thr Ser Val 1 5 <210> 3957 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3957 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 3958 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3958 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 3959 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3959 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3960 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3960 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3961 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3961 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 3962 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3962 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3963 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3963 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 3964 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3964 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 3965 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3965 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 3966 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3966 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 3967 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3967 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 3968 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3968 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 3969 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3969 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 3970 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3970 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 3971 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3971 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 3972 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3972 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 3973 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3973 Glu Val Ser One <210> 3974 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3974 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 3975 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3975 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 3976 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3976 Gln Leu Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 3977 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3977 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 3978 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 3978 Gln Leu Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 3979 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3979 Asn His Gly Met Ser 1 5 <210> 3980 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3980 Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr Tyr Pro Asp Asn Val Lys 1 5 10 15 Gly <210> 3981 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3981 Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr 1 5 10 <210> 3982 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3982 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3983 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3983 Glu Val Ser Lys Arg Pro Ser 1 5 <210> 3984 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3984 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu Val 1 5 10 <210> 3985 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3985 Gly Phe Thr Phe Ser Asn His 1 5 <210> 3986 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3986 Thr Arg Gly Gly Asp Thr 1 5 <210> 3987 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3987 Gly Pro Leu Thr Val Gly Tyr Ala Met Asp 1 5 10 <210> 3988 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3988 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 3989 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3989 Glu Val Ser One <210> 3990 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3990 Tyr Ala Gly Ser Asn Asn Phe Glu 1 5 <210> 3991 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3991 Gly Phe Thr Phe Ser Asn His Gly Met Ser 1 5 10 <210> 3992 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3992 Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr 1 5 10 <210> 3993 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3993 Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr 1 5 10 <210> 3994 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3994 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 3995 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3995 Glu Val Ser Lys Arg Pro Ser 1 5 <210> 3996 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3996 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu Val 1 5 10 <210> 3997 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3997 Ser Asn His Gly Met Ser 1 5 <210> 3998 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3998 Trp Val Ala Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr 1 5 10 <210> 3999 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3999 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp 1 5 10 <210> 4000 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4000 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 4001 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4001 Leu Met Ile Tyr Glu Val Ser Lys Arg Pro 1 5 10 <210> 4002 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4002 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu 1 5 10 <210> 4003 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4003 Gly Phe Thr Phe Ser Asn His Gly 1 5 <210> 4004 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4004 Ile Thr Arg Gly Gly Asp Thr Thr 1 5 <210> 4005 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4005 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr 1 5 10 <210> 4006 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4006 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 4007 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4007 Glu Val Ser One <210> 4008 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4008 Asn Ser Tyr Ala Gly Ser Asn Asn Phe Glu Val 1 5 10 <210> 4009 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4009 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn His 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Ser Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr Tyr Pro Asp Asn Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 4010 <211> 111 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4010 Gln Ser Val Val Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ala Gly Ser 85 90 95 Asn Asn Phe Glu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 4011 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4011 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn His 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Ser Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Ser Ile Thr Arg Gly Gly Asp Thr Thr Tyr Tyr Pro Asp Asn Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Thr Arg Gly Pro Leu Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 4012 <211> 217 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4012 Gln Ser Val Val Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Ala Gly Ser 85 90 95 Asn Asn Phe Glu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 4013 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4013 Asn Tyr Tyr Trp Ser 1 5 <210> 4014 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4014 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 4015 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4015 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 4016 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4016 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 4017 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4017 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 4018 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4018 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 4019 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4019 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 4020 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4020 Tyr Ser Ser Gly Ile 1 5 <210> 4021 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4021 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 4022 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4022 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 4023 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4023 Glu Val Ser One <210> 4024 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4024 Tyr Thr Ser Thr Ser Val 1 5 <210> 4025 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4025 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 4026 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4026 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 4027 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4027 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 4028 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4028 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 4029 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4029 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 4030 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4030 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 4031 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4031 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 4032 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4032 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 4033 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4033 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 4034 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4034 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 4035 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4035 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 4036 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4036 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 4037 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4037 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 4038 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4038 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 4039 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4039 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 4040 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4040 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 4041 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4041 Glu Val Ser One <210> 4042 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4042 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 4043 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4043 Gln Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 4044 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4044 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 4045 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4045 Gln Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 4046 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4046 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 4047 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4047 Ser Tyr Tyr Trp Ser 1 5 <210> 4048 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4048 Arg Ile His Thr Ile Gly Ser Ile Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 4049 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4049 Glu Gly Val Gly Ala Thr Asn Tyr Tyr Tyr Gly Met Ala Val 1 5 10 <210> 4050 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4050 Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp 1 5 10 15 <210> 4051 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4051 Leu Gly Ser Asn Arg Ala Ser 1 5 <210> 4052 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4052 Met Gln Ala Leu Gln Thr Pro Tyr Thr 1 5 <210> 4053 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4053 Gly Gly Ser Ile Ser Ser Tyr 1 5 <210> 4054 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4054 His Thr Ile Gly Ser 1 5 <210> 4055 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4055 Glu Gly Val Gly Ala Thr Asn Tyr Tyr Tyr Gly Met Ala 1 5 10 <210> 4056 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4056 Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr 1 5 10 <210> 4057 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4057 Leu Gly Ser One <210> 4058 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4058 Ala Leu Gln Thr Pro Tyr 1 5 <210> 4059 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4059 Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser 1 5 10 <210> 4060 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4060 Arg Ile His Thr Ile Gly Ser Ile Asn 1 5 <210> 4061 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4061 Glu Gly Val Gly Ala Thr Asn Tyr Tyr Tyr Gly Met Ala Val 1 5 10 <210> 4062 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4062 Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp 1 5 10 15 <210> 4063 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4063 Leu Gly Ser Asn Arg Ala Ser 1 5 <210> 4064 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4064 Met Gln Ala Leu Gln Thr Pro Tyr Thr 1 5 <210> 4065 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4065 Ser Ser Tyr Tyr Trp Ser 1 5 <210> 4066 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4066 Trp Ile Gly Arg Ile His Thr Ile Gly Ser Ile Asn 1 5 10 <210> 4067 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4067 Ala Met Glu Gly Val Gly Ala Thr Asn Tyr Tyr Tyr Gly Met Ala 1 5 10 15 <210> 4068 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4068 Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr 1 5 10 <210> 4069 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4069 Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala 1 5 10 <210> 4070 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4070 Met Gln Ala Leu Gln Thr Pro Tyr 1 5 <210> 4071 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4071 Gly Gly Ser Ile Ser Ser Tyr Tyr 1 5 <210> 4072 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4072 Ile His Thr Ile Gly Ser Ile 1 5 <210> 4073 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4073 Ala Met Glu Gly Val Gly Ala Thr Asn Tyr Tyr Tyr Gly Met Ala Val 1 5 10 15 <210> 4074 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4074 Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr 1 5 10 <210> 4075 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4075 Leu Gly Ser One <210> 4076 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4076 Met Gln Ala Leu Gln Thr Pro Tyr Thr 1 5 <210> 4077 <211> 122 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4077 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile His Thr Ile Gly Ser Ile Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Met Glu Gly Val Gly Ala Thr Asn Tyr Tyr Tyr Gly Met Ala Val Trp 100 105 110 Gly Arg Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 4078 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4078 Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Leu Gln Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 4079 <211> 452 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4079 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile His Thr Ile Gly Ser Ile Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Met Glu Gly Val Gly Ala Thr Asn Tyr Tyr Tyr Gly Met Ala Val Trp 100 105 110 Gly Arg Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Lys 450 <210> 4080 <211> 219 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4080 Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Leu Gln Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 4081 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4081 Thr Tyr Trp Met His 1 5 <210> 4082 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4082 Leu Ile Asp Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> 4083 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4083 Asn Arg Trp Leu Leu Gly 1 5 <210> 4084 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4084 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 4085 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4085 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 4086 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4086 Val Gln Thr Arg Glu Phe Pro Leu Thr 1 5 <210> 4087 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4087 Gly Tyr Ser Phe Thr Thr Tyr 1 5 <210> 4088 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4088 Asp Pro Ser Asp Ser Glu 1 5 <210> 4089 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4089 Asn Arg Trp Leu Leu 1 5 <210> 4090 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4090 Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 4091 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4091 Lys Ile Ser One <210> 4092 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4092 Thr Arg Glu Phe Pro Leu 1 5 <210> 4093 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4093 Gly Tyr Ser Phe Thr Thr Tyr Trp Met His 1 5 10 <210> 4094 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4094 Leu Ile Asp Pro Ser Asp Ser Glu Thr Arg 1 5 10 <210> 4095 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4095 Asn Arg Trp Leu Leu Gly 1 5 <210> 4096 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4096 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 4097 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4097 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 4098 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4098 Val Gln Thr Arg Glu Phe Pro Leu Thr 1 5 <210> 4099 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4099 Thr Thr Tyr Trp Met His 1 5 <210> 4100 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4100 Trp Ile Gly Leu Ile Asp Pro Ser Asp Ser Glu Thr Arg 1 5 10 <210> 4101 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4101 Ala Ser Asn Arg Trp Leu Leu 1 5 <210> 4102 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4102 Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu 1 5 10 <210> 4103 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4103 Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe 1 5 10 <210> 4104 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4104 Val Gln Thr Arg Glu Phe Pro Leu 1 5 <210> 4105 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4105 Gly Tyr Ser Phe Thr Thr Tyr Tyr Trp 1 5 <210> 4106 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4106 Ile Asp Pro Ser Asp Ser Glu Thr 1 5 <210> 4107 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4107 Ala Ser Asn Arg Trp Leu Leu Gly 1 5 <210> 4108 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4108 Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 4109 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4109 Lys Ile Ser One <210> 4110 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4110 Val Gln Thr Arg Glu Phe Pro Leu Thr 1 5 <210> 4111 <211> 115 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4111 Gln Val Gln Leu Gln Glu Ser Gly Pro Gln Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Asp Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Arg Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Asn Arg Trp Leu Leu Gly Trp Gly Gln Gly Thr Met Val Thr 100 105 110 Val Ser Ser 115 <210> 4112 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4112 Glu Ile Val Leu Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu His Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Thr Glu Asp Val Gly Val Tyr Tyr Cys Val Gln Thr 85 90 95 Arg Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 4113 <211> 445 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4113 Gln Val Gln Leu Gln Glu Ser Gly Pro Gln Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Asp Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Arg Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Asn Arg Trp Leu Leu Gly Trp Gly Gln Gly Thr Met Val Thr 100 105 110 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 115 120 125 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 165 170 175 Leu Tyr Ser Leu Ser Ser Val Val Val Thr Val Pro Ser Ser Ser Leu Gly 180 185 190 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 195 200 205 Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 225 230 235 240 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 260 265 270 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 325 330 335 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 340 345 350 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 355 360 365 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 370 375 380 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 405 410 415 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 420 425 430 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 4114 <211> 219 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4114 Glu Ile Val Leu Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu His Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Thr Glu Asp Val Gly Val Tyr Tyr Cys Val Gln Thr 85 90 95 Arg Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 4115 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4115 Ser Asn Arg Ala Ala Trp Asn 1 5 <210> 4116 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4116 Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Glu Tyr Ala Ala Ser Val 1 5 10 15 Lys Ser <210> 4117 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4117 Asp Leu Trp Glu Leu Arg Glu Ala Cys Asp Ile 1 5 10 <210> 4118 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4118 Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 4119 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4119 Val Ala Ser Thr Leu Gln Ser 1 5 <210> 4120 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4120 Gln Gln Leu Asn Ser Tyr Pro Phe Thr 1 5 <210> 4121 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4121 Gly Asp Ser Val Ser Ser Asn Arg Ala 1 5 <210> 4122 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4122 Tyr Tyr Arg Ser Lys Trp Tyr 1 5 <210> 4123 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4123 Asp Leu Trp Glu Leu Arg Glu Ala Cys Asp 1 5 10 <210> 4124 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4124 Ser Gln Gly Ile Ser Ser Tyr 1 5 <210> 4125 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4125 Val Ala Ser One <210> 4126 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4126 Leu Asn Ser Tyr Pro Phe 1 5 <210> 4127 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4127 Gly Asp Ser Val Ser Ser Asn Arg Ala Ala Trp Asn 1 5 10 <210> 4128 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4128 Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Glu 1 5 10 <210> 4129 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4129 Asp Leu Trp Glu Leu Arg Glu Ala Cys Asp Ile 1 5 10 <210> 4130 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4130 Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 4131 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4131 Val Ala Ser Thr Leu Gln Ser 1 5 <210> 4132 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4132 Gln Gln Leu Asn Ser Tyr Pro Phe Thr 1 5 <210> 4133 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4133 Ser Ser Asn Arg Ala Ala Trp Asn 1 5 <210> 4134 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4134 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Glu 1 5 10 <210> 4135 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4135 Ala Arg Asp Leu Trp Glu Leu Arg Glu Ala Cys Asp 1 5 10 <210> 4136 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4136 Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 4137 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4137 Leu Leu Ile Tyr Val Ala Ser Thr Leu Gln 1 5 10 <210> 4138 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4138 Gln Gln Leu Asn Ser Tyr Pro Phe 1 5 <210> 4139 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4139 Gly Asp Ser Val Ser Ser Asn Arg Ala Ala 1 5 10 <210> 4140 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4140 Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn 1 5 <210> 4141 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4141 Ala Arg Asp Leu Trp Glu Leu Arg Glu Ala Cys Asp Ile 1 5 10 <210> 4142 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4142 Gln Gly Ile Ser Ser Tyr 1 5 <210> 4143 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4143 Val Ala Ser One <210> 4144 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4144 Gln Gln Leu Asn Ser Tyr Pro Phe Thr 1 5 <210> 4145 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4145 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Arg Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Lys Gly Leu Glu 35 40 45 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Glu Tyr Ala 50 55 60 Ala Ser Val Lys Ser Arg Met Ser Ile Asn Pro Asp Thr Ser Lys Asn 65 70 75 80 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Leu 85 90 95 Tyr Tyr Cys Ala Arg Asp Leu Trp Glu Leu Arg Glu Ala Cys Asp Ile 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 4146 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4146 Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Thr Phe Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 35 40 45 Tyr Val Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 <210> 4147 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4147 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Arg Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Lys Gly Leu Glu 35 40 45 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Glu Tyr Ala 50 55 60 Ala Ser Val Lys Ser Arg Met Ser Ile Asn Pro Asp Thr Ser Lys Asn 65 70 75 80 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Leu 85 90 95 Tyr Tyr Cys Ala Arg Asp Leu Trp Glu Leu Arg Glu Ala Cys Asp Ile 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 4148 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4148 Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Thr Phe Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 35 40 45 Tyr Val Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 4149 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4149 Asn Tyr Asp Met Asn 1 5 <210> 4150 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4150 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 4151 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4151 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 4152 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4152 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 4153 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4153 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 4154 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4154 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 4155 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4155 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 4156 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4156 Ser Ser Ser Ser Ser Tyr 1 5 <210> 4157 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4157 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 4158 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4158 Ser Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 4159 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4159 Gly Ala Ser One <210> 4160 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4160 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 4161 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4161 Gly Phe Thr Phe Ser Asn Tyr Asp Met Asn 1 5 10 <210> 4162 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4162 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 4163 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4163 Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 4164 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4164 Arg Ala Ser Gln Ser Val Ala Ser Ser Tyr Leu Ala 1 5 10 <210> 4165 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4165 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 4166 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4166 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 4167 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4167 Ser Asn Tyr Asp Met Asn 1 5 <210> 4168 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4168 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 4169 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4169 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 4170 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4170 Ala Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 4171 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4171 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 4172 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4172 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 4173 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4173 Gly Phe Thr Phe Ser Asn Tyr Asp 1 5 <210> 4174 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4174 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 4175 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4175 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val <210> 4176 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4176 Gln Ser Val Ala Ser Ser Tyr 1 5 <210> 4177 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4177 Gly Ala Ser One <210> 4178 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4178 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 4179 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4179 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 4180 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4180 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100 105 <210> 4181 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4181 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr His Cys 85 90 95 Ala Arg Asp Val Gly Val Thr Thr Asp Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 4182 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4182 Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 4183 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4183 Thr Ile Gly Val Gly Val Gly 1 5 <210> 4184 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4184 Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 4185 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4185 Ser His Asp Trp Val His Ala Phe Asp Ile 1 5 10 <210> 4186 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4186 Gln Ala Ser Gln Asp Ile Ser His Tyr Leu Asn 1 5 10 <210> 4187 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4187 Asp Ala Ser Asn Leu Asp Thr 1 5 <210> 4188 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4188 Gln Gln Tyr Asp Asn Phe Pro Leu Thr 1 5 <210> 4189 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4189 Gly Phe Ser Leu Ser Thr Ile Gly Val 1 5 <210> 4190 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4190 Tyr Trp Asn Asp Asp 1 5 <210> 4191 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4191 Ser His Asp Trp Val His Ala Phe Asp 1 5 <210> 4192 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4192 Ser Gln Asp Ile Ser His Tyr 1 5 <210> 4193 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4193 Asp Ala Ser One <210> 4194 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4194 Tyr Asp Asn Phe Pro Leu 1 5 <210> 4195 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4195 Gly Phe Ser Leu Ser Thr Ile Gly Val Gly Val Gly 1 5 10 <210> 4196 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4196 Leu Ile Tyr Trp Asn Asp Asp Lys Arg 1 5 <210> 4197 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4197 Ser His Asp Trp Val His Ala Phe Asp Ile 1 5 10 <210> 4198 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4198 Gln Ala Ser Gln Asp Ile Ser His Tyr Leu Asn 1 5 10 <210> 4199 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4199 Asp Ala Ser Asn Leu Asp Thr 1 5 <210> 4200 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4200 Gln Gln Tyr Asp Asn Phe Pro Leu Thr 1 5 <210> 4201 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4201 Ser Thr Ile Gly Val Gly Val Gly 1 5 <210> 4202 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4202 Trp Leu Ser Leu Ile Tyr Trp Asn Asp Asp Lys Arg 1 5 10 <210> 4203 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4203 Ala His Ser His Asp Trp Val His Ala Phe Asp 1 5 10 <210> 4204 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4204 Ser His Tyr Leu Asn Trp Tyr 1 5 <210> 4205 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4205 Phe Leu Ile Tyr Asp Ala Ser Asn Leu Asp 1 5 10 <210> 4206 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4206 Gln Gln Tyr Asp Asn Phe Pro Leu 1 5 <210> 4207 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4207 Gly Phe Ser Leu Ser Thr Ile Gly Val Gly 1 5 10 <210> 4208 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4208 Ile Tyr Trp Asn Asp Asp Lys 1 5 <210> 4209 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4209 Ala His Ser His Asp Trp Val His Ala Phe Asp Ile 1 5 10 <210> 4210 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4210 Gln Asp Ile Ser His Tyr 1 5 <210> 4211 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4211 Asp Ala Ser One <210> 4212 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4212 Gln Gln Tyr Asp Asn Phe Pro Leu Thr 1 5 <210> 4213 <211> 120 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4213 Glu Val Gln Leu Leu Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ile 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ser Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala His Ser His Asp Trp Val His Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 4214 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4214 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser His Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Asp Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Phe Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 4215 <211> 450 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4215 Glu Val Gln Leu Leu Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ile 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ser Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala His Ser His Asp Trp Val His Ala Phe Asp Ile Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 4216 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4216 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser His Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Asp Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Phe Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 4217 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4217 Gly Tyr Tyr Met His 1 5 <210> 4218 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4218 Trp Ile Asn Pro Asn Ser Gly Ala Thr Asn Lys Glu Gln Lys Phe Gln 1 5 10 15 Gly <210> 4219 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4219 Glu Asp Asp Ala Phe Asp Val 1 5 <210> 4220 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4220 Gln Gly Asp Asn Leu Arg Asn Tyr Tyr Ala Thr 1 5 10 <210> 4221 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4221 Gly Lys Asn Asn Arg Pro Ser 1 5 <210> 4222 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4222 Asn Ser Arg Asp Ser Ser Gly Asn His Val Val 1 5 10 <210> 4223 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4223 Gly Tyr Thr Phe Thr Gly Tyr 1 5 <210> 4224 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4224 Asn Pro Asn Ser Gly Ala 1 5 <210> 4225 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4225 Glu Asp Asp Ala Phe Asp 1 5 <210> 4226 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4226 Asp Asn Leu Arg Asn Tyr Tyr 1 5 <210> 4227 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4227 Gly Lys Asn One <210> 4228 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4228 Arg Asp Ser Ser Gly Asn His Val 1 5 <210> 4229 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4229 Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His 1 5 10 <210> 4230 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4230 Trp Ile Asn Pro Asn Ser Gly Ala Thr Asn 1 5 10 <210> 4231 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4231 Glu Asp Asp Ala Phe Asp Val 1 5 <210> 4232 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4232 Gln Gly Asp Asn Leu Arg Asn Tyr Tyr Ala Thr 1 5 10 <210> 4233 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4233 Gly Lys Asn Asn Arg Pro Ser 1 5 <210> 4234 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4234 Asn Ser Arg Asp Ser Ser Gly Asn His Val Val 1 5 10 <210> 4235 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4235 Thr Gly Tyr Tyr Met His 1 5 <210> 4236 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4236 Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Ala Thr Asn 1 5 10 <210> 4237 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4237 Ala Arg Glu Asp Asp Ala Phe Asp 1 5 <210> 4238 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4238 Asn Tyr Tyr Ala Thr Trp Phe 1 5 <210> 4239 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4239 Leu Val Phe Phe Gly Lys Asn Asn Arg Pro 1 5 10 <210> 4240 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4240 Asn Ser Arg Asp Ser Ser Gly Asn His Val 1 5 10 <210> 4241 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4241 Gly Tyr Thr Phe Thr Gly Tyr Tyr 1 5 <210> 4242 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4242 Ile Asn Pro Asn Ser Gly Ala Thr 1 5 <210> 4243 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4243 Ala Arg Glu Asp Asp Ala Phe Asp Val 1 5 <210> 4244 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4244 Asn Leu Arg Asn Tyr Tyr 1 5 <210> 4245 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4245 Gly Lys Asn One <210> 4246 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4246 Asn Ser Arg Asp Ser Ser Gly Asn His Val Val 1 5 10 <210> 4247 <211> 116 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4247 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Ala Thr Asn Lys Glu Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Asp Asp Ala Phe Asp Val Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser 115 <210> 4248 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4248 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Asn Leu Arg Asn Tyr Tyr Ala 20 25 30 Thr Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Phe Phe 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asp Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 4249 <211> 446 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4249 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Ala Thr Asn Lys Glu Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Asp Asp Ala Phe Asp Val Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 115 120 125 Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 130 135 140 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 145 150 155 160 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 165 170 175 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 180 185 190 Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 195 200 205 Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr 210 215 220 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 225 230 235 240 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 260 265 270 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 305 310 315 320 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 325 330 335 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 340 345 350 Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 355 360 365 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 405 410 415 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 4250 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4250 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Asn Leu Arg Asn Tyr Tyr Ala 20 25 30 Thr Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Phe Phe 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asp Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys 100 105 110 Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 115 120 125 Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 130 135 140 Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 145 150 155 160 Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 165 170 175 Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 180 185 190 Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 195 200 205 Ala Pro Thr Glu Cys Ser 210 <210> 4251 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4251 Asn Tyr Gly Met Asn 1 5 <210> 4252 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4252 Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met Lys 1 5 10 15 Gly <210> 4253 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4253 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 4254 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4254 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 4255 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4255 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 4256 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4256 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 4257 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4257 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 4258 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4258 Ser Ser Gly Ser Ser Tyr 1 5 <210> 4259 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4259 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 4260 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4260 Ser Gln Gly Ile Asn Ser Trp 1 5 <210> 4261 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4261 Ala Ala Ser One <210> 4262 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4262 Ala Asn Ser Phe Pro Trp 1 5 <210> 4263 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4263 Gly Phe Thr Phe Ser Asn Tyr Gly Met Asn 1 5 10 <210> 4264 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4264 Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr 1 5 10 <210> 4265 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4265 Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 4266 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4266 Arg Ala Ser Gln Gly Ile Asn Ser Trp Leu Ala 1 5 10 <210> 4267 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4267 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 4268 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4268 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 4269 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4269 Ser Asn Tyr Gly Met Asn 1 5 <210> 4270 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4270 Trp Val Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr 1 5 10 <210> 4271 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4271 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 4272 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4272 Asn Ser Trp Leu Ala Trp Tyr 1 5 <210> 4273 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4273 Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln 1 5 10 <210> 4274 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4274 Gln Gln Ala Asn Ser Phe Pro Trp 1 5 <210> 4275 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4275 Gly Phe Thr Phe Ser Asn Tyr Gly 1 5 <210> 4276 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4276 Ile Ser Ser Gly Ser Ser Tyr Lys 1 5 <210> 4277 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4277 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 4278 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4278 Gln Gly Ile Asn Ser Trp 1 5 <210> 4279 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4279 Ala Ala Ser One <210> 4280 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4280 Gln Gln Ala Asn Ser Phe Pro Trp Thr 1 5 <210> 4281 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4281 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Leu Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Ser Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 4282 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4282 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 4283 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4283 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Lys Tyr Tyr Ala Asp Ser Met 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Leu Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Ser Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Val Val Thr Glu Tyr Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 4284 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4284 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ile Gly Ser Gly Thr Asp Phe Ile Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 4285 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4285 Ser Tyr Ser Met Ile 1 5 <210> 4286 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4286 Ser Ile Gly Ser Ser Ser Thr Tyr Ile Tyr Tyr Ala Asp Ser Val Arg 1 5 10 15 Gly <210> 4287 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4287 Asp Gly Glu Thr Gly Gly Phe Asp Tyr 1 5 <210> 4288 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4288 Arg Ala Ser Gln Ser Ile Ser Arg Ser Tyr Leu Ala 1 5 10 <210> 4289 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4289 Gly Pro Ser Asn Arg Ala Thr 1 5 <210> 4290 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4290 Gln Gln Tyr Gly Ser Leu Pro Leu Thr 1 5 <210> 4291 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4291 Gly Phe Thr Phe Ser Ser Tyr 1 5 <210> 4292 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4292 Gly Ser Ser Ser Thr Tyr 1 5 <210> 4293 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4293 Asp Gly Glu Thr Gly Gly Phe Asp 1 5 <210> 4294 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4294 Ser Gln Ser Ile Ser Arg Ser Tyr 1 5 <210> 4295 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4295 Gly Pro Ser One <210> 4296 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4296 Tyr Gly Ser Leu Pro Leu 1 5 <210> 4297 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4297 Gly Phe Thr Phe Ser Ser Tyr Ser Met Ile 1 5 10 <210> 4298 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4298 Ser Ile Gly Ser Ser Ser Thr Tyr Ile Tyr 1 5 10 <210> 4299 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4299 Asp Gly Glu Thr Gly Gly Phe Asp Tyr 1 5 <210> 4300 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4300 Arg Ala Ser Gln Ser Ile Ser Arg Ser Tyr Leu Ala 1 5 10 <210> 4301 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4301 Gly Pro Ser Asn Arg Ala Thr 1 5 <210> 4302 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4302 Gln Gln Tyr Gly Ser Leu Pro Leu Thr 1 5 <210> 4303 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4303 Ser Ser Tyr Ser Met Ile 1 5 <210> 4304 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4304 Trp Val Ser Ser Ile Gly Ser Ser Ser Thr Tyr Ile Tyr 1 5 10 <210> 4305 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4305 Ala Arg Asp Gly Glu Thr Gly Gly Phe Asp 1 5 10 <210> 4306 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4306 Ser Arg Ser Tyr Leu Ala Trp Tyr 1 5 <210> 4307 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4307 Leu Leu Ile Tyr Gly Pro Ser Asn Arg Ala 1 5 10 <210> 4308 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4308 Gln Gln Tyr Gly Ser Leu Pro Leu 1 5 <210> 4309 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4309 Gly Phe Thr Phe Ser Ser Tyr Ser 1 5 <210> 4310 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4310 Ile Gly Ser Ser Ser Thr Tyr Ile 1 5 <210> 4311 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4311 Ala Arg Asp Gly Glu Thr Gly Gly Phe Asp Tyr 1 5 10 <210> 4312 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4312 Gln Ser Ile Ser Arg Ser Tyr 1 5 <210> 4313 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4313 Gly Pro Ser One <210> 4314 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4314 Gln Gln Tyr Gly Ser Leu Pro Leu Thr 1 5 <210> 4315 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4315 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Gly Ser Ser Ser Thr Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Phe Cys 85 90 95 Ala Arg Asp Gly Glu Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Ile 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 4316 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4316 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Arg Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Pro Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Ala Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Asn Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 4317 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4317 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Gly Ser Ser Ser Thr Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Phe Cys 85 90 95 Ala Arg Asp Gly Glu Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Ile 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 4318 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4318 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Arg Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Pro Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Ala Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Asn Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 4319 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4319 Ser Tyr Asp Met Asn 1 5 <210> 4320 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4320 Tyr Ile Ser Ser Ser Ser Thr Ala Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 4321 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4321 Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln His 1 5 10 <210> 4322 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4322 Arg Ala Ser Gln Ser Val Ser Lys Asp Leu Ala 1 5 10 <210> 4323 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4323 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 4324 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4324 Gln Gln Arg Ile Asn Trp Pro Leu Phe Thr 1 5 10 <210> 4325 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4325 Gly Phe Thr Phe Ser Ser Tyr 1 5 <210> 4326 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4326 Ser Ser Ser Ser Thr Ala 1 5 <210> 4327 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4327 Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln 1 5 10 <210> 4328 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4328 Ser Gln Ser Val Ser Lys Asp 1 5 <210> 4329 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4329 Asp Ala Ser One <210> 4330 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4330 Arg Ile Asn Trp Pro Leu Phe 1 5 <210> 4331 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4331 Gly Phe Thr Phe Ser Ser Tyr Asp Met Asn 1 5 10 <210> 4332 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4332 Tyr Ile Ser Ser Ser Ser Thr Ala Lys Tyr 1 5 10 <210> 4333 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4333 Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln His 1 5 10 <210> 4334 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4334 Arg Ala Ser Gln Ser Val Ser Lys Asp Leu Ala 1 5 10 <210> 4335 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4335 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 4336 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4336 Gln Gln Arg Ile Asn Trp Pro Leu Phe Thr 1 5 10 <210> 4337 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4337 Ser Ser Tyr Asp Met Asn 1 5 <210> 4338 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4338 Trp Val Ser Tyr Ile Ser Ser Ser Ser Thr Ala Lys Tyr 1 5 10 <210> 4339 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4339 Ala Arg Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln 1 5 10 <210> 4340 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4340 Ser Lys Asp Leu Ala Trp Tyr 1 5 <210> 4341 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4341 Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala 1 5 10 <210> 4342 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4342 Gln Gln Arg Ile Asn Trp Pro Leu Phe 1 5 <210> 4343 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4343 Gly Phe Thr Phe Ser Ser Tyr Asp 1 5 <210> 4344 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4344 Ile Ser Ser Ser Ser Thr Ala Lys 1 5 <210> 4345 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4345 Ala Arg Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln His 1 5 10 <210> 4346 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4346 Gln Ser Val Ser Lys Asp 1 5 <210> 4347 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4347 Asp Ala Ser One <210> 4348 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4348 Gln Gln Arg Ile Asn Trp Pro Leu Phe Thr 1 5 10 <210> 4349 <211> 121 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4349 Glu Val Gln Leu Val Glu Ser Gly Gly Thr Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Ser Ser Thr Ala Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Trp Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln His Trp Gly 100 105 110 Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 4350 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4350 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Ile Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Lys Asp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Ile Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ile Asn Trp Pro Leu 85 90 95 Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys 100 105 <210> 4351 <211> 451 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4351 Glu Val Gln Leu Val Glu Ser Gly Gly Thr Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Tyr Ile Ser Ser Ser Ser Thr Ala Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Trp Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Asp Ile Val Val Val Thr Pro Ile Leu Gln His Trp Gly 100 105 110 Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys 450 <210> 4352 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4352 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Ile Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Lys Asp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Ile Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ile Asn Trp Pro Leu 85 90 95 Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 4353 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4353 Ser Asn Ser Ala Ala Trp Asn 1 5 <210> 4354 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4354 Gly Thr Tyr Tyr Arg Ser Lys Trp Phe Asn Asn Tyr Ala Val Ser Val 1 5 10 15 Lys Ser <210> 4355 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4355 Gly Glu Trp Gly Leu Arg Asp Ala Phe Asp Ile 1 5 10 <210> 4356 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4356 Arg Ala Ser Gln Gly Ile His Ser Tyr Leu Ala 1 5 10 <210> 4357 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4357 Val Ala Ser Thr Leu Gln Ser 1 5 <210> 4358 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4358 Gln Gln Leu Asn Ser Tyr Pro Trp Thr 1 5 <210> 4359 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4359 Gly Asp Ser Val Ser Ser Asn Ser Ala 1 5 <210> 4360 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4360 Tyr Tyr Arg Ser Lys Trp Phe 1 5 <210> 4361 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4361 Gly Glu Trp Gly Leu Arg Asp Ala Phe Asp 1 5 10 <210> 4362 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4362 Ser Gln Gly Ile His Ser Tyr 1 5 <210> 4363 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4363 Val Ala Ser One <210> 4364 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4364 Leu Asn Ser Tyr Pro Trp 1 5 <210> 4365 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4365 Gly Asp Ser Val Ser Ser Asn Ser Ala Ala Trp Asn 1 5 10 <210> 4366 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4366 Gly Thr Tyr Tyr Arg Ser Lys Trp Phe Asn Asn 1 5 10 <210> 4367 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4367 Gly Glu Trp Gly Leu Arg Asp Ala Phe Asp Ile 1 5 10 <210> 4368 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4368 Arg Ala Ser Gln Gly Ile His Ser Tyr Leu Ala 1 5 10 <210> 4369 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4369 Val Ala Ser Thr Leu Gln Ser 1 5 <210> 4370 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4370 Gln Gln Leu Asn Ser Tyr Pro Trp Thr 1 5 <210> 4371 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4371 Ser Ser Asn Ser Ala Ala Trp Asn 1 5 <210> 4372 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4372 Trp Leu Gly Gly Thr Tyr Tyr Arg Ser Lys Trp Phe Asn Asn 1 5 10 <210> 4373 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4373 Ala Arg Gly Glu Trp Gly Leu Arg Asp Ala Phe Asp 1 5 10 <210> 4374 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4374 His Ser Tyr Leu Ala Trp Tyr 1 5 <210> 4375 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4375 Leu Leu Ile Tyr Val Ala Ser Thr Leu Gln 1 5 10 <210> 4376 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4376 Gln Gln Leu Asn Ser Tyr Pro Trp 1 5 <210> 4377 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4377 Gly Asp Ser Val Ser Ser Asn Ser Ala Ala 1 5 10 <210> 4378 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4378 Thr Tyr Tyr Arg Ser Lys Trp Phe Asn 1 5 <210> 4379 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4379 Ala Arg Gly Glu Trp Gly Leu Arg Asp Ala Phe Asp Ile 1 5 10 <210> 4380 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4380 Gln Gly Ile His Ser Tyr 1 5 <210> 4381 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4381 Val Ala Ser One <210> 4382 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4382 Gln Gln Leu Asn Ser Tyr Pro Trp Thr 1 5 <210> 4383 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4383 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 35 40 45 Trp Leu Gly Gly Thr Tyr Tyr Arg Ser Lys Trp Phe Asn Asn Tyr Ala 50 55 60 Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Thr Asn 65 70 75 80 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Ala Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Ala Arg Gly Glu Trp Gly Leu Arg Asp Ala Phe Asp Ile 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 4384 <211> 107 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4384 Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Ile Ile Thr Cys Arg Ala Ser Gln Gly Ile His Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 35 40 45 Tyr Val Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 4385 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4385 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 35 40 45 Trp Leu Gly Gly Thr Tyr Tyr Arg Ser Lys Trp Phe Asn Asn Tyr Ala 50 55 60 Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Thr Asn 65 70 75 80 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Ala Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Ala Arg Gly Glu Trp Gly Leu Arg Asp Ala Phe Asp Ile 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 4386 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4386 Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Ile Ile Thr Cys Arg Ala Ser Gln Gly Ile His Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 35 40 45 Tyr Val Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 4387 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4387 Ser Tyr Asp Met Asn 1 5 <210> 4388 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4388 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 4389 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4389 Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 15 <210> 4390 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4390 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 4391 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4391 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 4392 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4392 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 4393 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4393 Arg Phe Thr Leu Ser Ser Tyr 1 5 <210> 4394 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4394 Ser Ser Ser Ser Ser Tyr 1 5 <210> 4395 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4395 Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu Asp 1 5 10 15 <210> 4396 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4396 Ser Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 4397 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4397 Gly Ala Ser One <210> 4398 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4398 Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 4399 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4399 Arg Phe Thr Leu Ser Ser Tyr Asp Met Asn 1 5 10 <210> 4400 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4400 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 4401 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4401 Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu Asp Val 1 5 10 15 <210> 4402 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4402 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 4403 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4403 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 4404 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4404 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 4405 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4405 Ser Ser Tyr Asp Met Asn 1 5 <210> 4406 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4406 Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr 1 5 10 <210> 4407 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4407 Ala Arg Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu 1 5 10 15 Asp <210> 4408 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4408 Ser Ser Ser Tyr Leu Ala Trp Tyr 1 5 <210> 4409 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4409 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala 1 5 10 <210> 4410 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4410 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr 1 5 <210> 4411 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4411 Arg Phe Thr Leu Ser Ser Tyr Asp 1 5 <210> 4412 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4412 Ile Ser Ser Ser Ser Ser Tyr Ile 1 5 <210> 4413 <211> 18 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4413 Ala Arg Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu 1 5 10 15 Asp Val <210> 4414 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4414 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 4415 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4415 Gly Ala Ser One <210> 4416 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4416 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 4417 <211> 125 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4417 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Thr Leu Ser Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu 100 105 110 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 4418 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4418 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 4419 <211> 455 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4419 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Thr Leu Ser Ser Tyr 20 25 30 Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Val Gly Gly Thr Asp Tyr Tyr Tyr Tyr Gly Leu 100 105 110 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr 115 120 125 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 130 135 140 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 145 150 155 160 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 165 170 175 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 180 185 190 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 195 200 205 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu 210 215 220 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 225 230 235 240 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 245 250 255 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 260 265 270 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 275 280 285 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 290 295 300 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 305 310 315 320 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 325 330 335 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 340 345 350 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 355 360 365 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 370 375 380 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 385 390 395 400 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 405 410 415 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 420 425 430 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 435 440 445 Leu Ser Leu Ser Pro Gly Lys 450 455 <210> 4420 <211> 216 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4420 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 4421 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4421 Gly Tyr Tyr Leu Gln 1 5 <210> 4422 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4422 Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asp Tyr Ala Gln Arg Phe Gln 1 5 10 15 Asp <210> 4423 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4423 Leu Asp Asp Ala Phe Asp Val 1 5 <210> 4424 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4424 Gln Gly Asp Ser Leu Arg Asn Tyr Tyr Ala Ile 1 5 10 <210> 4425 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4425 Gly Lys Asn Asn Arg Pro Ser 1 5 <210> 4426 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4426 Asn Ser Arg Asp Ser Ser Gly Asn His Trp Val 1 5 10 <210> 4427 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4427 Gly Phe Thr Phe Thr Gly Tyr 1 5 <210> 4428 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4428 Asn Pro Asn Ser Gly Tyr 1 5 <210> 4429 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4429 Leu Asp Asp Ala Phe Asp 1 5 <210> 4430 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4430 Asp Ser Leu Arg Asn Tyr Tyr 1 5 <210> 4431 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4431 Gly Lys Asn One <210> 4432 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4432 Arg Asp Ser Ser Gly Asn His Trp 1 5 <210> 4433 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4433 Gly Phe Thr Phe Thr Gly Tyr Tyr Leu Gln 1 5 10 <210> 4434 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4434 Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asp 1 5 10 <210> 4435 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4435 Leu Asp Asp Ala Phe Asp Val 1 5 <210> 4436 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4436 Gln Gly Asp Ser Leu Arg Asn Tyr Tyr Ala Ile 1 5 10 <210> 4437 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4437 Gly Lys Asn Asn Arg Pro Ser 1 5 <210> 4438 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4438 Asn Ser Arg Asp Ser Ser Gly Asn His Trp Val 1 5 10 <210> 4439 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4439 Thr Gly Tyr Tyr Leu Gln 1 5 <210> 4440 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4440 Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asp 1 5 10 <210> 4441 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4441 Ala Arg Leu Asp Asp Ala Phe Asp 1 5 <210> 4442 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4442 Asn Tyr Tyr Ala Ile Trp Tyr 1 5 <210> 4443 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4443 Leu Val Ile Phe Gly Lys Asn Asn Arg Pro 1 5 10 <210> 4444 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4444 Asn Ser Arg Asp Ser Ser Gly Asn His Trp 1 5 10 <210> 4445 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4445 Gly Phe Thr Phe Thr Gly Tyr Tyr 1 5 <210> 4446 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4446 Ile Asn Pro Asn Ser Gly Tyr Thr 1 5 <210> 4447 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4447 Ala Arg Leu Asp Asp Ala Phe Asp Val 1 5 <210> 4448 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4448 Ser Leu Arg Asn Tyr Tyr 1 5 <210> 4449 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4449 Gly Lys Asn One <210> 4450 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4450 Asn Ser Arg Asp Ser Ser Gly Asn His Trp Val 1 5 10 <210> 4451 <211> 116 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4451 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Gly Tyr 20 25 30 Tyr Leu Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asp Tyr Ala Gln Arg Phe 50 55 60 Gln Asp Arg Val Thr Met Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp Asp Ala Phe Asp Val Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser 115 <210> 4452 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4452 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Asn Tyr Tyr Ala 20 25 30 Ile Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Phe 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Thr Thr Ala Ser Leu Thr Ile Thr Gly Thr Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 4453 <211> 446 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4453 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Gly Tyr 20 25 30 Tyr Leu Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asp Tyr Ala Gln Arg Phe 50 55 60 Gln Asp Arg Val Thr Met Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp Asp Ala Phe Asp Val Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 115 120 125 Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 130 135 140 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 145 150 155 160 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 165 170 175 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 180 185 190 Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 195 200 205 Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr 210 215 220 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 225 230 235 240 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 260 265 270 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 305 310 315 320 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 325 330 335 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 340 345 350 Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 355 360 365 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 405 410 415 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 4454 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4454 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Asn Tyr Tyr Ala 20 25 30 Ile Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Phe 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Thr Thr Ala Ser Leu Thr Ile Thr Gly Thr Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys 100 105 110 Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 115 120 125 Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 130 135 140 Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 145 150 155 160 Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 165 170 175 Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 180 185 190 Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 195 200 205 Ala Pro Thr Glu Cys Ser 210 <210> 4455 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4455 Asn Tyr Ala Ile Ser 1 5 <210> 4456 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4456 Gly Ile Ile Pro Phe Phe Gly Thr Pro Asp Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 4457 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4457 Gly Gly Gly Tyr Gly Asp Tyr Asp Tyr Tyr Tyr Gly Ile Asn Val 1 5 10 15 <210> 4458 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4458 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 4459 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4459 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 4460 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4460 Met Gln Ala Lys Glu Phe Pro Leu Thr 1 5 <210> 4461 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4461 Gly Gly Ser Phe Ser Asn Tyr 1 5 <210> 4462 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4462 Ile Pro Phe Phe Gly Thr 1 5 <210> 4463 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4463 Gly Gly Gly Tyr Gly Asp Tyr Asp Tyr Tyr Tyr Gly Ile Asn 1 5 10 <210> 4464 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4464 Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 4465 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4465 Lys Ile Ser One <210> 4466 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4466 Ala Lys Glu Phe Pro Leu 1 5 <210> 4467 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4467 Gly Gly Ser Phe Ser Asn Tyr Ala Ile Ser 1 5 10 <210> 4468 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4468 Gly Ile Ile Pro Phe Phe Gly Thr Pro Asp 1 5 10 <210> 4469 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4469 Gly Gly Gly Tyr Gly Asp Tyr Asp Tyr Tyr Tyr Gly Ile Asn Val 1 5 10 15 <210> 4470 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4470 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 4471 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4471 Lys Ile Ser Asn Arg Phe Ser 1 5 <210> 4472 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4472 Met Gln Ala Lys Glu Phe Pro Leu Thr 1 5 <210> 4473 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4473 Ser Asn Tyr Ala Ile Ser 1 5 <210> 4474 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4474 Trp Met Gly Gly Ile Ile Pro Phe Phe Gly Thr Pro Asp 1 5 10 <210> 4475 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4475 Ser Thr Gly Gly Gly Tyr Gly Asp Tyr Asp Tyr Tyr Tyr Gly Ile Asn 1 5 10 15 <210> 4476 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4476 Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu 1 5 10 <210> 4477 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4477 Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe 1 5 10 <210> 4478 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4478 Met Gln Ala Lys Glu Phe Pro Leu 1 5 <210> 4479 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4479 Gly Gly Ser Phe Ser Asn Tyr Ala 1 5 <210> 4480 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4480 Ile Ile Pro Phe Phe Gly Thr Pro 1 5 <210> 4481 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4481 Ser Thr Gly Gly Gly Tyr Gly Asp Tyr Asp Tyr Tyr Tyr Gly Ile Asn 1 5 10 15 Val <210> 4482 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4482 Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 4483 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4483 Lys Ile Ser One <210> 4484 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4484 Met Gln Ala Lys Glu Phe Pro Leu Thr 1 5 <210> 4485 <211> 124 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4485 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ser Phe Ser Asn Tyr 20 25 30 Ala Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Phe Phe Gly Thr Pro Asp Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Thr Gly Gly Gly Tyr Gly Asp Tyr Asp Tyr Tyr Tyr Gly Ile Asn 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 4486 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4486 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Ser Pro Val Asp Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Lys Glu Phe Pro Leu Thr Leu Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 110 <210> 4487 <211> 454 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4487 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ser Phe Ser Asn Tyr 20 25 30 Ala Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Phe Phe Gly Thr Pro Asp Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Thr Gly Gly Gly Tyr Gly Asp Tyr Asp Tyr Tyr Tyr Gly Ile Asn 100 105 110 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 130 135 140 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 195 200 205 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 210 215 220 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 225 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 245 250 255 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 260 265 270 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 275 280 285 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 290 295 300 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310 315 320 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 325 330 335 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 340 345 350 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 355 360 365 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 370 375 380 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 385 390 395 400 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 405 410 415 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 420 425 430 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 445 Ser Leu Ser Pro Gly Lys 450 <210> 4488 <211> 219 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4488 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Ser Pro Val Asp Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Lys Glu Phe Pro Leu Thr Leu Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 4489 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4489 Gly Asp Tyr Ile His 1 5 <210> 4490 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4490 Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 4491 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4491 Glu Gly Gly Val Ala Pro Ala Ala Pro Asp Ala Phe Asp Ile 1 5 10 <210> 4492 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4492 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Arg 1 5 10 <210> 4493 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4493 Gly Lys Asn Asn Arg Pro Ser 1 5 <210> 4494 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4494 Asn Ser Arg Asp Ser Ser Gly Asn His Arg Val 1 5 10 <210> 4495 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4495 Gly Tyr Thr Phe Thr Gly Asp 1 5 <210> 4496 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4496 Asn Pro Asn Ser Gly Gly 1 5 <210> 4497 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4497 Glu Gly Gly Val Ala Pro Ala Ala Pro Asp Ala Phe Asp 1 5 10 <210> 4498 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4498 Asp Ser Leu Arg Ser Tyr Tyr 1 5 <210> 4499 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4499 Gly Lys Asn One <210> 4500 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4500 Arg Asp Ser Ser Gly Asn His Arg 1 5 <210> 4501 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4501 Gly Tyr Thr Phe Thr Gly Asp Tyr Ile His 1 5 10 <210> 4502 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4502 Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn 1 5 10 <210> 4503 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4503 Glu Gly Gly Val Ala Pro Ala Ala Pro Asp Ala Phe Asp Ile 1 5 10 <210> 4504 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4504 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Arg 1 5 10 <210> 4505 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4505 Gly Lys Asn Asn Arg Pro Ser 1 5 <210> 4506 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4506 Asn Ser Arg Asp Ser Ser Gly Asn His Arg Val 1 5 10 <210> 4507 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4507 Thr Gly Asp Tyr Ile His 1 5 <210> 4508 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4508 Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn 1 5 10 <210> 4509 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4509 Ala Arg Glu Gly Gly Val Ala Pro Ala Ala Pro Asp Ala Phe Asp 1 5 10 15 <210> 4510 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4510 Ser Tyr Tyr Ala Arg Trp Tyr 1 5 <210> 4511 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4511 Val Val Ile Tyr Gly Lys Asn Asn Arg Pro 1 5 10 <210> 4512 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4512 Asn Ser Arg Asp Ser Ser Gly Asn His Arg 1 5 10 <210> 4513 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4513 Gly Tyr Thr Phe Thr Gly Asp Tyr 1 5 <210> 4514 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4514 Ile Asn Pro Asn Ser Gly Gly Thr 1 5 <210> 4515 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4515 Ala Arg Glu Gly Gly Val Ala Pro Ala Ala Pro Asp Ala Phe Asp Ile 1 5 10 15 <210> 4516 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4516 Ser Leu Arg Ser Tyr Tyr 1 5 <210> 4517 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4517 Gly Lys Asn One <210> 4518 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4518 Asn Ser Arg Asp Ser Ser Gly Asn His Arg Val 1 5 10 <210> 4519 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4519 Glu Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Asp 20 25 30 Tyr Ile His Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Phe 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Gly Val Ala Pro Ala Ala Pro Asp Ala Phe Asp Ile 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 4520 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4520 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Arg Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Val Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 4521 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4521 Glu Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Asp 20 25 30 Tyr Ile His Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Phe 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Gly Val Ala Pro Ala Ala Pro Asp Ala Phe Asp Ile 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 4522 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4522 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Arg Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Val Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys 100 105 110 Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 115 120 125 Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 130 135 140 Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 145 150 155 160 Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 165 170 175 Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 180 185 190 Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 195 200 205 Ala Pro Thr Glu Cys Ser 210 <210> 4523 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4523 Asn Tyr Tyr Trp Ser 1 5 <210> 4524 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4524 Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 4525 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4525 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 4526 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4526 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 4527 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4527 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 4528 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4528 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 4529 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4529 Gly Gly Ser Ile Ser Asn Tyr 1 5 <210> 4530 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4530 Tyr Ser Ser Gly Ile 1 5 <210> 4531 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4531 Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 <210> 4532 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4532 Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 10 <210> 4533 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4533 Glu Val Ser One <210> 4534 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4534 Tyr Thr Ser Thr Ser Val 1 5 <210> 4535 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4535 Gly Gly Ser Ile Ser Asn Tyr Tyr Trp Ser 1 5 10 <210> 4536 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4536 Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 <210> 4537 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4537 Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 4538 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4538 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 4539 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4539 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 4540 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4540 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 4541 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4541 Ser Asn Tyr Tyr Trp Ser 1 5 <210> 4542 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4542 Trp Ile Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn 1 5 10 <210> 4543 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4543 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala 1 5 10 <210> 4544 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4544 Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr 1 5 10 <210> 4545 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4545 Leu Met Ile Tyr Glu Val Ser Asn Arg Pro 1 5 10 <210> 4546 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4546 Ser Ser Tyr Thr Ser Thr Ser Val 1 5 <210> 4547 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4547 Gly Gly Ser Ile Ser Asn Tyr Tyr 1 5 <210> 4548 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4548 Ile Tyr Ser Ser Gly Ile Thr 1 5 <210> 4549 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4549 Ala Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile 1 5 10 <210> 4550 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4550 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 4551 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4551 Glu Val Ser One <210> 4552 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4552 Ser Ser Tyr Thr Ser Thr Ser Val Val 1 5 <210> 4553 <211> 118 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4553 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 4554 <211> 109 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4554 Ser Tyr Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 4555 <211> 448 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4555 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Gly Trp Ile 35 40 45 Gly Arg Ile Tyr Ser Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gly Ile Val Gly Val Lys Gly Ala Phe Ala Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 4556 <211> 215 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4556 Ser Tyr Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr 85 90 95 Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Thr Glu Cys Ser 210 215 <210> 4557 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4557 Gly Tyr Tyr Ile His 1 5 <210> 4558 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4558 Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn Ser Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 4559 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4559 Glu Asp Asp Ala Phe Asp Ile 1 5 <210> 4560 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4560 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Arg 1 5 10 <210> 4561 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4561 Gly Lys Asn Asn Arg Pro Ser 1 5 <210> 4562 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4562 Asn Ser Arg Asp Asn Ser Gly Asn His Val Val 1 5 10 <210> 4563 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4563 Gly Tyr Thr Phe Thr Gly Tyr 1 5 <210> 4564 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4564 Asn Pro Asn Ser Gly Tyr 1 5 <210> 4565 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4565 Glu Asp Asp Ala Phe Asp 1 5 <210> 4566 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4566 Asp Ser Leu Arg Ser Tyr Tyr 1 5 <210> 4567 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4567 Gly Lys Asn One <210> 4568 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4568 Arg Asp Asn Ser Gly Asn His Val 1 5 <210> 4569 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4569 Gly Tyr Thr Phe Thr Gly Tyr Tyr Ile His 1 5 10 <210> 4570 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4570 Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn 1 5 10 <210> 4571 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4571 Glu Asp Asp Ala Phe Asp Ile 1 5 <210> 4572 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4572 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Arg 1 5 10 <210> 4573 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4573 Gly Lys Asn Asn Arg Pro Ser 1 5 <210> 4574 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4574 Asn Ser Arg Asp Asn Ser Gly Asn His Val Val 1 5 10 <210> 4575 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4575 Thr Gly Tyr Tyr Ile His 1 5 <210> 4576 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4576 Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn 1 5 10 <210> 4577 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4577 Ala Arg Glu Asp Asp Ala Phe Asp 1 5 <210> 4578 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4578 Ser Tyr Tyr Ala Arg Trp Tyr 1 5 <210> 4579 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4579 Leu Val Ile Tyr Gly Lys Asn Asn Arg Pro 1 5 10 <210> 4580 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4580 Asn Ser Arg Asp Asn Ser Gly Asn His Val 1 5 10 <210> 4581 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4581 Gly Tyr Thr Phe Thr Gly Tyr Tyr 1 5 <210> 4582 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4582 Ile Asn Pro Asn Ser Gly Tyr Thr 1 5 <210> 4583 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4583 Ala Arg Glu Asp Asp Ala Phe Asp Ile 1 5 <210> 4584 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4584 Ser Leu Arg Ser Tyr Tyr 1 5 <210> 4585 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4585 Gly Lys Asn One <210> 4586 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4586 Asn Ser Arg Asp Asn Ser Gly Asn His Val Val 1 5 10 <210> 4587 <211> 116 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4587 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly Ala 1 5 10 15 Ser Ala Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn Ser Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Ser Met Thr Arg Asp Thr Ser Ile Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Asp Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 4588 <211> 108 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4588 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Arg Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asp Thr Ala Ser Leu Thr Ile Thr Gly Ala Leu Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Asn Ser Gly Asn His 85 90 95 Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 <210> 4589 <211> 446 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4589 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly Ala 1 5 10 15 Ser Ala Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Tyr Thr Asn Ser Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Ser Met Thr Arg Asp Thr Ser Ile Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Asp Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 115 120 125 Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 130 135 140 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 145 150 155 160 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 165 170 175 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 180 185 190 Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 195 200 205 Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr 210 215 220 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 225 230 235 240 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 260 265 270 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 305 310 315 320 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 325 330 335 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 340 345 350 Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 355 360 365 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 405 410 415 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 4590 <211> 214 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4590 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Arg Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asp Thr Ala Ser Leu Thr Ile Thr Gly Ala Leu Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Asn Ser Gly Asn His 85 90 95 Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys 100 105 110 Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 115 120 125 Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 130 135 140 Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 145 150 155 160 Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 165 170 175 Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 180 185 190 Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 195 200 205 Ala Pro Thr Glu Cys Ser 210 <210> 4591 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4591 Asn Tyr Ala Ile Ser 1 5 <210> 4592 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4592 Gly Ile Ile Pro Ile Phe Ser Ala Gly Thr Tyr Ala Gln Arg Phe Gln 1 5 10 15 Gly <210> 4593 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4593 Asn Ser Gly Thr Tyr Tyr Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 4594 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4594 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 4595 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4595 Lys Ile Phe Asn Arg Leu Ser 1 5 <210> 4596 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4596 Met Gln Ala Lys Gln Phe Pro Leu Thr 1 5 <210> 4597 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4597 Gly Gly Thr Phe Ser Asn Tyr 1 5 <210> 4598 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4598 Ile Pro Ile Phe Ser Ala 1 5 <210> 4599 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4599 Asn Ser Gly Thr Tyr Tyr Asp Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 4600 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4600 Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 4601 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4601 Lys Ile Phe One <210> 4602 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4602 Ala Lys Gln Phe Pro Leu 1 5 <210> 4603 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4603 Gly Gly Thr Phe Ser Asn Tyr Ala Ile Ser 1 5 10 <210> 4604 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4604 Gly Ile Ile Pro Ile Phe Ser Ala Gly Thr 1 5 10 <210> 4605 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4605 Asn Ser Gly Thr Tyr Tyr Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 4606 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4606 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 4607 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4607 Lys Ile Phe Asn Arg Leu Ser 1 5 <210> 4608 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4608 Met Gln Ala Lys Gln Phe Pro Leu Thr 1 5 <210> 4609 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4609 Ser Asn Tyr Ala Ile Ser 1 5 <210> 4610 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4610 Trp Met Gly Gly Ile Ile Pro Ile Phe Ser Ala Gly Thr 1 5 10 <210> 4611 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4611 Ser Ser Asn Ser Gly Thr Tyr Tyr Asp Tyr Tyr Tyr Gly Met Asp 1 5 10 15 <210> 4612 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4612 Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu 1 5 10 <210> 4613 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4613 Leu Leu Ile Tyr Lys Ile Phe Asn Arg Leu 1 5 10 <210> 4614 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4614 Met Gln Ala Lys Gln Phe Pro Leu 1 5 <210> 4615 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4615 Gly Gly Thr Phe Ser Asn Tyr Ala 1 5 <210> 4616 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4616 Ile Ile Pro Ile Phe Ser Ala Gly 1 5 <210> 4617 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4617 Ser Ser Asn Ser Gly Thr Tyr Tyr Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 4618 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4618 Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 4619 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4619 Lys Ile Phe One <210> 4620 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4620 Met Gln Ala Lys Gln Phe Pro Leu Thr 1 5 <210> 4621 <211> 123 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4621 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr 20 25 30 Ala Ile Ser Trp Val Arg Leu Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Ser Ala Gly Thr Tyr Ala Gln Arg Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Ser Asn Ser Gly Thr Tyr Tyr Asp Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 4622 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4622 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Ser His Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Phe Asn Arg Leu Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Lys Gln Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 4623 <211> 453 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4623 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr 20 25 30 Ala Ile Ser Trp Val Arg Leu Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Ser Ala Gly Thr Tyr Ala Gln Arg Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Ser Asn Ser Gly Thr Tyr Tyr Asp Tyr Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 4624 <211> 219 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4624 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Ser His Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Ile Phe Asn Arg Leu Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Lys Gln Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 4625 <211> 5 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4625 Ser Tyr Ala Ile Ser 1 5 <210> 4626 <211> 17 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4626 Gly Ile Ile Pro Phe Phe Gly Thr Ala Asp Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 4627 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4627 Ala Thr Val Thr Thr Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 4628 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4628 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 4629 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4629 Glu Ile Ser Asn Arg Phe Thr 1 5 <210> 4630 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4630 Met Gln Ala Arg Gln Phe Pro Leu Thr 1 5 <210> 4631 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4631 Gly Gly Thr Phe Ser Ser Tyr 1 5 <210> 4632 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4632 Ile Pro Phe Phe Gly Thr 1 5 <210> 4633 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4633 Ala Thr Val Thr Thr Asp Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 4634 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4634 Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 4635 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4635 Glu Ile Ser One <210> 4636 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4636 Ala Arg Gln Phe Pro Leu 1 5 <210> 4637 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4637 Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser 1 5 10 <210> 4638 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4638 Gly Ile Ile Pro Phe Phe Gly Thr Ala Asp 1 5 10 <210> 4639 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4639 Ala Thr Val Thr Thr Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 4640 <211> 16 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4640 Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 4641 <211> 7 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4641 Glu Ile Ser Asn Arg Phe Thr 1 5 <210> 4642 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4642 Met Gln Ala Arg Gln Phe Pro Leu Thr 1 5 <210> 4643 <211> 6 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4643 Ser Ser Tyr Ala Ile Ser 1 5 <210> 4644 <211> 13 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4644 Trp Met Gly Gly Ile Ile Pro Phe Phe Gly Thr Ala Asp 1 5 10 <210> 4645 <211> 14 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4645 Ala Thr Ala Thr Val Thr Thr Asp Tyr Tyr Tyr Gly Met Asp 1 5 10 <210> 4646 <211> 12 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4646 Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu 1 5 10 <210> 4647 <211> 10 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4647 Leu Leu Ile Tyr Glu Ile Ser Asn Arg Phe 1 5 10 <210> 4648 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4648 Met Gln Ala Arg Gln Phe Pro Leu 1 5 <210> 4649 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4649 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 4650 <211> 8 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4650 Ile Ile Pro Phe Phe Gly Thr Ala 1 5 <210> 4651 <211> 15 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4651 Ala Thr Ala Thr Val Thr Thr Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 4652 <211> 11 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4652 Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr 1 5 10 <210> 4653 <211> 3 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4653 Glu Ile Ser One <210> 4654 <211> 9 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 4654 Met Gln Ala Arg Gln Phe Pro Leu Thr 1 5 <210> 4655 <211> 122 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4655 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Met Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Glu Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Phe Phe Gly Thr Ala Asp Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Thr Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Ala Thr Val Thr Thr Asp Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 4656 <211> 112 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4656 Glu Ile Val Met Thr Gln Ser Pro Leu Phe Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Glu Ile Ser Asn Arg Phe Thr Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Arg Gln Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 4657 <211> 452 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4657 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Met Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Glu Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Phe Phe Gly Thr Ala Asp Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Thr Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Ala Thr Val Thr Thr Asp Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Lys 450 <210> 4658 <211> 219 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4658 Glu Ile Val Met Thr Gln Ser Pro Leu Phe Ser Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro 35 40 45 Pro Arg Leu Leu Ile Tyr Glu Ile Ser Asn Arg Phe Thr Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Arg Gln Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 4659 <211> 493 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4659 Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser 1 5 10 15 Ile Gln Ala Ala Gly His Leu Glu Gln Pro Gln Ile Ser Ser Thr Lys 20 25 30 Thr Leu Ser Lys Thr Ala Arg Leu Glu Cys Val Val Ser Gly Ile Thr 35 40 45 Ile Ser Ala Thr Ser Val Tyr Trp Tyr Arg Glu Arg Pro Gly Glu Val 50 55 60 Ile Gln Phe Leu Val Ser Ile Ser Tyr Asp Gly Thr Val Arg Lys Glu 65 70 75 80 Ser Gly Ile Pro Ser Gly Lys Phe Glu Val Asp Arg Ile Pro Glu Thr 85 90 95 Ser Thr Ser Thr Leu Thr Ile His Asn Val Glu Lys Gln Asp Ile Ala 100 105 110 Thr Tyr Tyr Cys Ala Leu Trp Glu Ala Gln Gln Glu Leu Gly Lys Lys 115 120 125 Ile Lys Val Phe Gly Pro Gly Thr Lys Leu Ile Ile Thr Asp Lys Gln 130 135 140 Leu Asp Ala Asp Val Ser Pro Lys Pro Thr Ile Phe Leu Pro Ser Ile 145 150 155 160 Ala Glu Thr Lys Leu Gln Lys Ala Gly Thr Tyr Leu Cys Leu Leu Glu 165 170 175 Lys Phe Phe Pro Asp Val Ile Lys Ile His Trp Glu Glu Lys Lys Ser 180 185 190 Asn Thr Ile Leu Gly Ser Gln Glu Gly Asn Thr Met Lys Thr Asn Asp 195 200 205 Thr Tyr Met Lys Phe Ser Trp Leu Thr Val Pro Glu Lys Ser Leu Asp 210 215 220 Lys Glu His Arg Cys Ile Val Arg His Glu Asn Asn Lys Asn Gly Val 225 230 235 240 Asp Gln Glu Ile Ile Phe Pro Pro Ile Lys Thr Asp Val Ile Thr Met 245 250 255 Asp Pro Lys Asp Asn Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 260 265 270 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 275 280 285 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 290 295 300 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 305 310 315 320 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 325 330 335 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 340 345 350 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 355 360 365 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 370 375 380 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Tyr Pro Pro Ser 385 390 395 400 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 405 410 415 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 420 425 430 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 435 440 445 Ser Phe Ala Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 450 455 460 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 465 470 475 480 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 485 490 <210> 4660 <211> 480 <212> PRT <213> artificial sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 4660 Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser 1 5 10 15 Ile Gln Ala Ala Ile Glu Leu Val Pro Glu His Gln Thr Val Pro Val 20 25 30 Ser Ile Gly Val Pro Ala Thr Leu Arg Cys Ser Met Lys Gly Glu Ala 35 40 45 Ile Gly Asn Tyr Tyr Ile Asn Trp Tyr Arg Lys Thr Gln Gly Asn Thr 50 55 60 Met Thr Phe Ile Tyr Arg Glu Lys Asp Ile Tyr Gly Pro Gly Phe Lys 65 70 75 80 Asp Asn Phe Gln Gly Asp Ile Asp Ile Ala Lys Asn Leu Ala Val Leu 85 90 95 Lys Ile Leu Ala Pro Ser Glu Arg Asp Glu Gly Ser Tyr Tyr Cys Ala 100 105 110 Cys Asp Thr Leu Gly Met Gly Gly Glu Tyr Thr Asp Lys Leu Ile Phe 115 120 125 Gly Lys Gly Thr Arg Val Thr Val Glu Pro Arg Ser Gln Pro His Thr 130 135 140 Lys Pro Ser Val Phe Val Met Lys Asn Gly Thr Asn Val Ala Cys Leu 145 150 155 160 Val Lys Glu Phe Tyr Pro Lys Asp Ile Arg Ile Asn Leu Val Ser Ser 165 170 175 Lys Lys Ile Thr Glu Phe Asp Pro Ala Ile Val Ile Ser Pro Ser Gly 180 185 190 Lys Tyr Asn Ala Val Lys Leu Gly Lys Tyr Glu Asp Ser Asn Ser Val 195 200 205 Thr Cys Ser Val Gln His Asp Asn Lys Thr Val His Ser Thr Asp Phe 210 215 220 Glu Val Lys Thr Asp Ser Thr Asp His Val Lys Pro Lys Glu Thr Glu 225 230 235 240 Asn Thr Lys Gln Pro Ser Lys Ser Glu Pro Lys Ser Cys Asp Lys Thr 245 250 255 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 260 265 270 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 275 280 285 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 290 295 300 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 305 310 315 320 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 325 330 335 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 340 345 350 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 355 360 365 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Leu 370 375 380 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Leu Cys 385 390 395 400 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 405 410 415 Asn Gly Gln Pro Glu Asn Asn Tyr Leu Thr Trp Pro Pro Val Leu Asp 420 425 430 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 435 440 445 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 450 455 460 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 465 470 475 480

Claims (37)

Antibodies that bind T cell receptor (TCR) Vγ9 (TRGV9), including:
(1) (i) a VH having the amino acid sequence of SEQ ID NO: 31, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 32, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(2) (i) a VH having the amino acid sequence of SEQ ID NO: 65, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 66, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(3) (i) a VH having the amino acid sequence of SEQ ID NO: 99, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 100, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(4) (i) a VH having the amino acid sequence of SEQ ID NO: 133, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 134, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(5) (i) a VH having the amino acid sequence of SEQ ID NO: 167, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 168, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(6) (i) a VH having the amino acid sequence of SEQ ID NO: 201, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 202, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(7) (i) a VH having the amino acid sequence of SEQ ID NO: 235, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 236, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(8) (i) a VH having the amino acid sequence of SEQ ID NO: 269, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 270, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(9) (i) a VH having the amino acid sequence of SEQ ID NO: 303, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 304, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(10) (i) a VH having the amino acid sequence of SEQ ID NO: 337, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 338, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(11) (i) a VH having the amino acid sequence of SEQ ID NO: 371, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 372, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(12) (i) a VH having the amino acid sequence of SEQ ID NO: 405, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 406, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(13) (i) a VH having the amino acid sequence of SEQ ID NO: 439, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 440, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(14) (i) a VH having the amino acid sequence of SEQ ID NO: 473, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 474, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(15) (i) a VH having the amino acid sequence of SEQ ID NO: 507, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 508, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(16) (i) a VH having the amino acid sequence of SEQ ID NO: 541, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 542, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(17) (i) a VH having the amino acid sequence of SEQ ID NO: 575, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 576, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(18) (i) a VH having the amino acid sequence of SEQ ID NO: 609, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 610, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(19) (i) a VH having the amino acid sequence of SEQ ID NO: 643, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 644, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(20) (i) a VH having the amino acid sequence of SEQ ID NO: 677, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 678, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(21) (i) a VH having the amino acid sequence of SEQ ID NO: 711, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 712, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(22) (i) a VH having the amino acid sequence of SEQ ID NO: 745, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 746, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(23) (i) a VH having the amino acid sequence of SEQ ID NO: 779, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 780, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(24) (i) a VH having the amino acid sequence of SEQ ID NO: 813, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 814, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(25) (i) a VH having the amino acid sequence of SEQ ID NO: 847, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 848, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(26) (i) a VH having the amino acid sequence of SEQ ID NO: 881, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 882, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(27) (i) a VH having the amino acid sequence of SEQ ID NO: 915, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 916, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(28) (i) a VH having the amino acid sequence of SEQ ID NO: 949, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 950, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(29) (i) a VH having the amino acid sequence of SEQ ID NO: 983, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 984, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(30) (i) a VH having the amino acid sequence of SEQ ID NO: 1017, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1018, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(31) (i) a VH having the amino acid sequence of SEQ ID NO: 1051, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1052, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(32) (i) a VH having the amino acid sequence of SEQ ID NO: 1085, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1086, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(33) (i) a VH having the amino acid sequence of SEQ ID NO: 1119, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1120, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(34) (i) a VH having the amino acid sequence of SEQ ID NO: 1153, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1154, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(35) (i) a VH having the amino acid sequence of SEQ ID NO: 1187, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1188, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(36) (i) a VH having the amino acid sequence of SEQ ID NO: 1221, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1222, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(37) (i) a VH having the amino acid sequence of SEQ ID NO: 1255, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1256, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(38) (i) a VH having the amino acid sequence of SEQ ID NO: 1289, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1290, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(39) (i) a VH having the amino acid sequence of SEQ ID NO: 1323, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1324, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(40) (i) a VH having the amino acid sequence of SEQ ID NO: 1357, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1358, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(41) (i) a VH having the amino acid sequence of SEQ ID NO: 1391, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1392, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(42) (i) a VH having the amino acid sequence of SEQ ID NO: 1425, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1426, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(43) (i) a VH having the amino acid sequence of SEQ ID NO: 1459, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1460, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(44) (i) a VH having the amino acid sequence of SEQ ID NO: 1493, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1494, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(45) (i) a VH having the amino acid sequence of SEQ ID NO: 1527, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1528, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(46) (i) a VH having the amino acid sequence of SEQ ID NO: 1561, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1562, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(47) (i) a VH having the amino acid sequence of SEQ ID NO: 1595, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1596, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(48) (i) a VH having the amino acid sequence of SEQ ID NO: 1629, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1630, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(49) (i) a VH having the amino acid sequence of SEQ ID NO: 1663, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1664, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(50) (i) a VH having the amino acid sequence of SEQ ID NO: 1697, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1698, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(51) (i) a VH having the amino acid sequence of SEQ ID NO: 1731, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1732, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(52) (i) a VH having the amino acid sequence of SEQ ID NO: 1765, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1766, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(53) (i) a VH having the amino acid sequence of SEQ ID NO: 1799, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1800, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(54) (i) a VH having the amino acid sequence of SEQ ID NO: 1833, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1834, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(55) (i) a VH having the amino acid sequence of SEQ ID NO: 1867, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1868, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(56) (i) a VH having the amino acid sequence of SEQ ID NO: 1901, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1902, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(57) (i) a VH having the amino acid sequence of SEQ ID NO: 1935, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1936, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(58) (i) a VH having the amino acid sequence of SEQ ID NO: 1969, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1970, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively; or
(59) (i) a VH having the amino acid sequence of SEQ ID NO: 2003, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2004, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. Antibodies that bind to TCR Vδ2 (TRDV2), including:
(1) (i) a VH having the amino acid sequence of SEQ ID NO: 2037, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2038, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(2) (i) a VH having the amino acid sequence of SEQ ID NO: 2071, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2072, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(3) (i) a VH having the amino acid sequence of SEQ ID NO: 2105, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2106, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(4) (i) a VH having the amino acid sequence of SEQ ID NO: 2139, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2140, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(5) (i) a VH having the amino acid sequence of SEQ ID NO: 2173, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2174, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(6) (i) a VH having the amino acid sequence of SEQ ID NO: 2207, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2208, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(7) (i) a VH having the amino acid sequence of SEQ ID NO: 2241, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2242, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(8) (i) a VH having the amino acid sequence of SEQ ID NO: 2275, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2276, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(9) (i) a VH having the amino acid sequence of SEQ ID NO: 2309, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2310, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(10) (i) a VH having the amino acid sequence of SEQ ID NO: 2343, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2344, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(11) (i) a VH having the amino acid sequence of SEQ ID NO: 2377, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2378, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(12) (i) a VH having the amino acid sequence of SEQ ID NO: 2411, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2412, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(13) (i) a VH having the amino acid sequence of SEQ ID NO: 2445, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2446, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(14) (i) a VH having the amino acid sequence of SEQ ID NO: 2479, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2480, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(15) (i) a VH having the amino acid sequence of SEQ ID NO: 2513, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2514, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(16) (i) a VH having the amino acid sequence of SEQ ID NO: 2547, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2548, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(17) (i) a VH having the amino acid sequence of SEQ ID NO: 2581, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2582, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(18) (i) a VH having the amino acid sequence of SEQ ID NO: 2615, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2616, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(19) (i) a VH having the amino acid sequence of SEQ ID NO: 2649, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2650, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(20) (i) a VH having the amino acid sequence of SEQ ID NO: 2683, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2684, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(21) (i) a VH having the amino acid sequence of SEQ ID NO: 2717, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2718, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(22) (i) a VH having the amino acid sequence of SEQ ID NO: 2751, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2752, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(23) (i) a VH having the amino acid sequence of SEQ ID NO: 2785, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2786, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(24) (i) a VH having the amino acid sequence of SEQ ID NO: 2819, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2820, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(25) (i) a VH having the amino acid sequence of SEQ ID NO: 2853, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2854, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(26) (i) a VH having the amino acid sequence of SEQ ID NO: 2887, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2888, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(27) (i) a VH having the amino acid sequence of SEQ ID NO: 2921, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2922, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(28) (i) a VH having the amino acid sequence of SEQ ID NO: 2955, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2956, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(29) (i) a VH having the amino acid sequence of SEQ ID NO: 2989, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2990, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(30) (i) a VH having the amino acid sequence of SEQ ID NO: 3023, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3024, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(31) (i) a VH having the amino acid sequence of SEQ ID NO: 3057, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3058, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(32) (i) a VH having the amino acid sequence of SEQ ID NO: 3091, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3092, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(33) (i) a VH having the amino acid sequence of SEQ ID NO: 3125, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3126, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(34) (i) a VH having the amino acid sequence of SEQ ID NO: 3159, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3160, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(35) (i) a VH having the amino acid sequence of SEQ ID NO: 3193, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3194, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(36) (i) a VH having the amino acid sequence of SEQ ID NO: 3227, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3228, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(37) (i) a VH having the amino acid sequence of SEQ ID NO: 3261, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3262, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(38) (i) a VH having the amino acid sequence of SEQ ID NO: 3295, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3296, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(39) (i) a VH having the amino acid sequence of SEQ ID NO: 3329, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3330, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(40) (i) a VH having the amino acid sequence of SEQ ID NO: 3363, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3364, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(41) (i) a VH having the amino acid sequence of SEQ ID NO: 3397, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3398, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(42) (i) a VH having the amino acid sequence of SEQ ID NO: 3431, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3432, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(43) (i) a VH having the amino acid sequence of SEQ ID NO: 3465, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3466, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(44) (i) a VH having the amino acid sequence of SEQ ID NO: 3499, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3500, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(45) (i) a VH having the amino acid sequence of SEQ ID NO: 3533, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3534, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(46) (i) a VH having the amino acid sequence of SEQ ID NO: 3567, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3568, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(47) (i) a VH having the amino acid sequence of SEQ ID NO: 3601, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3602, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(48) (i) a VH having the amino acid sequence of SEQ ID NO: 3635, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3636, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(49) (i) a VH having the amino acid sequence of SEQ ID NO: 3669, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3670, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(50) (i) a VH having the amino acid sequence of SEQ ID NO: 3703, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3704, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(51) (i) a VH having the amino acid sequence of SEQ ID NO: 3737, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3738, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(52) (i) a VH having the amino acid sequence of SEQ ID NO: 3771, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3772, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(53) (i) a VH having the amino acid sequence of SEQ ID NO: 3805, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3806, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(54) (i) a VH having the amino acid sequence of SEQ ID NO: 3839, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3840, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(55) (i) a VH having the amino acid sequence of SEQ ID NO: 3873, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3874, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(56) (i) a VH having the amino acid sequence of SEQ ID NO: 3907, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3908, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(57) (i) a VH having the amino acid sequence of SEQ ID NO: 3941, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3942, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(58) (i) a VH having the amino acid sequence of SEQ ID NO: 3975, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3976, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(59) (i) a VH having the amino acid sequence of SEQ ID NO: 4009, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4010, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(60) (i) a VH having the amino acid sequence of SEQ ID NO: 4043, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4044, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(61) (i) a VH having the amino acid sequence of SEQ ID NO: 4077, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4078, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively; or
(62) (i) a VH having the amino acid sequence of SEQ ID NO: 4111, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4112, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. Antibodies that bind to the TCR gamma delta constant region (TRGDC), including:
(1) (i) a VH having the amino acid sequence of SEQ ID NO: 4145, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4146, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(2) (i) a VH having the amino acid sequence of SEQ ID NO: 4179, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4180, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(3) (i) a VH having the amino acid sequence of SEQ ID NO: 4213, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4214, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(4) (i) a VH having the amino acid sequence of SEQ ID NO: 4247, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4248, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(5) (i) a VH having the amino acid sequence of SEQ ID NO: 4281, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4282, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(6) (i) a VH having the amino acid sequence of SEQ ID NO: 4315, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4316, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(7) (i) a VH having the amino acid sequence of SEQ ID NO: 4349, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4350, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(8) (i) a VH having the amino acid sequence of SEQ ID NO: 4383, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4384, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(9) (i) a VH having the amino acid sequence of SEQ ID NO: 4417, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4418, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(10) (i) a VH having the amino acid sequence of SEQ ID NO: 4451, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4452, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(11) (i) a VH having the amino acid sequence of SEQ ID NO: 4485, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4486, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(12) (i) a VH having the amino acid sequence of SEQ ID NO: 4519, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4520, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(13) (i) a VH having the amino acid sequence of SEQ ID NO: 4553, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4554, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(14) (i) a VH having the amino acid sequence of SEQ ID NO: 4587, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4588, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(15) (i) a VH having the amino acid sequence of SEQ ID NO: 4621, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4622, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively; or
(16) (i) a VH having the amino acid sequence of SEQ ID NO: 4655, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4656, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. 4. The amino acid sequence of any one of claims 1 to 3, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are
(a) the Kabat numbering system;
(b) Chothia numbering scheme;
(c) the AbM numbering scheme;
(d) a contact numbering scheme; or
(e) according to the contact numbering scheme. 5. The antibody according to any one of claims 1 to 4, wherein the antibody is a humanized antibody. 6. The antibody according to any one of claims 1 to 5, wherein the antibody is an IgG antibody; Optionally, the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. 7. The antibody of any one of claims 1 to 6, wherein the antibody comprises a kappa light chain or a lambda light chain. 8. The antibody of any one of claims 1 to 7, wherein the antibody is a monoclonal antibody. 9. The antibody of any one of claims 1 or 4-8, wherein the antibody binds to a TRGV9 antigen or TRGV9 epitope. 10. The antibody of any one of claims 1 or 4 to 9, wherein the antibody specifically binds to TRGV9. 11. The method according to any one of claims 1 or 4 to 10, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for an antigen or epitope of TRGV9, Antibodies. 12. The antibody of any one of claims 1 or 4-11, wherein TRGV9 is present on the surface of a T cell. 9. The antibody of any one of claims 2 or 4-8, wherein the antibody binds to a TRDV2 antigen or TRDV2 epitope. 14. The antibody of any one of claims 2, 4-8, or 13, wherein the antibody specifically binds to TRDV2. The method according to any one of claims 2, 4 to 8, 13 or 14, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are antigens or epitopes of TRDV2 Forming a binding site for, antibody. 16. The antibody of any one of claims 2, 4-8, or 13-15, wherein TRDV2 is present on the surface of a T cell. 9. The antibody of any one of claims 3 to 8, wherein the antibody binds to a TRGDC antigen or TRGDC epitope. 18. The antibody of any one of claims 3 to 8 or 17, wherein the antibody specifically binds to TRGDC. The method according to any one of claims 3 to 8, 17 or 18, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are binding sites for an antigen or epitope of TRGDC Forming an antibody. 20. The antibody of any one of claims 3-8 or 17-19, wherein the TRGDC is present on the surface of a T cell. 21. The method of any one of claims 1-20, wherein the antibody is multivalent; Optionally,
(a) the antibody is capable of binding at least three antigens;
(b) the antibody is capable of binding at least 4 antigens; or
(c) an antibody capable of binding at least five antigens. 22. The antibody according to any one of claims 1 to 21, wherein the antibody is a multispecific antibody;
Optionally, the multispecific antibody is a bispecific antibody, a trispecific antibody, or a tetraspecific antibody. According to claim 22,
(a) the multispecific antibody is a multispecific TRGV9 antibody comprising a first binding domain that binds TRGV9 and a second binding domain that binds a second target; The first binding domain that binds TRGV9 is:
(1) (i) a VH having the amino acid sequence of SEQ ID NO: 31, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 32, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(2) (i) a VH having the amino acid sequence of SEQ ID NO: 65, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 66, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(3) (i) a VH having the amino acid sequence of SEQ ID NO: 99, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 100, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(4) (i) a VH having the amino acid sequence of SEQ ID NO: 133, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 134, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(5) (i) a VH having the amino acid sequence of SEQ ID NO: 167, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 168, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(6) (i) a VH having the amino acid sequence of SEQ ID NO: 201, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 202, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(7) (i) a VH having the amino acid sequence of SEQ ID NO: 235, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 236, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(8) (i) a VH having the amino acid sequence of SEQ ID NO: 269, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 270, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(9) (i) a VH having the amino acid sequence of SEQ ID NO: 303, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 304, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(10) (i) a VH having the amino acid sequence of SEQ ID NO: 337, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 338, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(11) (i) a VH having the amino acid sequence of SEQ ID NO: 371, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 372, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(12) (i) a VH having the amino acid sequence of SEQ ID NO: 405, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 406, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(13) (i) a VH having the amino acid sequence of SEQ ID NO: 439, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 440, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(14) (i) a VH having the amino acid sequence of SEQ ID NO: 473, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 474, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(15) (i) a VH having the amino acid sequence of SEQ ID NO: 507, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 508, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(16) (i) a VH having the amino acid sequence of SEQ ID NO: 541, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 542, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(17) (i) a VH having the amino acid sequence of SEQ ID NO: 575, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 576, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(18) (i) a VH having the amino acid sequence of SEQ ID NO: 609, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 610, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(19) (i) a VH having the amino acid sequence of SEQ ID NO: 643, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 644, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(20) (i) a VH having the amino acid sequence of SEQ ID NO: 677, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 678, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(21) (i) a VH having the amino acid sequence of SEQ ID NO: 711, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 712, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(22) (i) a VH having the amino acid sequence of SEQ ID NO: 745, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 746, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(23) (i) a VH having the amino acid sequence of SEQ ID NO: 779, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 780, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(24) (i) a VH having the amino acid sequence of SEQ ID NO: 813, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 814, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(25) (i) a VH having the amino acid sequence of SEQ ID NO: 847, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 848, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(26) (i) a VH having the amino acid sequence of SEQ ID NO: 881, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 882, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(27) (i) a VH having the amino acid sequence of SEQ ID NO: 915, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 916, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(28) (i) a VH having the amino acid sequence of SEQ ID NO: 949, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 950, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(29) (i) a VH having the amino acid sequence of SEQ ID NO: 983, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 984, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(30) (i) a VH having the amino acid sequence of SEQ ID NO: 1017, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1018, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(31) (i) a VH having the amino acid sequence of SEQ ID NO: 1051, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1052, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(32) (i) a VH having the amino acid sequence of SEQ ID NO: 1085, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1086, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(33) (i) a VH having the amino acid sequence of SEQ ID NO: 1119, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1120, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(34) (i) a VH having the amino acid sequence of SEQ ID NO: 1153, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1154, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(35) (i) a VH having the amino acid sequence of SEQ ID NO: 1187, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1188, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(36) (i) a VH having the amino acid sequence of SEQ ID NO: 1221, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1222, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(37) (i) a VH having the amino acid sequence of SEQ ID NO: 1255, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1256, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(38) (i) a VH having the amino acid sequence of SEQ ID NO: 1289, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1290, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(39) (i) a VH having the amino acid sequence of SEQ ID NO: 1323, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1324, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(40) (i) a VH having the amino acid sequence of SEQ ID NO: 1357, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1358, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(41) (i) a VH having the amino acid sequence of SEQ ID NO: 1391, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1392, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(42) (i) a VH having the amino acid sequence of SEQ ID NO: 1425, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1426, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(43) (i) a VH having the amino acid sequence of SEQ ID NO: 1459, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1460, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(44) (i) a VH having the amino acid sequence of SEQ ID NO: 1493, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1494, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(45) (i) a VH having the amino acid sequence of SEQ ID NO: 1527, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1528, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(46) (i) a VH having the amino acid sequence of SEQ ID NO: 1561, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1562, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(47) (i) a VH having the amino acid sequence of SEQ ID NO: 1595, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1596, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(48) (i) a VH having the amino acid sequence of SEQ ID NO: 1629, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1630, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(49) (i) a VH having the amino acid sequence of SEQ ID NO: 1663, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1664, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(50) (i) a VH having the amino acid sequence of SEQ ID NO: 1697, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1698, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(51) (i) a VH having the amino acid sequence of SEQ ID NO: 1731, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1732, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(52) (i) a VH having the amino acid sequence of SEQ ID NO: 1765, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1766, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(53) (i) a VH having the amino acid sequence of SEQ ID NO: 1799, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1800, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(54) (i) a VH having the amino acid sequence of SEQ ID NO: 1833, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1834, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(55) (i) a VH having the amino acid sequence of SEQ ID NO: 1867, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1868, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(56) (i) a VH having the amino acid sequence of SEQ ID NO: 1901, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1902, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(57) (i) a VH having the amino acid sequence of SEQ ID NO: 1935, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 1936, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(58) (i) a VH having the amino acid sequence of SEQ ID NO: 1969, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 1970, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively; or
(59) (i) a VH having the amino acid sequence of SEQ ID NO: 2003, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2004, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(b) the multispecific antibody is a multispecific TRDV2 antibody comprising a first binding domain that binds TRDV2 and a second binding domain that binds a second target; The first binding domain that binds TRDV2 is:
(1) (i) a VH having the amino acid sequence of SEQ ID NO: 2037, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2038, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(2) (i) a VH having the amino acid sequence of SEQ ID NO: 2071, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2072, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(3) (i) a VH having the amino acid sequence of SEQ ID NO: 2105, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2106, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(4) (i) a VH having the amino acid sequence of SEQ ID NO: 2139, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2140, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(5) (i) a VH having the amino acid sequence of SEQ ID NO: 2173, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2174, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(6) (i) a VH having the amino acid sequence of SEQ ID NO: 2207, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2208, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(7) (i) a VH having the amino acid sequence of SEQ ID NO: 2241, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2242, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(8) (i) a VH having the amino acid sequence of SEQ ID NO: 2275, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2276, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(9) (i) a VH having the amino acid sequence of SEQ ID NO: 2309, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2310, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(10) (i) a VH having the amino acid sequence of SEQ ID NO: 2343, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2344, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(11) (i) a VH having the amino acid sequence of SEQ ID NO: 2377, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2378, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(12) (i) a VH having the amino acid sequence of SEQ ID NO: 2411, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2412, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(13) (i) a VH having the amino acid sequence of SEQ ID NO: 2445, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2446, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(14) (i) a VH having the amino acid sequence of SEQ ID NO: 2479, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2480, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(15) (i) a VH having the amino acid sequence of SEQ ID NO: 2513, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2514, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(16) (i) a VH having the amino acid sequence of SEQ ID NO: 2547, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2548, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(17) (i) a VH having the amino acid sequence of SEQ ID NO: 2581, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2582, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(18) (i) a VH having the amino acid sequence of SEQ ID NO: 2615, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2616, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(19) (i) a VH having the amino acid sequence of SEQ ID NO: 2649, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2650, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(20) (i) a VH having the amino acid sequence of SEQ ID NO: 2683, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2684, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(21) (i) a VH having the amino acid sequence of SEQ ID NO: 2717, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2718, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(22) (i) a VH having the amino acid sequence of SEQ ID NO: 2751, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2752, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(23) (i) a VH having the amino acid sequence of SEQ ID NO: 2785, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2786, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(24) (i) a VH having the amino acid sequence of SEQ ID NO: 2819, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2820, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(25) (i) a VH having the amino acid sequence of SEQ ID NO: 2853, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2854, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(26) (i) a VH having the amino acid sequence of SEQ ID NO: 2887, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2888, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(27) (i) a VH having the amino acid sequence of SEQ ID NO: 2921, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 2922, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(28) (i) a VH having the amino acid sequence of SEQ ID NO: 2955, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2956, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(29) (i) a VH having the amino acid sequence of SEQ ID NO: 2989, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 2990, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(30) (i) a VH having the amino acid sequence of SEQ ID NO: 3023, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3024, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(31) (i) a VH having the amino acid sequence of SEQ ID NO: 3057, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3058, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(32) (i) a VH having the amino acid sequence of SEQ ID NO: 3091, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3092, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(33) (i) a VH having the amino acid sequence of SEQ ID NO: 3125, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3126, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(34) (i) a VH having the amino acid sequence of SEQ ID NO: 3159, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3160, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(35) (i) a VH having the amino acid sequence of SEQ ID NO: 3193, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3194, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(36) (i) a VH having the amino acid sequence of SEQ ID NO: 3227, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3228, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(37) (i) a VH having the amino acid sequence of SEQ ID NO: 3261, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3262, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(38) (i) a VH having the amino acid sequence of SEQ ID NO: 3295, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3296, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(39) (i) a VH having the amino acid sequence of SEQ ID NO: 3329, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3330, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(40) (i) a VH having the amino acid sequence of SEQ ID NO: 3363, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3364, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(41) (i) a VH having the amino acid sequence of SEQ ID NO: 3397, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3398, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(42) (i) a VH having the amino acid sequence of SEQ ID NO: 3431, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3432, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(43) (i) a VH having the amino acid sequence of SEQ ID NO: 3465, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3466, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(44) (i) a VH having the amino acid sequence of SEQ ID NO: 3499, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3500, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(45) (i) a VH having the amino acid sequence of SEQ ID NO: 3533, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3534, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(46) (i) a VH having the amino acid sequence of SEQ ID NO: 3567, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3568, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(47) (i) a VH having the amino acid sequence of SEQ ID NO: 3601, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3602, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(48) (i) a VH having the amino acid sequence of SEQ ID NO: 3635, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3636, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(49) (i) a VH having the amino acid sequence of SEQ ID NO: 3669, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3670, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(50) (i) a VH having the amino acid sequence of SEQ ID NO: 3703, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3704, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(51) (i) a VH having the amino acid sequence of SEQ ID NO: 3737, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3738, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(52) (i) a VH having the amino acid sequence of SEQ ID NO: 3771, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3772, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(53) (i) a VH having the amino acid sequence of SEQ ID NO: 3805, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3806, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(54) (i) a VH having the amino acid sequence of SEQ ID NO: 3839, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3840, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(55) (i) a VH having the amino acid sequence of SEQ ID NO: 3873, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3874, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(56) (i) a VH having the amino acid sequence of SEQ ID NO: 3907, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3908, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(57) (i) a VH having the amino acid sequence of SEQ ID NO: 3941, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 3942, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(58) (i) a VH having the amino acid sequence of SEQ ID NO: 3975, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 3976, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(59) (i) a VH having the amino acid sequence of SEQ ID NO: 4009, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4010, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(60) (i) a VH having the amino acid sequence of SEQ ID NO: 4043, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4044, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(61) (i) a VH having the amino acid sequence of SEQ ID NO: 4077, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4078, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively; or
(62) (i) a VH having the amino acid sequence of SEQ ID NO: 4111, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4112, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively; or
(c) the multispecific antibody is a multispecific TRGDC antibody comprising a first binding domain that binds TRGDC and a second binding domain that binds a second target; The first binding domain that binds TRGDC is:
(1) (i) a VH having the amino acid sequence of SEQ ID NO: 4145, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4146, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(2) (i) a VH having the amino acid sequence of SEQ ID NO: 4179, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4180, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(3) (i) a VH having the amino acid sequence of SEQ ID NO: 4213, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4214, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(4) (i) a VH having the amino acid sequence of SEQ ID NO: 4247, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4248, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(5) (i) a VH having the amino acid sequence of SEQ ID NO: 4281, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4282, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(6) (i) a VH having the amino acid sequence of SEQ ID NO: 4315, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4316, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(7) (i) a VH having the amino acid sequence of SEQ ID NO: 4349, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4350, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(8) (i) a VH having the amino acid sequence of SEQ ID NO: 4383, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4384, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(9) (i) a VH having the amino acid sequence of SEQ ID NO: 4417, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4418, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(10) (i) a VH having the amino acid sequence of SEQ ID NO: 4451, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4452, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(11) (i) a VH having the amino acid sequence of SEQ ID NO: 4485, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4486, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(12) (i) a VH having the amino acid sequence of SEQ ID NO: 4519, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4520, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(13) (i) a VH having the amino acid sequence of SEQ ID NO: 4553, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4554, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(14) (i) a VH having the amino acid sequence of SEQ ID NO: 4587, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4588, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively;
(15) (i) a VH having the amino acid sequence of SEQ ID NO: 4621, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL comprising VL having the amino acid sequence of SEQ ID NO: 4622, VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively; or
(16) (i) a VH having the amino acid sequence of SEQ ID NO: 4655, a VH comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3, respectively; and (ii) a VL having the amino acid sequence of SEQ ID NO: 4656, a VL comprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3, respectively. . A nucleic acid sequence encoding the antibody of any one of claims 1-23. A vector comprising the nucleic acid sequence of claim 24 . A host cell comprising the vector of claim 25 . A kit comprising the vector of claim 25 and packaging therefor. A kit comprising the antibody of any one of claims 1 to 23 and packaging therefor. A pharmaceutical composition comprising the antibody of any one of claims 1 to 23 and a pharmaceutically acceptable carrier. A method of producing the pharmaceutical composition of claim 28 comprising combining the antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition. A method of inducing γδ T cells into target cells, comprising contacting the γδ T cells with the multispecific antibody of claim 23 , wherein the target cells express a second target, wherein contacting the γδ T cells targets the γδ T cells. How to induce into a cell. 24. A method of inhibiting the growth or proliferation of a target cell, comprising contacting the target cell with the multispecific antibody of claim 23, wherein the target cell expresses a second target on its cell surface, and the target cell is contacted with the multispecific antibody. Wherein the contacting step inhibits the growth or proliferation of the target cell. 33. The method of claim 32, wherein the target cell is in the presence of γδ T cells while in contact with the multispecific antibody. A method of depleting a target cell in a subject comprising administering to the subject an effective amount of the multispecific antibody of claim 23 , wherein the target cell expresses a second target. A method of treating a disease in a subject caused in whole or in part by target cells, comprising administering to the subject an effective amount of the multispecific antibody of claim 23 , wherein the target cells express a second target. 36. The method of claim 34 or 35, wherein the subject is in need of treatment. As a method of activating T cells,
(a) the T cell expresses TRGV9 and the method comprises contacting the T cell with an antibody of any one of claims 1 , 4 - 12 , or 21 - 23 ;
Optionally, the contacting step results in increased expression of CD69, CD25, and/or granzyme B as compared to control T cells expressing TRGV9;
(b) the T cell expresses TRDV2, and the method comprises combining the T cell with the antibody of any one of claims 2, 4-8, 13-16, or 21-23. Including contacting
Optionally, the contacting step results in increased expression of CD69, CD25, and/or granzyme B compared to control T cells expressing TRDV2; or
(c) the T cell expresses TRGDC and the method comprises contacting the T cell with the antibody of any one of claims 3-8 or 17-23;
Optionally, the contacting step results in increased expression of CD69, CD25, and/or granzyme B as compared to control T cells expressing TRGDC.